

(19)



(11)

EP 1 373 508 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
24.04.2013 Bulletin 2013/17

(51) Int Cl.:
C12N 9/12 (2006.01)

(21) Application number: **02721533.4**

(86) International application number:
PCT/US2002/008811

(22) Date of filing: **22.03.2002**

(87) International publication number:
WO 2002/077174 (03.10.2002 Gazette 2002/40)

(54) **HUMAN CYTOKINE RECEPTOR**

MENSCHLICHER CYTOKIN-REZEPTOR
RECEPTEUR DE CYTOKINE HUMAINE

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

• **HUGHES, Steven, D.**
Seattle, WA 98028 (US)

(30) Priority: **27.03.2001 US 279222 P**

(74) Representative: **Griffin, Philippa Jane et al**
Mathys & Squire LLP
120 Holborn
London
EC1N 2SQ (GB)

(43) Date of publication of application:
02.01.2004 Bulletin 2004/01

(73) Proprietor: **ZymoGenetics, Inc.**
Seattle, Washington 98102 (US)

(56) References cited:
EP-A- 1 191 035 WO-A-01/36467
WO-A-01/40467 WO-A-01/46422
WO-A-01/98342 WO-A-02/20569
WO-A-03/035096 WO-A1-98/02542
US-A- 5 965 704

(72) Inventors:
• **PRESNELL, Scott, R.**
Tacoma, WA 98407 (US)
• **XU, Wenfeng**
Seattle, WA 98115 (US)
• **KINDSVOGEL, Wayne**
Seattle, WA 98115 (US)
• **CHEN, Zhi**
Bellevue, WA 98006 (US)

• **LIU ET AL.: 'Expression cloning and characterization of a human IL-10 receptor'**
JOURNAL OF IMMUNOLOGY vol. 152, February 1994, pages 1821 - 1829, XP002046437

EP 1 373 508 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates generally to a new protein expressed by human cells. In particular, the present invention relates to a novel gene that encodes a receptor, designated as "Zcytor16," and to nucleic acid molecules encoding Zcytor16 polypeptides, and to producing antibodies to the polypeptide.

[0002] Cytokines are soluble, small proteins that mediate a variety of biological effects, including the regulation of the growth and differentiation of many cell types (see, for example, Arai et al., *Annu. Rev. Biochem.* 59:783 (1990); Mosmann, *Curr. Opin. Immunol.* 3:311 (1991); Paul and Seder, *Cell* 76:241 (1994)). Proteins that constitute the cytokine group include interleukins, interferons, colony stimulating factors, tumor necrosis factors, and other regulatory molecules. For example, human interleukin-17 is a cytokine which stimulates the expression of interleukin-6, intracellular adhesion molecule 1, interleukin-8, granulocyte macrophage colony-stimulating factor, and prostaglandin E2 expression, and plays a role in the preferential maturation of CD34+ hematopoietic precursors into neutrophils (Yao et al., *J. Immunol.* 155:5483 (1995); Fossiez et al., *J. Exp. Med.* 183:2593 (1996)).

[0003] Receptors that bind cytokines are typically composed of one or more integral membrane proteins that bind the cytokine with high affinity and transduce this binding event to the cell through the cytoplasmic portions of the certain receptor subunits. Cytokine receptors have been grouped into several classes on the basis of similarities in their extracellular ligand binding domains. For example, the receptor chains responsible for binding and/or transducing the effect of interferons are members of the class II cytokine receptor family, based upon a characteristic 200 residue extracellular domain.

[0004] The demonstrated *in vivo* activities of cytokines and their receptors illustrate the clinical potential of, and need for, other cytokines, cytokine receptors, cytokine agonists, and cytokine antagonists.

[0005] The present invention provides Zcytor16 polypeptides and Zcytor16 fusion proteins, as well as nucleic acid molecules encoding such polypeptides and proteins, and methods for using these nucleic acid molecules and amino acid sequences, as defined in the claims.

1. Overview

[0006] An illustrative nucleotide sequence that encodes Zcytor16 is provided by SEQ ID NO:1, and SEQ ID NO:37. The encoded polypeptide has the following amino acid sequence: MMPKHCF LGF LISFFLTGVA GTQSTHESLK PQRVQFQSRN FHNILQWQPG RALTGNSSVY FVQYKIYQQR QWKNKEDCWG TQELSCDLTS ETSDIQEPYY GRVRAASAGS YSEWSMTPRF TPWWETKIDP PVMNITQVNG SLLVILHAPN LPYRYQKEKN VSIEDYYELL YRVFI-INNSL EKEQKVYEGA HRAVEIEALT PHSSYCVVAE IQPMLDRRS QRSEERCVEI P (SEQ ID NO:2). The 231 amino acid polypeptide represents the extracellular domain, also called a cytokine-binding domain, of a new class II cytokine receptor. Features of the Zcytor16 polypeptide include putative signal sequences at amino acid residues 1 to 21, or 1 to 22 of SEQ ID NO:2 (also shown in SEQ ID NO:38), and a mature soluble receptor polypeptide from residues 23 to 231 or 23 to 231 of SEQ ID NO:2. The receptor has two fibronectin III domains, also called immunoglobulin superfamily (Ig) domains, characteristic of the class II cytokine receptor family that comprise amino acid residues 32 to 123 (fibronectin III domain I), and 132 to 230 (fibronectin III domain II) of SEQ ID NO:2, and a linker that resides between the Ig domains (i.e., at amino acid residues 128-131 of SEQ ID NO:2). Thus molecules of the present invention include polypeptides that consist of a cytokine binding domain consisting of amino acids 32 to 230 of SEQ ID NO:2. Moreover, additional variants of the zcytor16 polypeptide include polypeptides that consist of amino acid residues 28 to 127 (fibronectin III domain I), and 132 to 230 (fibronectin III domain II) of SEQ ID NO:2, and a linker that resides between the Ig domains (i.e., at amino acid residues 128-131 of SEQ ID NO:2). Thus molecules of the present invention include polypeptides as defined in the claims that include a cytokine binding domain consisting of amino acids 22, 23, or 28 to 132 to 230 or 231 of SEQ ID NO:2. In addition, zcytor16 contains conserved motifs and residues characteristic of class II cytokines: an SXWS (SEQ ID NO:39) motif from residue 220-223 of SEQ ID NO:2; conserved Tryptophan residues at residues 47, 72, and 114 of SEQ ID NO:2; and conserved Cysteine residues at residues 78, 86, 206, and 227 of SEQ ID NO:2. The *Zcytor16* gene is expressed in monocytes, lymphoid, placenta, spleen, tonsil and other tissues, and resides in human chromosome 6q23-q24. The full-length mRNA, and consequently the cDNA, is shown in SEQ ID NO:37 that, upstream of the initiating methionine (nucleotide 237 of SEQ ID NO:37), includes a 5' untranslated region (UTR) (nucleotides 1-236 of SEQ ID NO:37) that includes a stop codon (TGA) embedded in a consensus Kozak sequence typical of translation in vertebrates. Moreover, the 3' UTR (nucleotides 933-1610 of SEQ ID NO:37) contains an mRNA stability motif (e.g., nucleotides 1458-1465 of SEQ ID NO:37) and a polyA tail.

[0007] As described below, the present specification describes isolated polypeptides comprising an amino acid sequence that is at least 70%, at least 80%, or at least 90% identical to a reference amino acid sequence of SEQ ID NO:2 selected from the group consisting of: (a) amino acid residues 28 to 127; (b) amino acid residues 132 to 231; (c) amino acid residues 28 to 231; (d) amino acid residues 23 to 230; (e) amino acid residues 23 to 231; (f) amino acid residues 22 to 230; (g) amino acid residues 22 to 231; and (h) amino acid residues 1 to 231, wherein the isolated polypeptide

specifically binds with an antibody that specifically binds with a polypeptide consisting of the amino acid sequence of SEQ ID NO:2. Illustrative polypeptides of the invention include polypeptides consisting of amino acid residues 28 to 231 of SEQ ID NO:2. Moreover, the present invention also provides isolated polypeptides as defined in the claims that bind IL-TIF (e.g., human IL-TIF polypeptide sequence as shown in SEQ ID NO:15). The human IL-TIF polynucleotide sequence is shown in SEQ ID NO:14. The mouse IL-TIF polynucleotide sequence is shown in SEQ ID NO:42, and corresponding polypeptide is shown in SEQ ID NO:43.

[0008] The present specification describes isolated polypeptides comprising at least 15 contiguous amino acid residues of an amino acid sequence of SEQ ID NO:2 selected from the group consisting of: (a) amino acid residues 28 to 127; (b) amino acid residues 132 to 231; (c) amino acid residues 28 to 231; (d) amino acid residues 23 to 230; (e) amino acid residues 23 to 231; (f) amino acid residues 22 to 230; (g) amino acid residues 22 to 231; and (h) amino acid residues 1 to 231. Illustrative polypeptides include polypeptides that either comprise, or consist of, amino acid residues (a) to (h). Moreover, the present specification describes isolated polypeptides as disclosed above that bind IL-TIF.

[0009] The present specification describes variant Zcytor16 polypeptides, wherein the amino acid sequence of the variant polypeptide shares an identity with amino acid residues 22 to 231, or 28 to 231 of SEQ ID NO:2 selected from the group consisting of at least 70% identity, at least 80% identity, at least 90% identity, at least 95% identity, or greater than 95% identity, and wherein any difference between the amino acid sequence of the variant polypeptide and the corresponding amino acid sequence of SEQ ID NO:2 is due to one or more conservative amino acid substitutions. Moreover, the present invention also provides isolated polypeptides as disclosed above that bind IL-TIF.

[0010] The present specification describes antibodies and antibody fragments that specifically bind with such polypeptides. Exemplary antibodies include polyclonal antibodies, murine monoclonal antibodies, humanized antibodies derived from murine monoclonal antibodies, and human monoclonal antibodies. Illustrative antibody fragments include F(ab')₂, F(ab)₂, Fab', Fab, Fv, scFv, and minimal recognition units. The present invention further includes compositions comprising a carrier and a peptide, polypeptide, or antibody described herein.

[0011] The present specification describes isolated nucleic acid molecules that encode a Zcytor16 polypeptide, wherein the nucleic acid molecule is selected from the group consisting of: (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3, (b) a nucleic acid molecule encoding an amino acid sequence that comprises either amino acid residues 22 to 231 of SEQ ID NO:2 or amino acid residues 28 to 231 of SEQ ID NO:2, and (c) a nucleic acid molecule that remains hybridized following stringent wash conditions to a nucleic acid molecule comprising the nucleotide sequence of nucleotides 64 or 82, to 690 or 693 of SEQ ID NO:1, or the complement of the nucleotide sequence of nucleotides 64 or 82, to 690 or 693 of SEQ ID NO:1. Illustrative nucleic acid molecules include those in which any difference between the amino acid sequence encoded by nucleic acid molecule (c) and the corresponding amino acid sequence of SEQ ID NO:2 is due to a conservative amino acid substitution. The present invention further contemplates isolated nucleic acid molecules as defined in the claims that comprise nucleotides 64, 67, 82, or 94 to 690 or 693 of SEQ ID NO:1. Moreover, the present invention also provides isolated polynucleotides as defined in the claims that encode polypeptides as defined in the claims that bind IL-TIF.

[0012] The present invention also includes vectors and expression vectors comprising such nucleic acid molecules, as defined in the claims. Such expression vectors may comprise a transcription promoter, and a transcription terminator, wherein the promoter is operably linked with the nucleic acid molecule, and wherein the nucleic acid molecule is operably linked with the transcription terminator. The present invention further includes recombinant host cells comprising these vectors and expression vectors, as defined in the claims. Illustrative host cells include bacterial, yeast, fungal, insect, mammalian, and plant cells. Recombinant host cells comprising such expression vectors can be used to produce Zcytor16 polypeptides by culturing such recombinant host cells that comprise the expression vector and that produce the Zcytor16 protein, and, optionally, isolating the Zcytor16 protein from the cultured recombinant host cells.

[0013] In addition, the present specification describes pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of such an expression vector or recombinant virus comprising such expression vectors. The present specification also describes pharmaceutical compositions, comprising a pharmaceutically acceptable carrier and a polypeptide described herein.

[0014] The present specification describes methods for detecting the presence of Zcytor16 RNA in a biological sample, comprising the steps of (a) contacting a Zcytor16 nucleic acid probe under hybridizing conditions with either (i) test RNA molecules isolated from the biological sample, or (ii) nucleic acid molecules synthesized from the isolated RNA molecules, wherein the probe has a nucleotide sequence comprising a portion of the nucleotide sequence of SEQ ID NO:1, or its complement, and (b) detecting the formation of hybrids of the nucleic acid probe and either the test RNA molecules or the synthesized nucleic acid molecules, wherein the presence of the hybrids indicates the presence of Zcytor16 RNA in the biological sample. For example, suitable probes consist of the following nucleotide sequences of SEQ ID NO:1: nucleotides 64, 67, 82 or 94 to 690 or 693; nucleotides 64, 67, 82 or 94 to 369 or 381; 394 to 690 or 693; and nucleotides 1 to 690 or 693. Other suitable probes consist of the complement of these nucleotide sequences, or a portion of the nucleotide sequences or their complements.

[0015] The present specification describes methods for detecting the presence of Zcytor16 polypeptide in a biological

sample, comprising the steps of: (a) contacting the biological sample with an antibody or an antibody fragment that specifically binds with a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, wherein the contacting is performed under conditions that allow the binding of the antibody or antibody fragment to the biological sample, and (b) detecting any of the bound antibody or bound antibody fragment. Such an antibody or antibody fragment may further

comprise a detectable label selected from the group consisting of radioisotope, fluorescent label, chemiluminescent label, enzyme label, bioluminescent label, and colloidal gold. label, and colloidal gold.

[0016] The present specification describes kits for performing these detection methods. For example, a kit for detection of *Zcytor16* gene expression may comprise a container that comprises a nucleic acid molecule, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of nucleotides 64, 67, 82, or 94 to 693 of SEQ ID NO:1, (b) a nucleic acid molecule comprising the complement of nucleotides 64, 67, 82, or 94 to 693 of the nucleotide sequence of SEQ ID NO:1, (c) a nucleic acid molecule that is a fragment of (a) consisting of at least eight nucleotides, and (d) a nucleic acid molecule that is a fragment of (b) consisting of at least eight nucleotides. Such a kit may also comprise a second container that comprises one or more reagents capable of indicating the presence of the nucleic acid molecule. On the other hand, a kit for detection of *Zcytor16* protein may comprise a container that comprises an antibody, or an antibody fragment, that specifically binds with a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

[0017] The present specification describes anti-idiotypic antibodies, or anti-idiotypic antibody fragments, that specifically bind an antibody or antibody fragment that specifically binds a polypeptide consisting of the amino acid sequence of SEQ ID NO:2. An exemplary anti-idiotypic antibody binds with an antibody that specifically binds a polypeptide consisting of amino acid residues 22 to 231, or 28 to 231 of SEQ ID NO:2.

[0018] The present specification describes isolated nucleic acid molecules comprising a nucleotide sequence that encodes a *Zcytor16* secretion signal sequence and a nucleotide sequence that encodes a biologically active polypeptide, wherein the *Zcytor16* secretion signal sequence comprises an amino acid sequence of residues 1 to 21, of SEQ ID NO:2. Illustrative biologically active polypeptides include Factor VIIa, proinsulin, insulin, follicle stimulating hormone, tissue type plasminogen activator, tumor necrosis factor, interleukin, colony stimulating factor, interferon, erythropoietin, and thrombopoietin. Moreover, the present specification describes fusion proteins comprising a *Zcytor16* secretion signal sequence and a polypeptide, wherein the *Zcytor16* secretion signal sequence comprises an amino acid sequence of residues 1 to 21, of SEQ ID NO:2.

[0019] The present invention also provides fusion proteins as defined in the claims, consisting of a *Zcytor16* polypeptide and an immunoglobulin heavy chain constant region, such as a human F_C fragment. The present isolated nucleic acid molecules that encode such fusion proteins.

[0020] The present invention also provides isolated soluble monomeric, homodimeric, heterodimeric and multimeric receptors comprising a *zcytor16* extracellular domain, as defined in the claims. Such receptors act as antagonists of the *zcytor16* ligand, IL-TIF (e.g., the human IL-TIF as shown in SEQ ID NO:15). The present invention further includes isolated nucleic acid molecules that encode such receptor polypeptides, as defined in the claims.

[0021] The present specification describes polyclonal and monoclonal antibodies to monomeric, homodimeric, heterodimeric and multimeric receptors comprising a *zcytor16* extracellular domain such as those described above. Moreover, such antibodies can be used to antagonize the binding to the *zcytor16* ligand, IL-TIF (SEQ ID NO:15), to the *zcytor16* receptor.

[0022] The present specification describes detecting a genetic abnormality in a patient, comprising: obtaining a genetic sample from a patient; producing a first reaction product by incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence; visualizing the first reaction product; and comparing said first reaction product to a control reaction product from a wild type patient, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.

[0023] The present specification describes detecting a cancer in a patient, comprising: obtaining a tissue or biological sample from a patient; incubating the tissue or biological sample with an antibody as described above under conditions wherein the antibody binds to its complementary polypeptide in the tissue or biological sample; visualizing the antibody bound in the tissue or biological sample; and comparing levels of antibody bound in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the level of antibody bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.

[0024] The present specification describes detecting a cancer in a patient, comprising: obtaining a tissue or biological sample from a patient; labeling a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1; incubating the tissue or biological sample with under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence; visualizing the labeled polynucleotide in the tissue or biological sample; and comparing the level of labeled polynucleotide hybridization in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the labeled polynucleotide hybridization to the

patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.

[0025] These and other aspects of the invention will become evident upon reference to the following detailed description. Various references are identified below.

5

2. Definitions

[0026] In the description that follows, a number of terms are used extensively. The following definitions are provided to facilitate understanding of the invention.

10 **[0027]** As used herein, "nucleic acid" or "nucleic acid molecule" refers to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., α -enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like. The term "nucleic acid molecule" also includes so-called "peptide nucleic acids," which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.

20 **[0028]** The term "complement of a nucleic acid molecule" refers to a nucleic acid molecule having a complementary nucleotide sequence and reverse orientation as compared to a reference nucleotide sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

25 **[0029]** The term "contig" denotes a nucleic acid molecule that has a contiguous stretch of identical or complementary sequence to another nucleic acid molecule. Contiguous sequences are said to "overlap" a given stretch of a nucleic acid molecule either in their entirety or along a partial stretch of the nucleic acid molecule.

30 **[0030]** The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons as compared to a reference nucleic acid molecule that encodes a polypeptide. Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (*i.e.*, GAU and GAC triplets each encode Asp).

35 **[0031]** The term "structural gene" refers to a nucleic acid molecule that is transcribed into messenger RNA (mRNA), which is then translated into a sequence of amino acids characteristic of a specific polypeptide.

[0032] An "isolated nucleic acid molecule" is a nucleic acid molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes a growth factor that has been separated from the genomic DNA of a cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the genome of an organism. A nucleic acid molecule that has been isolated from a particular species is smaller than the complete DNA molecule of a chromosome from that species.

40 **[0033]** A "nucleic acid molecule construct" is a nucleic acid molecule, either single- or double-stranded, that has been modified through human intervention to contain segments of nucleic acid combined and juxtaposed in an arrangement not existing in nature.

45 **[0034]** "Linear DNA" denotes non-circular DNA molecules having free 5' and 3' ends. Linear DNA can be prepared from closed circular DNA molecules, such as plasmids, by enzymatic digestion or physical disruption.

[0035] "Complementary DNA (cDNA)" is a single-stranded DNA molecule that is formed from an mRNA template by the enzyme reverse transcriptase. Typically, a primer complementary to portions of mRNA is employed for the initiation of reverse transcription. Those skilled in the art also use the term "cDNA" to refer to a double-stranded DNA molecule consisting of such a single-stranded DNA molecule and its complementary DNA strand. The term "cDNA" also refers to a clone of a cDNA molecule synthesized from an RNA template.

50 **[0036]** A "promoter" is a nucleotide sequence that directs the transcription of a structural gene. Typically, a promoter is located in the 5' non-coding region of a gene, proximal to the transcriptional start site of a structural gene. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites, TATA sequences, CAAT sequences, differentiation-specific elements (DSEs; McGehee et al., *Mol. Endocrinol.* 7:551 (1993)), cyclic AMP response elements (CREs), serum response elements (SREs; Treisman, *Seminars in Cancer Biol.* 1:47 (1990)), glucocorticoid response elements (GREs), and binding sites for other transcription factors, such as CRE/ATF (O'Reilly et al., *J. Biol. Chem.* 267:

55

19938 (1992)), AP2 (Ye et al., J. Biol. Chem. 269:25728 (1994)), SP1, cAMP response element binding protein (CREB; Loeken, Gene Expr. 3:253 (1993)) and octamer factors (see, in general, Watson et al., eds., Molecular Biology of the Gene, 4th ed. (The Benjamin/Cummings Publishing Company, Inc. 1987), and Lemaigre and Rousseau, Biochem. J. 303:1 (1994)). If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. Repressible promoters are also known.

[0037] A "core promoter" contains essential nucleotide sequences for promoter function, including the TATA box and start of transcription. By this definition, a core promoter may or may not have detectable activity in the absence of specific sequences that may enhance the activity or confer tissue specific activity.

[0038] A "regulatory element" is a nucleotide sequence that modulates the activity of a core promoter. For example, a regulatory element may contain a nucleotide sequence that binds with cellular factors enabling transcription exclusively or preferentially in particular cells, tissues, or organelles. These types of regulatory elements are normally associated with genes that are expressed in a "cell-specific," "tissue-specific," or "organelle-specific" manner.

[0039] An "enhancer" is a type of regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.

[0040] "Heterologous DNA" refers to a DNA molecule, or a population of DNA molecules, that does not exist naturally within a given host cell. DNA molecules heterologous to a particular host cell may contain DNA derived from the host cell species (i.e., endogenous DNA) so long as that host DNA is combined with non-host DNA (i.e., exogenous DNA). For example, a DNA molecule containing a non-host DNA segment encoding a polypeptide operably linked to a host DNA segment comprising a transcription promoter is considered to be a heterologous DNA molecule. Conversely, a heterologous DNA molecule can comprise an endogenous gene operably linked with an exogenous promoter. As another illustration, a DNA molecule comprising a gene derived from a wild-type cell is considered to be heterologous DNA if that DNA molecule is introduced into a mutant cell that lacks the wild-type gene.

[0041] A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides."

[0042] A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

[0043] A peptide or polypeptide encoded by a non-host DNA molecule is a "heterologous" peptide or polypeptide.

[0044] An "integrated genetic element" is a segment of DNA that has been incorporated into a chromosome of a host cell after that element is introduced into the cell through human manipulation. Within the present invention, integrated genetic elements are most commonly derived from linearized plasmids that are introduced into the cells by electroporation or other techniques. Integrated genetic elements are passed from the original host cell to its progeny.

[0045] A "cloning vector" is a nucleic acid molecule, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell. Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites that allow insertion of a nucleic acid molecule in a determinable fashion without loss of an essential biological function of the vector, as well as nucleotide sequences encoding a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance.

[0046] An "expression vector" is a nucleic acid molecule encoding a gene that is expressed in a host cell. Typically, an expression vector comprises a transcription promoter, a gene, and a transcription terminator. Gene expression is usually placed under the control of a promoter, and such a gene is said to be "operably linked to" the promoter. Similarly, a regulatory element and a core promoter are operably linked if the regulatory element modulates the activity of the core promoter.

[0047] A "recombinant host" is a cell that contains a heterologous nucleic acid molecule, such as a cloning vector or expression vector. In the present context, an example of a recombinant host is a cell that produces Zcytor16 from an expression vector. In contrast, Zcytor16 can be produced by a cell that is a "natural source" of Zcytor16, and that lacks an expression vector.

[0048] "Integrative transformants" are recombinant host cells, in which heterologous DNA has become integrated into the genomic DNA of the cells.

[0049] A "fusion protein" is a hybrid protein expressed by a nucleic acid molecule comprising nucleotide sequences of at least two genes. For example, a fusion protein can comprise at least part of a Zcytor16 polypeptide fused with a polypeptide that binds an affinity matrix. Such a fusion protein provides a means to isolate large quantities of Zcytor16 using affinity chromatography.

[0050] The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule termed a "ligand." This interaction mediates the effect of the ligand on the cell. Receptors can be membrane bound, cytosolic or nuclear;

monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor). Membrane-bound receptors are characterized by a multi-domain structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. In certain membrane-bound receptors, the extracellular ligand-binding domain and the intracellular effector domain are located in separate polypeptides that comprise the complete functional receptor.

[0051] In general, the binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell, which in turn leads to an alteration in the metabolism of the cell. Metabolic events that are often linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids.

[0052] A "soluble receptor" is a receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides that lack transmembrane and cytoplasmic domains, and other linkage to the cell membrane such as via glycosylphosphatidylinositol (gpi). Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate, or immunoglobulin constant region sequences. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis or translated from alternatively spliced mRNAs. Soluble receptors can be monomeric, homodimeric, heterodimeric, or multimeric, with multimeric receptors generally not comprising more than 9 subunits, preferably not comprising more than 6 subunits, and most preferably not comprising more than 3 subunits. Receptor polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively. Soluble receptors of class I and class II cytokine receptors generally comprise the extracellular cytokine binding domain free of a transmembrane domain and intracellular domain. For example, representative soluble receptors include a soluble receptor for CRF2-4 (Genbank Accession No. Z17227) as shown in SEQ ID NO:35; a soluble receptor for IL-10R (Genbank Accession No.s U00672 and NM_001558) as shown in SEQ ID NO:36; and a soluble receptor for zcytor11 (US Patent No. 5,965,704) as shown in SEQ ID NO:34. It is well within the level of one of skill in the art to delineate what sequences of a known class I or class II cytokine sequence comprise the extracellular cytokine binding domain free of a transmembrane domain and intracellular domain. Moreover, one of skill in the art using the genetic code can readily determine polynucleotides that encode such soluble receptor polypeptides.

[0053] The term "secretory signal sequence" denotes a DNA sequence that encodes a peptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

[0054] An "isolated polypeptide" is a polypeptide that is essentially free from contaminating cellular components, such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. Typically, a preparation of isolated polypeptide contains the polypeptide in a highly purified form, *i.e.*, at least about 80% pure, at least about 90% pure, at least about 95% pure, greater than 95% pure, or greater than 99% pure. One way to show that a particular protein preparation contains an isolated polypeptide is by the appearance of a single band following sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of the protein preparation and Coomassie Brilliant Blue staining of the gel. However, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

[0055] The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

[0056] The term "expression" refers to the biosynthesis of a gene product. For example, in the case of a structural gene, expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.

[0057] The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a polypeptide encoded by a splice variant of an mRNA transcribed from a gene.

[0058] As used herein, the term "immunomodulator" includes cytokines, stem cell growth factors, lymphotoxins, co-stimulatory molecules, hematopoietic factors, and synthetic analogs of these molecules.

[0059] The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members

of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of less than 10^9 M^{-1} .

[0060] An "anti-idiotypic antibody" is an antibody that binds with the variable region domain of an immunoglobulin. In the present context, an anti-idiotypic antibody binds with the variable region of an anti-Zcytor16 antibody, and thus, an anti-idiotypic antibody mimics an epitope of Zcytor16.

[0061] An "antibody fragment" is a portion of an antibody such as $F(ab')_2$, $F(ab)_2$, Fab' , Fab , and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. For example, an anti-Zcytor16 monoclonal antibody fragment binds with an epitope of Zcytor16.

[0062] The term "antibody fragment" also includes a synthetic or a genetically engineered polypeptide that binds to a specific antigen, such as polypeptides consisting of the light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("scFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

[0063] A "chimeric antibody" is a recombinant protein that contains the variable domains and complementary determining regions derived from a rodent antibody, while the remainder of the antibody molecule is derived from a human antibody.

[0064] "Humanized antibodies" are recombinant proteins in which murine complementarity determining regions of a monoclonal antibody have been transferred from heavy and light variable chains of the murine immunoglobulin into a human variable domain.

[0065] As used herein, a "therapeutic agent" is a molecule or atom which is conjugated to an antibody moiety to produce a conjugate which is useful for therapy. Examples of therapeutic agents include drugs, toxins, immunomodulators, chelators, boron compounds, photoactive agents or dyes, and radioisotopes.

[0066] A "detectable label" is a molecule or atom which can be conjugated to an antibody moiety to produce a molecule useful for diagnosis. Examples of detectable labels include chelators, photoactive agents, radioisotopes, fluorescent agents, paramagnetic ions, or other marker moieties.

[0067] The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4: 1075 (1985); Nilsson et al., Methods Enzymol. 198:3 (1991)), glutathione S transferase (Smith and Johnson, Gene 67: 31 (1988)), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952 (1985)), substance P, FLAG peptide (Hopp et al., Biotechnology 6:1204 (1988)), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2:95 (1991). DNA molecules encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

[0068] A "naked antibody" is an entire antibody, as opposed to an antibody fragment, which is not conjugated with a therapeutic agent. Naked antibodies include both polyclonal and monoclonal antibodies, as well as certain recombinant antibodies, such as chimeric and humanized antibodies.

[0069] As used herein, the term "antibody component" includes both an entire antibody and an antibody fragment.

[0070] An "immunoconjugate" is a conjugate of an antibody component with a therapeutic agent or a detectable label.

[0071] As used herein, the term "antibody fusion protein" refers to a recombinant molecule that comprises an antibody component and a Zcytor16 polypeptide component. Examples of an antibody fusion protein include a protein that comprises a Zcytor16 extracellular domain, and either an Fc domain or an antigen-binding region.

[0072] A "target polypeptide" or a "target peptide" is an amino acid sequence that comprises at least one epitope, and that is expressed on a target cell, such as a tumor cell, or a cell that carries an infectious agent antigen. T cells recognize peptide epitopes presented by a major histocompatibility complex molecule to a target polypeptide or target peptide and typically lyse the target cell or recruit other immune cells to the site of the target cell, thereby killing the target cell.

[0073] An "antigenic peptide" is a peptide which will bind a major histocompatibility complex molecule to form an MHC-peptide complex which is recognized by a T cell, thereby inducing a cytotoxic lymphocyte response upon presentation to the T cell. Thus, antigenic peptides are capable of binding to an appropriate major histocompatibility complex molecule and inducing a cytotoxic T cells response, such as cell lysis or specific cytokine release against the target cell which binds or expresses the antigen. The antigenic peptide can be bound in the context of a class I or class II major histocompatibility complex molecule, on an antigen presenting cell or on a target cell.

[0074] In eukaryotes, RNA polymerase II catalyzes the transcription of a structural gene to produce mRNA. A nucleic acid molecule can be designed to contain an RNA polymerase II template in which the RNA transcript has a sequence that is complementary to that of a specific mRNA. The RNA transcript is termed an "anti-sense RNA" and a nucleic acid molecule that encodes the anti-sense RNA is termed an "anti-sense gene." Anti-sense RNA molecules are capable of

binding to mRNA molecules, resulting in an inhibition of mRNA translation.

[0075] An "anti-sense oligonucleotide specific for *Zcytor16*" or a "*Zcytor16* anti-sense oligonucleotide" is an oligonucleotide having a sequence (a) capable of forming a stable triplex with a portion of the *Zcytor16* gene, or (b) capable of forming a stable duplex with a portion of an mRNA transcript of the *Zcytor16* gene.

[0076] A "ribozyme" is a nucleic acid molecule that contains a catalytic center. The term includes RNA enzymes, self-splicing RNAs, self-cleaving RNAs, and nucleic acid molecules that perform these catalytic functions. A nucleic acid molecule that encodes a ribozyme is termed a "ribozyme gene."

[0077] An "external guide sequence" is a nucleic acid molecule that directs the endogenous ribozyme, RNase P, to a particular species of intracellular mRNA, resulting in the cleavage of the mRNA by RNase P. A nucleic acid molecule that encodes an external guide sequence is termed an "external guide sequence gene."

[0078] The term "variant *Zcytor16* gene" refers to nucleic acid molecules that encode a polypeptide having an amino acid sequence that is a modification of SEQ ID NO:2. Such variants include naturally-occurring polymorphisms of *Zcytor16* genes, as well as synthetic genes that contain conservative amino acid substitutions of the amino acid sequence of SEQ ID NO:2. Additional variant forms of *Zcytor16* genes are nucleic acid molecules that contain insertions or deletions of the nucleotide sequences described herein. A variant *Zcytor16* gene can be identified, for example, by determining whether the gene hybridizes with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, or its complement, under stringent conditions.

[0079] Alternatively, variant *Zcytor16* genes can be identified by sequence comparison. Two amino acid sequences have "100% amino acid sequence identity" if the amino acid residues of the two amino acid sequences are the same when aligned for maximal correspondence. Similarly, two nucleotide sequences have "100% nucleotide sequence identity" if the nucleotide residues of the two nucleotide sequences are the same when aligned for maximal correspondence. Sequence comparisons can be performed using standard software programs such as those included in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Other methods for comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, *The Internet and the New Biology: Tools for Genomic and Molecular Research* (ASM Press, Inc. 1997), Wu et al. (eds.), *Information Superhighway and Computer Databases of Nucleic Acids and Proteins*, in *Methods in Gene Biotechnology*, pages 123-151 (CRC Press, Inc. 1997), and Bishop (ed.), *Guide to Human Genome Computing*, 2nd Edition (Academic Press, Inc. 1998)). Particular methods for determining sequence identity are described below.

[0080] Regardless of the particular method used to identify a variant *Zcytor16* gene or variant *Zcytor16* polypeptide, a variant gene or polypeptide encoded by a variant gene may be functionally characterized the ability to bind specifically to an anti-*Zcytor16* antibody. A variant *Zcytor16* gene or variant *Zcytor16* polypeptide may also be functionally characterized the ability to bind to its ligand, IL-TIF, using a biological or biochemical assay described herein.

[0081] The term "allelic variant" is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

[0082] The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

[0083] "Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, α -globin, β -globin, and myoglobin are paralogs of each other.

[0084] The present invention includes functional fragments of *Zcytor16* genes. Within the context of this invention, a "functional fragment" of a *Zcytor16* gene refers to a nucleic acid molecule that encodes a portion of a *Zcytor16* polypeptide which is a domain described herein or at least specifically binds with an anti-*Zcytor16* antibody.

[0085] Due to the imprecision of standard analytical methods, molecular weights and lengths of polymers are understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to $\pm 10\%$.

3. Production of *Zcytor 16* Polynucleotides or Genes

[0086] Nucleic acid molecules encoding a human *Zcytor16* gene can be obtained by screening a human cDNA or genomic library using polynucleotide probes based upon SEQ ID NO:1 or SEQ ID NO:37. These techniques are standard and well-established.

[0087] As an illustration, a nucleic acid molecule that encodes a human *Zcytor16* gene can be isolated from a cDNA library. In this case, the first step would be to prepare the cDNA library by isolating RNA from a tissue, such as tonsil tissue, using methods well-known to those of skill in the art. In general, RNA isolation techniques must provide a method for breaking cells, a means of inhibiting RNase-directed degradation of RNA, and a method of separating RNA from

DNA, protein, and polysaccharide contaminants. For example, total RNA can be isolated by freezing tissue in liquid nitrogen, grinding the frozen tissue with a mortar and pestle to lyse the cells, extracting the ground tissue with a solution of phenol/chloroform to remove proteins, and separating RNA from the remaining impurities by selective precipitation with lithium chloride (see, for example, Ausubel et al. (eds.), *Short Protocols in Molecular Biology*, 3rd Edition, pages 4-1 to 4-6 (John Wiley & Sons 1995) ["Ausubel (1995)"]; Wu et al., *Methods in Gene Biotechnology*, pages 33-41 (CRC Press, Inc. 1997) ["Wu (1997)"]).

[0088] Alternatively, total RNA can be isolated by extracting ground tissue with guanidinium isothiocyanate, extracting with organic solvents, and separating RNA from contaminants using differential centrifugation (see, for example, Chirgwin et al., *Biochemistry* 18:52 (1979); Ausubel (1995) at pages 4-1 to 4-6; Wu (1997) at pages 33-41).

[0089] In order to construct a cDNA library, poly(A)⁺ RNA must be isolated from a total RNA preparation. Poly(A)⁺ RNA can be isolated from total RNA using the standard technique of oligo(dT)-cellulose chromatography (see, for example, Aviv and Leder, *Proc. Nat'l Acad. Sci. USA* 69:1408 (1972); Ausubel (1995) at pages 4-11 to 4-12).

[0090] Double-stranded cDNA molecules are synthesized from poly(A)⁺ RNA using techniques well-known to those in the art. (see, for example, Wu (1997) at pages 41-46). Moreover, commercially available kits can be used to synthesize double-stranded cDNA molecules. For example, such kits are available from Life Technologies, Inc. (Gaithersburg, MD), CLONTECH Laboratories, Inc. (Palo Alto, CA), Promega Corporation (Madison, WI) and STRATAGENE (La Jolla, CA).

[0091] Various cloning vectors are appropriate for the construction of a cDNA library. For example, a cDNA library can be prepared in a vector derived from bacteriophage, such as a λ gt10 vector. See, for example, Huynh et al., "Constructing and Screening cDNA Libraries in λ gt10 and λ gt11," in *DNA Cloning: A Practical Approach Vol. I*, Glover (ed.), page 49 (IRL Press, 1985); Wu (1997) at pages 47-52.

[0092] Alternatively, double-stranded cDNA molecules can be inserted into a plasmid vector, such as a pBLUESCRIPT vector (STRATAGENE; La Jolla, CA), a LAMDA GEM-4 (Promega Corp.) or other commercially available vectors. Suitable cloning vectors also can be obtained from the American Type Culture Collection (Manassas, VA).

[0093] To amplify the cloned cDNA molecules, the cDNA library is inserted into a prokaryotic host, using standard techniques. For example, a cDNA library can be introduced into competent *E. coli* DH5 or DH10B cells, which can be obtained, for example, from Life Technologies, Inc. or GIBCO BRL (Gaithersburg, MD).

[0094] A human genomic library can be prepared by means well known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327). Genomic DNA can be isolated by lysing tissue with the detergent Sarkosyl, digesting the lysate with proteinase K, clearing insoluble debris from the lysate by centrifugation, precipitating nucleic acid from the lysate using isopropanol, and purifying resuspended DNA on a cesium chloride density gradient.

[0095] DNA fragments that are suitable for the production of a genomic library can be obtained by the random shearing of genomic DNA or by the partial digestion of genomic DNA with restriction endonucleases. Genomic DNA fragments can be inserted into a vector, such as a bacteriophage or cosmid vector, in accordance with conventional techniques, such as the use of restriction enzyme digestion to provide appropriate termini, the use of alkaline phosphatase treatment to avoid undesirable joining of DNA molecules, and ligation with appropriate ligases. Techniques for such manipulation are well known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327).

[0096] Alternatively, human genomic libraries can be obtained from commercial sources such as Research Genetics (Huntsville, AL) and the American Type Culture Collection (Manassas, VA).

[0097] A library containing cDNA or genomic clones can be screened with one or more polynucleotide probes based upon SEQ ID NO:1, using standard methods (see, for example, Ausubel (1995) at pages 6-1 to 6-11).

[0098] Nucleic acid molecules that encode a human *Zcytor16* gene can also be obtained using the polymerase chain reaction (PCR) with oligonucleotide primers having nucleotide sequences that are based upon the nucleotide sequences of the *Zcytor16* gene, as described herein. General methods for screening libraries with PCR are provided by, for example, Yu et al., "Use of the Polymerase Chain Reaction to Screen Phage Libraries," in *Methods in Molecular Biology*, Vol. 15: PCR Protocols: Current Methods and Applications, White (ed.), pages 211-215 (Humana Press, Inc. 1993). Moreover, techniques for using PCR to isolate related genes are described by, for example, Preston, "Use of Degenerate Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members," in *Methods in Molecular Biology*, Vol. 15: PCR Protocols: Current Methods and Applications, White (ed.), pages 317-337 (Humana Press, Inc. 1993).

[0099] Anti-Zcytor16 antibodies, produced as described below, can also be used to isolate DNA sequences that encode human *Zcytor16* genes from cDNA libraries. For example, the antibodies can be used to screen λ gt11 expression libraries, or the antibodies can be used for immunoscreening following hybrid selection and translation (see, for example, Ausubel (1995) at pages 6-12 to 6-16; Margolis et al., "Screening λ expression libraries with antibody and protein probes," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), pages 1-14 (Oxford University Press 1995)).

[0100] As an alternative, a *Zcytor16* gene can be obtained by synthesizing nucleic acid molecules using mutually priming long oligonucleotides and the nucleotide sequences described herein (see, for example, Ausubel (1995) at pages 8-8 to 8-9). Established techniques using the polymerase chain reaction provide the ability to synthesize DNA molecules at least two kilobases in length (Adang et al., *Plant Molec. Biol.* 21:1131 (1993), Bambot et al., *PCR Methods*

and Applications 2:266 (1993), Dillon et al., "Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes," in *Methods in Molecular Biology*, Vol 15; PCR Protocols; Current Methods and Applications, White (ed.), pages 263-268, (Humana Press, Inc. 1993), and Holowachuk et al., *PCR Methods Appl.* 4:299 (1995).

[0101] The nucleic acid molecules of the present invention can also be synthesized with "gene machines" using protocols such as the phosphoramidite method. If chemically-synthesized double stranded DNA is required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short genes (60 to 80 base pairs) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them. For the production of longer genes (>300 base pairs), however, special strategies may be required, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length. For reviews on polynucleotide synthesis, see, for example, Glick and Pasternak, *Molecular Biotechnology, Principles and Applications of Recombinant DNA* (ASM Press 1994), Itakura et al., *Annu. Rev. Biochem.* 53:323 (1984), and Climie et al., *Proc. Nat'l Acad. Sci. USA* 87:633 (1990).

[0102] The sequence of a *Zcytor16* cDNA or *Zcytor16* genomic fragment can be determined using standard methods. *Zcytor16* polynucleotide sequences disclosed herein can also be used as probes or primers to clone 5' non-coding regions of a *Zcytor16* gene. Promoter elements from a *Zcytor16* gene can be used to direct the expression of heterologous genes in, for example, tonsil tissue of transgenic animals or patients treated with gene therapy. The identification of genomic fragments containing a *Zcytor16* promoter or regulatory element can be achieved using well-established techniques, such as deletion analysis (see, generally, Ausubel (1995)).

[0103] Cloning of 5' flanking sequences also facilitates production of *Zcytor16* proteins by "gene activation," as disclosed in U.S. Patent No. 5,641,670. Briefly, expression of an endogenous *Zcytor16* gene in a cell is altered by introducing into the *Zcytor16* locus a DNA construct comprising at least a targeting sequence, a regulatory sequence, an exon, and an unpaired splice donor site. The targeting sequence is a *Zcytor16* 5' non-coding sequence that permits homologous recombination of the construct with the endogenous *Zcytor16* locus, whereby the sequences within the construct become operably linked with the endogenous *Zcytor16* coding sequence. In this way, an endogenous *Zcytor16* promoter can be replaced or supplemented with other regulatory sequences to provide enhanced, tissue-specific, or otherwise regulated expression.

4. Production of *Zcytor16* Gene Variants

[0104] The present invention provides a variety of nucleic acid molecules, as defined in the claims that encode the *Zcytor16* polypeptides disclosed as defined in claims that encode the *Zcytor16* polypeptides disclosed herein. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among polynucleotide molecules. SEQ ID NO:3 is a degenerate nucleotide sequence that encompasses all nucleic acid molecules that encode the *Zcytor16* polypeptide of SEQ ID NO:2. Those skilled in the art will recognize that the degenerate sequence of SEQ ID NO:3 also provides all RNA sequences encoding SEQ ID NO:2, by substituting U for T. Moreover, the present specification describes isolated soluble monomeric, homodimeric, heterodimeric and multimeric receptor polypeptides that comprise at least one *zcytor16* receptor subunit that is substantially homologous to the receptor polypeptide of SEQ ID NO:3. Thus, the present specification describes *Zcytor16* polypeptide-encoding nucleic acid molecules comprising nucleotide 1 to nucleotide 693 of SEQ ID NO:1, and their RNA equivalents.

[0105] Table 1 sets forth the one-letter codes used within SEQ ID NO:3 to denote degenerate nucleotide positions. "Resolutions" are the nucleotides denoted by a code letter. "Complement" indicates the code for the complementary nucleotide(s). For example, the code Y denotes either C or T, and its complement R denotes A or G, A being complementary to T, and G being complementary to C.

Table 1

Nucleotide	Resolution	Complement	Resolution
A	A	T	T
C	C	G	G
G	G	C	C
T	T	A	A
R	A G	Y	C T
Y	C T	R	A G
M	A C	K	G T

EP 1 373 508 B1

(continued)

Nucleotide	Resolution	Complement	Resolution
K	G T	M	A C
S	C G	S	C G
W	A T	W	A T
H	A C T	D	A G T
B	C G T	V	A C G
V	A C G	B	C G T
D	A G T	H	A C T
N	A C G T	N	A C G T

[0106] The degenerate codons used in SEQ ID NO:3, encompassing all possible codons for a given amino acid, are set forth in Table 2.

Table 2

Amino Acid	One Letter Code	Codons	Degenerate Codon
Cys	C	TGC TGT	TGY
Ser	S	AGC AGT TCA TCC TCG TCT	WSN
Thr	T	ACA ACC ACG ACT	ACN
Pro	P	CCA CCC CCG CCT	CCN
Ala	A	GCA GCC GCG GCT	GCN
Gly	G	GGA GGC GGG GGT	GGN
Asn	N	AAC AAT	AAY
Asp	D	GAC GAT	GAY
Glu	E	GAA GAG	GAR
Gln	Q	CAA CAG	CAR
His	H	CAC CAT	CAY
Arg	R	AGA AGG CGA CGC CGG CGT	MGN
Lys	K	AAA AAG	AAR
Met	M	ATG	ATG
Ile	I	ATA ATC ATT	ATH
Leu	L	CTA CTC CTG CTT TTA TTG	YTN
Val	V	GTA GTC GTG GTT	GTN
Phe	F	TTC TTT	TTY
Tyr	Y	TAC TAT	TAY
Trp	W	TGG	TGG
Ter	.	TAA TAG TGA	TRR
Asn Asp	B		RAY
Glu Gln	Z		SAR
Any	X		NNN

[0107] One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate

codon, representative of all possible codons encoding an amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequences of SEQ ID NO:2. Variant sequences can be readily tested for functionality as described herein.

[0108] Different species can exhibit "preferential codon usage." In general, see, Grantham et al., Nucl. Acids Res. 8:1893 (1980), Haas et. al. Curr. Biol. 6:315 (1996), Wain-Hobson et al., Gene 13:355 (1981), Grosjean and Fiers, Gene 18:199 (1982), Holm, Nuc. Acids Res. 14:3075 (1986), Ikemura, J. Mol. Biol. 158:573 (1982), Sharp and Matassi, Curr. Opin. Genet. Dev. 4:851 (1994), Kane, Curr. Opin. Biotechnol. 6:494 (1995), and Makrides, Microbiol. Rev. 60:512 (1996). As used herein, the term "preferential codon usage" or "preferential codons" is a term of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino acid (See Table 2). For example, the amino acid threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequences disclosed herein serve as a template for optimizing expression of polynucleotides in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein.

[0109] The present specification describes variant polypeptides and nucleic acid molecules that represent counterparts from other species (orthologs). These species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species. Of particular interest are Zcytor16 polypeptides from other mammalian species, including mouse, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides. Orthologs of human Zcytor16 can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a *Zcytor16* cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses *Zcytor16* as disclosed herein. Suitable sources of mRNA can be identified by probing northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line.

[0110] A *Zcytor16*-encoding cDNA can be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using the polymerase chain reaction with primers designed from the representative human *Zcytor16* sequences disclosed herein. In addition, a cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to Zcytor16 polypeptide.

[0111] Those skilled in the art will recognize that the sequence disclosed in SEQ ID NO:1 or SEQ ID NO:37 represents a single allele of human *Zcytor16*, and that allelic variation and alternative splicing are expected to occur. Allelic variants of this sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the nucleotide sequences disclosed herein, including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of the amino acid sequences disclosed herein. cDNA molecules generated from alternatively spliced mRNAs, which retain the properties of the Zcytor16 polypeptide are included within the scope of the present invention, as are polypeptides encoded by such cDNAs and mRNAs. Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals or tissues according to standard procedures known in the art.

[0112] Using the methods discussed above, one of ordinary skill in the art can prepare a variety of polypeptides that comprise a soluble receptor subunit that is substantially homologous to SEQ ID NO:1 or SEQ ID NO:2, SEQ ID NO:13, or SEQ ID NO:37 amino acids 22 to 231 or 28-231 of SEQ ID NO:2, or allelic variants thereof and retain the ligand-binding properties of the wild-type zcytor16 receptor. Such polypeptides may also include additional polypeptide segments as generally disclosed herein.

[0113] Isolated nucleic acid molecules described herein may hybridize under stringent conditions to nucleic acid molecules comprising nucleotide sequences disclosed herein. For example, such nucleic acid molecules can hybridize under stringent conditions to nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO:1, to nucleic acid molecules consisting of the nucleotide sequence of nucleotides 64, 67, 82, or 94 to 693 of SEQ ID NO:1, or to nucleic acid molecules comprising a nucleotide sequence complementary to SEQ ID NO:1 or to nucleotides 64, 67, 82, or 94 to 693 of SEQ ID NO:1, or fragments thereof. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.

[0114] A pair of nucleic acid molecules, such as DNA-DNA, RNA-RNA and DNA-RNA, can hybridize if the nucleotide sequences have some degree of complementarity. Hybrids can tolerate mismatched base pairs in the double helix, but the stability of the hybrid is influenced by the degree of mismatch. The T_m of the mismatched hybrid decreases by 1°C for every 1-1.5% base pair mismatch. Varying the stringency of the hybridization conditions allows control over the degree of mismatch that will be present in the hybrid. The degree of stringency increases as the hybridization temperature increases and the ionic strength of the hybridization buffer decreases. Stringent hybridization conditions encompass temperatures of about 5-25°C below the T_m of the hybrid and a hybridization buffer having up to 1 M Na⁺. Higher degrees of stringency at lower temperatures can be achieved with the addition of formamide which reduces the T_m of the hybrid about 1°C for each 1% formamide in the buffer solution. Generally, such stringent conditions include temperatures of 20-70°C and a hybridization buffer containing up to 6x SSC and 0-50% formamide. A higher degree of stringency can be achieved at temperatures of from 40-70°C with a hybridization buffer having up to 4x SSC and from 0-50% formamide. Highly stringent conditions typically encompass temperatures of 42-70°C with a hybridization buffer having up to 1x SSC and 0-50% formamide. Different degrees of stringency can be used during hybridization and washing to achieve maximum specific binding to the target sequence. Typically, the washes following hybridization are performed at increasing degrees of stringency to remove non-hybridized polynucleotide probes from hybridized complexes.

[0115] The above conditions are meant to serve as a guide and it is well within the abilities of one skilled in the art to adapt these conditions for use with a particular polynucleotide hybrid. The T_m for a specific target sequence is the temperature (under defined conditions) at which 50% of the target sequence will hybridize to a perfectly matched probe sequence. Those conditions which influence the T_m include, the size and base pair content of the polynucleotide probe, the ionic strength of the hybridization solution, and the presence of destabilizing agents in the hybridization solution. Numerous equations for calculating T_m are known in the art, and are specific for DNA, RNA and DNA-RNA hybrids and polynucleotide probe sequences of varying length (see, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition (Cold Spring Harbor Press 1989); Ausubel et al., (eds.), *Current Protocols in Molecular Biology* (John Wiley and Sons, Inc. 1987); Berger and Kimmel (eds.), *Guide to Molecular Cloning Techniques*, (Academic Press, Inc. 1987); and Wetmur, *Crit. Rev. Biochem. Mol. Biol.* 26:227 (1990)). Sequence analysis software such as OLIGO 6.0 (LSR; Long Lake, MN) and *Primer Premier 4.0* (Premier Biosoft International; Palo Alto, CA), as well as sites on the Internet, are available tools for analyzing a given sequence and calculating T_m based on user defined criteria. Such programs can also analyze a given sequence under defined conditions and identify suitable probe sequences. Typically, hybridization of longer polynucleotide sequences, >50 base pairs, is performed at temperatures of about 20-25°C below the calculated T_m . For smaller probes, <50 base pairs, hybridization is typically carried out at the T_m or 5-10°C below. This allows for the maximum rate of hybridization for DNA-DNA and DNA-RNA hybrids.

[0116] The length of the polynucleotide sequence influences the rate and stability of hybrid formation. Smaller probe sequences, <50 base pairs, reach equilibrium with complementary sequences rapidly, but may form less stable hybrids. Incubation times of anywhere from minutes to hours can be used to achieve hybrid formation. Longer probe sequences come to equilibrium more slowly, but form more stable complexes even at lower temperatures. Incubations are allowed to proceed overnight or longer. Generally, incubations are carried out for a period equal to three times the calculated Cot time. Cot time, the time it takes for the polynucleotide sequences to reassociate, can be calculated for a particular sequence by methods known in the art.

[0117] The base pair composition of polynucleotide sequence will effect the thermal stability of the hybrid complex, thereby influencing the choice of hybridization temperature and the ionic strength of the hybridization buffer. A-T pairs are less stable than G-C pairs in aqueous solutions containing sodium chloride. Therefore, the higher the G-C content, the more stable the hybrid. Even distribution of G and C residues within the sequence also contribute positively to hybrid stability. In addition, the base pair composition can be manipulated to alter the T_m of a given sequence. For example, 5-methyldeoxycytidine can be substituted for deoxycytidine and 5-bromodeoxyuridine can be substituted for thymidine to increase the T_m , whereas 7-deaz-2'-deoxyguanosine can be substituted for guanosine to reduce dependence on T_m .

[0118] The ionic concentration of the hybridization buffer also affects the stability of the hybrid. Hybridization buffers generally contain blocking agents such as Denhardt's solution (Sigma Chemical Co., St. Louis, Mo.), denatured salmon sperm DNA, tRNA, milk powders (BLOTTO), heparin or SDS, and a Na⁺ source, such as SSC (1x SSC: 0.15 M sodium chloride, 15 mM sodium citrate) or SSPE (1x SSPE: 1.8 M NaCl, 10 mM NaH₂PO₄, 1 mM EDTA, pH 7.7). Typically, hybridization buffers contain from between 10 mM - 1 M Na⁺. The addition of destabilizing or denaturing agents such as formamide, tetraalkylammonium salts, guanidinium cations or thiocyanate cations to the hybridization solution will alter the T_m of a hybrid. Typically, formamide is used at a concentration of up to 50% to allow incubations to be carried out at more convenient and lower temperatures. Formamide also acts to reduce non-specific background when using RNA probes.

[0119] As an illustration, a nucleic acid molecule encoding a variant Zcytor16 polypeptide can be hybridized with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:37 (or its complement) at 42°C overnight in a solution comprising 50% formamide, 5x SSC, 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution (100x Denhardt's solution: 2% (w/v) Ficoll 400, 2% (w/v) polyvinylpyrrolidone, and 2% (w/v) bovine serum albumin),

10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA. One of skill in the art can devise variations of these hybridization conditions. For example, the hybridization mixture can be incubated at a higher temperature, such as about 65°C, in a solution that does not contain formamide. Moreover, premixed hybridization solutions are available (e.g., EXPRESSHYB Hybridization Solution from CLONTECH Laboratories, Inc.), and hybridization can be performed

5 according to the manufacturer's instructions.
[0120] Following hybridization, the nucleic acid molecules can be washed to remove non-hybridized nucleic acid molecules under stringent conditions, or under highly stringent conditions. Typical stringent washing conditions include washing in a solution of 0.5x - 2x SSC with 0.1% sodium dodecyl sulfate (SDS) at 55 - 65°C. As an illustration, nucleic acid molecules encoding a variant Zcytor16 polypeptide remain hybridized with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under stringent washing conditions, in which the wash stringency is equivalent to 0.5x - 2x SSC with 0.1% SDS at 55 - 65°C, including 0.5x SSC with 0.1% SDS at 55°C, or 2xSSC with 0.1 % SDS at 65°C. One of skill in the art can readily devise equivalent conditions, for example, by substituting SSPE for SSC in the wash solution.

10
[0121] Typical highly stringent washing conditions include washing in a solution of 0.1x - 0.2x SSC with 0.1% sodium dodecyl sulfate (SDS) at 50 - 65°C. For example, nucleic acid molecules encoding a variant Zcytor16 polypeptide remain hybridized with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1x - 0.2x SSC with 0.1% SDS at 50 - 65°C, including 0.1x SSC with 0.1% SDS at 50°C, or 0.2xSSC with 0.1% SDS at 65°C.

15
[0122] The present specification describes isolated Zcytor16 polypeptides that have a substantially similar sequence identity to the polypeptides of SEQ ID NO:2, or their orthologs. The term "substantially similar sequence identity" is used herein to denote polypeptides having at least 70%, at least 80%, at least 90%, at least 95% or greater than 95% sequence identity to the sequences shown in SEQ ID NO:2, or their orthologs.

20
[0123] The present specification describes Zcytor16 variant nucleic acid molecules that can be identified using two criteria: a determination of the similarity between the encoded polypeptide with the amino acid sequence of SEQ ID NO:2, and a hybridization assay, as described above. Such Zcytor16 variants include nucleic acid molecules (1) that remain hybridized with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:37 (or its complement) under stringent washing conditions, in which the wash stringency is equivalent to 0.5x - 2x SSC with 0.1% SDS at 55 - 65°C, and (2) that encode a polypeptide having at least 70%, at least 80%, at least 90%, at least 95% or greater than 95% sequence identity to the amino acid sequence of SEQ ID NO:2. Alternatively, Zcytor16 variants can be characterized as nucleic acid molecules (1) that remain hybridized with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:37 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1x - 0.2x SSC with 0.1% SDS at 50 - 65°C, and (2) that encode a polypeptide having at least 70%, at least 80%, at least 90%, at least 95% or greater than 95% sequence identity to the amino acid sequence of SEQ ID NO:2.

25
[0124] Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48:603 (1986), and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff and Henikoff (*ibid.*) as shown in Table 3 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as: $(\text{[Total number of identical matches]} / \text{[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences]}) \times 100$.

Table 3

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
45	A	4																		
	R	-1	5																	
	N	-2	0	6																
	D	-2	-2	1	6															
50	C	0	-3	-3	-3	9														
	Q	-1	1	0	0	-3	5													
	E	-1	0	0	2	-4	2	5												
	G	0	-2	0	-1	-3	-2	-2	6											
	H	-2	0	1	-1	-3	0	0	-2	8										
55	I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4									
	L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4								
	K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5							

(continued)

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V	
5	M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
	F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
	P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7					
	S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
	T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-2	-1	1	5				
	w	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
10	Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
	V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

[0125] Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of a putative Zcytor16 variant. The FASTA algorithm is described by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85: 2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990). Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., SEQ ID NO:2) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, SIAM J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions. Illustrative parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, Meth. Enzymol. 183:63 (1990).

[0126] FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as described above.

[0127] The present specification describes nucleic acid molecules that encode a polypeptide having a conservative amino acid change, compared with an amino acid sequence disclosed herein. For example, variants can be obtained that contain one or more amino acid substitutions of SEQ ID NO:2, in which an alkyl amino acid is substituted for an alkyl amino acid in a Zcytor16 amino acid sequence, an aromatic amino acid is substituted for an aromatic amino acid in a Zcytor16 amino acid sequence, a sulfur-containing amino acid is substituted for a sulfur-containing amino acid in a Zcytor16 amino acid sequence, a hydroxy-containing amino acid is substituted for a hydroxy-containing amino acid in a Zcytor16 amino acid sequence, an acidic amino acid is substituted for an acidic amino acid in a Zcytor16 amino acid sequence, a basic amino acid is substituted for a basic amino acid in a Zcytor16 amino acid sequence, or a dibasic monocarboxylic amino acid is substituted for a dibasic monocarboxylic amino acid in a Zcytor16 amino acid sequence. Among the common amino acids, for example, a "conservative amino acid substitution" is illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine. The BLOSUM62 table is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, Proc. Nat'l Acad. Sci. USA 89:10915 (1992)). Accordingly, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention. Although it is possible to design amino acid substitutions based solely upon chemical properties (as discussed above), the language "conservative amino acid substitution" preferably refers to a substitution represented by a BLOSUM62 value of greater than -1. For example, an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3. According to this system, preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).

[0128] Particular variants of Zcytor16 are characterized by having at least 70%, at least 80%, at least 90%, at least

95% or greater than 95% sequence identity to the corresponding amino acid sequence (e.g., SEQ ID NO:2), wherein the variation in amino acid sequence is due to one or more conservative amino acid substitutions.

[0129] Conservative amino acid changes in a *Zcytor16* gene can be introduced, for example, by substituting nucleotides for the nucleotides recited in SEQ ID NO:1. Such "conservative amino acid" variants can be obtained by oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like (see Ausubel (1995) at pages 8-10 to 8-22; and McPherson (ed.), *Directed Mutagenesis: A Practical Approach* (IRL Press 1991)). A variant *Zcytor16* polypeptide can be identified by the ability to specifically bind anti-*Zcytor16* antibodies.

[0130] The proteins described herein can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without limitation, trans-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipercolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-dimethylproline, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is typically carried out in a cell-free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See, for example, Robertson et al., *J. Am. Chem. Soc.* 113:2722 (1991), Ellman et al., *Methods Enzymol.* 202:301 (1991), Chung et al., *Science* 259:806 (1993), and Chung et al., *Proc. Nat'l Acad. Sci. USA* 90:10145 (1993).

[0131] In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., *J. Biol. Chem.* 271:19991 (1996)). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide et al., *Biochem.* 33:7470 (1994). Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, *Protein Sci.* 2:395 (1993)).

[0132] A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for *Zcytor16* amino acid residues.

[0133] Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081 (1989), Bass et al., *Proc. Nat'l Acad. Sci. USA* 88:4498 (1991), Coombs and Corey, "Site-Directed Mutagenesis and Protein Engineering," in *Proteins: Analysis and Design*, Angeletti (ed.), pages 259-311 (Academic Press, Inc. 1998)). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., *J. Biol. Chem.* 271:4699 (1996).

[0134] Although sequence analysis can be used to further define the *Zcytor16* ligand binding region, amino acids that play a role in *Zcytor16* binding activity (such as binding of *zcytor16* to ligand IL-TIF, or to an anti-*zcytor16* antibody) can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., *Science* 255:306 (1992), Smith et al., *J. Mol. Biol.* 224:899 (1992), and Wlodaver et al., *FEBS Lett.* 309:59 (1992).

[0135] Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (*Science* 241:53 (1988)) or Bowie and Sauer (*Proc. Nat'l Acad. Sci. USA* 86:2152 (1989)). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., *Biochem.* 30:10832 (1991), Ladner et al., U.S. Patent No. 5,223,409, Huse, international publication No. WO 92/06204, and region-directed mutagenesis (Derbyshire et al., *Gene* 46:145 (1986), and Ner et al., *DNA* 7:127, (1988)). Moreover, *Zcytor16* labeled with biotin or FITC can be used for expression cloning of *Zcytor16* ligands.

[0136] Variants of the disclosed *Zcytor16* nucleotide and polypeptide sequences can also be generated through DNA shuffling as disclosed by Stemmer, *Nature* 370:389 (1994), Stemmer, *Proc. Nat'l Acad. Sci. USA* 91:10747 (1994), and international publication No. WO 97/20078. Briefly, variant DNA molecules are generated by *in vitro* homologous recombination by random fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using a family of parent DNA molecules, such as allelic variants or DNA molecules from different species, to introduce additional variability into the process. Selection or screening for

the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.

[0137] Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells. Mutagenized DNA molecules that encode biologically active polypeptides, or polypeptides that bind with anti-Zcytor16 antibodies, can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

[0138] The present invention also includes "functional fragments" of Zcytor16 polypeptides and nucleic acid molecules encoding such functional fragments, as defined in the claims. Routine deletion analyses of nucleic acid molecules can be performed to obtain functional fragments of a nucleic acid molecule that encodes a Zcytor16 polypeptide. As an illustration, DNA molecules having the nucleotide sequence of SEQ ID NO:1 can be digested with *Bal31* nuclease to obtain a series of nested deletions. The fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for the ability to bind anti-Zcytor16 antibodies. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce deletions or stop codons to specify production of a desired fragment. Alternatively, particular fragments of a *Zcytor16* gene can be synthesized using the polymerase chain reaction.

[0139] This general approach is exemplified by studies on the truncation at either or both termini of interferons have been summarized by Horisberger and Di Marco, *Pharmac. Ther.* 66:507 (1995). Moreover, standard techniques for functional analysis of proteins are described by, for example, Treuter et al., *Molec. Gen. Genet.* 240:113 (1993), Content et al., "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in *Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems*, Cantell (ed.), pages 65-72 (Nijhoff 1987), Herschman, "The EGF Receptor," in *Control of Animal Cell Proliferation*, Vol. 1, Boynton et al., (eds.) pages 169-199 (Academic Press 1985), Coumilleau et al., *J. Biol. Chem.* 270:29270 (1995); Fukunaga et al., *J. Biol. Chem.* 270:25291 (1995); Yamaguchi et al., *Biochem. Pharmacol.* 50:1295 (1995), and Meisel et al., *Plant Molec. Biol.* 30:1 (1996).

[0140] Analysis of the particular sequences disclosed herein provide a set of illustrative functional fragments presented in Table 4. The nucleotides encoding additional human zcytor16 functional variant domains described herein, not shown in Table 4, can be determined with reference to SEQ ID NO:1 or SEQ ID NO:37. Such functional fragments include, for example, the following nucleotide sequences of SEQ ID NO:1: nucleotides 64, 67, 82 or 94 to 690 or 693; nucleotides 64, 67, 82 or 94 to 369 or 381; 394 to 690 or 693; and nucleotides 1 to 690 or 693, and amino acid sequences encoded thereby, e.g., such as those shown in SEQ ID NO:2 respectively.

Table 4

Zcytor16 Feature	Amino acid residues (SEQ ID NO:2)	Nucleotides (SEQ ID NO:1)
First Ig Domain	32-123	94-369
Second Ig Domain	132-230	394-690
Both Ig Domains	32-230	94-690

[0141] The present specification describes functional fragments of a *Zcytor16* gene that have amino acid changes, compared with an amino acid sequence disclosed herein. A variant *Zcytor16* gene can be identified on the basis of structure by determining the level of identity with disclosed nucleotide and amino acid sequences, as discussed above. An alternative approach to identifying a variant gene on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant *Zcytor16* gene can hybridize to a nucleic acid molecule comprising a nucleotide sequence, such as SEQ ID NO:1 or SEQ ID NO:37.

[0142] The present specification describes fragments or peptides comprising an epitope-bearing portion of a Zcytor16 polypeptide described herein. Such fragments or peptides may comprise an "immunogenic epitope," which is a part of a protein that elicits an antibody response when the entire protein is used as an immunogen. Immunogenic epitope-bearing peptides can be identified using standard methods (see, for example, Geysen et al., *Proc. Nat'l Acad. Sci. USA* 81:3998 (1983)).

[0143] In contrast, polypeptide fragments or peptides may comprise an "antigenic epitope," which is a region of a protein molecule to which an antibody can specifically bind. Certain epitopes consist of a linear or contiguous stretch of amino acids, and the antigenicity of such an epitope is not disrupted by denaturing agents. It is known in the art that relatively short synthetic peptides that can mimic epitopes of a protein can be used to stimulate the production of antibodies against the protein (see, for example, Sutcliffe et al., *Science* 219:660 (1983)). Accordingly, antigenic epitope-bearing peptides and polypeptides of the present invention are useful to raise antibodies that bind with the polypeptides

described herein.

[0144] Antigenic epitope-bearing peptides and polypeptides can contain at least four to ten amino acids, at least ten to fifteen amino acids, or about 15 to about 30 amino acids of an amino acid sequence disclosed herein. Such epitope-bearing peptides and polypeptides can be produced by fragmenting a Zcytor16 polypeptide, or by chemical peptide synthesis, as described herein. Moreover, epitopes can be selected by phage display of random peptide libraries (see, for example, Lane and Stephen, *Curr. Opin. Immunol.* 5:268 (1993), and Cortese et al., *Curr. Opin. Biotechnol.* 7:616 (1996)). Standard methods for identifying epitopes and producing antibodies from small peptides that comprise an epitope are described, for example, by Mole, "Epitope Mapping," in *Methods in Molecular Biology*, Vol. 10, Manson (ed.), pages 105-116 (The Humana Press; Inc. 1992), Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies," in *Monoclonal Antibodies: Production, Engineering, and Clinical Application*, Ritter and Ladyman (eds.), pages 60-84 (Cambridge University Press 1995), and Coligan et al. (eds.), *Current Protocols in Immunology*, pages 9.3.1 - 9.3.5 and pages 9.4.1 - 9.4.11 (John Wiley & Sons 1997).

[0145] For any Zcytor16 polypeptide, including variants and fusion proteins, one of ordinary skill in the art can readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 1 and 2 above. Moreover, those of skill in the art can use standard software to devise Zcytor16 variants based upon the nucleotide and amino acid sequences described herein. Accordingly, the present specification describes a computer-readable medium encoded with a data structure that provides at least one of the following sequences: SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO:3. Suitable forms of computer-readable media include magnetic media and optically-readable media. Examples of magnetic media include a hard or fixed drive, a random access memory (RAM) chip, a floppy disk, digital linear tape (DLT), a disk cache, and a ZIP disk. Optically readable media are exemplified by compact discs (e.g., CD-read only memory (ROM), CD-rewritable (RW), and CD-recordable), and digital versatile/video discs (DVD) (e.g., DVD-ROM, DVD-RAM, and DVD+RW).

6. Production of Zcytor16 Polypeptides

[0146] The polypeptides described herein, including full-length polypeptides; soluble monomeric, homodimeric, heterodimeric and multimeric receptors; full-length receptors; receptor fragments (e.g. ligand-binding fragments), functional fragments, and fusion proteins, can be produced in recombinant host cells following conventional techniques. To express a Zcytor16 gene, a nucleic acid molecule encoding the polypeptide must be operably linked to regulatory sequences that control transcriptional expression in an expression vector and then, introduced into a host cell. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene which is suitable for selection of cells that carry the expression vector.

[0147] Expression vectors that are suitable for production of a foreign protein in eukaryotic cells typically contain (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance marker to provide for the growth and selection of the expression vector in a bacterial host; (2) eukaryotic DNA elements that control initiation of transcription, such as a promoter; and (3) DNA elements that control the processing of transcripts, such as a transcription termination/polyadenylation sequence. As discussed above, expression vectors can also include nucleotide sequences encoding a secretory sequence that directs the heterologous polypeptide into the secretory pathway of a host cell. For example, a Zcytor16 expression vector may comprise a Zcytor16 gene and a secretory sequence derived from any secreted gene.

[0148] Zcytor16 proteins of the present invention as defined in the claims may be expressed in mammalian cells. Examples of suitable mammalian host cells include African green monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21, BHK-570; ATCC CRL 8544, ATCC CRL 10314), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61; CHO DG44 (Chasin et al., *Som. Cell. Molec. Genet.* 12:555, 1986)), rat pituitary cells (GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658).

[0149] For a mammalian host, the transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, in which the regulatory signals are associated with a particular gene which has a high level of expression. Suitable transcriptional and translational regulatory sequences also can be obtained from mammalian genes, such as actin, collagen, myosin, and metallothionein genes.

[0150] Transcriptional regulatory sequences include a promoter region sufficient to direct the initiation of RNA synthesis. Suitable eukaryotic promoters include the promoter of the mouse *metallothionein 1* gene (Hamer et al., *J. Molec. Appl. Genet.* 1:273 (1982)), the TK promoter of *Herpes* virus (McKnight, *Cell* 31:355 (1982)), the SV40 early promoter (Benoist et al., *Nature* 290:304 (1981)), the Rous sarcoma virus promoter (Gorman et al., *Proc. Nat'l Acad. Sci. USA* 79:6777 (1982)), the cytomegalovirus promoter (Foecking et al., *Gene* 45:101 (1980)), and the mouse mammary tumor virus promoter (see, generally, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163-181 (John Wiley & Sons, Inc. 1996)).

[0151] Alternatively, a prokaryotic promoter, such as the bacteriophage T3 RNA polymerase promoter, can be used to control *Zcytor16* gene expression in mammalian cells if the prokaryotic promoter is regulated by a eukaryotic promoter (Zhou et al., Mol. Cell. Biol. 10:4529 (1990), and Kaufman et al., Nucl. Acids Res. 19:4485 (1991)).

5 [0152] In certain embodiments, a DNA sequence encoding a *Zcytor16* monomeric or homodimeric soluble receptor polypeptide, or a DNA sequence encoding an additional subunit of a heterodimeric or multimeric *Zcytor16* soluble receptor, e.g., CRF2-4 or IL10R, polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the
10 exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers. Multiple components of a soluble receptor complex can be co-transfected on individual expression vectors or be contained in a single expression vector. Such techniques of expressing multiple components of protein complexes are well known in the art.

15 [0153] An expression vector can be introduced into host cells using a variety of standard techniques including calcium phosphate transfection, liposome-mediated transfection, microprojectile-mediated delivery, electroporation, and the like. The transfected cells can be selected and propagated to provide recombinant host cells that comprise the expression vector stably integrated in the host cell genome. Techniques for introducing vectors into eukaryotic cells and techniques for selecting such stable transformants using a dominant selectable marker are described, for example, by Ausubel
20 (1995) and by Murray (ed.), Gene Transfer and Expression Protocols (Humana Press 1991).

[0154] For example, one suitable selectable marker is a gene that provides resistance to the antibiotic neomycin. In this case, selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then
25 increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A suitable amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g., hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used. Alternatively, markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from
30 untransfected cells by such means as FACS sorting or magnetic bead separation technology.

[0155] *Zcytor16* polypeptides can also be produced by cultured mammalian cells using a viral delivery system. Exemplary viruses for this purpose include adenovirus, retroviruses, herpesvirus, vaccinia virus and adeno-associated virus (AAV). Adenovirus, a double-stranded DNA virus, is currently the best studied gene transfer vector for delivery of
35 heterologous nucleic acid (for a review, see Becker et al., Meth. Cell Biol. 43:161 (1994), and Douglas and Curiel, Science & Medicine 4:44 (1997)). Advantages of the adenovirus system include the accommodation of relatively large DNA inserts, the ability to grow to high-titer, the ability to infect a broad range of mammalian cell types, and flexibility that allows use with a large number of available vectors containing different promoters.

[0156] By deleting portions of the adenovirus genome, larger inserts (up to 7 kb) of heterologous DNA can be accommodated. These inserts can be incorporated into the viral DNA by direct ligation or by homologous recombination with
40 a co-transfected plasmid. An option is to delete the essential *E1* gene from the viral vector, which results in the inability to replicate unless the *E1* gene is provided by the host cell. Adenovirus vector-infected human 293 cells (ATCC Nos. CRL-1573, 45504, 45505), for example, can be grown as adherent cells or in suspension culture at relatively high cell density to produce significant amounts of protein (see Garnier et al., Cytotechnol. 15:145 (1994)).

[0157] *Zcytor16* can also be expressed in other higher eukaryotic cells, such as avian, fungal, insect, yeast, or plant
45 cells. The baculovirus system provides an efficient means to introduce cloned *Zcytor16* genes into insect cells. Suitable expression vectors are based upon the *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV), and contain well-known promoters such as *Drosophila heat shock protein (hsp) 70* promoter, *Autographa californica nuclear polyhedrosis virus immediate-early* gene promoter (*ie-1*) and the *delayed early 39K* promoter, baculovirus *p10* promoter, and the *Drosophila metallothionein* promoter. A second method of making recombinant baculovirus utilizes a transposon-based system described by Luckow (Luckow, et al., J. Virol. 67:4566 (1993)). This system, which utilizes transfer vectors,
50 is sold in the BAC-to-BAC kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector, PFASTBAC (Life Technologies) containing a Tn7 transposon to move the DNA encoding the *Zcytor16* polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." See, Hill-Perkins and Possee, J. Gen. Virol. 71:971 (1990), Bonning, et al., J. Gen. Virol. 75:1551 (1994), and Chazenbalk, and Rapoport, J. Biol. Chem. 270:1543 (1995).
55 In addition, transfer vectors can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed *Zcytor16* polypeptide, for example, a Glu-Glu epitope tag (Grussenmeyer et al., Proc. Nat'l Acad. Sci. 82:7952 (1985)). Using a technique known in the art, a transfer vector containing a *Zcytor16* gene is transformed into *E. coli*, and screened for bacmids which contain an interrupted *lacZ* gene indicative of recombinant baculovirus. The

bacmid DNA containing the recombinant baculovirus genome is then isolated using common techniques.

[0158] The illustrative PFASTBAC vector can be modified to a considerable degree. For example, the polyhedrin promoter can be removed and substituted with the baculovirus basic protein promoter (also known as *Pcor*, p6.9 or MP promoter) which is expressed earlier in the baculovirus infection, and has been shown to be advantageous for expressing secreted proteins (see, for example, Hill-Perkins and Possee, *J. Gen. Virol.* 71:971 (1990), Bonning, et al., *J. Gen. Virol.* 75:1551 (1994), and Chazenbalk and Rapoport, *J. Biol. Chem.* 270:1543 (1995). In such transfer vector constructs, a short or long version of the basic protein promoter can be used. Moreover, transfer vectors can be constructed which replace the native Zcytor16 secretory signal sequences with secretory signal sequences derived from insect proteins. For example, a secretory signal sequence from Ecdysteroid Glucosyltransferase (EGT), honey bee Melittin (Invitrogen Corporation; Carlsbad, CA), or baculovirus gp67 (PharMingen; San Diego, CA) can be used in constructs to replace the native Zcytor16 secretory signal sequence.

[0159] The recombinant virus or bacmid is used to transfect host cells. Suitable insect host cells include cell lines derived from IPLB-*Sf*-21, a *Spodoptera frugiperda* pupal ovarian cell line, such as *SJ9* (ATCC CRL 1711), *Sf21AE*, and *Sf21* (Invitrogen Corporation; San Diego, CA), as well as *Drosophila* Schneider-2 cells, and the HIGH FIVEO cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent No. 5,300,435). Commercially available serum-free media can be used to grow and to maintain the cells. Suitable media are Sf900 II™ (Life Technologies) or ESF 921™ (Expression Systems) for the Sf9 cells; and Ex-cello405™ (JRH Biosciences, Lenexa, KS) or Express FiveO™ (Life Technologies) for the *T. ni* cells. When recombinant virus is used, the cells are typically grown up from an inoculation density of approximately $2\text{-}5 \times 10^5$ cells to a density of $1\text{-}2 \times 10^6$ cells at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3.

[0160] Established techniques for producing recombinant proteins in baculovirus systems are provided by Bailey et al., "Manipulation of Baculovirus Vectors," in *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols*, Murray (ed.), pages 147-168 (The Humana Press, Inc. 1991), by Patel et al., "The baculovirus expression system," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), pages 205-244 (Oxford University Press 1995), by Ausubel (1995) at pages 16-37 to 16-57, by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995), and by Lucknow, "Insect Cell Expression Technology," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 183-218 (John Wiley & Sons, Inc. 1996).

[0161] Fungal cells, including yeast cells, can also be used to express the genes described herein. Yeast species of particular interest in this regard include *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*. Suitable promoters for expression in yeast include promoters from *GAL1* (galactose), *PGK* (phosphoglycerate kinase), *ADH* (alcohol dehydrogenase), *AOX1* (alcohol oxidase), *HIS4* (histidinol dehydrogenase), and the like. Many yeast cloning vectors have been designed and are readily available. These vectors include YIp-based vectors, such as YIp5, YRp vectors, such as YRp17, YEp vectors such as YEpl3 and YCp vectors, such as YCp19. Methods for transforming *S. cerevisiae* cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311, Kawasaki et al., U.S. Patent No. 4,931,373, Brake, U.S. Patent No. 4,870,008, Welch et al., U.S. Patent No. 5,037,743, and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A suitable vector system for use in *Saccharomyces cerevisiae* is the *POT1* vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Additional suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311, Kingsman et al., U.S. Patent No. 4,615,974, and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446, 5,063,154, 5,139,936, and 4,661,454.

[0162] Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., *J. Gen. Microbiol.* 132:3459 (1986), and Cregg, U.S. Patent No. 4,882,279. *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

[0163] For example, the use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed by Raymond, U.S. Patent No. 5,716,808, Raymond, U.S. Patent No. 5,736,383, Raymond et al., *Yeast* 14:11-23 (1998), and in international publication Nos. WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, the promoter and terminator in the plasmid can be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilization gene (*AUG1* or *AUG2*). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A suitable selectable marker for use

in *Pichia methanolica* is a *P. methanolica ADE2* gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), and which allows *ade2* host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, host cells can be used in which both methanol utilization genes (*AUG1* and *AUG2*) are deleted. For production of secreted proteins, host cells can be deficient in vacuolar protease genes (*PEP4* and *PRB1*). Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. *P. methanolica* cells can be transformed by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

[0164] Expression vectors can also be introduced into plant protoplasts, intact plant tissues, or isolated plant cells. Methods for introducing expression vectors into plant tissue include the direct infection or co-cultivation of plant tissue with *Agrobacterium tumefaciens*, microprojectile-mediated delivery, DNA injection, electroporation, and the like. See, for example, Horsch et al., *Science* 227:1229 (1985), Klein et al., *Biotechnology* 10:268 (1992), and Miki et al., "Procedures for Introducing Foreign DNA into Plants," in *Methods in Plant Molecular Biology and Biotechnology*, Glick et al. (eds.), pages 67-88 (CRC Press, 1993).

[0165] Alternatively, *Zcytor16* genes can be expressed in prokaryotic host cells. Suitable promoters that can be used to express *Zcytor16* polypeptides in a prokaryotic host are well-known to those of skill in the art and include promoters capable of recognizing the T4, T3, Sp6 and T7 polymerases, the P_R and P_L promoters of bacteriophage lambda, the *trp*, *recA*, heat shock, *lacUV5*, *tac*, *lpp-lacSpr*, *phoA*, and *lacZ* promoters of *E. coli*, promoters of *B. subtilis*, the promoters of the bacteriophages of *Bacillus*, *Streptomyces* promoters, the *int* promoter of bacteriophage lambda, the *bla* promoter of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene. Prokaryotic promoters have been reviewed by Glick, *J. Ind. Microbiol.* 1:277 (1987), Watson et al., *Molecular Biology of the Gene*, 4th Ed. (Benjamin Cummins 1987), and by Ausubel et al. (1995).

[0166] Suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Suitable strains of *E. coli* include BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, DH1, DH4I, DH5, DH5I, DH5IF', DH5IMCR, DH10B, DH10B/p3, DH11S, C600, HB101, JM101, JM105, JM109, JM110, K38, RR1, Y1088, Y1089, CSH18, ER1451, and ER1647 (see, for example, Brown (ed.), *Molecular Biology Labfax* (Academic Press 1991)). Suitable strains of *Bacillus subtilis* include BR151, YB886, MI119, MI120, and B170 (see, for example, Hardy, "Bacillus Cloning Methods," in *DNA Cloning: A Practical Approach*, Glover (ed.) (IRL Press 1985)).

[0167] When expressing a *Zcytor16* polypeptide in bacteria such as *E. coli*, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.

[0168] Methods for expressing proteins in prokaryotic hosts are well-known to those of skill in the art (see, for example, Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), page 15 (Oxford University Press 1995), Ward et al., "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, page 137 (Wiley-Liss, Inc. 1995), and Georgiou, "Expression of Proteins in Bacteria," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), page 101 (John Wiley & Sons, Inc. 1996)).

[0169] Standard methods for introducing expression vectors into bacterial, yeast, insect, and plant cells are provided, for example, by Ausubel (1995).

[0170] General methods for expressing and recovering foreign protein produced by a mammalian cell system are provided by, for example, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163 (Wiley-Liss, Inc. 1996). Standard techniques for recovering protein produced by a bacterial system is provided by, for example, Grisshammer et al., "Purification of over-produced proteins from *E. coli* cells," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), pages 59-92 (Oxford University Press 1995). Established methods for isolating recombinant proteins from a baculovirus system are described by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995).

[0171] As an alternative, polypeptides of the present invention can be synthesized by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. These synthesis methods are well-known to those of skill in the art (see, for example, Merrifield, *J. Am. Chem. Soc.* 85:2149 (1963), Stewart et al., "Solid Phase Peptide Synthesis" (2nd Edition), (Pierce Chemical Co. 1984), Bayer and Rapp, *Chem. Pept. Prot.* 3:3 (1986), Atherton et al., *Solid Phase Peptide Synthesis: A Practical Approach* (IRL Press 1989), Fields and Colowick, "Solid-Phase Peptide Synthesis," *Methods in Enzymology* Volume 289 (Academic Press 1997), and Lloyd-Williams et al., *Chemical Approaches to the Synthesis of Peptides and Proteins* (CRC Press, Inc. 1997)). Variations in total chemical

synthesis strategies, such as "native chemical ligation" and "expressed protein ligation" are also standard (see, for example, Dawson et al., *Science* 266:776 (1994), Hackeng et al., *Proc. Nat'l Acad. Sci. USA* 94:7845 (1997), Dawson, *Methods Enzymol.* 287: 34 (1997), Muir et al, *Proc. Nat'l Acad. Sci. USA* 95:6705 (1998), and Severinov and Muir, *J. Biol. Chem.* 273:16205 (1998)).

[0172] Peptides and polypeptides described herein comprise at least six, at least nine, or at least 15 contiguous amino acid residues of SEQ ID NO:2. As an illustration, polypeptides can comprise at least six, at least nine, or at least 15 contiguous amino acid residues of any of the following amino acid sequences of SEQ ID NO:2: amino acid residues amino acid residues 22 to 230 or 231, amino acid residues 23 to 230 or 231, amino acid residues 28 to 230 or 231, or amino acids 32 to to 230 or 231; amino acid residues 22, 23, 28 or 32 to 127; amino acid residues 22, 23, 28 or 32 to 123, and amino acid residues 132 to 230 or 231. The polypeptides may comprise 20, 30, 40, 50, 100, or more contiguous residues of these amino acid sequences. Nucleic acid molecules encoding such peptides and polypeptides are useful as polymerase chain reaction primers and probes.

[0173] Moreover, zcytor16 polypeptides can be expressed as monomers, homodimers, heterodimers, or multimers within higher eukaryotic cells. Such cells can be used to produce zcytor16 monomeric, homodimeric, heterodimeric and multimeric receptor polypeptides that comprise at least one zcytor16 polypeptide ("zcytor16-comprising receptors" or "zcytor16-comprising receptor polypeptides"), or can be used A as assay cells in screening systems. A polypeptide of the present invention comprising the zcytor16 extracellular domain may be produced by a cultured cell, and the cell is used to screen for ligands for the receptor, including the natural ligand, IL-TIF, as well as agonists and antagonists of the natural ligand. To summarize this approach, a cDNA or gene encoding the receptor is combined with other genetic elements required for its expression (e.g., a transcription promoter), and the resulting expression vector is inserted into a host cell. Cells that express the DNA and produce functional receptor are selected and used within a variety of screening systems. Each component of the monomeric, homodimeric, heterodimeric and multimeric receptor complex can be expressed in the same cell. Moreover, the components of the monomeric, homodimeric, heterodimeric and multimeric receptor complex can also be fused to a transmembrane domain or other membrane fusion moiety to allow complex assembly and screening of transfectants as described above.

[0174] Mammalian cells suitable for use in expressing Zcytor16 receptors and transducing a receptor-mediated signal include cells that express other receptor subunits that may form a functional complex with Zcytor16. These subunits may include those of the interferon receptor family or nf other class II nr class I cytokine receptors, e.g., CRF2-4 (Genbank Accession No. Z17227), IL-10R (Genbank Accession No.s U00672 and NM_001558), zcytor11 (US Patent No. 5,965,704), zcytor7 (US Patent No. 5,945,511), and IL-9R. It is also preferred to use a cell from the same species as the receptor to be expressed. Within a preferred embodiment, the cell is dependent upon an exogenously supplied hematopoietic growth factor for its proliferation. Preferred cell lines of this type are the human TF-1 cell line (ATCC number CRL-2003) and the AML-193 cell line (ATCC number CRL-9589), which are GM-CSF-dependent human leukemic cell lines and BaF3 (Palacios and Steinmetz, *Cell* 41: 727-734, (1985)) which is an IL-3 dependent murine pre-B cell line. Other cell lines include BHK, COS-1 and CHO cells.

[0175] Suitable host cells can be engineered to produce the necessary receptor subunits or other cellular component needed for the desired cellular response. This approach is advantageous because cell lines can be engineered to express receptor subunits from any species, thereby overcoming potential limitations arising from species specificity. Species orthologs of the human receptor cDNA can be cloned and used within cell lines from the same species, such as a mouse cDNA in the BaF3 cell line. Cell lines that are dependent upon one hematopoietic growth factor, such as GM-CSF or IL-3, can thus be engineered to become dependent upon another cytokine that acts through the zcytor16 receptor, such as IL-TIF.

[0176] Cells expressing functional receptor are used within screening assays. A variety of suitable assays are known in the art. These assays are based on the detection of a biological response in a target cell. One such assay is a cell proliferation assay. Cells are cultured in the presence or absence of a test compound, and cell proliferation is detected by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic breakdown of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Mosman, *J. Immunol. Meth.* 65: 55-63, (1983)). An alternative assay format uses cells that are further engineered to express a reporter gene. The reporter gene is linked to a promoter element that is responsive to the receptor-linked pathway, and the assay detects activation of transcription of the reporter gene. A preferred promoter element in this regard is a serum response element, or SRE. See, e.g., Shaw et al., *Cell* 56:563-572, (1989). A preferred such reporter gene is a luciferase gene (de Wet et al., *Mol. Cell. Biol.* 7:725, (1987)). Expression of the luciferase gene is detected by luminescence using methods known in the art (e.g., Baumgartner et al., *J. Biol. Chem.* 269:29094-29101, (1994); Schenborn and Goiffin, *Promega_Notes* 41:11, 1993). Luciferase activity assay kits are commercially available from, for example, Promega Corp., Madison, WI. Target cell lines of this type can be used to screen libraries of chemicals, cell-conditioned culture media, fungal broths, soil samples, water samples, and the like. For example, a bank of cell-conditioned media samples can be assayed on a target cell to identify cells that produce ligand. Positive cells are then used to produce a cDNA library in a mammalian expression vector, which is divided into pools, transfected into host cells, and expressed. Media samples from the transfected cells are then assayed,

with subsequent division of pools, re-transfection, subculturing, and re-assay of positive cells to isolate a cloned cDNA encoding the ligand.

[0177] A natural ligand for the Zcytor16 receptor can also be identified by mutagenizing a cell line expressing the full-length receptor or receptor fusion (e.g., comprising the zcytor16 extracellular domain fused to the transmembrane and signaling domain of another cytokine receptor) and culturing it under conditions that select for autocrine growth. See WIPO publication WO 95/21930. Within a typical procedure, IL-3 dependent BaF3 cells expressing Zcytor16 and the necessary additional subunits are mutagenized, such as with 2-ethylmethanesulfonate (EMS). The cells are then allowed to recover in the presence of IL-3, then transferred to a culture medium lacking IL-3 and IL-4. Surviving cells are screened for the production of a zcytor16 ligand (e.g., IL-TIF), such as by adding soluble receptor to the culture medium or by assaying conditioned media on wild-type BaF3 cells and BaF3 cells expressing the receptor. Using this method, cells and tissues expressing IL-TIF can be identified.

[0178] Moreover several IL-TIF responsive cell lines are known (Dumontier et al., J. Immunol. 164:1814-1819, 2000; Dumoutier, L. et al., Proc. Nat'l. Acad. Sci. 97:10144-10149, 2000; Xie MH et al., J. Biol. Chem. 275: 31335-31339, 2000; Kotenko SV et al., JBC in press), as well as those that express the IL-TIF receptor subunit zcytor11. For example, the following cells are responsive to IL-TIF: TK-10 (Xie MH et al., *supra.*) (human renal carcinoma); SW480 (ATCC No. CCL-228) (human colon adenocarcinoma); HepG2 (ATCC No. HB-8065) (human hepatoma); PC12 (ATCC No. CRL-1721) (murine neuronal cell model; rat pheochromocytoma); and MES13 (ATCC No. CRL-1927) (murine kidney mesangial cell line). In addition, some cell lines express zcytor11 (IL-TIF receptor) are also candidates for responsive cell lines to IL-TIF: A549 (ATCC No. CCL-185) (human lung carcinoma); G-361 (ATCC No. CRL-1424) (human melanoma); and Caki-1 (ATCC No. HTB-46) (human renal carcinoma). These cells can be used in assays to assess the functionality of zcytor16 as an IL-TIF antagonist or anti-inflammatory factor.

[0179] An additional screening approach includes the use of hybrid receptor polypeptides. These hybrid polypeptides fall into two general classes. Within the first class, the intracellular domain of Zcytor16, is joined to the ligand-binding domain of a second receptor. It is preferred that the second receptor be a hematopoietic cytokine receptor, such as mpl receptor (Souyri et al., Cell 63: 1137-1147, (1990). The hybrid receptor will further comprise a transmembrane domain, which may be derived from either receptor. A DNA construct encoding the hybrid receptor is then inserted into a host cell. Cells expressing the hybrid receptor are cultured in the presence of a ligand for the binding domain (e.g., TPO in the case the mpl receptor extracellular domain is used) and assayed for a response. This system provides a means for analyzing signal transduction mediated by Zcytor16 while using readily available ligands. This system can also be used to determine if particular cell lines are capable of responding to signals transduced by Zcytor16 monomeric, homodimeric, heterodimeric and multimeric receptors of the present invention.

[0180] A second class of hybrid receptor polypeptides comprise the extracellular (ligand-binding) domain of Zcytor16 (approximately residues 23 to 231 of SEQ ID NO:2; SEQ ID NO:13) with an intracellular domain of a second receptor, preferably a hematopoietic cytokine receptor, and a transmembrane domain. Hybrid zacytor11 monomers, homodimers, heterodimers and multimers of this second class are expressed in cells known to be capable of responding to signals transduced by the second receptor. Together, these two classes of hybrid receptors enable the identification of a responsive cell type for the development of an assay for detecting IL-TIF. Moreover, such cells can be used in the presence of IL-TIF to assay the soluble receptor antagonists of the present invention in a competition-type assay. In such assay, a decrease in the proliferation or signal transduction activity of IL-TIF in the presence of a soluble receptor of the present invention demonstrates antagonistic activity. Moreover IL-TIF-soluble receptor binding assays can also be used to assess whether a soluble receptor antagonizes IL-TIF activity.

7. Production of Zcytor16 Fusion Proteins and Conjugates

[0181] One general class of Zcytor16 analogs are variants having an amino acid sequence that is a mutation of the amino acid sequence disclosed herein. Another general class of Zcytor16 analogs is provided by anti-idiotypic antibodies, and fragments thereof, as described below. Moreover, recombinant antibodies comprising anti-idiotypic variable domains can be used as analogs (see, for example, Monfardini et al., Proc. Assoc. Am. Physicians 108:420 (1996)). Since the variable domains of anti-idiotypic Zcytor16 antibodies mimic Zcytor16, these domains can provide Zcytor16 binding activity. Methods of producing anti-idiotypic catalytic antibodies are known to those of skill in the art (see, for example, Joron et al., Ann. N Y Acad. Sci. 672:216 (1992), Friboulet et al., Appl. Biochem. Biotechnol. 47:229 (1994), and Avalle et al., Ann. N Y Acad. Sci. 864:118 (1998)).

[0182] Another approach to identifying Zcytor16 analogs is provided by the use of combinatorial libraries. Methods for constructing and screening phage display and other combinatorial libraries are provided, for example, by Kay et al., Phage Display of Peptides and Proteins (Academic Press 1996), Verdine, U.S. Patent No. 5,783,384, Kay, *et. al.*, U.S. Patent No. 5,747,334, and Kauffman *et al.*, U.S. Patent No. 5,723,323.

[0183] Zcytor16 polypeptides have both *in vivo* and *in vitro* uses. As an illustration, a soluble form of Zcytor16 can be added to cell culture medium to inhibit the effects of the Zcytor16 ligand produced by the cultured cells.

[0184] Fusion proteins of Zcytor16 can be used to express *Zcytor16* in a recombinant host, and to isolate the produced Zcytor16. As described below, particular Zcytor16 fusion proteins also have uses in diagnosis and therapy. One type of fusion protein comprises a peptide that guides a Zcytor16 polypeptide from a recombinant host cell. To direct a Zcytor16 polypeptide into the secretory pathway of a eukaryotic host cell, a secretory signal sequence (also known as a signal peptide, a leader sequence, prepro sequence or pre sequence) is provided in the *Zcytor16* expression vector. While the secretory signal sequence may be derived from Zcytor16, a suitable signal sequence may also be derived from another secreted protein or synthesized *de novo*. The secretory signal sequence is operably linked to a *Zcytor16*-encoding sequence such that the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the nucleotide sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the nucleotide sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

[0185] Although the secretory signal sequence of Zcytor16 or another protein produced by mammalian cells (e.g., tissue-type plasminogen activator signal sequence, as described, for example, in U.S. Patent No. 5,641,655) is useful for expression of Zcytor16 in recombinant mammalian hosts, a yeast signal sequence is preferred for expression in yeast cells. Examples of suitable yeast signal sequences are those derived from yeast mating pheromone α -factor (encoded by the *MF α 1* gene), invertase (encoded by the *SUC2* gene), or acid phosphatase (encoded by the *PHO5* gene). See, for example, Romanos et al., "Expression of Cloned Genes in Yeast," in *DNA Cloning 2: A Practical Approach*, 2nd Edition, Glover and Hames (eds.), pages 123-167 (Oxford University Press 1995).

[0186] Zcytor16 monomeric, homodimeric, heterodimeric and multimeric receptor polypeptides can be prepared by expressing a truncated DNA encoding the extracellular domain, for example, a polypeptide which contains SEQ ID NO:13, amino acids 22-210 of SEQ ID NO:2, or the corresponding region of a non-human receptor. It is preferred that the extracellular domain polypeptides be prepared in a form substantially free of transmembrane and intracellular polypeptide segments. To direct the export of the receptor domain from the host cell, the receptor DNA is linked to a second DNA segment encoding a secretory peptide, such as a t-PA secretory peptide. To facilitate purification of the secreted receptor domain, a C-terminal extension, such as a poly-histidine tag, substance P, Flag™ peptide (Hopp et al., *Bio-technology* 6:1204-1210, (1988); available from Eastman Kodak Co., New Haven, CT) or another polypeptide or protein for which an antibody or other specific binding agent is available, can be fused to the receptor polypeptide. Moreover, heterodimeric and multimeric non-zcytor16 subunit extracellular cytokine binding domains are also prepared as above.

[0187] In an alternative approach, a receptor extracellular domain of zcytor16 or other class I or II cytokine receptor component can be expressed as a fusion with immunoglobulin heavy chain constant regions, typically an F_c fragment, which contains two constant region domains and a hinge region but lacks the variable region (See, Sledziewski, AZ et al., US Patent No. 6,018,026 and 5,750,375). The soluble zcytor16, soluble zcytor16/CRF2-4 heterodimers, and monomeric, homodimeric, heterodimeric and multimeric polypeptides defined in the claims include such fusions. Such fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two receptor polypeptides are arrayed in closed proximity to each other. Fusions of this type can be used to affinity purify the cognate ligand from solution, as an *in vitro* assay tool, to block signals *in vitro* by specifically titrating out ligand, and as antagonists *in vivo* by administering them parenterally to bind circulating ligand and clear it from the circulation. To purify ligand, a Zcytor16-Ig chimera is added to a sample containing the ligand (e.g., cell-conditioned culture media or tissue extracts) under conditions that facilitate receptor-ligand binding (typically near-physiological temperature, pH, and ionic strength). The chimera-ligand complex is then separated by the mixture using protein A, which is immobilized on a solid support (e.g., insoluble resin beads). The ligand is then eluted using conventional chemical techniques, such as with a salt or pH gradient. In the alternative, the chimera itself can be bound to a solid support, with binding and elution carried out as above. The chimeras may be used *in vivo* to regulate inflammatory responses including acute phase responses such as serum amyloid A (SAA), C-reactive protein (CRP), and the like. Chimeras with high binding affinity are administered parenterally (e.g., by intramuscular, subcutaneous or intravenous injection). Circulating molecules bind ligand and are cleared from circulation by normal physiological processes. For use in assays, the chimeras are bound to a support via the F_c region and used in an ELISA format.

[0188] The present specification describes a variety of other polypeptide fusions and related multimeric proteins comprising one or more polypeptide fusions. For example, a soluble zcytor16 receptor or soluble zcytor16 heterodimeric polypeptide, such as soluble zcytor16/CRF2-4, can be prepared as a fusion to a dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Preferred dimerizing proteins in this regard include immunoglobulin constant region domains, e.g., IgG₁, and the human κ light chain. Immunoglobulin-soluble zcytor16 receptor or immunoglobulin-soluble zcytor16 heterodimeric or multimeric polypeptide, such as immunoglobulin-soluble zcytor16/CRF2-4 fusions can be expressed in genetically engineered cells to produce a variety of multimeric zcytor16 receptor analogs. Auxiliary domains can be fused to soluble zcytor16 receptor or soluble zcytor16 heterodimeric or multimeric polypeptides, such as soluble zcytor16/CRF2-4 to target them to specific cells, tissues, or macromolecules (e.g., collagen, or cells expressing the zcytor16 ligand, IL-TIF). A zcytor16 polypeptide can be fused to two or more moieties, such as an affinity tag for

purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., *Connective Tissue Research* 34:1-9, 1996.

[0189] In bacterial cells, it is often desirable to express a heterologous protein as a fusion protein to decrease toxicity, increase stability, and to enhance recovery of the expressed protein. For example, *Zcytor16* can be expressed as a fusion protein comprising a glutathione S-transferase polypeptide. Glutathione S-transferase fusion proteins are typically soluble, and easily purifiable from *E. coli* lysates on immobilized glutathione columns. In similar approaches, a *Zcytor16* fusion protein comprising a maltose binding protein polypeptide can be isolated with an amylose resin column, while a fusion protein comprising the C-terminal end of a truncated Protein A gene can be purified using IgG-Sepharose. Established techniques for expressing a heterologous polypeptide as a fusion protein in a bacterial cell are described, for example, by Williams et al., "Expression of Foreign Proteins in *E. coli* Using Plasmid Vectors and Purification of Specific Polyclonal Antibodies," in *DNA Cloning 2: A Practical Approach*, 2nd Edition, Glover and Hames (Eds.), pages 15-58 (Oxford University Press 1995). In addition, commercially available expression systems are available. For example, the PINPOINT Xa protein purification system (Promega Corporation; Madison, WI) provides a method for isolating a fusion protein comprising a polypeptide that becomes biotinylated during expression with a resin that comprises avidin.

[0190] Peptide tags that are useful for isolating heterologous polypeptides expressed by either prokaryotic or eukaryotic cells include polyHistidine tags (which have an affinity for nickel-chelating resin), c-myc tags, calmodulin binding protein (isolated with calmodulin affinity chromatography), substance P, the RYIRS tag (which binds with anti-RYIRS antibodies), the Glu-Glu tag, and the FLAG tag (which binds with anti-FLAG antibodies). See, for example, Luo et al., *Arch. Biochem. Biophys.* 329:215 (1996), Morganti et al., *Biotechnol. Appl. Biochem.* 23:67 (1996), and Zheng et al., *Gene* 186:55 (1997). Nucleic acid molecules encoding such peptide tags are available, for example, from Sigma-Aldrich Corporation (St. Louis, MO).

[0191] The present specification describes the use of the secretory signal sequence contained in the *Zcytor16* polypeptides of the present invention to direct other polypeptides into the secretory pathway. A signal fusion polypeptide can be made wherein a secretory signal sequence derived from amino acid residues 1 to 21, or 1 to 22, of SEQ ID NO:2 is operably linked to another polypeptide using methods known in the art and disclosed herein. The secretory signal sequence contained in the fusion polypeptides of the present invention is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway. Such constructs have numerous applications known in the art. For example, these novel secretory signal sequence fusion constructs can direct the secretion of an active component of a normally non-secreted protein, such as a receptor. Such fusions may be used in a transgenic animal or in a cultured recombinant host to direct peptides through the secretory pathway. With regard to the latter, exemplary polypeptides include pharmaceutically active molecules such as Factor VIIa, proinsulin, insulin, follicle stimulating hormone, tissue type plasminogen activator, tumor necrosis factor, interleukins (e.g., interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, and IL-15), colony stimulating factors (e.g., granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF)), interferons (e.g., interferons- α , - β , γ , - ω , - δ , and - τ), the stem cell growth factor designated "S1 factor," erythropoietin, and thrombopoietin. The *Zcytor16* secretory signal sequence contained in the fusion polypeptides is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway. Fusion proteins comprising a *Zcytor16* secretory signal sequence can be constructed using standard techniques.

[0192] Another form of fusion protein comprises a *Zcytor16* polypeptide and an immunoglobulin heavy chain constant region, typically an F_c fragment, which contains two or three constant region domains and a hinge region but lacks the variable region. As an illustration, Chang et al., U.S. Patent No. 5,723,125, describe a fusion protein comprising a human interferon and a human immunoglobulin Fc fragment. The C-terminal of the interferon is linked to the N-terminal of the Fc fragment by a peptide linker moiety. An example of a peptide linker is a peptide comprising primarily a T cell inert sequence, which is immunologically inert. An exemplary peptide linker has the amino acid sequence: GGSGG SGGGG S (SEQ ID NO:4). In this fusion protein, an illustrative Fc moiety is a human γ 4 chain, which is stable in solution and has little or no complement activating activity. Accordingly, the present invention contemplates a *Zcytor16* fusion protein that consists a *Zcytor16* moiety as defined in the claims and a human Fc fragment, wherein the C-terminus of the *Zcytor16* moiety is attached to the N-terminus of the Fc fragment via a peptide linker, such as a peptide consisting of the amino acid sequence of SEQ ID NO:4. The *Zcytor16* moiety can be a *Zcytor16* molecule or a fragment thereof. For example, a fusion protein can comprise amino acid residues 22 to 231, or 28 to 231 of SEQ ID NO:2 and an Fc fragment (e.g., a human Fc fragment).

[0193] In another variation, a *Zcytor16* fusion protein comprises an IgG sequence, a *Zcytor16* moiety covalently joined to the aminoterminal end of the IgG sequence, and a signal peptide that is covalently joined to the aminoterminal of the *Zcytor16* moiety, wherein the IgG sequence consists of the following elements in the following order: a hinge region, a CH₂ domain, and a CH₃ domain. Accordingly, the IgG sequence lacks a CH₁ domain. The *Zcytor16* moiety displays a *Zcytor16* activity, as described herein, such as the ability to bind with a *Zcytor16* ligand. This general approach to producing fusion proteins that comprise both antibody and nonantibody portions has been described by LaRochelle et al., EP 742830 (WO 95/21258).

[0194] Fusion proteins comprising a Zcytor16 moiety and an Fc moiety can be used, for example, as an *in vitro* assay tool. For example, the presence of a Zcytor16 ligand in a biological sample can be detected using a Zcytor16-immunoglobulin fusion protein, in which the Zcytor16 moiety is used to bind the ligand, and a macromolecule, such as Protein A or anti-Fc antibody, is used to bind the fusion protein to a solid support. Such systems can be used to identify agonists and antagonists that interfere with the binding of a Zcytor16 ligand to its receptor.

[0195] Other examples of antibody fusion proteins include polypeptides that comprise an antigen-binding domain and a Zcytor16 fragment that contains a Zcytor16 extracellular domain. Such molecules can be used to target particular tissues for the benefit of Zcytor16 binding activity.

[0196] The present specification describes a variety of other polypeptide fusions. For example, part or all of a domain(s) conferring a biological function can be swapped between Zcytor16 of the present invention with the functionally equivalent domain(s) from another member of the cytokine receptor family. Polypeptide fusions can be expressed in recombinant host cells to produce a variety of Zcytor16 fusion analogs. A Zcytor16 polypeptide can be fused to two or more moieties or domains, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, for example, Tuan et al., *Connective Tissue Research* 34: 1 (1996).

[0197] Fusion proteins can be prepared by methods known to those skilled in the art by preparing each component of the fusion protein and chemically conjugating them. Alternatively, a polynucleotide encoding both components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein. General methods for enzymatic and chemical cleavage of fusion proteins are described, for example, by Ausubel (1995) at pages 16-19 to 16-25.

[0198] Zcytor16 polypeptides can be used to identify and to isolate Zcytor16 ligands. For example, proteins and peptides of the present invention can be immobilized on a column and used to bind ligands from a biological sample that is run over the column (Hermanson et al. (eds.), *Immobilized Affinity Ligand Techniques*, pages 195-202 (Academic Press 1992)). As such, zcytor16 polypeptides of the present invention can be used to identify and isolate IL-TIF for either diagnostic, or production purposes.

[0199] The activity of a Zcytor16 polypeptide can also be observed by a silicon-based biosensor microphysiometer, which measures the extracellular acidification rate or proton excretion associated with receptor binding and subsequent physiologic cellular responses. An exemplary device is the CYTOSENSOR Microphysiometer manufactured by Molecular Devices, Sunnyvale, CA. A variety of cellular responses, such as cell proliferation, ion transport, energy production, inflammatory response, regulatory and receptor activation, and the like, can be measured by this method (see, for example, McConnell et al., *Science* 257:1906 (1992), Pitchford et al., *Meth. Enzymol.* 228:84 (1997), Arimilli et al., *J. Immunol. Meth.* 212:49 (1998), Van Liefde et al., *Eur. J. Pharmacol.* 346:87 (1998)). The microphysiometer can be used for assaying eukaryotic, prokaryotic, adherent, or non-adherent cells. By measuring extracellular acidification changes in cell media over time, the microphysiometer directly measures cellular responses to various stimuli, including agonists, ligands, or antagonists of Zcytor16.

[0200] For example, the microphysiometer is used to measure responses of an Zcytor16-expressing eukaryotic cell, compared to a control eukaryotic cell that does not express Zcytor16 polypeptide. Suitable cells responsive to Zcytor16-modulating stimuli include recombinant host cells comprising a Zcytor16 expression vector, and cells that naturally express Zcytor16. Extracellular acidification provides one measure for a Zcytor16-modulated cellular response. In addition, this approach can be used to identify ligands, agonists, and antagonists of Zcytor16 ligand, IL-TIF. For example, a molecule can be identified as an agonist of Zcytor16 ligand by providing cells that express a Zcytor16 polypeptide, culturing a first portion of the cells in the absence of the test compound, culturing a second portion of the cells in the presence of the test compound, and determining whether the second portion exhibits a cellular response, in comparison with the first portion.

[0201] Alternatively, a solid phase system can be used to identify a Zcytor16 ligand, or an agonist or antagonist of a Zcytor16 ligand. For example, a Zcytor16 polypeptide or Zcytor16 fusion protein, or zcytor16 monomeric, homodimeric, heterodimeric or multimeric soluble receptor can be immobilized onto the surface of a receptor chip of a commercially available biosensor instrument (BIACORE, Biacore AB; Uppsala, Sweden). The use of this instrument is disclosed, for example, by Karlsson, *Immunol. Methods* 145:229 (1991), and Cunningham and Wells, *J. Mol. Biol.* 234:554 (1993).

[0202] In brief, a Zcytor16 polypeptide or fusion protein is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within a flow cell. A test sample is then passed through the cell. If a ligand is present in the sample, it will bind to the immobilized polypeptide or fusion protein, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding. This system can also be used to examine antibody-antigen interactions, and the interactions of other complement/anti-complement pairs.

[0203] Zcytor16 binding domains can be further characterized by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction

with mutation of putative contact site amino acids of Zcytor16 ligand agonists. See, for example, de Vos et al., *Science* 255:306 (1992), Smith et al., *J. Mol. Biol.* 224:899 (1992), and Wlodaver et al., *FEBS Lett.* 309:59 (1992).

[0204] The present specification describes modified Zcytor16 compositions, in which a Zcytor16 polypeptide is linked with a polymer. Illustrative Zcytor16 polypeptides are soluble polypeptides that lack a functional transmembrane domain, such as a polypeptide consisting of amino acid residues 22 to 231, or 28 to 231 of SEQ ID NO:2. Typically, the polymer is water soluble so that the Zcytor16 conjugate does not precipitate in an aqueous environment, such as a physiological environment. An example of a suitable polymer is one that has been modified to have a single reactive group, such as an active ester for acylation, or an aldehyde for alkylation. In this way, the degree of polymerization can be controlled. An example of a reactive aldehyde is polyethylene glycol propionaldehyde, or mono-(C1-C10) alkoxy, or aryloxy derivatives thereof (see, for example, Harris, et al., U.S. Patent No. 5,252,714). The polymer may be branched or unbranched. Moreover, a mixture of polymers can be used to produce Zcytor16 conjugates.

[0205] Zcytor16 conjugates used for therapy can comprise pharmaceutically acceptable water-soluble polymer moieties. Suitable water-soluble polymers include polyethylene glycol (PEG), monomethoxy-PEG, mono-(C1-C10)alkoxy-PEG, aryloxy-PEG, poly-(N-vinyl pyrrolidone)PEG, tresyl monomethoxy PEG, PEG propionaldehyde, bis-succinimidyl carbonate PEG, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, dextran, cellulose, or other carbohydrate-based polymers. Suitable PEG may have a molecular weight from about 600 to about 60,000, including, for example, 5,000, 12,000, 20,000 and 25,000. A Zcytor16 conjugate can also comprise a mixture of such water-soluble polymers.

[0206] One example of a Zcytor16 conjugate comprises a Zcytor16 moiety and a polyalkyl oxide moiety attached to the N-terminus of the Zcytor16 moiety. PEG is one suitable polyalkyl oxide. As an illustration, Zcytor16 can be modified with PEG, a process known as "PEGylation." PEGylation of Zcytor16 can be carried out by any of the PEGylation reactions known in the art (see, for example, EP 0 154 316, Delgado et al., *Critical Reviews in Therapeutic Drug Carrier Systems* 9:249 (1992), Duncan and Spreafico, *Clin. Pharmacokinet.* 27:290 (1994), and Francis et al., *Int J Hematol* 68:1 (1998)). For example, PEGylation can be performed by an acylation reaction or by an alkylation reaction with a reactive polyethylene glycol molecule. In an alternative approach, Zcytor16 conjugates are formed by condensing activated PEG, in which a terminal hydroxy or amino group of PEG has been replaced by an activated linker (see, for example, Karasiewicz et al., U.S. Patent No. 5,382,657).

[0207] PEGylation by acylation typically requires reacting an active ester derivative of PEG with a Zcytor16 polypeptide. An example of an activated PEG ester is PEG esterified to N-hydroxysuccinimide. As used herein, the term "acylation" includes the following types of linkages between Zcytor16 and a water soluble polymer: amide, carbamate, urethane, and the like. Methods for preparing PEGylated Zcytor16 by acylation will typically comprise the steps of (a) reacting a Zcytor16 polypeptide with PEG (such as a reactive ester of an aldehyde derivative of PEG) under conditions whereby one or more PEG groups attach to Zcytor16, and (b) obtaining the reaction product(s). Generally, the optimal reaction conditions for acylation reactions will be determined based upon known parameters and desired results. For example, the larger the ratio of PEG:Zcytor16, the greater the percentage of polyPEGylated Zcytor16 product.

[0208] The product of PEGylation by acylation is typically a polyPEGylated Zcytor16 product, wherein the lysine ϵ -amino groups are PEGylated via an acyl linking group. An example of a connecting linkage is an amide. Typically, the resulting Zcytor16 will be at least 95% mono-, di-, or tri-pegylated, although some species with higher degrees of PEGylation may be formed depending upon the reaction conditions. PEGylated species can be separated from unconjugated Zcytor16 polypeptides using standard purification methods, such as dialysis, ultrafiltration, ion exchange chromatography, affinity chromatography, and the like.

[0209] PEGylation by alkylation generally involves reacting a terminal aldehyde derivative of PEG with Zcytor16 in the presence of a reducing agent. PEG groups can be attached to the polypeptide via a $-\text{CH}_2\text{-NH}$ group.

[0210] Derivatization via reductive alkylation to produce a monoPEGylated product takes advantage of the differential reactivity of different types of primary amino groups available for derivatization. Typically, the reaction is performed at a pH that allows one to take advantage of the pKa differences between the ϵ -amino groups of the lysine residues and the α -amino group of the N-terminal residue of the protein. By such selective derivatization, attachment of a water-soluble polymer that contains a reactive group such as an aldehyde, to a protein is controlled. The conjugation with the polymer occurs predominantly at the N-terminus of the protein without significant modification of other reactive groups such as the lysine side chain amino groups. The present invention provides a substantially homogenous preparation of Zcytor16 monopolymer conjugates.

[0211] Reductive alkylation to produce a substantially homogenous population of monopolymer Zcytor16 conjugate molecule can comprise the steps of: (a) reacting a Zcytor16 polypeptide with a reactive PEG under reductive alkylation conditions at a pH suitable to permit selective modification of the α -amino group at the amino terminus of the Zcytor16, and (b) obtaining the reaction product(s). The reducing agent used for reductive alkylation should be stable in aqueous solution and able to reduce only the Schiff base formed in the initial process of reductive alkylation. Illustrative reducing agents include sodium borohydride, sodium cyanoborohydride, dimethylamine borane, trimethylamine borane, and pyridine borane.

[0212] For a substantially homogenous population of monopolymer Zcytor16 conjugates, the reductive alkylation reaction conditions are those that permit the selective attachment of the water-soluble polymer moiety to the *N*-terminus of Zcytor16. Such reaction conditions generally provide for pKa differences between the lysine amino groups and the α -amino group at the *N*-terminus. The pH also affects the ratio of polymer to protein to be used. In general, if the pH is lower, a larger excess of polymer to protein will be desired because the less reactive the *N*-terminal α -group, the more polymer is needed to achieve optimal conditions. If the pH is higher, the polymer:Zcytor16 need not be as large because more reactive groups are available. Typically, the pH will fall within the range of 3 to 9, or 3 to 6. This method can be employed for making zcytor16-comprising homodimeric, heterodimeric or multimeric soluble receptor conjugates.

[0213] Another factor to consider is the molecular weight of the water-soluble polymer. Generally, the higher the molecular weight of the polymer, the fewer number of polymer molecules which may be attached to the protein. For PEGylation reactions, the typical molecular weight is about 2 kDa to about 100 kDa, about 5 kDa to about 50 kDa, or about 12 kDa to about 25 kDa. The molar ratio of water-soluble polymer to Zcytor16 will generally be in the range of 1:1 to 100:1. Typically, the molar ratio of water-soluble polymer to Zcytor16 will be 1:1 to 20:1 for polyPEGylation, and 1:1 to 5:i for monoPEGylation.

[0214] General methods for producing conjugates comprising a polypeptide and water-soluble polymer moieties are known in the art. See, for example, Karasiewicz et al., U.S. Patent No. 5,382,657, Greenwald et al., U.S. Patent No. 5,738, 846, Nieforth et al., Clin. Pharmacol. Ther. 59:636 (1996), Monkarsch et al., Anal. Biochem. 247:434 (1997)). This method can be employed for making zcytor16-comprising homodimeric, heterodimeric or multimeric soluble receptor conjugates.

[0215] The present specification describes compositions comprising a peptide or polypeptide described herein. Such compositions can further comprise a carrier. The carrier can be a conventional organic or inorganic carrier. Examples of carriers include water, buffer solution, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and the like.

8. Isolation of Zcytor16 Polypeptides

[0216] The polypeptides of the present invention can be purified to at least about 80% purity, to at least about 90% purity, to at least about 95% purity, or greater than 95% purity with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. The polypeptides of the present invention may also be purified to a pharmaceutically pure state, which is greater than 99.9% pure. In certain preparations, purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.

[0217] Fractionation and/or conventional purification methods can be used to obtain preparations of Zcytor16 purified from natural sources (e.g., tonsil tissue), synthetic Zcytor16 polypeptides, and recombinant Zcytor16 polypeptides and fusion Zcytor16 polypeptides purified from recombinant host cells. In general, ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are suitable. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties.

[0218] Examples of coupling chemistries include cyanogen bromide activation, *N*-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Selection of a particular method for polypeptide isolation and purification is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, Affinity Chromatography: Principles & Methods (Pharmacia LKB Biotechnology 1988), and Doonan, Protein Purification Protocols (The Humana Press 1996).

[0219] Additional variations in Zcytor16 isolation and purification can be devised by those of skill in the art. For example, anti-Zcytor16 antibodies, obtained as described below, can be used to isolate large quantities of protein by immunoaffinity purification.

[0220] The polypeptides of the present invention can also be isolated by exploitation of particular properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate (Sulkowski, Trends in Biochem. 3:1 (1985)). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion

exchange chromatography (M. Deutscher, (ed.), Meth. Enzymol. 182:529 (1990)). Within additional embodiments of the invention, a fusion of the polypeptide of interest and an affinity tag (e.g., maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification. Moreover, the ligand-binding properties of zcytor16 extracellular domain can be exploited for purification, for example, of zcytor16-comprising soluble receptors; for example, by using affinity chromatography wherein IL-TIF ligand is bound to a column and the zcytor16-comprising receptor is bound and subsequently eluted using standard chromatography methods.

[0221] Zcytor16 polypeptides or fragments thereof may also be prepared through chemical synthesis, as described above. Zcytor16 polypeptides may be monomers or multimers; glycosylated or non-glycosylated; PEGylated or non-PEGylated; and may or may not include an initial methionine amino acid residue.

9. Production of Antibodies to Zcytor16 Proteins

[0222] Antibodies to Zcytor16 can be obtained, for example, using the product of a Zcytor16 expression vector or Zcytor16 isolated from a natural source as an antigen. Particularly useful anti-Zcytor16 antibodies "bind specifically" with Zcytor16. Antibodies are considered to be specifically binding if the antibodies exhibit at least one of the following two properties: (1) antibodies bind to Zcytor16 with a threshold level of binding activity, and (2) antibodies do not significantly cross-react with polypeptides related to Zcytor16.

[0223] With regard to the first characteristic, antibodies specifically bind if they bind to a Zcytor16 polypeptide, peptide or epitope with a binding affinity (K_a) of $10^6 M^{-1}$ or greater, preferably $10^7 M^{-1}$ or greater, more preferably $10^8 M^{-1}$ or greater, and most preferably $10^9 M^{-1}$ or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, Ann. NY Acad. Sci. 51:660 (1949)). With regard to the second characteristic, antibodies do not significantly cross-react with related polypeptide molecules, for example, if they detect Zcytor16, but not presently known polypeptides using a standard Western blot analysis. Examples of known related polypeptides include known cytokine receptors.

[0224] Anti-Zcytor16 antibodies can be produced using antigenic Zcytor16 epitope-bearing peptides and polypeptides. Antigenic epitope-bearing peptides and polypeptides of the present invention contain a sequence of at least nine, or between 15 to about 30 amino acids contained within SEQ ID NO:2 or another amino acid sequence disclosed herein. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of the invention, containing from 30 to 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are useful for inducing antibodies that bind with Zcytor16. It is desirable that the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (*i.e.*, the sequence includes relatively hydrophilic residues, while hydrophobic residues are typically avoided). Moreover, amino acid sequences containing proline residues may be also be desirable for antibody production.

[0225] As an illustration, potential antigenic sites in Zcytor16 were identified using the Jameson-Wolf method, Jameson and Wolf, CABIOS 4:181, (1988), as implemented by the PROTEAN program (version 3.14) of LASERGENE (DNASTAR; Madison, WI). Default parameters were used in this analysis.

[0226] The Jameson-Wolf method predicts potential antigenic determinants by combining six major subroutines for protein structural prediction. Briefly, the Hopp-Woods method, Hopp et al., Proc. Nat'l Acad. Sci. USA 78:3824 (1981), was first used to identify amino acid sequences representing areas of greatest local hydrophilicity (parameter: seven residues averaged). In the second step, Emini's method, Emini et al., J. Virology 55:836 (1985), was used to calculate surface probabilities (parameter: surface decision threshold (0.6) = 1). Third, the Karplus-Schultz method, Karplus and Schultz, Naturwissenschaften 72:212 (1985), was used to predict backbone chain flexibility (parameter: flexibility threshold (0.2) = 1). In the fourth and fifth steps of the analysis, secondary structure predictions were applied to the data using the methods of Chou-Fasman, Chou, "Prediction of Protein Structural Classes from Amino Acid Composition," in Prediction of Protein Structure and the Principles of Protein Conformation, Fasman (ed.), pages 549-586 (Plenum Press 1990), and Garnier-Robson, Garnier et al., J. Mol. Biol. 120:97 (1978) (Chou-Fasman parameters: conformation table = 64 proteins; α region threshold = 103; β region threshold = 105; Garnier-Robson parameters: α and β decision constants = 0). In the sixth subroutine, flexibility parameters and hydropathy/solvent accessibility factors were combined to determine a surface contour value, designated as the "antigenic index." Finally, a peak broadening function was applied to the antigenic index, which broadens major surface peaks by adding 20, 40, 60, or 80% of the respective peak value to account for additional free energy derived from the mobility of surface regions relative to interior regions. This calculation was not applied, however, to any major peak that resides in a helical region, since helical regions tend to be less flexible.

[0227] The results of this analysis indicated that the following amino acid sequences of SEQ ID NO:2 would provide suitable antigenic peptides: amino acids 24 to 42 ("antigenic peptide 1"), amino acids 24 to 33 ("antigenic peptide 2"), 37 to 42 ("antigenic peptide 3"), amino acids 48 to 55 ("antigenic peptide 4"), amino acids 68 to 81 ("antigenic peptide 5"), amino acids 88 to 97 ("antigenic peptide 6"), amino acids 126 to 132 ("antigenic peptide 7"), amino acids 156 to 165 ("antigenic peptide 8"), amino acids 178 to 185 ("antigenic peptide 9"), and amino acids 216 to 227 ("antigenic peptide 10"). The present specification describes the use of any one of antigenic peptides 1 to 10 to generate antibodies to

Zcytor16. The present specification describes polypeptides comprising at least one of antigenic peptides 1 to 10.

[0228] Moreover, suitable antigens also include the zcytor16 polypeptides comprising a zcytor16 cytokine binding, or extracellular domain disclosed above in combination with another class I or II cytokine extracellular domain, such as those that form soluble zcytor16 heterodimeric or multimeric polypeptides, such as soluble zcytor16/CRF2-4, zcytor16/zcytor11, zcytor16/zcytor7, and the like.

[0229] Polyclonal antibodies to recombinant Zcytor16 protein or to Zcytor16 isolated from natural sources can be prepared using methods well-known to those of skill in the art. See, for example, Green et al., "Production of Polyclonal Antisera," in *Immunochemical Protocols* (Manson, ed.), pages 1-5 (Humana Press 1992), and Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), page 15 (Oxford University Press 1995). The immunogenicity of a Zcytor16 polypeptide can be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zcytor16 or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like," such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

[0230] Although polyclonal antibodies are typically raised in animals such as horses, cows, dogs, chicken, rats, mice, rabbits, guinea pigs, goats, or sheep, an anti-Zcytor16 antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in Goldenberg et al., international patent publication No. WO 91/11465, and in Losman et al., *Int. J. Cancer* 46:310 (1990).

[0231] Alternatively, monoclonal anti-Zcytor16 antibodies can be generated. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler et al., *Nature* 256:495 (1975), Coligan et al. (eds.), *Current Protocols in Immunology*, Vol. 1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991) ["Coligan"], Picklesley et al., "Production of monoclonal antibodies against proteins expressed in *E. coli*," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), page 93 (Oxford University Press 1995)).

[0232] Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising a *Zcytor16* gene product, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

[0233] In addition, an anti-Zcytor16 antibody may be derived from a human monoclonal antibody. Human monoclonal antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, for example, by Green et al., *Nature Genet.* 7:13 (1994), Lonberg et al., *Nature* 368:856 (1994), and Taylor et al., *Int. Immun.* 6:579 (1994).

[0234] Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines et al., "Purification of Immunoglobulin G (IgG)," in *Methods in Molecular Biology*, Vol. 10, pages 79-104 (The Humana Press, Inc. 1992)).

[0235] For particular uses, it may be desirable to prepare fragments of anti-Zcytor16 antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted $F(ab')_2$. This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patent No. 4,331,647, Nisonoff et al., *Arch Biochem. Biophys.* 89:230 (1960), Porter, *Biochem. J.* 73:119 (1959), Edelman et al., in *Methods in Enzymology* Vol. 1, page 422 (Academic Press 1967), and by Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.

[0236] Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

[0237] For example, Fv fragments comprise an association of V_H and V_L chains. This association can be noncovalent,

as described by Inbar et al., Proc. Nat'l Acad. Sci. USA 69:2659 (1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde (see, for example, Sandhu, Crit. Rev. Biotech. 12:437 (1992)).

[0238] The Fv fragments may comprise V_H and V_L chains which are connected by a peptide linker. These single-chain antigen binding proteins (scFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains which are connected by an oligonucleotide. The structural gene is inserted into an expression vector which is subsequently introduced into a host cell, such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing scFvs are described, for example, by Whitlow et al., Methods: A Companion to Methods in Enzymology 2:97 (1991) (also see, Bird et al., Science 242:423 (1988), Ladner et al., U.S. Patent No. 4,946,778, Pack et al., Bio/Technology 11:1271 (1993), and Sandhu, *supra*).

[0239] As an illustration, a scFV can be obtained by exposing lymphocytes to Zcytor16 polypeptide *in vitro*, and selecting antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled Zcytor16 protein or peptide). Genes encoding polypeptides having potential Zcytor16 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., U.S. Patent No. 5,223,409, Ladner et al., U.S. Patent No. 4,946,778, Ladner et al., U.S. Patent No. 5,403,484, Ladner et al., U.S. Patent No. 5,571,698, and Kay et al., Phage Display of Peptides and Proteins (Academic Press, Inc. 1996)) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from CLONTECH Laboratories, Inc. (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA), and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the Zcytor16 sequences disclosed herein to identify proteins which bind to Zcytor16.

[0240] Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (see, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2:106 (1991), Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), page 166 (Cambridge University Press 1995), and Ward et al., "Genetic Manipulation and Expression of Antibodies," in Monoclonal Antibodies: Principles and Applications, Birch et al., (eds.), page 137 (Wiley-Liss, Inc. 1995)).

[0241] Alternatively, an anti-Zcytor16 antibody may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementary determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain. Typical residues of human antibodies are then substituted in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi et al., Proc. Nat'l Acad. Sci. USA 86:3833 (1989). Techniques for producing humanized monoclonal antibodies are described, for example, by Jones et al., Nature 321:522 (1986), Carter et al., Proc. Nat'l Acad. Sci. USA 89:4285 (1992), Sandhu, Crit. Rev. Biotech. 12:437 (1992), Singer et al., J. Immun. 150:2844 (1993), Sudhir (ed.), Antibody Engineering Protocols (Humana Press, Inc. 1995), Kelley, "Engineering Therapeutic Antibodies," in Protein Engineering: Principles and Practice, Cleland et al. (eds.), pages 399-434 (John Wiley & Sons, Inc. 1996), and by Queen et al., U.S. Patent No. 5,693,762 (1997).

[0242] Polyclonal anti-idiotypic antibodies can be prepared by immunizing animals with anti-Zcytor16 antibodies or antibody fragments, using standard techniques. See, for example, Green et al., "Production of Polyclonal Antisera," in Methods In Molecular Biology: Immunochemical Protocols, Manson (ed.), pages 1-12 (Humana Press 1992). Also, see Coligan at pages 2.4.1-2.4.7. Alternatively, monoclonal anti-idiotypic antibodies can be prepared using anti-Zcytor16 antibodies or antibody fragments as immunogens with the techniques, described above. As another alternative, humanized anti-idiotypic antibodies or subhuman primate anti-idiotypic antibodies can be prepared using the above-described techniques. Methods for producing anti-idiotypic antibodies are described, for example, by Irie, U.S. Patent No. 5,208,146, Greene, *et. al.*, U.S. Patent No. 5,637,677, and Varthakavi and Minocha, J. Gen. Virol. 77:1875 (1996).

10. Use of Zcytor16 Nucleotide Sequences to Detect Gene Expression and Gene Structure

[0243] Nucleic acid molecules can be used to detect the expression of a Zcytor16 gene in a biological sample. Suitable

probe molecules include double-stranded nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO: 1, or a portion thereof, as well as single-stranded nucleic acid molecules having the complement of the nucleotide sequence of SEQ ID NO:1, or a portion thereof. Probe molecules may be DNA, RNA, oligonucleotides, and the like. As used herein, the term "portion" refers to at least eight nucleotides to at least 20 or more nucleotides. Illustrative probes bind with regions of the *Zcytor16* gene that have a low sequence similarity to comparable regions in other cytokine receptor genes.

[0244] In a basic assay, a single-stranded probe molecule is incubated with RNA, isolated from a biological sample, under conditions of temperature and ionic strength that promote base pairing between the probe and target *Zcytor16* RNA species. After separating unbound probe from hybridized molecules, the amount of hybrids is detected.

[0245] In addition, as *zcytor16* is spleen-specific, polynucleotide probes, anti-*zcytor16* antibodies, and detection the presence of *zcytor16* polypeptides in tissue can be used to assess whether spleen tissue is present, for example, after surgery involving the excision of a diseased or cancerous spleen. As such, the polynucleotides, polypeptides, and antibodies describe herein can be used as an aid to determined whether all spleen tissue is excised after surgery, for example, after surgery for spleen cancer. In such instances, it is especially important to remove all potentially diseased tissue to maximize recovery from the cancer, and to minimize recurrence. Preferred embodiments include fluorescent, radiolabeled, or calorimetrically labeled antibodies, that can be *used in situ*.

[0246] Moreover, anti-*zcytor16* antibodies and binding fragments can be used for tagging and sorting cells that specifically-express *Zcytor16*, such as mononuclear cells, lymphoid cells, e.g. activated CD4+ T-cells and CD19+ B-cells, and other described herein. Such methods of cell tagging and sorting are well known in the art (see, e.g., "Molecular Biology of the Cell", 3rd Ed., Albert, B. et al. (Garland Publishing, London & New York, 1994). One of skill in the art would recognize the importance of separating cell tissue types to study cells, and the use of antibodies to separate specific cell tissue types. Basically, antibodies that bind to the surface of a cell type are coupled to various matrices such as collagen, polysaccharide beads, or plastic to form an affinity surface to which only cells recognized by the antibodies will adhere. The bound cells are then recovered by conventional techniques. Other methods involve separating cells by a fluorescence-activated cell sorter (FACS). In this technique one labels cells with antibodies that are coupled to a fluorescent dye. The labeled cells are then separated from unlabeled cells in a FACS machine. In FACS sorting individual cells traveling in single file pass through a laser beam and the fluorescence of each cell is measured. Slightly further down-stream, tiny droplets, most containing either one or no cells, are formed by a vibrating nozzle. The droplets containing a single cell are automatically give a positive or negative charge at the moment of formation, depending on whether the cell they contain is fluorescent, and then deflected by a strong electric field into an appropriate container. Such machines can select 1 cell in 1000 and sort about 5000 cells each second. This produces a uniform population of cells for cell culture.

[0247] One of skill in the art would recognize that the antibodies to the *Zcytor16* polypeptides of the present invention are useful, because not all tissue types express the *Zcytor16* receptor and because it is important that biologists be able to separate specific cell types for further study and/or therapeutic re-implantation into the body. This is particularly relevant in cells such as immune cells, wherein *zcytor16* is expressed.

[0248] Moreover, use of *Zcytor16* polynucleotide probes, anti-*zcytor16* antibodies, and detection the presence of *zcytor16* polypeptides in tissue can be used in the diagnosis and/or prevention of spontaneous abortions, or to monitor placental health and function. Since *Zcytor16* is expressed in the placenta, it could play a role in the critical functions of placenta, such as proliferation or survival of trophoblast cells, and the like. Thus, *zcytor16* could be essential for the function of the placenta, thus maturation of embryos. Therefore, a supplement of *Zcytor16* polypeptide, or anti-*zcytor16* antibodies may be beneficial in the prevention and treatment of certain types of spontaneous abortions, or premature birth of babies caused by abnormal expression of *Zcytor16* in the placenta, or as a diagnostic to assess the function of the placenta. For example, as *zcytor16* is normally expressed in placenta, the absence of *zcytor16* expression may be indicative of abnormal placenta function.

[0249] Well-established hybridization methods of RNA detection include northern analysis and dot/slot blot hybridization (see, for example, Ausubel (1995) at pages 4-1 to 4-27, and Wu et al. (eds.), "Analysis of Gene Expression at the RNA Level," in Methods in Gene Biotechnology, pages 225-239 (CRC Press, Inc. 1997)). Nucleic acid probes can be detectably labeled with radioisotopes such as ³²P or ³⁵S. Alternatively, *Zcytor16* RNA can be detected with a nonradioactive hybridization method (see, for example, Isaac (ed.), Protocols for Nucleic Acid Analysis by Nonradioactive Probes (Humana Press, Inc. 1993)). Typically, nonradioactive detection is achieved by enzymatic conversion of chromogenic or chemiluminescent substrates. Illustrative nonradioactive moieties include biotin, fluorescein, and digoxigenin.

[0250] *Zcytor16* oligonucleotide probes are also useful for *in vivo* diagnosis. As an illustration, ¹⁸F-labeled oligonucleotides can be administered to a subject and visualized by positron emission tomography (Tavitian et al., Nature Medicine 4:467 (1998)).

[0251] Numerous diagnostic procedures take advantage of the polymerase chain reaction (PCR) to increase sensitivity of detection methods. Standard techniques for performing PCR are well-known (see, generally, Mathew (ed.), Protocols in Human Molecular Genetics (Humana Press, Inc. 1991), White (ed.), PCR Protocols: Current . Methods and Applications

(Humana Press, Inc. 1993), Cotter (ed.), *Molecular Diagnosis of Cancer* (Humana Press, Inc. 1996), Hanausek and Walaszek (eds.), *Tumor Marker Protocols* (Humana Press, Inc. 1998), Lo (ed.), *Clinical Applications of PCR* (Humana Press, Inc. 1998), and Meltzer (ed.), *PCR in Bioanalysis* (Humana Press, Inc. 1998)).

[0252] PCR primers can be designed to amplify a portion of the *Zcytor16* gene that has a low sequence similarity to a comparable region in other proteins, such as other cytokine receptor proteins.

[0253] One variation of PCR for diagnostic assays is reverse transcriptase-PCR (RT-PCR). In the RT-PCR technique, RNA is isolated from a biological sample, reverse transcribed to cDNA, and the cDNA is incubated with *Zcytor16* primers (see, for example, Wu et al. (eds.), "Rapid Isolation of Specific cDNAs or Genes by PCR," in *Methods in Gene Biotechnology*, pages 15-28 (CRC Press, Inc. 1997)). PCR is then performed and the products are analyzed using standard techniques.

[0254] As an illustration, RNA is isolated from biological sample using, for example, the guanidium-thiocyanate cell lysis procedure described above. Alternatively, a solid-phase technique can be used to isolate mRNA from a cell lysate. A reverse transcription reaction can be primed with the isolated RNA using random oligonucleotides, short homopolymers of dT, or *Zcytor16* anti-sense oligomers. Oligo-dT primers offer the advantage that various mRNA nucleotide sequences are amplified that can provide control target sequences. *Zcytor16* sequences are amplified by the polymerase chain reaction using two flanking oligonucleotide primers that are typically 20 bases in length.

[0255] PCR amplification products can be detected using a variety of approaches. For example, PCR products can be fractionated by gel electrophoresis, and visualized by ethidium bromide staining. Alternatively, fractionated PCR products can be transferred to a membrane, hybridized with a detectably-labeled *Zcytor16* probe, and examined by autoradiography. Additional alternative approaches include the use of digoxigenin-labeled deoxyribonucleic acid triphosphates to provide chemiluminescence detection, and the C-TRAK colorimetric assay.

[0256] Another approach for detection of *Zcytor16* expression is cycling probe technology (CPT), in which a single-stranded DNA target binds with an excess of DNA-RNA-DNA chimeric probe to form a complex, the RNA portion is cleaved with RNAase H, and the presence of cleaved chimeric probe is detected (see, for example, Beggs et al., *J. Clin. Microbiol.* 34:2985 (1996), Bekkaoui et al., *Biotechniques* 20:240 (1996)). Alternative methods for detection of *Zcytor16* sequences can utilize approaches such as nucleic acid sequence-based amplification (NASBA), cooperative amplification of templates by cross-hybridization (CATCH), and the ligase chain reaction (LCR) (see, for example, Marshall et al., U.S. Patent No. 5,686,272 (1997), Dyer et al., *J. Virol. Methods* 60:161 (1996), Ehricht et al., *Eur. J. Biochem.* 243:358 (1997), and Chadwick et al., *J. Virol. Methods* 70:59 (1998)). Other standard methods are known to those of skill in the art.

[0257] *Zcytor16* probes and primers can also be used to detect and to localize *Zcytor16* gene expression in tissue samples. Methods for such *in situ* hybridization are well-known to those of skill in the art (see, for example, Choo (ed.), *In Situ Hybridization Protocols* (Humana Press, Inc. 1994), Wu et al. (eds.), "Analysis of Cellular DNA or Abundance of mRNA by Radioactive In Situ Hybridization (RISH)," in *Methods in Gene Biotechnology*, pages 259-278 (CRC Press, Inc. 1997), and Wu et al. (eds.), "Localization of DNA or Abundance of mRNA by Fluorescence In Situ Hybridization (RISH)," in *Methods in Gene Biotechnology*, pages 279-289 (CRC Press, Inc. 1997)). Various additional diagnostic approaches are well-known to those of skill in the art (see, for example, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), Coleman and Tsongalis, *Molecular Diagnostics* (Humana Press, Inc. 1996), and Elles, *Molecular Diagnosis of Genetic Diseases* (Humana Press, Inc., 1996)). Suitable test samples include blood, urine, saliva, tissue biopsy, and autopsy material.

[0258] The *Zcytor16* gene resides in human chromosome 6q23-q24 (e.g., Example 24). This region is associated with various disorders, including insulin dependent diabetes mellitus, retinal cone dystrophy, breast cancer, and Parkinson disease. Moreover, defects in the *zcytor16* locus itself may result in a heritable human disease states as discussed herein. One of skill in the art would appreciate that defects in cytokine receptors are known to cause particular diseases in humans. For example, polymorphisms of cytokine receptors are associated with pulmonary alveolar proteinosis, familial periodic fever, and erythroleukemia. Moreover, growth hormone receptor mutation results in dwarfism (Amselem, S et al., *New Eng. J. Med.* 321: 989-995, 1989), IL-2 receptor gamma mutation results in severe combined immunodeficiency (SCID) (Noguchi, M et al., *Cell* 73: 147-157, 1993), c-Mpl mutation results in thrombocytopenia (Ihara, K et al., *Proc. Nat. Acad. Sci.* 96: 3132-3136, 1999), and severe mycobacterial and *Salmonella* infections result in interleukin-12 receptor-deficient patients (de Jong, R et al., *Science* 280: 1435-1438, 1998), amongst others. Thus, similarly, defects in *zcytor16* can cause a disease state or susceptibility to disease or infection. As the *Zcytor16* gene is located at 6q23-q24, *zcytor16* polynucleotide probes can be used to detect chromosome 6q23-q24 loss, trisomy, duplication or translocation associated with human diseases, such as inflammatory diseases, chronic inflammation, dysfunction of inflammatory response, immune cell cancers, bone marrow cancers, spleen cancers, prostate cancer, thyroid, parathyroid or other cancers, or immune diseases. Moreover, the polypeptides, antagonists, agonists, polynucleotides and antibodies described herein would aid in the detection, diagnosis prevention, and treatment associated with a *zcytor16* genetic defect. Thus, *Zcytor16* nucleotide sequences can be used in linkage-based testing for various diseases, and to determine whether a subject's chromosomes contain a mutation in the *Zcytor16* gene. Detectable chromosomal aberrations at the *Zcytor16* gene locus include, but are not limited to, aneuploidy, gene copy number changes, loss of heterogeneity of

6q23-q24, translocation in 6q23-q24, insertions, deletions, restriction site changes and rearrangements. Human diseases associated with such detectable rearrangements are known in the art, for example see, OMIM™, National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD gene map, e.g., translocations, LOH, trisomy, and the like. Of particular interest are genetic alterations that inactivate a *Zcytor16* gene, or gross chromosomal alterations in and around the *zcytor16* locus.

[0259] Similarly, defects in the *Zcytor16* gene itself may result in a heritable human disease state. Moreover, one of skill in the art would appreciate that defects in cytokine receptors are known to cause disease states in humans. For example, growth hormone receptor mutation results in dwarfism (Amselem, S et al., *New Eng. J. Med.* 321: 989-995, 1989), IL-2 receptor gamma mutation results in severe combined immunodeficiency (SCID) (Noguchi, M et al., *Cell* 73: 147-157, 1993), c-Mpl mutation results in thrombocytopenia (Ihara, K et al., *Proc. Nat. Acad. Sci.* 96: 3132-3136, 1999), and severe mycobacterial and *Salmonella* infections result in interleukin-12 receptor-deficient patients (de Jong, R et al., *Science* 280: 1435-1438, 1998), amongst others. Thus, similarly, defects in *zcytor16* can cause a disease state or susceptibility to disease or infection. As, *zcytor16* is a cytokine receptor within a chromosomal region where aberrations may be involved in cancer, and is shown to be expressed in ovarian cancer, the molecules of the present invention could also be directly involved in cancer formation or metastasis. As the *Zcytor16* gene is located at the 6q23-q24 region *zcytor16*, polynucleotide probes can be used to detect chromosome 6q23-q24 loss, loss of heterogeneity (LOH), trisomy, duplication or translocation associated with human diseases, such as immune cell cancers, neuroblastoma, bone marrow cancers, thyroid, parathyroid, prostate, melanoma, or other cancers, or immune diseases. Moreover, molecules described herein, such as the polypeptides, antagonists, agonists, polynucleotides and antibodies described herein would aid in the detection, diagnosis prevention, and treatment associated with a *Zcytor16* genetic defect.

[0260] A diagnostic could assist physicians in determining the type of disease and appropriate associated therapy, or assistance in genetic counseling. As such, the inventive anti-*zcytor16* antibodies, polynucleotides, and polypeptides can be used for the detection of *zcytor16* polypeptide, mRNA or anti-*zcytor16* antibodies, thus serving as markers and be directly used for detecting or genetic diseases or cancers, as described herein, using methods known in the art and described herein. Further, *zcytor16* polynucleotide probes can be used to detect abnormalities or genotypes associated with chromosome 6q23-q24 deletions and translocations associated with human diseases, other translocations involved with malignant progression of tumors or other 6q23-q24 mutations, which are expected to be involved in chromosome rearrangements in malignancy; or in other cancers, or in spontaneous abortion. Similarly, *zcytor16* polynucleotide probes can be used to detect abnormalities or genotypes associated with chromosome 6q23-q24 trisomy and chromosome loss associated with human diseases. Thus, *zcytor16* polynucleotide probes can be used to detect abnormalities or genotypes associated with these defects.

[0261] As discussed above, defects in the *Zcytor16* gene itself may result in a heritable human disease state. For example, *zcytor16* expression is elevated in several tissue-specific human cancers, as described herein. Molecules described herein such as the polypeptides, antagonists, agonists, polynucleotides and antibodies described herein would aid in the detection, diagnosis prevention, and treatment associated with a *zcytor16* genetic defect. In addition, *zcytor16* polynucleotide probes can be used to detect allelic differences between diseased or non-diseased individuals at the *zcytor16* chromosomal locus. As such, the *zcytor16* sequences can be used as diagnostics in forensic DNA profiling.

[0262] In general, the diagnostic methods used in genetic linkage analysis, to detect a genetic abnormality or aberration in a patient, are known in the art. Analytical probes will be generally at least 20 nt in length, although somewhat shorter probes can be used (e.g., 14-17 nt). PCR primers are at least 5 nt in length, preferably 15 or more, more preferably 20-30 nt. For gross analysis of genes, or chromosomal DNA, a *zcytor16* polynucleotide probe may comprise an entire exon or more. Exons are readily determined by one of skill in the art by comparing *zcytor16* sequences (SEQ ID NO:1) with the human genomic DNA for *zcytor16*. In general, the diagnostic methods used in genetic linkage analysis, to detect a genetic abnormality or aberration in a patient, are known in the art. Most diagnostic methods comprise the steps of (a) obtaining a genetic sample from a potentially diseased patient, diseased patient or potential non-diseased carrier of a recessive disease allele; (b) producing a first reaction product by incubating the genetic sample with a *zcytor16* polynucleotide probe wherein the polynucleotide will hybridize to complementary polynucleotide sequence, such as in RFLP analysis or by incubating the genetic sample with sense and antisense primers in a PCR reaction under appropriate PCR reaction conditions; (iii) Visualizing the first reaction product by gel electrophoresis and/or other known method such as visualizing the first reaction product with a *zcytor16* polynucleotide probe wherein the polynucleotide will hybridize to the complementary polynucleotide sequence of the first reaction; and (iv) comparing the visualized first reaction product to a second control reaction product of a genetic sample from wild type patient. A difference between the first reaction product and the control reaction product is indicative of a genetic abnormality in the diseased or potentially diseased patient, or the presence of a heterozygous recessive carrier phenotype for a non-diseased patient, or the presence of a genetic defect in a tumor from a diseased patient, or the presence of a genetic abnormality in a fetus or pre-implantation embryo. For example, a difference in restriction fragment pattern, length of PCR products, length of repetitive sequences at the *zcytor16* genetic locus, and the like, are indicative of a genetic abnormality, genetic aberration, or allelic difference in comparison to the normal wild type control. Controls can be from unaffected family members, or

unrelated individuals, depending on the test and availability of samples. Genetic samples for use as described herein include genomic DNA, mRNA, and cDNA isolated from any tissue or other biological sample from a patient, such as but not limited to, blood, saliva, semen, embryonic cells, amniotic fluid, and the like. The polynucleotide probe or primer can be RNA or DNA, and will comprise a portion of SEQ ID NO:1, the complement of SEQ ID NO:1, or an RNA equivalent thereof. Such methods of showing genetic linkage analysis to human disease phenotypes are well known in the art. For reference to PCR based methods in diagnostics see generally, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), White (ed.), *PCR Protocols: Current Methods and Applications* (Humana Press, Inc. 1993), Cotter (ed.), *Molecular Diagnosis of Cancer* (Humana Press, Inc. 1996), Hanausek and Walaszek (eds.), *Tumor Marker Protocols* (Humana Press, Inc. 1998), Lo (ed.), *Clinical Applications of PCR* (Humana Press, Inc. 1998), and Meltzer (ed.), *PCR in Bioanalysis* (Humana Press, Inc. 1998)).

[0263] Aberrations associated with the *Zcytor16* locus can be detected using nucleic acid molecules of the present invention by employing molecular genetic techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, amplification-refractory mutation system analysis (ARMS), single-strand conformation polymorphism (SSCP) detection, RNase cleavage methods, denaturing gradient gel electrophoresis, fluorescence-assisted mismatch analysis (FAMA), and other genetic analysis techniques known in the art (see, for example, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), Marian, Chest 108:255 (1995), Coleman and Tsongalis, *Molecular Diagnostics* (Human Press, Inc. 1996), Elles (ed.) *Molecular Diagnosis of Genetic Diseases* (Humana Press, Inc. 1996), Landegren (ed.), *Laboratory Protocols for Mutation Detection* (Oxford University Press 1996), Birren et al. (eds.), *Genome Analysis, Vol. 2: Detecting Genes* (Cold Spring Harbor Laboratory Press 1998), Dracopoli et al. (eds.), *Current Protocols in Human Genetics* (John Wiley & Sons 1998), and Richards and Ward, "Molecular Diagnostic Testing," in *Principles of Molecular Medicine*, pages 83-88 (Humana Press, Inc. 1998)).

[0264] The protein truncation test is also useful for detecting the inactivation of a gene in which translation-terminating mutations produce only portions of the encoded protein (see, for example, Stoppa-Lyonnet et al., *Blood* 91:3920 (1998)). According to this approach, RNA is isolated from a biological sample, and used to synthesize cDNA. PCR is then used to amplify the *Zcytor16* target sequence and to introduce an RNA polymerase promoter, a translation initiation sequence, and an in-frame ATG triplet. PCR products are transcribed using an RNA polymerase, and the transcripts are translated *in vitro* with a T7-coupled reticulocyte lysate system. The translation products are then fractionated by SDS-PAGE to determine the lengths of the translation products. The protein truncation test is described, for example, by Dracopoli et al. (eds.), *Current Protocols in Human Genetics*, pages 9.11.1 - 9.11.18 (John Wiley & Sons 1998).

[0265] The present specification describes kits for performing a diagnostic assay for *Zcytor16* gene expression or to detect mutations in the *Zcytor16* gene. Such kits comprise nucleic acid probes, such as double-stranded nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO:1, or a portion thereof, as well as single-stranded nucleic acid molecules having the complement of the nucleotide sequence of SEQ ID NO:1, or a portion thereof. Probe molecules may be DNA, RNA, oligonucleotides, and the like. Kits may comprise nucleic acid primers for performing PCR.

[0266] Such kits can contain all the necessary elements to perform a nucleic acid diagnostic assay described above. A kit will comprise at least one container comprising a *Zcytor16* probe or primer. The kit may also comprise a second container comprising one or more reagents capable of indicating the presence of *Zcytor16* sequences. Examples of such indicator reagents include detectable labels such as radioactive labels, fluorochromes, chemiluminescent agents, and the like. A kit may also comprise a means for conveying to the user that the *Zcytor16* probes and primers are used to detect *Zcytor16* gene expression. For example, written instructions may state that the enclosed nucleic acid molecules can be used to detect either a nucleic acid molecule that encodes *Zcytor16*, or a nucleic acid molecule having a nucleotide sequence that is complementary to a *Zcytor16*-encoding nucleotide sequence. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.

11. Use of Anti-Zcytor16 Antibodies to Detect Zcytor16 or Antagonize Zcytor16 Binding to IL-TIF

[0267] The present specification describes the use of anti-Zcytor16 antibodies to screen biological samples *in vitro* for the presence of Zcytor16. In one type of *in vitro* assay, anti-Zcytor16 antibodies are used in liquid phase. For example, the presence of Zcytor16 in a biological sample can be tested by mixing the biological sample with a trace amount of labeled Zcytor16 and an anti-Zcytor16 antibody under conditions that promote binding between Zcytor16 and its antibody. Complexes of Zcytor16 and anti-Zcytor16 in the sample can be separated from the reaction mixture by contacting the complex with an immobilized protein which binds with the antibody, such as an Fc antibody or *Staphylococcus* protein A. The concentration of Zcytor16 in the biological sample will be inversely proportional to the amount of labeled Zcytor16 bound to the antibody and directly related to the amount of free labeled Zcytor16. Illustrative biological samples include blood, urine, saliva, tissue biopsy, and autopsy material.

[0268] Alternatively, *in vitro* assays can be performed in which anti-Zcytor16 antibody is bound to a solid-phase carrier. For example, antibody can be attached to a polymer, such as aminodextran, in order to link the antibody to an insoluble

support such as a polymer-coated bead, a plate or a tube. Other suitable *in vitro* assays will be readily apparent to those of skill in the art.

5 [0269] In another approach, anti-Zcytor16 antibodies can be used to detect Zcytor16 in tissue sections prepared from a biopsy specimen. Such immunochemical detection can be used to determine the relative abundance of Zcytor16 and to determine the distribution of Zcytor16 in the examined tissue. General immunochemistry techniques are well established (see, for example, Ponder, "Cell Marking Techniques and Their Application," in *Mammalian Development: A Practical Approach*, Monk (ed.), pages 115-38 (IRL Press 1987), Coligan at pages 5.8.1-5.8.8, Ausubel (1995) at pages 14.6.1 to 14.6.13 (Wiley Interscience 1990), and Manson (ed.), *Methods In Molecular Biology*, Vol. 10: *Immunochemical Protocols* (The Humana Press, Inc. 1992)).

10 [0270] Immunochemical detection can be performed by contacting a biological sample with an anti-Zcytor16 antibody, and then contacting the biological sample with a detectably labeled molecule which binds to the antibody. For example, the detectably labeled molecule can comprise an antibody moiety that binds to anti-Zcytor16 antibody. Alternatively, the anti-Zcytor16 antibody can be conjugated with avidin/streptavidin (or biotin) and the detectably labeled molecule can comprise biotin (or avidin/streptavidin). Numerous variations of this basic technique are well-known to those of skill in the art.

15 [0271] Alternatively, an anti-Zcytor16 antibody can be conjugated with a detectable label to form an anti-Zcytor16 immunoconjugate. Suitable detectable labels include, for example, a radioisotope, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label or colloidal gold. Methods of making and detecting such detectably-labeled immunoconjugates are well-known to those of ordinary skill in the art, and are described in more detail below.

20 [0272] The detectable label can be a radioisotope that is detected by autoradiography. Isotopes that are particularly useful for the purpose of the present invention are ^3H , ^{125}I , ^{131}I , ^{35}S and ^{14}C .

25 [0273] Anti-Zcytor16 immunoconjugates can also be labeled with a fluorescent compound. The presence of a fluorescently-labeled antibody is determined by exposing the immunoconjugate to light of the proper wavelength and detecting the resultant fluorescence. Fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

30 [0274] Alternatively, anti-Zcytor16 immunoconjugates can be detectably labeled by coupling an antibody component to a chemiluminescent compound. The presence of the chemiluminescent-tagged immunoconjugate is determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of chemiluminescent labeling compounds include luminol, isoluminol, an aromatic acridinium ester, an imidazole, an acridinium salt and an oxalate ester.

35 [0275] Similarly, a bioluminescent compound can be used to label anti-Zcytor16 immunoconjugates of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Bioluminescent compounds that are useful for labeling include luciferin, luciferase and aequorin.

40 [0276] Alternatively, anti-Zcytor16 immunoconjugates can be detectably labeled by linking an anti-Zcytor16 antibody component to an enzyme. When the anti-Zcytor16-enzyme conjugate is incubated in the presence of the appropriate substrate, the enzyme moiety reacts with the substrate to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means. Examples of enzymes that can be used to detectably label polyspecific immunoconjugates include β -galactosidase, glucose oxidase, peroxidase and alkaline phosphatase.

45 [0277] Those of skill in the art will know of other suitable labels which can be employed in accordance with the present invention. The binding of marker moieties to anti-Zcytor16 antibodies can be accomplished using standard techniques known to the art. Typical methodology in this regard is described by Kennedy et al., *Clin. Chim. Acta* 70:1 (1976), Schurs et al., *Clin. Chim. Acta* 81:1 (1977), Shih et al., *Int'l J. Cancer* 46:1101 (1990), Stein et al., *Cancer Res.* 50:1330 (1990), and Coligan, *supra*.

50 [0278] Moreover, the convenience and versatility of immunochemical detection can be enhanced by using anti-Zcytor16 antibodies that have been conjugated with avidin, streptavidin, and biotin (see, for example, Wilchek et al. (eds.), "Avidin-Biotin Technology," *Methods In Enzymology*, Vol. 184 (Academic Press 1990), and Bayer et al., "Immunochemical Applications of Avidin-Biotin Technology," in *Methods In Molecular Biology*, Vol. 10, Manson (ed.), pages 149-162 (The Humana Press, Inc. 1992)).

55 [0279] Methods for performing immunoassays are well-established. See, for example, Cook and Self, "Monoclonal Antibodies in Diagnostic Immunoassays," in *Monoclonal Antibodies: Production, Engineering, and Clinical Application*, Ritter and Ladyman (eds.), pages 180-208, (Cambridge University Press, 1995), Perry, "The Role of Monoclonal Antibodies in the Advancement of Immunoassay Technology," in *Monoclonal Antibodies: Principles and Applications*, Birch and Lennox (eds.), pages 107-120 (Wiley-Liss, Inc. 1995), and Diamandis, *Immunoassay* (Academic Press, Inc. 1996).

[0280] The present specification describes kits for performing an immunological diagnostic assay for Zcytor16 gene expression. Such kits comprise at least one container comprising an anti-Zcytor16 antibody, or antibody fragment. A kit may also comprise a second container comprising one or more reagents capable of indicating the presence of Zcytor16

antibody or antibody fragments. Examples of such indicator reagents include detectable labels such as a radioactive label, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label, colloidal gold, and the like. A kit may also comprise a means for conveying to the user that Zcytor16 antibodies or antibody fragments are used to detect Zcytor16 protein. For example, written instructions may state that the enclosed antibody or antibody fragment can be used to detect Zcytor16. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.

[0281] Alternative techniques for generating or selecting antibodies useful herein include *in vitro* exposure of lymphocytes to soluble zcytor16 monomeric receptor or soluble zcytor16 homodimeric, heterodimeric or multimeric polypeptides, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled soluble zcytor16 monomeric receptor or soluble zcytor16 homodimeric, heterodimeric or multimeric polypeptides). Genes encoding polypeptides having potential binding domains such as soluble zcytor16 monomeric receptor or soluble zcytor16 homodimeric, heterodimeric or multimeric polypeptide can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., US Patent NO. 5,223,409; Ladner et al., US Patent NO. 4,946,778; Ladner et al., US Patent NO. 5,403,484 and Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the soluble zcytor16 monomeric receptor or soluble zcytor16 homodimeric, heterodimeric or multimeric polypeptide sequences disclosed herein to identify proteins which bind to zcytor16-comprising receptor polypeptides. These "binding polypeptides," which interact with soluble zcytor16-comprising receptor polypeptides, can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding polypeptides can also be used in analytical methods such as for screening expression libraries and neutralizing activity, e.g., for blocking interaction between IL-TIF ligand and receptor, or viral binding to a receptor. The binding polypeptides can also be used for diagnostic assays for determining circulating levels of soluble zcytor16-comprising receptor polypeptides; for detecting or quantitating soluble or non-soluble zcytor16-comprising receptors as marker of underlying pathology or disease. These binding polypeptides can also act as "antagonists" to block soluble or membrane-bound zcytor16 monomeric receptor or zcytor16 homodimeric, heterodimeric or multimeric polypeptide binding (e.g. to ligand) and signal transduction *in vitro* and *in vivo*. Again, these binding polypeptides serve as anti-zcytor16 monomeric receptor or anti-zcytor16 homodimeric, heterodimeric or multimeric polypeptides and are useful for inhibiting IL-TIF activity, as well as receptor activity or protein-binding. Antibodies raised to the natural receptor complexes of the present invention may be preferred embodiments, as they may act more specifically against the IL-TIF, or more potently than antibodies raised to only one subunit. Moreover, the antagonistic and binding activity of the antibodies can be assayed in the IL-TIF proliferation, signal trap, luciferase or binding assays in the presence of IL-TIF and zcytor16-comprising soluble receptors, and other biological or biochemical assays described herein.

[0282] Antibodies to monomeric zcytor16 receptor or zcytor16 homodimeric, heterodimeric or multimeric zcytor16-containing receptors may be used for tagging cells that express zcytor16 receptors; for isolating soluble zcytor16-comprising receptor polypeptides by affinity purification; for diagnostic assays for determining circulating levels of soluble zcytor16-comprising receptor polypeptides; for detecting or quantitating soluble zcytor16-comprising receptors as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies that can act as IL-TIF agonists; and as neutralizing antibodies or as antagonists to block zcytor16 receptor function, or to block IL-TIF activity *in vitro* and *in vivo*. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, biotin, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. Moreover, antibodies to soluble zcytor16-comprising receptor polypeptides, or fragments thereof may be used *in vitro* to detect denatured or non-denatured zcytor16-comprising receptor polypeptides or fragments thereof in assays, for example, Western Blots or other assays known in the art.

[0283] Antibodies to soluble zcytor16 receptor or soluble zcytor16 homodimeric, heterodimeric or multimeric receptor polypeptides are useful for tagging cells that express the corresponding receptors and assaying their expression levels, for affinity purification, within diagnostic assays for determining circulating levels of receptor polypeptides, analytical methods employing fluorescence-activated cell sorting. Moreover, divalent antibodies, and anti-idiotypic antibodies may be used as agonists to mimic the effect of the zcytor16 ligand, IL-TIF.

[0284] Antibodies herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. For instance, antibodies or binding polypeptides which recognize soluble zcytor16 receptor or soluble zcytor16 homodimeric, heterodimeric or multimeric receptor polypeptides of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (i.e., a zcytor16-comprising soluble or membrane-bound receptor). More specifically, antibodies to soluble zcytor16-comprising receptor polypeptides, or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the zcytor16-comprising receptor such as zcytor16-expressing cancers, or certain disease states.

[0285] Suitable detectable molecules may be directly or indirectly attached to polypeptides that bind zcytor16-comprising receptor polypeptides, such as "binding polypeptides," (including binding peptides disclosed above), antibodies, or bioactive fragments or portions thereof. Suitable detectable molecules include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Binding polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the binding polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair.

[0286] In another embodiment, binding polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the binding polypeptide has multiple functional domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the fusion protein including only a single domain includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/ cytotoxic molecule conjugates.

[0287] In another embodiment, zcytor16 binding polypeptide-cytokine or antibody-cytokine fusion proteins can be used for enhancing *in vivo* killing of target tissues (for example, spleen, pancreatic, blood, lymphoid, colon, and bone marrow cancers), if the binding polypeptide-cytokine or anti-zcytor16 receptor antibody targets the hyperproliferative cell (See, generally, Hornick et al., Blood 89:4437-47, 1997). The described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable anti-zcytor16 monomer, homodimer, heterodimer or multimer antibodies target an undesirable cell or tissue (i.e., a tumor or a leukemia), and the fused cytokine mediates improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance.

[0288] Alternatively, zcytor16 receptor binding polypeptides or antibody fusion proteins described herein can be used for enhancing *in vivo* killing of target tissues by directly stimulating a zcytor16 receptor-modulated apoptotic pathway, resulting in cell death of hyperproliferative cells expressing zcytor16-comprising receptors.

12. Therapeutic Uses of Polypeptides Having Zcytor16 Activity

[0289] Amino acid sequences having Zcytor16 activity can be used to modulate the immune system by binding Zcytor16 ligand, and thus, preventing the binding of Zcytor16 ligand with endogenous Zcytor16 receptor. Zcytor16 antagonists, such as anti-Zcytor16 antibodies, can also be used to modulate the immune system by inhibiting the binding of Zcytor16 ligand with the endogenous Zcytor16 receptor. Accordingly, the present specification describes the use of proteins, polypeptides, and peptides having Zcytor16 activity (such as Zcytor16 polypeptides, Zcytor16 analogs (e.g., anti-Zcytor16 anti-idiotypic antibodies), and Zcytor16 fusion proteins) in a subject which lacks an adequate amount of this polypeptide, or which produces an excess of Zcytor16 ligand. Zcytor16 antagonists (e.g., anti-Zcytor16 antibodies) can be also used to treat a subject which produces an excess of either Zcytor16 ligand or Zcytor16. Suitable subjects include mammals, such as humans.

[0290] Moreover, we have shown that the zcytor16 receptor binds a ligand called T-cell inducible Factor (IL-TIF) (SEQ ID NO:15; Dumontier, L. et al., Proc. Nat'l. Acad. Sci. 97:10144-10149, 2000; mouse IL-TIF sequence is shown in Dumontier et al., J. Immunol. 164:1814-1819, 2000). Moreover, commonly owned zcytor11 (US Patent No. 5,965,704) and CRF2-4 receptor also bind IL-TIF (See, WIPO publication WO 00/24758; Dumontier et al., J. Immunol. 164: 1814-1819, 2000; Spencer, SD et al., J. Exp. Med. 187:571-578, 1998; Gibbs, VC and Pennica Gene 186:97-101, 1997 (CRF2-4 cDNA); Xie, MH et al., J. Biol. Chem. 275: 31335-31339, 2000; and Kottenko, SV et al., J. Biol. Chem. manuscript

in press M007837200). Moreover, IL-10 β receptor may be involved as a receptor for IL-TIF, and it is believed to be synonymous with CRF2-4 (Dumoutier, L. et al., Proc. Nat'l. Acad. Sci. 97:10144-10149, 2000; Liu Y et al, J Immunol. 152: 1821-1829, 1994 (IL-10R cDNA). Within preferred embodiments, the soluble receptor form of zcytor16, residues 22-231 of SEQ ID NO:2, (SEQ ID NO:13) is a monomer, homodimer, heterodimer, or multimer that antagonizes the effects of IL-TIF *in vivo*. Antibodies and binding polypeptides to such zcytor16 monomer, homodimer, heterodimer, or multimers also serve as antagonists of zcytor16 activity.

[0291] IL-TIF has been shown to be induced in the presence of IL-9, and is suspected to be involved in promoting Th1-type immune responses, and inflammation. IL-9 stimulates proliferation, activation, differentiation and/or induction of immune function in a variety of ways and is implicated in asthma, lung mastocytosis, and other diseases, as well as activates STAT pathways. Antagonists of IL-TIF or IL-9 function can have beneficial use against such human diseases. The present invention provides novel antagonists of IL-TIF, as defined in the claims.

[0292] IL-TIF has been shown to be involved in up-regulate the production of acute phase reactants, such as serum amyloid A (SAA), α 1-antichymotrypsin, and haptoglobin, and that IL-TIF expression is increased upon injection of lipopolysaccharide (LPS) *in vivo* suggesting that IL-TIF is involved in inflammatory response (Dumoutier, L. et al., Proc. Nat'l. Acad. Sci. 97:10144-10149, 2000). Production of acute phase proteins, such as SAA, is considered a short-term survival mechanism where inflammation is beneficial; however, maintenance of acute phase proteins for longer periods contributes to chronic inflammation and can be harmful to human health. For review, see Uhlar, CM and Whitehead, AS, Eur. J. Biochem. 265:501-523, 1999, and Baumann H. and Gaudie, J. Immunology Today 15:74-80, 1994. Moreover, the acute phase protein SAA is implicated in the pathogenesis of several chronic inflammatory diseases, is implicated in atherosclerosis and rheumatoid arthritis, and is the precursor to the amyloid A protein deposited in amyloidosis (Uhlar, CM and Whitehead, supra.). Thus, as IL-TIF acts as a pro-inflammatory molecule and induces production of SAA, antagonists would be useful in treating inflammatory disease and other diseases associated with acute phase response proteins induced by IL-TIF. Antagonists are defined in the claims. Reducing IL-TIF-induced or IL-9 induced inflammation comprises administering to a mammal with inflammation an amount of a composition of soluble zcytor16-comprising receptor sufficient to reduce inflammation. Moreover, suppressing an inflammatory response in a mammal with inflammation can comprise: (1) determining a level of serum amyloid A protein; (2) administering a composition comprising a soluble zcytor16 cytokine receptor polypeptide as described herein in an acceptable pharmaceutical vehicle; (3) determining a post administration level of serum amyloid A protein; (4) comparing the level of serum amyloid A protein in step (1) to the level of serum amyloid A protein in step (3), wherein a lack of increase or a decrease in serum amyloid A protein level is indicative of suppressing an inflammatory response.

[0293] The receptors of the present invention as defined in the claims include at least one zcytor16 receptor subunit. A second receptor polypeptide included in the heterodimeric soluble receptor belongs to the receptor subfamily that includes Interleukin-10 receptor, the interferons (e.g., interferon-gamma alpha and beta chains and the interferon-alpha/beta receptor alpha and beta chains), zcytor7, zcytor11, and CRF2-4. A second soluble receptor polypeptide included in a heterodimeric soluble receptor can also include a zcytor11 soluble receptor subunit, disclosed in the commonly owned US Patent No. 5,965,704; an IL-10R subunit, such as IL-10R α ; or a zcytor7 soluble receptor subunit, disclosed in the commonly owned US Patent No. 5,945,511. The zcytor11 receptor in conjunction with CRF2-4 and IL-10 Receptor was shown to signal JAK-STAT pathway in response to IL-TIF (Xie et al., supra.; Kotenko et al., supra.). According to the present invention, in addition to a monomeric or homodimeric zcytor16 receptor polypeptide, a heterodimeric soluble zcytor16 receptor, as exemplified by an embodiment consisting of a soluble zcytor16 receptor + soluble CRF2-4 receptor heterodimer (zcytor16/CRF2-4) as defined in the claims, can act as an antagonist of the IL-TIF. Other receptors include soluble heterodimers comprising zcytor16/IL-10R, zcytor16/IL-9R, zcytor16/zcytor11, zcytor16/zcytor7, and other class II receptor subunits, as well as multimeric receptors including but not limited to zcytor16/CRF2-4/zcytor11 or zcytor16/CRF2-4/IL-10R.

[0294] Analysis of the tissue distribution of the mRNA corresponding zcytor16 cDNA showed that mRNA level was highest in placenta and spleen, and the ligand to which zcytor16 binds (IL-TIF) is implicated in inducing inflammatory response including induction of the acute-phase response (Dumoutier, L. et al., Proc. Nat'l. Acad. Sci. 97:10144-10149, 2000). Thus, the present specification describes the use of soluble zcytor16 heterodimers as antagonists in inflammatory and immune diseases or conditions such as pancreatitis, type I diabetes (IDDM), pancreatic cancer, pancreatitis, Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, colon and intestinal cancer, diverticulosis, autoimmune disease, sepsis, organ or bone marrow transplant; inflammation due to trauma, surgery or infection; amyloidosis; splenomegaly; graft versus host disease; and where inhibition of inflammation, immune suppression, reduction of proliferation of hematopoietic, immune, inflammatory or lymphoid cells, macrophages, T-cells (including Th1 and Th2 cells), suppression of immune response to a pathogen or antigen, or other instances where inhibition of IL-TIF or IL-9 cytokine production is desired.

[0295] Moreover, antibodies or binding polypeptides that bind zcytor16 polypeptides, monomers, homodimers, heterodimers and multimers described herein and/or zcytor16 polypeptides, monomers, homodimers, heterodimers and multimers themselves are useful to:

1) Antagonize or block signaling via the IL-TIF receptors in the treatment of acute inflammation, inflammation as a result of trauma, tissue injury, surgery, sepsis or infection, and chronic inflammatory diseases such as asthma, inflammatory bowel disease (IBD), chronic colitis, splenomegaly, rheumatoid arthritis, recurrent acute inflammatory episodes (e.g., tuberculosis), and treatment of amyloidosis, and atherosclerosis, Castleman's Disease, asthma, and other diseases associated with the induction of acute-phase response.

2) Antagonize or block signaling via the IL-TIF receptors in the treatment of autoimmune diseases such as IDDM, multiple sclerosis (MS), systemic Lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, and IBD to prevent or inhibit signaling in immune cells (e.g. lymphocytes, monocytes, leukocytes) via zcytor16 (Hughes C et al., J. Immunol 153: 3319-3325, 1994). Alternatively antibodies, such as monoclonal antibodies (MAb) to zcytor16-comprising receptors, can also be used as an antagonist to deplete unwanted immune cells to treat autoimmune disease. Asthma, allergy and other atopic disease may be treated with an MAb against, for example, soluble zcytor16 soluble receptors or zcytor16/CRF2-4 heterodimers, to inhibit the immune response or to deplete offending cells. Blocking or inhibiting signaling via zcytor16, using the polypeptides of the present invention and antibodies present may also benefit diseases of the pancreas, kidney, pituitary and neuronal cells. IDDM, NIDDM, pancreatitis, and pancreatic carcinoma may benefit. Zcytor16 may serve as a target for MAb therapy of cancer where an antagonizing MAb inhibits cancer growth and targets immune-mediated killing. (Holliger P, and Hoogenboom, H: Nature Biotech. 16: 1015-1016, 1998). Mabs to soluble zcytor16 monomers, homodimers, heterodimers and multimers may also be useful to treat nephropathies such as glomerulosclerosis, membranous neuropathy, amyloidosis (which also affects the kidney among other tissues), renal arteriosclerosis, glomerulonephritis of various origins, fibroproliferative diseases of the kidney, as well as kidney dysfunction associated with SLE, IDDM, type II diabetes (NIDDM), renal tumors and other diseases.

3) Agonize or initiate signaling via the IL-TIF receptors in the treatment of autoimmune diseases such as IDDM, MS, SLE, myasthenia gravis, rheumatoid arthritis, and IBD. Anti-soluble zcytor16, anti-soluble zcytor16/CRF2-4 heterodimers and multimer monoclonal antibodies may signal lymphocytes or other immune cells to differentiate, alter proliferation, or change production of cytokines or cell surface proteins that ameliorate autoimmunity. Specifically, modulation of a T-helper cell response to an alternate pattern of cytokine secretion may deviate an autoimmune response to ameliorate disease (Smith JA et al., J. Immunol. 160:4841-4849, 1998). Similarly, agonistic Anti-soluble zcytor16, anti-soluble zcytor16/CRF2-4 heterodimers and multimer monoclonal antibodies may be used to signal, deplete and deviate immune cells involved in asthma, allergy and atopic disease. Signaling via zcytor16 may also benefit diseases of the pancreas, kidney, pituitary and neuronal cells. IDDM, NIDDM, pancreatitis, and pancreatic carcinoma may benefit. Zcytor16 may serve as a target for MAb therapy of pancreatic cancer where a signaling MAb inhibits cancer growth and targets immune-mediated killing (Tutt, AL et al., J Immunol. 161: 3175-3185, 1998). Similarly renal cell carcinoma may be treated with monoclonal antibodies to zcytor16-comprising soluble receptors of the present invention.

[0296] Soluble zcytor16 monomeric, homodimeric, heterodimeric and multimeric polypeptides described herein can be used to neutralize/block IL-TIF activity in the treatment of autoimmune disease, atopic disease, NIDDM, pancreatitis and kidney dysfunction as described above. A soluble form of zcytor16 may be used to promote an antibody response mediated by Th cells and/or to promote the production of IL-4 or other cytokines by lymphocytes or other immune cells.

[0297] The soluble zcytor16-comprising receptors of the present invention are useful as antagonists of the IL-TIF cytokine. Such antagonistic effects can be achieved by direct neutralization or binding of the IL-TIF. In addition to antagonistic uses, the soluble receptors of the present invention can bind IL-TIF and act as carrier proteins for the IL-TIF cytokine, in order to transport the Ligand to different tissues, organs, and cells within the body. As such, the soluble receptors of the present invention can be fused or coupled to molecules, polypeptides or chemical moieties that direct the soluble-receptor-Ligand complex to a specific site, such as a tissue, specific immune cell, or tumor. For example, in acute infection or some cancers, benefit may result from induction of inflammation and local acute phase response proteins by the action of IL-TIF. Thus, the soluble receptors of the present invention can be used to specifically direct the action of the IL-TIF. See, Cosman, D. Cytokine 5: 95-106, 1993; and Fernandez-Botran, R. Exp. Opin. Invest. Drugs 9:497-513, 2000.

[0298] Moreover, the soluble receptors of the present invention can be used to stabilize the IL-TIF, to increase the bioavailability, therapeutic longevity, and/or efficacy of the Ligand by stabilizing the Ligand from degradation or clearance, or by targeting the ligand to a site of action within the body. For example the naturally occurring IL-6/soluble IL-6R complex stabilizes IL-6 and can signal through the gp130 receptor. See, Cosman, D. *supra.*, and Fernandez-Botran, R. *supra.* Moreover, Zcytor16 may be combined with a cognate ligand such as IL-TIF to comprise a ligand/soluble receptor complex. Such complexes may be used to stimulate responses from cells presenting a companion receptor subunit such as, for example, zcytor11 or CRF2-4. The cell specificity of zcytor16/ligand complexes may differ from that seen for the ligand administered alone. Furthermore the complexes may have distinct pharmacokinetic properties such as affecting half-life, dose/response and organ or tissue specificity. ZcytoR16/IL-TIF complexes thus may have agonist

activity to enhance an immune response or stimulate mesangial cells or to stimulate hepatic cells. Alternatively only tissues expressing a signaling subunit the heterodimerizes with the complex may be affected analogous to the response to IL6/IL6R complexes (Hirota H. et al., Proc. Nat'l. Acad. Sci. 92:4862-4866, 1995; Hirano, T. in Thomason, A. (Ed.) "The Cytokine Handbook", 3rd Ed., p. 208-209). Soluble receptor/cytokine complexes for IL12 and CNTF display similar activities.

[0299] Moreover Inflammation is a protective response by an organism to fend off an invading agent. Inflammation is a cascading event that involves many cellular and humoral mediators. On one hand, suppression of inflammatory responses can leave a host immunocompromised; however, if left unchecked, inflammation can lead to serious complications including chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and the like), septic shock and multiple organ failure. Importantly, these diverse disease states share common inflammatory mediators. The collective diseases that are characterized by inflammation have a large impact on human morbidity and mortality. Therefore it is clear that anti-inflammatory proteins, such as zcytor16, could have crucial therapeutic potential for a vast number of human and animal diseases, from asthma and allergy to autoimmunity and septic shock.

1. Arthritis

[0300] Arthritis, including osteoarthritis, rheumatoid arthritis, arthritic joints as a result of injury, and the like, are common inflammatory conditions which would benefit from the therapeutic use of anti-inflammatory proteins, such as zcytor16 polypeptides of the present invention. For Example, rheumatoid arthritis (RA) is a systemic disease that affects the entire body and is one of the most common forms of arthritis. It is characterized by the inflammation of the membrane lining the joint, which causes pain, stiffness, warmth, redness and swelling. Inflammatory cells release enzymes that may digest bone and cartilage. As a result of rheumatoid arthritis, the inflamed joint lining, the synovium, can invade and damage bone and cartilage leading to joint deterioration and severe pain amongst other physiologic effects. The involved joint can lose its shape and alignment, resulting in pain and loss of movement.

[0301] Rheumatoid arthritis (RA) is an immune-mediated disease particularly characterized by inflammation and subsequent tissue damage leading to severe disability and increased mortality. A variety of cytokines are produced locally in the rheumatoid joints. Numerous studies have demonstrated that IL-1 and TNF-alpha, two prototypic pro-inflammatory cytokines, play an important role in the mechanisms involved in synovial inflammation and in progressive joint destruction. Indeed, the administration of TNF-alpha and IL-1 inhibitors in patients with RA has led to a dramatic improvement of clinical and biological signs of inflammation and a reduction of radiological signs of bone erosion and cartilage destruction. However, despite these encouraging results, a significant percentage of patients do not respond to these agents, suggesting that other mediators are also involved in the pathophysiology of arthritis (Gabay, Expert. Opin. Biol. Ther. 2(2): 135-149, 2002). One of those mediators could be IL-9 or IL-TIF, and as such a molecule that binds or inhibits IL-TIF, such as zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, could serve as a valuable therapeutic to reduce inflammation in rheumatoid arthritis, and other arthritic diseases.

[0302] There are several animal models for rheumatoid arthritis known in the art. For example, in the collagen-induced arthritis (CIA) model, mice develop chronic inflammatory arthritis that closely resembles human rheumatoid arthritis. Since CIA shares similar immunological and pathological features with RA, this makes it an ideal model for screening potential human anti-inflammatory compounds. The CIA model is a well-known model in mice that depends on both an immune response, and an inflammatory response, in order to occur. The immune response comprises the interaction of B-cells and CD4+ T-cells in response to collagen, which is given as antigen, and leads to the production of anti-collagen antibodies. The inflammatory phase is the result of tissue responses from mediators of inflammation, as a consequence of some of these antibodies cross-reacting to the mouse's native collagen and activating the complement cascade. An advantage in using the CIA model is that the basic mechanisms of pathogenesis are known. The relevant T-cell and B-cell epitopes on type II collagen have been identified, and various immunological (e.g., delayed-type hypersensitivity and anti-collagen antibody) and inflammatory (e.g., cytokines, chemokines, and matrix-degrading enzymes) parameters relating to immune-mediated arthritis have been determined, and can thus be used to assess test compound efficacy in the CIA model (Wooley, Curr. Opin. Rheum. 3:407-20, 1999; Williams et al., Immunol. 89:9784-788, 1992; Myers et al., Life Sci. 61:1861-78, 1997; and Wang et al., Immunol. 92:8955-959, 1995).

[0303] The administration of soluble zcytor16 comprising polypeptides, such as zcytor16-Fc4 or other zcytor16 soluble and fusion proteins to these CIA model mice was used to evaluate the use of zcytor16 to ameliorate symptoms and alter the course of disease. Since the ligand of zcytor16, IL-TIF, induces production of SAA, which is implicated in the pathogenesis of rheumatoid arthritis, and zcytor16 was demonstrated to be able to inhibit IL-TIF and SAA activity *in vitro* and *in vivo*, the systemic or local administration of zcytor16 comprising polypeptides, such as zcytor16-Fc4 or other zcytor16 soluble and fusion proteins can potentially suppress the inflammatory response in RA. The injection of 10 ug zcytor16-Fc (three times a week for 4 weeks) significantly reduced the disease score (paw score, incident of inflammation or disease). Other potential therapeutics include Zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, and the like.

2. Endotoxemia

[0304] Endotoxemia is a severe condition commonly resulting from infectious agents such as bacteria and other infectious disease agents, sepsis, toxic shock syndrome, or in immunocompromised patients subjected to opportunistic infections, and the like. Therapeutically useful of anti-inflammatory proteins, such as zcytor16 polypeptides of the present invention, could aid in preventing and treating endotoxemia in humans and animals. Zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, could serve as a valuable therapeutic to reduce inflammation and pathological effects in endotoxemia.

[0305] Lipopolysaccharide (LPS) induced endotoxemia engages many of the proinflammatory mediators that produce pathological effects in the infectious diseases and LPS induced endotoxemia in rodents is a widely used and acceptable model for studying the pharmacological effects of potential pro-inflammatory or immunomodulating agents. LPS, produced in gram-negative bacteria, is a major causative agent in the pathogenesis of septic shock (Glausner et al., Lancet 338:732, 1991). A shock-like state can indeed be induced experimentally by a single injection of LPS into animals. Molecules produced by cells responding to LPS can target pathogens directly or indirectly. Although these biological responses protect the host against invading pathogens, they may also cause harm. Thus, massive stimulation of innate immunity, occurring as a result of severe Gram-negative bacterial infection, leads to excess production of cytokines and other molecules, and the development of a fatal syndrome, septic shock syndrome, which is characterized by fever, hypotension, disseminated intravascular coagulation, and multiple organ failure (Dumitru et al. Cell 103:1071-1083, 2000).

[0306] These toxic effects of LPS are mostly related to macrophage activation leading to the release of multiple inflammatory mediators. Among these mediators, TNF appears to play a crucial role, as indicated by the prevention of LPS toxicity by the administration of neutralizing anti-TNF antibodies (Beutler et al., Science 229:869, 1985). It is well established that 1ug injection of *E. coli* LPS into a C57Bl/6 mouse will result in significant increases in circulating IL-6, TNF-alpha, IL-1, and acute phase proteins (for example, SAA) approximately 2 hours post injection. The toxicity of LPS appears to be mediated by these cytokines as passive immunization against these mediators can result in decreased mortality (Beutler et al., Science 229:869, 1985). The potential immunointervention strategies for the prevention and/or treatment of septic shock include anti-TNF mAb, IL-1 receptor antagonist, LIF, IL-10, and G-CSF.

[0307] The administration of soluble zcytor16 comprising polypeptides, such as zcytor16-Fc4 or other zcytor16 soluble and fusion proteins to these LPS-induced model was used to evaluate the use of zcytor16 to ameliorate symptoms and alter the course of LPS-induced disease. The model showed induction of IL-TIF by LPS injection and the potential treatment of disease by zcytor16 polypeptides. Since LPS induces the production of pro-inflammatory IL-TIF, SAA or other pro-inflammatory factors possibly contributing to the pathology of endotoxemia, the neutralization of IL-TIF activity, SAA or other pro-inflammatory factors by its antagonist zcytor16 polypeptide can be used to reduce the symptoms of endotoxemia, such as seen in endotoxic shock. Other potential therapeutics include Zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, and the like.

3 Inflammatory Bowel Disease. IBD

[0308] In the United States approximately 500,000 people suffer from Inflammatory Bowel Disease (IBD) which can affect either colon and rectum (Ulcerative colitis) or both, small and large intestine (Crohn's Disease). The pathogenesis of these diseases is unclear, but they involve chronic inflammation of the affected tissues. Zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, could serve as a valuable therapeutic to reduce inflammation and pathological effects in IBD and related diseases.

[0309] Ulcerative colitis (UC) is an inflammatory disease of the large intestine, commonly called the colon, characterized by inflammation and ulceration of the mucosa or innermost lining of the colon. This inflammation causes the colon to empty frequently, resulting in diarrhea. Symptoms include loosening of the stool and associated abdominal cramping, fever and weight loss. Although the exact cause of UC is unknown, recent research suggests that the body's natural defenses are operating against proteins in the body which the body thinks are foreign (an "autoimmune reaction"). Perhaps because they resemble bacterial proteins in the gut, these proteins may either instigate or stimulate the inflammatory process that begins to destroy the lining of the colon. As the lining of the colon is destroyed, ulcers form releasing mucus, pus and blood. The disease usually begins in the rectal area and may eventually extend through the entire large bowel. Repeated episodes of inflammation lead to thickening of the wall of the intestine and rectum with scar tissue. Death of colon tissue or sepsis may occur with severe disease. The symptoms of ulcerative colitis vary in severity and their onset may be gradual or sudden. Attacks may be provoked by many factors, including respiratory infections or stress.

[0310] Although there is currently no cure for UC available, treatments are focused on suppressing the abnormal inflammatory process in the colon lining. Treatments including corticosteroids immunosuppressives (eg. azathioprine, mercaptopurine, and methotrexate) and aminosalicicylates are available to treat the disease. However, the long-term use of immunosuppressives such as corticosteroids and azathioprine can result in serious side effects including thinning of

bones, cataracts, infection, and liver and bone marrow effects. In the patients in whom current therapies are not successful, surgery is an option. The surgery involves the removal of the entire colon and the rectum.

[0311] There are several animal models that can partially mimic chronic ulcerative colitis. The most widely used model is the 2,4,6-trinitrobenzenesulfonic acid/ethanol (TNBS) induced colitis model, which induces chronic inflammation and ulceration in the colon. When TNBS is introduced into the colon of susceptible mice via intra-rectal instillation, it induces T-cell mediated immune response in the colonic mucosa, in this case leading to a massive mucosal inflammation characterized by the dense infiltration of T-cells and macrophages throughout the entire wall of the large bowel. Moreover, this histopathologic picture is accompanied by the clinical picture of progressive weight loss (wasting), bloody diarrhea, rectal prolapse, and large bowel wall thickening (Neurath et al. Intern. Rev. Immunol. 19:51-62, 2000).

[0312] Another colitis model uses dextran sulfate sodium (DSS), which induces an acute colitis manifested by bloody diarrhea, weight loss, shortening of the colon and mucosal ulceration with neutrophil infiltration. DSS-induced colitis is characterized histologically by infiltration of inflammatory cells into the lamina propria, with lymphoid hyperplasia, focal crypt damage, and epithelial ulceration. These changes are thought to develop due to a toxic effect of DSS on the epithelium and by phagocytosis of lamina propria cells and production of TNF-alpha and IFN-gamma. Despite its common use, several issues regarding the mechanisms of DSS about the relevance to the human disease remain unresolved. DSS is regarded as a T cell-independent model because it is observed in T cell-deficient animals such as SCID mice.

[0313] The administration of soluble zcytor16 comprising polypeptides, such as zcytor16-Fc4 or other zcytor16 soluble and fusion proteins to these TNBS or DSS models can be used to evaluate the use of zcytor16 to ameliorate symptoms and alter the course of gastrointestinal disease. We observed the increased expression of IL-TIF in colon tissues of DSS-mice by RT-PCR, and the synergistic activity of IL-TIF with IL-1beta on intestinal cell lines. It indicates IL-TIF may play a role in the inflammatory response in colitis, and the neutralization of IL-TIF activity by administering zcytor16 polypeptides is a potential therapeutic approach for IBD. Other potential therapeutics include Zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, and the like.

4. Psoriasis

[0314] Psoriasis is a chronic skin condition that affects more than seven million Americans. Psoriasis occurs when new skin cells grow abnormally, resulting in inflamed, swollen, and scaly patches of skin where the old skin has not shed quickly enough. Plaque psoriasis, the most common form, is characterized by inflamed patches of skin ("lesions") topped with silvery white scales. Psoriasis may be limited to a few plaques or involve moderate to extensive areas of skin, appearing most commonly on the scalp, knees, elbows and trunk. Although it is highly visible, psoriasis is not a contagious disease. The pathogenesis of the diseases involves chronic inflammation of the affected tissues. Zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, could serve as a valuable therapeutic to reduce inflammation and pathological effects in psoriasis, other inflammatory skin diseases, skin and mucosal allergies, and related diseases.

[0315] Psoriasis is a T-cell mediated inflammatory disorder of the skin that can cause considerable discomfort. It is a disease for which there is no cure and affects people of all ages. Psoriasis affects approximately two percent of the populations of European and North America. Although individuals with mild psoriasis can often control their disease with topical agents, more than one million patients worldwide require ultraviolet or systemic immunosuppressive therapy. Unfortunately, the inconvenience and risks of ultraviolet radiation and the toxicities of many therapies limit their long-term use. Moreover, patients usually have recurrence of psoriasis, and in some cases rebound, shortly after stopping immunosuppressive therapy.

[0316] IL-20 is a novel IL-10 homologue that causes neonatal lethality with skin abnormalities including aberrant epidermal differentiation in IL-20 transgenic mice (Blumberg H et al., Cell 104:9-19, 2001) IL-20 receptor is dramatically upregulated in psoriatic skin. Since IL-TIF shares a receptor subunit (zcytor11) with IL-20 receptor, and IL-TIF transgenic mice display a similar phenotype, it is possible that IL-TIF is also involved in the inflammatory skin diseases such as psoriasis. The administration of zcytor16 polypeptide, either subcutaneous or topically, may potential reduce the inflammation and symptom. Other potential therapeutics include Zcytor16 polypeptides, soluble zcytor11/CRF2-4 receptor polypeptides, or anti IL-TIF antibodies or binding partners, and the like.

[0317] Zcytor16 homodimeric, heterodimeric and multimeric receptor polypeptides may also be used within diagnostic systems for the detection of circulating levels of IL-TIF ligand, and in the detection of IL-TIF associated with acute phase inflammatory response. Within a related embodiment, antibodies or other agents that specifically bind to Zcytor16 soluble receptors of the present invention can be used to detect circulating receptor polypeptides; conversely, Zcytor16 soluble receptors themselves can be used to detect circulating or locally-acting IL-TIF polypeptides. Elevated or depressed levels of ligand or receptor polypeptides may be indicative of pathological conditions, including inflammation or cancer. IL-TIF is known to induce associated acute phase inflammatory response. Moreover, detection of acute phase proteins or molecules such as IL-TIF can be indicative of a chronic inflammatory condition in certain disease states (e.g., rheumatoid arthritis). Detection of such conditions serves to aid in disease diagnosis as well as help a physician in choosing

proper therapy.

[0318] Moreover, soluble zcytor16 receptor polypeptides of the present invention can be used as a "ligand sink," i.e., antagonist, to bind ligand *in vivo* or *in vitro* in therapeutic or other applications where the presence of the ligand is not desired. For example, in chronic inflammatory conditions or cancers that are expressing large amounts of bioactive IL-TIF, soluble zcytor16 receptor or soluble zcytor16 heterodimeric and multimeric receptor polypeptides, such as soluble zcytor16/CRF2-4 can be used as a direct antagonist of the ligand *in vivo*, and may aid in reducing progression and symptoms associated with the disease, and can be used in conjunction with other therapies (e.g., steroid or chemotherapy) to enhance the effect of the therapy in reducing progression and symptoms, and preventing relapse. Moreover, soluble zcytor16 receptor polypeptides can be used to slow the progression of cancers that over-express zcytor16 receptors, by binding ligand *in vivo* that could otherwise enhance proliferation of those cancers.

[0319] Moreover, soluble zcytor16 receptor polypeptides of the present invention can be used *in vivo* or in diagnostic applications to detect IL-TIF-expressing inflammation or cancers *in vivo* or in tissue samples. For example, the soluble zcytor16 receptors of the present invention can be conjugated to a radio-label or fluorescent label as described herein, and used to detect the presence of the IL-TIF in a tissue sample using an *in vitro* ligand-receptor type binding assay, or fluorescent imaging assay. Moreover, radiolabeled soluble zcytor16 receptors of the present invention could be administered *in vivo* to detect Ligand-expressing solid tumors through a radio-imaging method known in the art.

[0320] Generally, the dosage of administered Zcytor16 (or Zcytor16 analog or fusion protein) will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. Typically, it is desirable to provide the recipient with a dosage of Zcytor16 polypeptide which is in the range of from about 1 pg/kg to 10 mg/kg (amount of agent/body weight of patient), although a lower or higher dosage also may be administered as circumstances dictate.

[0321] Administration of a Zcytor16 polypeptide to a subject can be intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, by perfusion through a regional catheter, or by direct intralesional injection. When administering therapeutic proteins by injection, the administration may be by continuous infusion or by single or multiple boluses.

[0322] Additional routes of administration include oral, mucosal-membrane, pulmonary, and transcutaneous. Oral delivery is suitable for polyester microspheres, zein microspheres, proteinoid microspheres, polycyanoacrylate microspheres, and lipid-based systems (see, for example, DiBase and Morrel, "Oral Delivery of Microencapsulated Proteins," in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 255-288 (Plenum Press 1997)). The feasibility of an intranasal delivery is exemplified by such a mode of insulin administration (see, for example, Hinchcliffe and Illum, Adv. Drug Deliv. Rev. 35:199 (1999)). Dry or liquid particles comprising Zcytor16 can be prepared and inhaled with the aid of dry-powder dispersers, liquid aerosol generators, or nebulizers (e.g., Pettit and Gombotz, TIBTECH 16:343 (1998); Patton et al., Adv. Drug Deliv. Rev. 35:235 (1999)). This approach is illustrated by the AERX diabetes management system, which is a hand-held electronic inhaler that delivers aerosolized insulin into the lungs. Studies have shown that proteins as large as 48,000 kDa have been delivered across skin at therapeutic concentrations with the aid of low-frequency ultrasound, which illustrates the feasibility of transcutaneous administration (Mitragotri et al., Science 269:850 (1995)). Transdermal delivery using electroporation provides another means to administer a molecule having Zcytor16 binding activity (Potts et al., Pharm. Biotechnol. 10:213 (1997)).

[0323] A pharmaceutical composition comprising a protein, polypeptide, or peptide having Zcytor16 binding activity can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient patient. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers are well-known to those in the art. See, for example, Gennaro (ed.), Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company 1995).

[0324] For purposes of therapy, molecules having Zcytor16 binding activity and a pharmaceutically acceptable carrier are administered to a patient in a therapeutically effective amount. A combination of a protein, polypeptide, or peptide having Zcytor16 binding activity and a pharmaceutically acceptable carrier is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient. For example, an agent used to treat inflammation is physiologically significant if its presence alleviates the inflammatory response.

[0325] A pharmaceutical composition comprising Zcytor16 (or Zcytor16 analog or fusion protein) can be furnished in liquid form, in an aerosol, or in solid form. Liquid forms, are illustrated by injectable solutions and oral suspensions. Exemplary solid forms include capsules, tablets, and controlled-release forms. The latter form is illustrated by miniosmotic pumps and implants (Bremer et al., Pharm. Biotechnol. 10:239 (1997); Ranade, "Implants in Drug Delivery," in Drug Delivery Systems, Ranade and Hollinger (eds.), pages 95-123 (CRC Press 1995); Bremer et al., "Protein Delivery with Infusion Pumps," in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 239-254 (Plenum Press 1997); Yewey et al., "Delivery of Proteins from a Controlled Release Injectable Implant," in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 93-117 (Plenum Press 1997)).

[0326] Liposomes provide one means to deliver therapeutic polypeptides to a subject intravenously, intraperitoneally, intrathecally, intramuscularly, subcutaneously, or via oral administration, inhalation, or intranasal administration. Liposomes are microscopic vesicles that consist of one or more lipid bilayers surrounding aqueous compartments (see, generally, Bakker-Woudenberg et al., *Eur. J. Clin. Microbiol. Infect. Dis.* 12 (Suppl. 1):S61 (1993), Kim, *Drugs* 46:618 (1993), and Ranade, "Site-Specific Drug Delivery Using Liposomes as Carriers," in *Drug Delivery Systems*, Ranade and Hollinger (eds.), pages 3-24 (CRC Press 1995)). Liposomes are similar in composition to cellular membranes and as a result, liposomes can be administered safely and are biodegradable. Depending on the method of preparation, liposomes may be unilamellar or multilamellar, and liposomes can vary in size with diameters ranging from 0.02 μm to greater than 10 μm . A variety of agents can be encapsulated in liposomes: hydrophobic agents partition in the bilayers and hydrophilic agents partition within the inner aqueous space(s) (see, for example, Machy et al., *Liposomes In Cell Biology And Pharmacology* (John Libbey 1987), and Ostro et al., *American J. Hosp. Pharm.* 46:1576 (1989)). Moreover, it is possible to control the therapeutic availability of the encapsulated agent by varying liposome size, the number of bilayers, lipid composition, as well as the charge and surface characteristics of the liposomes.

[0327] Liposomes can adsorb to virtually any type of cell and then slowly release the encapsulated agent. Alternatively, an absorbed liposome may be endocytosed by cells that are phagocytic. Endocytosis is followed by intralysosomal degradation of liposomal lipids and release of the encapsulated agents (Scherphof et al., *Ann. N.Y. Acad. Sci.* 446:368 (1985)). After intravenous administration, small liposomes (0.1 to 1.0 μm) are typically taken up by cells of the reticuloendothelial system, located principally in the liver and spleen, whereas liposomes larger than 3.0 μm are deposited in the lung. This preferential uptake of smaller liposomes by the cells of the reticuloendothelial system has been used to deliver chemotherapeutic agents to macrophages and to tumors of the liver.

[0328] The reticuloendothelial system can be circumvented by several methods including saturation with large doses of liposome particles, or selective macrophage inactivation by pharmacological means (Claassen et al., *Biochim. Biophys. Acta* 802:428 (1984)). In addition, incorporation of glycolipid- or polyethelene glycol-derivatized phospholipids into liposome membranes has been shown to result in a significantly reduced uptake by the reticuloendothelial system (Allen et al., *Biochim. Biophys. Acta* 1068:133 (1991); Allen et al., *Biochim. Biophys. Acta* 1150:9 (1993)).

[0329] Liposomes can also be prepared to target particular cells or organs by varying phospholipid composition or by inserting receptors or ligands into the liposomes. For example, liposomes, prepared with a high content of a nonionic surfactant, have been used to target the liver (Hayakawa et al., Japanese Patent 04-244,018; Kato et al., *Biol. Pharm. Bull.* 16:960 (1993)). These formulations were prepared by mixing soybean phosphatidylcholine, α -tocopherol, and ethoxylated hydrogenated castor oil (HCO-60) in methanol, concentrating the mixture under vacuum, and then reconstituting the mixture with water. A liposomal formulation of dipalmitoylphosphatidylcholine (DPPC) with a soybean-derived sterylglucoside mixture (SG) and cholesterol (Ch) has also been shown to target the liver (Shimizu et al., *Biol. Pharm. Bull.* 20:881 (1997)).

[0330] Alternatively, various targeting ligands can be bound to the surface of the liposome, such as antibodies, antibody fragments, carbohydrates, vitamins, and transport proteins. For example, liposomes can be modified with branched type galactosyllipid derivatives to target asialoglycoprotein (galactose) receptors, which are exclusively expressed on the surface of liver cells (Kato and Sugiyama, *Crit. Rev. Ther. Drug Carrier Syst.* 14:287 (1997); Murahashi et al., *Biol. Pharm. Bull.* 20:259 (1997)). Similarly, Wu et al., *Hepatology* 27:772 (1998), have shown that labeling liposomes with asialofetuin led to a shortened liposome plasma half-life and greatly enhanced uptake of asialofetuin-labeled liposome by hepatocytes. On the other hand, hepatic accumulation of liposomes comprising branched type galactosyllipid derivatives can be inhibited by preinjection of asialofetuin (Murahashi et al., *Biol. Pharm. Bull.* 20:259 (1997)). Polyaconitylated human serum albumin liposomes provide another approach for targeting liposomes to liver cells (Kamps et al., *Proc. Nat'l Acad. Sci. USA* 94:11681 (1997)). Moreover, Geho, et al. U.S. Patent No. 4,603,044, describe a hepatocyte-directed liposome vesicle delivery system, which has specificity for hepatobiliary receptors associated with the specialized metabolic cells of the liver.

[0331] In a more general approach to tissue targeting, target cells are prelabeled with biotinylated antibodies specific for a ligand expressed by the target cell (Harasym et al., *Adv. Drug Deliv. Rev.* 32:99 (1998)). After plasma elimination of free antibody, streptavidin-conjugated liposomes are administered. In another approach, targeting antibodies are directly attached to liposomes (Harasym et al., *Adv. Drug Deliv. Rev.* 32:99 (1998)).

[0332] Polypeptides having Zcytor16 binding activity can be encapsulated within liposomes using standard techniques of protein microencapsulation (see, for example, Anderson et al., *Infect. Immun.* 31:1099 (1981), Anderson et al., *Cancer Res.* 50:1853 (1990), and Cohen et al., *Biochim. Biophys. Acta* 1063:95 (1991), Alving et al. "Preparation and Use of Liposomes in Immunological Studies," in *Liposome Technology*, 2nd Edition, Vol. III, Gregoriadis (ed.), page 317 (CRC Press 1993), Wassef et al., *Meth. Enzymol.* 149:124 (1987)). As noted above, therapeutically useful liposomes may contain a variety of components. For example, liposomes may comprise lipid derivatives of poly(ethylene glycol) (Allen et al., *Biochim. Biophys. Acta* 1150:9 (1993)).

[0333] Degradable polymer microspheres have been designed to maintain high systemic levels of therapeutic proteins. Microspheres are prepared from degradable polymers such as poly(lactide-co-glycolide) (PLG), polyanhydrides, poly

(ortho esters), nonbiodegradable ethylvinyl acetate polymers, in which proteins are entrapped in the polymer (Gombotz and Pettit, *Bioconjugate Chem.* 6:332 (1995); Ranade, "Role of Polymers in Drug Delivery," in *Drug Delivery Systems*, Ranade and Hollinger (eds.), pages 51-93 (CRC Press 1995); Roskos and Maskiewicz, "Degradable Controlled Release Systems Useful for Protein Delivery," in *Protein Delivery: Physical Systems*, Sanders and Hendren (eds.), pages 45-92 (Plenum Press 1997); Bartus et al., *Science* 281:1161 (1998); Putney and Burke, *Nature Biotechnology* 16:153 (1998); Putney, *Curr. Opin. Chem. Biol.* 2:548 (1998)). Polyethylene glycol (PEG)-coated nanospheres can also provide carriers for intravenous administration of therapeutic proteins (see, for example, Gref et al., *Pharm. Biotechnol.* 10:167 (1997)).

[0334] The present specification describes chemically modified polypeptides having binding Zcytor16 activity such as zcytor16 monomeric, homodimeric, heterodimeric or multimeric soluble receptors, and Zcytor16 antagonists, for example anti-zcytor16 antibodies or binding polypeptides, which a polypeptide is linked with a polymer, as discussed above.

[0335] Other dosage forms can be devised by those skilled in the art, as shown, for example, by Ansel and Popovich, *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 5th Edition (Lea & Febiger 1990), Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 19th Edition (Mack Publishing Company 1995), and by Ranade and Hollinger, *Drug Delivery Systems* (CRC Press 1996).

[0336] As an illustration, pharmaceutical compositions may be supplied as a kit comprising a container that comprises a polypeptide with a Zcytor16 extracellular domain, e.g., zcytor16 monomeric, homodimeric, heterodimeric or multimeric soluble receptors, or a Zcytor16 antagonist (e.g., an antibody or antibody fragment that binds a Zcytor16 polypeptide). Therapeutic polypeptides can be provided in the form of an injectable solution for single or multiple doses, or as a sterile powder that will be reconstituted before injection. Alternatively, such a kit can include a dry-powder disperser, liquid aerosol generator, or nebulizer for administration of a therapeutic polypeptide. Such a kit may further comprise written information on indications and usage of the pharmaceutical composition. Moreover, such information may include a statement that the Zcytor16 composition is contraindicated in patients with known hypersensitivity to Zcytor16.

13. Therapeutic Uses of Zcytor16 Nucleotide Sequences

[0337] The present .specification describes the use of *Zcytor16* nucleotide sequences to provide Zcytor16 to a subject in need of such treatment. In addition, a therapeutic expression vector can be provided that inhibits *Zcytor16* gene expression, such as an anti-sense molecule, a ribozyme, or an external guide sequence molecule.

[0338] There are numerous approaches to introduce a *Zcytor16* gene to a subject, including the use of recombinant host cells that express *Zcytor16*, delivery of naked nucleic acid encoding Zcytor16, use of a cationic lipid carrier with a nucleic acid molecule that encodes Zcytor16, and the use of viruses that express *Zcytor16*, such as recombinant retroviruses, recombinant adeno-associated viruses, recombinant adenoviruses, and recombinant Herpes simplex viruses (see, for example, Mulligan, *Science* 260:926 (1993), Rosenberg et al., *Science* 242:1575 (1988), LaSalle et al., *Science* 259:988 (1993), Wolff et al., *Science* 247:1465 (1990), Breakfield and Deluca, *The New Biologist* 3:203 (1991)). In an *ex vivo* approach, for example, cells are isolated from a subject, transfected with a vector that expresses a *Zcytor16* gene, and then transplanted into the subject.

[0339] In order to effect expression of a *Zcytor16* gene, an expression vector is constructed in which a nucleotide sequence encoding a *Zcytor16* gene is operably linked to a core promoter, and optionally a regulatory element, to control gene transcription. The general requirements of an expression vector are described above.

[0340] Alternatively, a *Zcytor16* gene can be delivered using recombinant viral vectors, including for example, adenoviral vectors (e.g., Kass-Eisler et al., *Proc. Nat'l Acad. Sci. USA* 90:11498 (1993), Kolls et al., *Proc. Nat'l Acad. Sci. USA* 91:215 (1994), Li et al., *Hum. Gene Ther.* 4:403 (1993), Vincent et al., *Nat. Genet.* 5:130 (1993), and Zabner et al., *Cell* 75:207 (1993)), adenovirus-associated viral vectors (Flotte et al., *Proc. Nat'l Acad. Sci. USA* 90:10613 (1993)), alphaviruses such as Semliki Forest Virus and Sindbis Virus (Hertz and Huang, *J. Vir.* 66:857 (1992), Raju and Huang, *J. Vir.* 65:2501 (1991), and Xiong et al., *Science* 243:1188 (1989)), herpes viral vectors (e.g., U.S. Patent Nos. 4,769,331, 4,859,587, 5,288,641 and 5,328,688), parvovirus vectors (Koering et al., *Hum. Gene Therap.* 5:457 (1994)), pox virus vectors (Ozaki et al., *Biochem. Biophys. Res. Comm.* 193:653 (1993), Panicali and Paoletti, *Proc. Nat'l Acad. Sci. USA* 79:4927 (1982)), pox viruses, such as canary pox virus or vaccinia virus (Fisher-Hoch et al., *Proc. Nat'l Acad. Sci. USA* 86:317 (1989), and Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86 (1989)), and retroviruses (e.g., Baba et al., *J. Neurosurg* 79:729 (1993), Ram et al., *Cancer Res.* 53:83 (1993), Takamiya et al., *J. Neurosci. Res* 33:493 (1992), Vile and Hart, *Cancer Res.* 53:962 (1993), Vile and Hart, *Cancer Res.* 53:3860 (1993), and Anderson et al., U.S. Patent No. 5,399,346). Within various embodiments, either the viral vector itself, or a viral particle which contains the viral vector may be utilized in the methods and compositions described below.

[0341] As an illustration of one system, adenovirus, a double-stranded DNA virus, is a well-characterized gene transfer vector for delivery of a heterologous nucleic acid molecule (for a review, see Becker et al., *Meth. Cell Biol.* 43:161 (1994); Douglas and Curiel, *Science & Medicine* 4:44 (1997)). The adenovirus system offers several advantages including: (i) the ability to accommodate relatively large DNA inserts, (ii) the ability to be grown to high-titer, (iii) the ability to infect a broad range of mammalian cell types, and (iv) the ability to be used with many different promoters including ubiquitous,

tissue specific, and regulatable promoters. In addition, adenoviruses can be administered by intravenous injection, because the viruses are stable in the bloodstream.

5 [0342] Using adenovirus vectors where portions of the adenovirus genome are deleted, inserts are incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential E1 gene is deleted from the viral vector, and the virus will not replicate unless the E1 gene is provided by the host cell. When intravenously administered to intact animals, adenovirus primarily targets the liver. Although an adenoviral delivery system with an E1 gene deletion cannot replicate in the host cells, the host's tissue will express and process an encoded heterologous protein. Host cells will also secrete the heterologous protein if the corresponding gene includes a secretory signal sequence. Secreted proteins will enter the circulation from tissue that expresses the heterologous gene (e.g., the highly vascularized liver).

10 [0343] Moreover, adenoviral vectors containing various deletions of viral genes can be used to reduce or eliminate immune responses to the vector. Such adenoviruses are E1-deleted, and in addition, contain deletions of E2A or E4 (Lusky et al., J. Virol. 72:2022 (1998); Raper et al., Human Gene Therapy 9:671 (1998)). The deletion of E2b has also been reported to reduce immune responses (Amalfitano et al., J. Virol. 72:926 (1998)). By deleting the entire adenovirus genome, very large inserts of heterologous DNA can be accommodated. Generation of so called "gutless" adenoviruses, where all viral genes are deleted, are particularly advantageous for insertion of large inserts of heterologous DNA (for a review, see Yeh. and Perricaudet, FASEB J. 11:615 (1997)).

15 [0344] High titer stocks of recombinant viruses capable of expressing a therapeutic gene can be obtained from infected mammalian cells using standard methods. For example, recombinant herpes simplex virus can be prepared in Vero cells, as described by Brandt et al., J. Gen. Virol. 72:2043 (1991), Herold et al., J. Gen. Virol. 75:1211 (1994), Visalli and Brandt, Virology 185:419 (1991), Grau et al., Invest. Ophthalmol. Vis. Sci. 30:2474 (1989), Brandt et al., J. Virol. Meth. 36:209 (1992), and by Brown and MacLean (eds.), HSV Virus Protocols (Humana Press 1997).

20 [0345] Alternatively, an expression vector comprising a *Zcytor16* gene can be introduced into a subject's cells by lipofection *in vivo* using liposomes. Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker (Felgner et al., Proc. Nat'l Acad. Sci. USA 84:7413 (1987); Mackey et al., Proc. Nat'l Acad. Sci. USA 85:8027 (1988)). The use of lipofection to introduce exogenous genes into specific organs *in vivo* has certain practical advantages. Liposomes can be used to direct transfection to particular cell types, which is particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules for the purpose of targeting. Targeted peptides (e.g., hormones or neurotransmitters), proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.

25 [0346] Electroporation is another alternative mode of administration. For example, Aihara and Miyazaki, Nature Biotechnology 16:867 (1998), have demonstrated the use of *in vivo* electroporation for gene transfer into muscle.

30 [0347] In an alternative approach to gene therapy, a therapeutic gene may encode a *Zcytor16* anti-sense RNA that inhibits the expression of *Zcytor16*. Suitable sequences for anti-sense molecules can be derived from the nucleotide sequences of *Zcytor16* disclosed herein.

35 [0348] Alternatively, an expression vector can be constructed in which a regulatory element is operably linked to a nucleotide sequence that encodes a ribozyme. Ribozymes can be designed to express endonuclease activity that is directed to a certain target sequence in a mRNA molecule (see, for example, Draper and Macejak, U.S. Patent No. 5,496,698, McSwiggen, U.S. Patent No. 5,525,468, Chowrira and McSwiggen, U.S. Patent No. 5,631,359, and Robertson and Goldberg, U.S. Patent No. 5,225,337). In the context of the present invention, ribozymes include nucleotide sequences that bind with *Zcytor16* mRNA.

40 [0349] In another approach, expression vectors can be constructed in which a regulatory element directs the production of RNA transcripts capable of promoting RNase P-mediated cleavage of mRNA molecules that encode a *Zcytor16* gene. According to this approach, an external guide sequence can be constructed for directing the endogenous ribozyme, RNase P, to a particular species of intracellular mRNA, which is subsequently cleaved by the cellular ribozyme (see, for example, Altman et al., U.S. Patent No. 5,168,053, Yuan et al., Science 263:1269 (1994), Pace et al., international publication No. WO 96/18733, George et al., international publication No. WO 96/21731, and Werner et al., international publication No. WO 97/33991). For example, the external guide sequence can comprise a ten to fifteen nucleotide sequence complementary to *Zcytor16* mRNA, and a 3'-NCCA nucleotide sequence, wherein N is preferably a purine. The external guide sequence transcripts bind to the targeted mRNA species by the formation of base pairs between the mRNA and the complementary external guide sequences, thus promoting cleavage of mRNA by RNase P at the nucleotide located at the 5'-side of the base-paired region.

45 [0350] In general, the dosage of a composition comprising a therapeutic vector having a *Zcytor16* nucleotide sequence, such as a recombinant virus, will vary depending upon such factors as the subject's age, weight, height, sex, general medical condition and previous medical history. Suitable routes of administration of therapeutic vectors include intravenous injection, intraarterial injection, intraperitoneal injection, intramuscular injection, intratumoral injection, and injection into a cavity that contains a tumor. As an illustration, Horton et al., Proc. Nat'l Acad. Sci. USA 96:1553 (1999), demonstrated that intramuscular injection of plasmid DNA encoding interferon- α produces potent antitumor effects on primary and

metastatic tumors in a murine model.

[0351] A composition comprising viral vectors, non-viral vectors, or a combination of viral and non-viral vectors of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby vectors or viruses are combined in a mixture with a pharmaceutically acceptable carrier. As noted above, a composition, such as phosphate-buffered saline is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient subject. Other suitable carriers are well-known to those in the art (see, for example, Remington's Pharmaceutical Sciences, 19th Ed. (Mack Publishing Co. 1995), and Gilman's the Pharmacological Basis of Therapeutics, 7th Ed. (MacMillan Publishing Co. 1985)).

[0352] For purposes of therapy, a therapeutic gene expression vector, or a recombinant virus comprising such a vector, and a pharmaceutically acceptable carrier are administered to a subject in a therapeutically effective amount. A combination of an expression vector (or virus) and a pharmaceutically acceptable carrier is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient subject. For example, an agent used to treat inflammation is physiologically significant if its presence alleviates the inflammatory response.

[0353] When the subject treated with a therapeutic gene expression vector or a recombinant virus is a human, then the therapy is preferably somatic cell gene therapy. That is, the preferred treatment of a human with a therapeutic gene expression vector or a recombinant virus does not entail introducing into cells a nucleic acid molecule that can form part of a human germ line and be passed onto successive generations (*i.e.*, human germ line gene therapy).

14. Production of Transgenic Mice

[0354] Transgenic mice can be engineered to over-express the *Zcytor16* gene in all tissues or under the control of a tissue-specific or tissue-preferred regulatory element. These over-producers of *Zcytor16* can be used to characterize the phenotype that results from over-expression, and the transgenic animals can serve as models for human disease caused by excess *Zcytor16*. Transgenic mice that over-express *Zcytor16* also provide model bioreactors for production of *Zcytor16*, such as soluble *Zcytor16*, in the milk or blood of larger animals. Methods for producing transgenic mice are well-known to those of skill in the art (see, for example, Jacob, "Expression and Knockout of Interferons in Transgenic Mice," in Overexpression and Knockout of Cytokines in Transgenic Mice, Jacob (ed.), pages 111-124 (Academic Press, Ltd. 1994), Monastersky and Robl (eds.), Strategies in Transgenic Animal Science (ASM Press 1995), and Abbud and Nilson, "Recombinant Protein Expression in Transgenic Mice," in Gene Expression Systems: Using Nature for the Art of Expression, Fernandez and Hoeffler (eds.), pages 367-397 (Academic Press, Inc. 1999)).

[0355] For example, a method for producing a transgenic mouse that expresses a *Zcytor16* gene can begin with adult, fertile males (studs) (B6C3f1, 2-8 months of age (Taconic Farms, Germantown, NY)), vasectomized males (duds) (B6D2f1, 2-8 months, (Taconic Farms)), prepubescent fertile females (donors) (B6C3f1, 4-5 weeks, (Taconic Farms)) and adult fertile females (recipients) (B6D2f1, 2-4 months, (Taconic Farms)). The donors are acclimated for one week and then injected with approximately 8 IU/mouse of Pregnant Mare's Serum gonadotrophin (Sigma Chemical Company; St. Louis, MO) I.P., and 46-47 hours later, 8 IU/mouse of human Chorionic Gonadotropin (hCG (Sigma)) I.P. to induce superovulation. Donors are mated with studs subsequent to hormone injections. Ovulation generally occurs within 13 hours of hCG injection. Copulation is confirmed by the presence of a vaginal plug the morning following mating.

[0356] Fertilized eggs are collected under a surgical scope. The oviducts are collected and eggs are released into urinalysis slides containing hyaluronidase (Sigma). Eggs are washed once in hyaluronidase, and twice in Whitten's W640 medium (described, for example, by Menino and O'Claray, Biol. Reprod. 77:159 (1986), and Dienhart and Downs, Zygote 4:129 (1996)) that has been incubated with 5% CO₂, 5% O₂, and 90% N₂ at 37°C. The eggs are then stored in a 37°C/5% CO₂ incubator until microinjection.

[0357] Ten to twenty micrograms of plasmid DNA containing a *Zcytor16* encoding sequence is linearized, gel-purified, and resuspended in 10 mM Tris-HCl (pH 7.4), 0.25 mM EDTA (pH 8.0), at a final concentration of 5-10 nanograms per microliter for microinjection. For example, the *Zcytor16* encoding sequences can encode a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

[0358] Plasmid DNA is microinjected into harvested eggs contained in a drop of W640 medium overlaid by warm, CO₂-equilibrated mineral oil. The DNA is drawn into an injection needle (pulled from a 0.75mm ID, 1mm OD borosilicate glass capillary), and injected into individual eggs. Each egg is penetrated with the injection needle, into one or both of the haploid pronuclei.

[0359] Picoliters of DNA are injected into the pronuclei, and the injection needle withdrawn without coming into contact with the nucleoli. The procedure is repeated until all the eggs are injected. Successfully microinjected eggs are transferred into an organ tissue-culture dish with pre-gassed W640 medium for storage overnight in a 37°C/5% CO₂ incubator.

[0360] The following day, two-cell embryos are transferred into pseudopregnant recipients. The recipients are identified by the presence of copulation plugs, after copulating with vasectomized duds. Recipients are anesthetized and shaved on the dorsal left side and transferred to a surgical microscope. A small incision is made in the skin and through the

muscle wall in the middle of the abdominal area outlined by the ribcage, the saddle, and the hind leg, midway between knee and spleen. The reproductive organs are exteriorized onto a small surgical drape. The fat pad is stretched out over the surgical drape, and a baby serrefine (Roboz, Rockville, MD) is attached to the fat pad and left hanging over the back of the mouse, preventing the organs from sliding back in.

5 **[0361]** With a fine transfer pipette containing mineral oil followed by alternating W640 and air bubbles, 12-17 healthy two-cell embryos from the previous day's injection are transferred into the recipient. The swollen ampulla is located and holding the oviduct between the ampulla and the bursa, a nick in the oviduct is made with a 28 g needle close to the bursa, making sure not to tear the ampulla or the bursa.

10 **[0362]** The pipette is transferred into the nick in the oviduct, and the embryos are blown in, allowing the first air bubble to escape the pipette. The fat pad is gently pushed into the peritoneum, and the reproductive organs allowed to slide in. The peritoneal wall is closed with one suture and the skin closed with a wound clip. The mice recuperate on a 37°C slide warmer for a minimum of four hours.

15 **[0363]** The recipients are returned to cages in pairs, and allowed 19-21 days gestation. After birth, 19-21 days post-partum is allowed before weaning. The weanlings are sexed and placed into separate sex cages, and a 0.5 cm biopsy (used for genotyping) is snipped off the tail with clean scissors.

20 **[0364]** Genomic DNA is prepared from the tail snips using, for example, a QIAGEN DNEASY kit following the manufacturer's instructions. Genomic DNA is analyzed by PCR using primers designed to amplify a *Zcytor16* gene or a selectable marker gene that was introduced in the same plasmid. After animals are confirmed to be transgenic, they are back-crossed into an inbred strain by placing a transgenic female with a wild-type male, or a transgenic male with one or two wild-type female(s). As pups are born and weaned, the sexes are separated, and their tails snipped for genotyping.

25 **[0365]** To check for expression of a transgene in a live animal, a partial hepatectomy is performed. A surgical prep is made of the upper abdomen directly below the zyphoid process. Using sterile technique, a small 1.5-2 cm incision is made below the sternum and the left lateral lobe of the liver exteriorized. Using 4-0 silk, a tie is made around the lower lobe securing it outside the body cavity. An atraumatic clamp is used to hold the tie while a second loop of absorbable Dexon (American Cyanamid; Wayne, N.J.) is placed proximal to the first tie. A distal cut is made from the Dexon tie and approximately 100 mg of the excised liver tissue is placed in a sterile petri dish. The excised liver section is transferred to a 14 ml polypropylene round bottom tube and snap frozen in liquid nitrogen and then stored on dry ice. The surgical site is closed with suture and wound clips, and the animal's cage placed on a 37°C heating pad for 24 hours post operatively. The animal is checked daily post operatively and the wound clips removed 7-10 days after surgery. The expression level of *Zcytor16* mRNA is examined for each transgenic mouse using an RNA solution hybridization assay or polymerase chain reaction.

30 **[0366]** In addition to producing transgenic mice that over-express *Zcytor16*, it is useful to engineer transgenic mice with either abnormally low or no expression of the gene. Such transgenic mice provide useful models for diseases associated with a lack of *Zcytor16*. As discussed above, *Zcytor16* gene expression can be inhibited using anti-sense genes, ribozyme genes, or external guide sequence genes. To produce transgenic mice that under-express the *Zcytor16* gene, such inhibitory sequences are targeted to *Zcytor16* mRNA, including the fragments or the entire 5' UTR, coding region, and 3' UTR, e.g., as shown in SEQ ID NO:37 and described herein. Methods for producing transgenic mice that have abnormally low expression of a particular gene are known to those in the art (see, for example, Wu et al., "Gene Underexpression in Cultured Cells and Animals by Antisense DNA and RNA Strategies," in *Methods in Gene Biotechnology*, pages 205-224 (CRC Press 1997)).

35 **[0367]** An alternative approach to producing transgenic mice that have little or no *Zcytor16* gene expression is to generate mice having at least one normal *Zcytor16* allele replaced by a nonfunctional *Zcytor16* gene. One method of designing a nonfunctional *Zcytor16* gene is to insert another gene, such as a selectable marker gene, within a nucleic acid molecule that encodes *Zcytor16*. Standard methods for producing these so-called "knockout mice" are known to those skilled in the art (see, for example, Jacob, "Expression and Knockout of Interferons in Transgenic Mice," in *Over-expression and Knockout of Cytokines in Transgenic Mice*, Jacob (ed.), pages 111-124 (Academic Press, Ltd. 1994), and Wu et al., "New Strategies for Gene Knockout," in *Methods in Gene Biotechnology*, pages 339-365 (CRC Press 1997)).

40 **[0368]** Polynucleotides and polypeptides of the present invention will additionally find use as educational tools as a laboratory practicum kits for courses related to genetics and molecular biology, protein chemistry and antibody production and analysis. Due to its unique polynucleotide and polypeptide sequence molecules of *zcytor16* can be used as standards or as "unknowns" for testing purposes. For example, *zcytor16* polynucleotides can be used as an aid, such as, for example, to teach a student how to prepare expression constructs for bacterial, viral, and/or mammalian expression, including fusion constructs, wherein *zcytor16* is the gene to be expressed; for determining the restriction endonuclease cleavage sites of the polynucleotides; determining mRNA and DNA localization of *zcytor16* polynucleotides in tissues (i.e., by Northern and Southern blotting as well as polymerase chain reaction); and for identifying related polynucleotides and polypeptides by nucleic acid hybridization.

45 **[0369]** *Zcytor16* polypeptides can be used educationally as an aid to teach preparation of antibodies; identifying

proteins by Western blotting; protein purification; determining the weight of expressed zcytor16 polypeptides as a ratio to total protein expressed; identifying peptide cleavage sites; coupling amino and carboxyl terminal tags; amino acid sequence analysis, as well as, but not limited to monitoring biological activities of both the native and tagged protein (i.e., receptor binding, signal transduction, proliferation, and differentiation) *in vitro and in vivo*. Zcytor16 polypeptides can also be used to teach analytical skills such as mass spectrometry, circular dichroism to determine conformation, especially of the four alpha helices, x-ray crystallography to determine the three-dimensional structure in atomic detail, nuclear magnetic resonance spectroscopy to reveal the structure of proteins in solution. For example, a kit containing the zcytor16 can be given to the student to analyze. Since the amino acid sequence would be known by the professor, the specific protein can be given to the student as a test to determine the skills or develop the skills of the student, the teacher would then know whether or not the student has correctly analyzed the polypeptide. Since every polypeptide is unique, the educational utility of zcytor16 would be unique unto itself.

[0370] Moreover, since zcytor16 has a tissue-specific expression and is a polypeptide with a class II cytokine receptor structure and a distinct chromosomal localization, and expression pattern, activity can be measured using proliferation assays; luciferase and binding assays described herein. Moreover, expression of zcytor16 polynucleotides and polypeptides in lymphoid and other tissues can be analyzed in order to train students in the use of diagnostic and tissue-specific identification and methods. Moreover zcytor16 polynucleotides can be used to train students on the use of chromosomal detection and diagnostic methods, since its locus is known. Moreover, students can be specifically trained and educated about human chromosome 1, and more specifically the locus 6q23-q24 wherein the zcytor16 gene is localized. Such assays are well known in the art, and can be used in an educational setting to teach students about cytokine receptor proteins and examine different properties, such as cellular effects on cells, enzyme kinetics, varying antibody binding affinities, tissue specificity, and the like, between zcytor16 and other cytokine receptor polypeptides in the art.

[0371] The antibodies which bind specifically to zcytor16 can be used as a teaching aid to instruct students how to prepare affinity chromatography columns to purify zcytor16, cloning and sequencing the polynucleotide that encodes an antibody and thus as a practicum for teaching a student how to design humanized antibodies. Moreover, antibodies which bind specifically to zcytor16 can be used as a teaching aid for use in detection e.g., of activated CD91+ cells, cell sorting, or ovarian cancer tissue using histological, and *in situ* methods amongst others known in the art. The zcytor16 gene, polypeptide or antibody would then be packaged by reagent companies and sold to universities and other educational entities so that the students gain skill in art of molecular biology. Because each gene and protein is unique, each gene and protein creates unique challenges and learning experiences for students in a lab practicum. Such educational kits containing the zcytor16 gene, polypeptide or antibody are considered within the scope of the present invention.

15. Therapeutic Uses of Antibodies or Polypeptides that bind to IL-TIF or have IL-TIF antagonizing Activity

[0372] IL-TIF polynucleotides are expressed in T-cells, activated T- and B-cells, and lymphoid tissue. The human IL-TIF nucleotide sequence is represented in SEQ ID NO:14.

[0373] Analysis of SEQ ID NO:14 reveals that there are two possible initiation Methionine residues for a IL-TIF cytokine polypeptide translated therefrom. The two deduced IL-TIF polypeptide amino acid sequences are shown in SEQ ID NO: 15 (a 179 amino acid polypeptide having the initiating Met at nucleotide 21 in SEQ ID NO:14 a 167 amino acid polypeptide having the initiating Met at nucleotide 57 in SEQ ID NO:14). Although both of these sequences encode a IL-TIF polypeptide, based on similarity of the IL-TIF sequence to IL-10 and other cytokines, and the presence of a strong signal sequence, amino acid 34 (Ala) to 179 (Ile) of SEQ ID NO:15 encodes a fully functional secreted IL-TIF cytokine polypeptide. N-terminal sequence analysis shows that the mature start at residue 34 (Ala) of SEQ ID NO:15.

[0374] In general, cytokines are predicted to have a four-alpha helix structure, with the 1st and 4th helices being most important in ligand-receptor interactions. The 1st and 4th helices are more highly conserved among members of the family. Referring to the human IL-TIF amino acid sequence shown in SEQ ID NO:15, alignment of human IL-TIF, human IL-10, human zcyto10 (WO US98/25228), and human Human MDA7 (Genbank Accession No. Q13007) amino acid sequences suggests that IL-TIF helix A is defined by amino acid residues 53 (Thr) to 65 (Leu) of SEQ ID NO:15 ; helix B by amino acid residues 92 (Met) to 103 (Val) of SEQ ID NO:15 ; helix C by amino acid residues 115 (Met) to 128 (Arg) of SEQ ID NO:15 ; and helix D by amino acid residues 161 (Ile) to 174 (Leu) of SEQ ID NO:15. Structural analysis suggests that the A/B loop is long, the B/C loop is short and the C/D loop is long. This loop structure results in an up-up-down-down helical organization. Four cysteine residues are conserved between IL-10 and IL-TIF corresponding to amino acid residues 20, 40, 89 and 132 of SEQ ID NO:15. Consistent cysteine placement is further confirmation of the four-helical-bundle structure.

[0375] The corresponding polynucleotides encoding the IL-TIF polypeptide regions, domains, motifs, residues and sequences described herein are as shown in SEQ ID NO:1. Moreover, the corresponding IL-TIF polypeptide regions, domains, motifs, residues and sequences described herein are also as shown in SEQ ID NO:15.

[0376] Four-helical bundle cytokines are also grouped by the length of their component helices. "Long-helix" form

cytokines generally consist of between 24-30 residue helices and include IL-6, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and human growth hormone (hGH). "Short-helix" form cytokines generally consist of between 18-21 residue helices and include IL-2, IL-4 and GM-CSF. IL-TIF is believed to be a new member of the short-helix form cytokine group. Studies using CNTF and IL-6 demonstrated that a CNTF helix can be exchanged for the equivalent helix in IL-6, conferring CTNF-binding properties to the chimera. Thus, it appears that functional domains of four-helical cytokines determined on the basis of structural homology, irrespective of sequence identity, and can maintain functional integrity in a chimera (Kallen et al., J. Biol. Chem. 274:11859-11867, 1999). Using similar methods, putative regions conferring receptor binding specificity in IL-TIF comprise the regions of amino acid residues of 34 (Ala) to 179 (Ile) of SEQ ID NO:15 that include: residues 65-72, residues 97-103, and residues 133-152. These regions will be useful for preparing chimeric molecules, particularly with other short-helix form cytokines to determine and modulate receptor binding specificity.

[0377] The present specification describes polypeptide fragments or peptides comprising an epitope-bearing portion of a IL-TIF polypeptide described herein. Such fragments or peptides may comprise an "immunogenic epitope," which is a part of a protein that elicits an antibody response when the entire protein is used as an immunogen. Immunogenic epitope-bearing peptides can be identified using standard methods (see, for example, Geysen et al., Proc. Nat'l Acad. Sci. USA 81:3998 (1983)).

[0378] In contrast, polypeptide fragments or peptides may comprise an "antigenic epitope," which is a region of a protein molecule to which an antibody can specifically bind. Certain epitopes consist of a linear or contiguous stretch of amino acids, and the antigenicity of such an epitope is not disrupted by denaturing agents. It is known in the art that relatively short synthetic peptides that can mimic epitopes of a protein can be used to stimulate the production of antibodies against the protein (see, for example, Sutcliffe et al., Science 219:660 (1983)). Accordingly, antigenic epitope-bearing peptides and polypeptides are useful to raise antibodies that bind with the polypeptides described herein. Hopp/Woods hydrophilicity profiles can be used to determine regions that have the most antigenic potential (Hopp et al., 1981, *ibid.* and Hopp, 1986, *ibid.*). In IL-TIF these regions include: (1) amino acid number 41 (Arg) to amino acid number 46 (Asn) of SEQ ID NO:15; (2) amino acid number 133 (His) to amino acid number 138 (Asp) of SEQ ID NO:15; (3) amino acid number 146 (Gln) to amino acid number 151 (Thr) of SEQ ID NO:15; (4) amino acid number 149 (Lys) to amino acid number 154 (Lys) of SEQ ID NO:15; and (5) amino acid number 157 (Glu) to amino acid number 162 (Lys) of SEQ ID NO:15. Moreover, IL-TIF antigenic epitopes as predicted by a Jameson-Wolf plot, e.g., using DNASTAR Protean program (DNASTAR, Inc., Madison, WI) serve as preferred antigens, and are readily determined by one of skill in the art. Such antigens include (1) amino acid number 40 (Cys) to amino acid number 47 (Phe) of SEQ ID NO:15; (2) amino acid number 64 (Ser) or 67 (Asp) to amino acid number 71 (Asp) or 74 (Leu) of SEQ ID NO:15; (3) amino acid number 106 (Pro) or 107 (Gln) to amino acid number 112 (Gln) or 115 (Met) of SEQ ID NO:15; (4) amino acid number 125 (Leu) to amino acid number 130 (Ser) or 131 (Thr) of SEQ ID NO:15; (5) amino acid number 135 (Glu) to amino acid number 138 (Asp) or 140 (His) of SEQ ID NO:15; and (6) amino acid number 146 (Gln) or 156 (Gly) to amino acid number 159 (Gly) of SEQ ID NO:15.

[0379] Antigenic epitope-bearing peptides and polypeptides preferably contain at least four to ten amino acids, at least ten to fifteen amino acids, or about 15 to about 30 amino acids of 34 (Ala) to 179 (Ile) of SEQ ID NO:15. Such epitope-bearing peptides and polypeptides can be produced by fragmenting a IL-TIF polypeptide, or by chemical peptide synthesis, as described herein. Moreover, epitopes can be selected by phage display of random peptide libraries (see, for example, Lane and Stephen, Curr. Opin. Immunol. 5:268 (1993); and Cortese et al., Curr. Opin. Biotechnol. 7:616 (1996)). Standard methods for identifying epitopes and producing antibodies from small peptides that comprise an epitope are described, for example, by Mole, "Epitope Mapping," in Methods in Molecular Biology, Vol. 10, Manson (ed.), pages 105-116 (The Humana Press, Inc. 1992); Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies," in Monoclonal Antibodies: Production, Engineering, and Clinical Application, Ritter and Ladyman (eds.), pages 60-84 (Cambridge University Press 1995), and Coligan et al. (eds.), Current Protocols in Immunology, pages 9.3.1 - 9.3.5 and pages 9.4.1 - 9.4.11 (John Wiley & Sons 1997).

[0380] IL-TIF polypeptides can also be used to prepare antibodies that bind to IL-TIF epitopes, peptides or polypeptides. The IL-TIF polypeptide or a fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response. Such antibodies can be used to block the biological action of pro-inflammatory IL-TIF and are useful as anti-inflammatory therapeutics in a variety of diseases as described herein. One of skill in the art would recognize that antigenic, epitope-bearing polypeptides contain a sequence of at least 6, preferably at least 9, and more preferably at least 15 to about 30 contiguous amino acid residues of a IL-TIF polypeptide (e.g., from 34 (Ala) to 179 (Ile) of SEQ ID NO:15). Polypeptides comprising a larger portion of a IL-TIF polypeptide, i.e., from 30 to 100 residues up to the entire length of the amino acid sequence of SEQ ID NO:15 are included. Antigens or immunogenic epitopes can also include attached tags, adjuvants and carriers, as described herein. Suitable antigens include the IL-TIF polypeptide encoded by 34 (Ala) to 179 (Ile) of SEQ ID NO:15 from amino acid number 34 to amino acid number 179, or a contiguous 9 to 144, or 30 to 144 amino acid fragment thereof. Other suitable antigens include polypeptides comprising isolated helices and fragments of the four-helical-bundle structure, as described herein. Preferred peptides to use as antigens are

hydrophilic peptides such as those predicted by one of skill in the art from a hydrophobicity plot, as described herein. Moreover, IL-TIF antigenic epitopes as predicted by a Jameson-Wolf plot, e.g., using DNASTAR Protean program (DNASTAR, Inc., Madison, WI) serve as preferred antigens, and are readily determined by one of skill in the art, and described herein.

5 **[0381]** Antibodies from an immune response generated by inoculation of an animal with these antigens (or immunogens) can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, FL, 1982.

10 **[0382]** As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a IL-TIF polypeptide or a fragment thereof. The immunogenicity of a IL-TIF polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of IL-TIF or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "haptent-like", such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

15 **[0383]** As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as $F(ab')_2$ and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced. Moreover, human antibodies can be produced in transgenic, non-human animals that have been engineered to contain human immunoglobulin genes as disclosed in WIPO Publication WO 98/24893. It is preferred that the endogenous immunoglobulin genes in these animals be inactivated or eliminated, such as by homologous recombination.

20 **[0384]** Antibodies are considered to be specifically binding if: 1) they exhibit a threshold level of binding activity, and 2) they do not significantly cross-react with related polypeptide molecules. A threshold level of binding is determined if anti-IL-TIF antibodies herein bind to a IL-TIF polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non-IL-TIF) polypeptide. It is preferred that the antibodies exhibit a binding affinity (K_a) of $10^6 M^{-1}$ or greater, preferably $10^7 M^{-1}$ or greater, more preferably $10^8 M^{-1}$ or greater, and most preferably $10^9 M^{-1}$ or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672, 1949).

25 **[0385]** Whether anti-IL-TIF antibodies do not significantly cross-react with related polypeptide molecules is shown, for example, by the antibody detecting IL-TIF polypeptide but not known related polypeptides using a standard Western blot analysis (Ausubel et al., *ibid.*). Examples of known related polypeptides are those disclosed in the prior art, such as known orthologs, and paralogs, and similar known members of a protein family. Screening can also be done using non-human IL-TIF, and IL-TIF mutant polypeptides. Moreover, antibodies can be "screened against" known related polypeptides, to isolate a population that specifically binds to the IL-TIF polypeptides. For example, antibodies raised to IL-TIF are adsorbed to related polypeptides adhered to insoluble matrix; antibodies specific to IL-TIF will flow through the matrix under the proper buffer conditions. Screening allows isolation of polyclonal and monoclonal antibodies non-crossreactive to known closely related polypeptides (Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; Current Protocols in Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995). Screening and isolation of specific antibodies is well known in the art. See, Fundamental Immunology, Paul (eds.), Raven Press, 1993; Getzoff et al., Adv. in Immunol. 43: 1-98, 1988; Monoclonal Antibodies: Principles and Practice, Goding, J.W. (eds.), Academic Press Ltd., 1996; Benjamin et al., Ann. Rev. Immunol. 2: 67-101, 1984. Specifically binding anti-IL-TIF antibodies can be detected by a number of methods in the art, and disclosed below.

30 **[0386]** A variety of assays known to those skilled in the art can be utilized to detect antibodies which bind to IL-TIF proteins or polypeptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be

screened for binding to wild-type versus mutant IL-TIF protein or polypeptide.

[0387] Alternative techniques for generating or selecting antibodies useful herein include *in vitro* exposure of lymphocytes to IL-TIF protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled IL-TIF protein or peptide). Genes encoding polypeptides having potential IL-TIF polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., US Patent NO. 5,223,409; Ladner et al., US Patent NO. 4,946,778; Ladner et al., US Patent NO. 5,403,484 and Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the IL-TIF sequences disclosed herein to identify proteins which bind to IL-TIF. These "binding polypeptides" which interact with IL-TIF polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding polypeptides can also be used in analytical methods such as for screening expression libraries and neutralizing activity, e.g., for blocking interaction between ligand and receptor, or viral binding to a receptor. The binding polypeptides can also be used for diagnostic assays for determining circulating levels of IL-TIF polypeptides; for detecting or quantitating soluble IL-TIF polypeptides as marker of underlying pathology or disease. These binding polypeptides can also act as IL-TIF "antagonists" to block IL-TIF binding and signal transduction *in vitro* and *in vivo*. These anti-IL-TIF binding polypeptides would be useful for inhibiting IL-TIF activity or protein-binding. Such anti-IL-TIF binding polypeptides can be used to block the biological action of pro-inflammatory IL-TIF and are useful as anti-inflammatory therapeutics in a variety of diseases as described herein.

[0388] Antibodies to IL-TIF may be used for tagging cells that express IL-TIF; for isolating IL-TIF by affinity purification; for diagnostic assays for determining circulating levels of IL-TIF polypeptides; for detecting or quantitating soluble IL-TIF as a marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block IL-TIF activity *in vitro* and *in vivo*. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. Moreover, antibodies to IL-TIF or fragments thereof may be used *in vitro* to detect denatured IL-TIF or fragments thereof in assays, for example, Western Blots or other assays known in the art.

[0389] Antibodies or polypeptides herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. For instance, polypeptides or antibodies of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance). More specifically, anti-IL-TIF antibodies, or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule.

[0390] Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair.

[0391] In another embodiment, polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the polypeptide has multiple functional domains (i.e., an activation domain or a receptor binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/

tissue-specific delivery of generic anti-complementary-detectable/ cytotoxic molecule conjugates. Such cytokine toxin fusion proteins can be used for *in vivo* killing of target tissues.

5 [0392] In another embodiment, IL-TIF cytokine fusion proteins or antibody-cytokine fusion proteins can be used for *in vivo* killing of target tissues (for example, leukemia, lymphoma, lung cancer, colon cancer, melanoma, pancreatic cancer, ovarian cancer, blood and bone marrow cancers, or other cancers wherein IL-TIF receptors are expressed) (See, generally, Hornick et al., Blood 89:4437-47, 1997). The described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable IL-TIF polypeptides or anti-IL-TIF antibodies target an undesirable cell or tissue (i.e., a tumor or a leukemia), and the fused cytokine mediated improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance.

10 [0393] In yet another embodiment, if the IL-TIF polypeptide or anti-IL-TIF antibody targets vascular cells or tissues, such polypeptide or antibody may be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis. Such therapeutic approaches pose less danger to clinicians who administer the radioactive therapy. For instance, iridium-192 impregnated ribbons placed into stented vessels of patients until the required radiation dose was delivered showed decreased tissue growth in the vessel and greater luminal diameter than the control group, which received placebo ribbons. Further, revascularisation and stent thrombosis were significantly lower in the treatment group. Similar results are predicted with targeting of a bioactive conjugate containing a radionuclide, as described herein.

15 [0394] The bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.

20 [0395] Moreover, Inflammation is a protective response by an organism to fend off an invading agent. Inflammation is a cascading event that involves many cellular and humoral mediators. On one hand, suppression of inflammatory responses can leave a host immunocompromised; however, if left unchecked, inflammation can lead to serious complications including chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and the like), septic shock and multiple organ failure. Importantly, these diverse disease states share common inflammatory mediators. The collective diseases that are characterized by inflammation have a large impact on human morbidity and mortality. Therefore it is clear that anti-inflammatory antibodies and binding polypeptides, such as anti-IL-TIF antibodies and binding polypeptides described herein, could have crucial therapeutic potential for a vast number of human and animal diseases, from asthma and allergy to autoimmunity and septic shock. As such, use of anti-inflammatory anti-IL-TIF antibodies and binding polypeptides described herein can be used therapeutically as IL-TIF antagonists described herein, particularly in diseases such as arthritis, endotoxemia, inflammatory bowel disease, psoriasis, related disease and the like.

25 [0396] Within one aspect the present specification describes an isolated polypeptide, comprising at least 15 contiguous amino acid residues of an amino acid sequence of SEQ ID NO:2 selected from the group consisting of: (a) amino acid residues 28 to 127; (b) amino acid residues 132 to 231; (c) amino acid residues 28 to 231; (d) amino acid residues 23 to 230; (e) amino acid residues 23 to 231; (f) amino acid residues 22 to 230; (g) amino acid residues 22 to 231; and (h) amino acid residues 1 to 231. In one embodiment, the isolated polypeptide disclosed above comprises an amino acid sequence selected from the group consisting of: (a) amino acid residues 28 to 127; (b) amino acid residues 132 to 231; (c) amino acid residues 28 to 231; (d) amino acid residues 23 to 230; (e) amino acid residues 23 to 231; (f) amino acid residues 22 to 230; (g) amino acid residues 22 to 231; and (h) amino acid residues 1 to 231. In another embodiment, the isolated polypeptide disclosed above consists of an amino acid sequence selected from the group consisting of: (a) amino acid residues 28 to 127; (b) amino acid residues 132 to 231; (c) amino acid residues 28 to 231; (d) amino acid residues 23 to 230; (e) amino acid residues 23 to 231; (f) amino acid residues 22 to 230; (g) amino acid residues 22 to 231; and (h) amino acid residues 1 to 231.

30 [0397] Within a second aspect the present specification describes an isolated polypeptide, comprising an amino acid sequence that is at least 70% identical to a reference amino acid sequence of SEQ ID NO:2 selected from the group consisting of: (a) amino acid residues 28 to 127; (b) amino acid residues 132 to 231; (c) amino acid residues 28 to 231; (d) amino acid residues 23 to 230; (e) amino acid residues 23 to 231; (f) amino acid residues 22 to 230; (g) amino acid residues 22 to 231; and (h) amino acid residues 1 to 231. In one embodiment, the isolated polypeptide disclosed above has an amino acid sequence that is at least 80% identical to the reference amino acid sequence. In another embodiment, the isolated polypeptide disclosed above has an amino acid sequence that is at least 90% identical to the reference amino acid sequence. In another embodiment, the isolated polypeptide disclosed above comprises either amino acid residues 22 to 231 of SEQ ID NO:2 or amino acid residues 28 to 231 of SEQ ID NO:2.

35 [0398] Within a third aspect the present specification describes an isolated nucleic acid molecule, wherein the nucleic acid molecule is either (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3, or (b) a nucleic acid molecule that remains hybridized following stringent wash conditions to a nucleic acid molecule consisting of the nucleotide sequence of nucleotides 64 to 693, or 82 to 693 of SEQ ID NO:1, or the complement of the nucleotide sequence of nucleotides 64 to 693, or 82 to 693 of SEQ ID NO:1; or (c) SEQ ID NO:1 or SEQ ID NO:37, or the complement of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:37. In one embodiment, the isolated nucleic acid molecule

is as disclosed above wherein any difference between the amino acid sequence encoded by the nucleic acid molecule and the corresponding amino acid sequence of SEQ ID NO:2 is due to a conservative amino acid substitution. In another embodiment, the isolated nucleic acid molecule disclosed above comprises the nucleotide sequence of nucleotides 1 to 693 of SEQ ID NO:1.

5 **[0399]** Within another aspect the present invention provides a vector, comprising an isolated nucleic acid molecule, as defined in the claims.

[0400] Within another aspect the present invention provides an expression vector as defined in the claims, consisting of an isolated nucleic acid molecule, a transcription promoter, and a transcription terminator, wherein the promoter is operably linked with the nucleic acid molecule, and wherein the nucleic acid molecule is operably linked with the transcription terminator.

10 **[0401]** Within another aspect the present invention provides a recombinant host cell comprising the expression vector as defined in the claims, wherein the host cell is selected from the group consisting of bacterium, yeast cell, fungal cell, insect cell, mammalian cell, and plant cell.

15 **[0402]** Within another aspect the present invention provides a method as defined in the claims producing Zcytor16 protein, the method comprising culturing recombinant host cells that comprise the expression vector as disclosed above, and that produce the Zcytor16 protein. In one embodiment, the method further comprises isolating the Zcytor16 protein from the cultured recombinant host cells.

20 **[0403]** Within another aspect the present specification describes antibody or antibody fragment that specifically binds with the polypeptide as disclosed above. The antibody may be selected from the group consisting of: (a) polyclonal antibody, (b) murine monoclonal antibody, (c) humanized antibody derived from (b), and (d) human monoclonal antibody.

[0404] Within another aspect the present specification describes an anti-idiotypic antibody that specifically binds with the antibody as disclosed above.

25 **[0405]** Within another aspect the present invention provides a fusion protein as defined in the claims, comprising the polypeptide as disclosed above. In one embodiment, the fusion protein disclosed above further comprises an immunoglobulin moiety.

[0406] Within another aspect the present specification describes an isolated polynucleotide that encodes a soluble cytokine receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:2 from amino acid 22 to 231 or 28 to 231, and wherein the soluble cytokine receptor polypeptide encoded by the polynucleotide sequence binds IL-TIF or antagonizes IL-TIF activity.

30 **[0407]** Within another aspect the present invention provides an isolated polynucleotide as defined in the claims, wherein the soluble cytokine receptor polypeptide encoded by the polynucleotide forms a homodimeric, heterodimeric or multimeric receptor complex. In one embodiment, the isolated polynucleotide is as defined in the claims, wherein the soluble cytokine receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I or Class II cytokine receptor. In another embodiment, the isolated polynucleotide is as defined in the claims, wherein the soluble cytokine receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

35 **[0408]** Within another aspect the present specification describes an isolated polynucleotide that encodes a soluble cytokine receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 22 to 231 or 28 to 231, wherein the soluble cytokine receptor polypeptide encoded by the polynucleotide forms a homodimeric, heterodimeric or multimeric receptor complex. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble cytokine receptor polypeptide encoded by the polynucleotide further comprises a soluble Class I or Class II cytokine receptor. In another embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble cytokine receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34). In another embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble cytokine receptor polypeptide further encodes an intracellular domain. In another embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble cytokine receptor polypeptide further comprises an affinity tag.

40 **[0409]** Within another aspect the present invention provides an expression vector consisting of the following operably linked elements: (a) a first transcription promoter; a first DNA segment as defined in the claims; and a transcription terminator; and (b) a second transcription promoter; a second DNA segment encoding a soluble Class I or Class II cytokine receptor polypeptide; and a transcription terminator. The first and second DNA segments may be contained within a single expression vector or within independent expression vectors, as defined in claims. An expression vector defined in the claims may include a secretory signal sequence operably linked to the first and second DNA segments. In another embodiment, the expression vector is as defined in the claims, wherein the second DNA segment encodes a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

[0410] Within another aspect the present invention provides a cultured cell comprising an expression vector as defined in the claims, wherein the cell expresses the polypeptides encoded by the DNA segments.

[0411] Within another aspect the present invention provides a cultured cell comprising an expression vector as defined in the claims wherein the first and second DNA segments are located on independent expression vectors and are
5 co-transfected into the cell, and cell expresses the polypeptides encoded by the DNA segments.

[0412] Within another aspect the present invention provides a cultured cell into which has been introduced an expression vector as defined in the claims, wherein the cell expresses a heterodimeric or multimeric soluble receptor polypeptide encoded by the DNA segments. In one embodiment is provided a cell as defined in the claims, wherein the cell secretes
10 a soluble cytokine receptor polypeptide heterodimer or multimeric complex. In another embodiment is provided a cell as defined in the claims, wherein the cell secretes a soluble cytokine receptor polypeptide heterodimer or multimeric complex that binds IL-TIF or antagonizes IL-TIF activity.

[0413] Within another aspect the present invention provides a DNA construct encoding a fusion protein consisting of : a first DNA segment encoding a polypeptide as defined in the claims, and at least one other DNA segment encoding a soluble Class I or Class II cytokine receptor polypeptide, wherein the first and other DNA segments are connected in-
15 frame; and wherein the first and other DNA segments encode the fusion protein. In one embodiment the DNA construct encoding a fusion protein is as defined in the claims, wherein at least one other DNA segment encodes a polypeptide consisting of a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO: 36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

[0414] Within another aspect the present invention provides an expression vector consisting of the following operably
20 linked elements: a transcription promoter; a DNA construct encoding a fusion protein as defined in the claims, and a transcription terminator, wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.

[0415] Within another aspect the present invention provides a cultured cell comprising an expression vector as defined
25 in the claims, wherein the cell expresses a polypeptide encoded by the DNA construct.

[0416] Within another aspect the present invention provides a method as defined in the claims of producing a fusion
protein comprising: culturing a cell as; and isolating the polypeptide produced by the cell.

[0417] Within another aspect the present specification describes an isolated soluble cytokine receptor polypeptide
30 comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:2 from amino acid 22 to 231 or 28 to 231, and wherein the soluble cytokine receptor polypeptide binds IL-TIF or antagonizes IL-TIF activity.

[0418] Within another aspect the present specification describes an isolated polypeptide as disclosed above, wherein
35 the soluble cytokine receptor polypeptide forms a homodimeric, heterodimeric or multimeric receptor complex. In one embodiment, the isolated polypeptide is as disclosed above, wherein the soluble cytokine receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I or Class II cytokine receptor. In another embodiment, the isolated polypeptide is as disclosed above, wherein the soluble cytokine receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble CRF2-4 receptor polypeptide (SEQ ID NO: 35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

[0419] Within another aspect the present invention provides an isolated soluble cytokine receptor polypeptide a se-
40 quence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 230 or 28 to 231, and an affinity tag, chemical moiety, toxin, or label wherein the soluble cytokine receptor polypeptide forms a homodimeric, heterodimeric or multimeric receptor complex. In one embodiment, the isolated soluble cytokine receptor polypeptide is as defined in the claims, wherein the soluble cytokine receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I or Class II cytokine receptor. In another embodiment, the isolated soluble cytokine receptor polypeptide is as defined in the claims, wherein the soluble cytokine receptor polypeptide forms a heterodimeric
45 or multimeric receptor complex comprising a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

[0420] Within another aspect the present invention provides an isolated heterodimeric or multimeric soluble receptor
50 complex consisting of soluble receptor subunits, wherein at least one of the soluble receptor subunits consists of the sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 230 or 28 to 231. In one embodiment, the isolated heterodimeric or multimeric soluble receptor complex defined in the claims includes a soluble Class I or Class II cytokine receptor polypeptide. In another embodiment, the isolated heterodimeric or multimeric soluble receptor complex defined in the claims includes a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

[0421] Within another aspect the present invention provides a method as defined in the claims of producing a soluble
55 cytokine receptor polypeptide that forms a heterodimeric or multimeric complex comprising: culturing a cell as defined the claims, and isolating the soluble receptor polypeptides produced by the cell.

[0422] Within another aspect the present specification describes a method of producing an antibody to soluble cytokine
receptor polypeptide comprising: inoculating an animal with a soluble cytokine receptor polypeptide selected from the

group consisting of: (a) a polypeptide comprising a monomeric or homodimeric soluble cytokine receptor comprising a polypeptide as shown in SEQ ID NO:2 from amino acid 22 to 231 or 28 to 231; (b) a polypeptide of (a) further comprising a soluble cytokine receptor heterodimeric or multimeric receptor complex comprising a soluble Class I or Class II cytokine receptor polypeptide; (c) a polypeptide of (a) further comprising a soluble cytokine receptor heterodimeric or multimeric receptor complex comprising a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35); (d) a polypeptide of (a) further comprising a soluble cytokine receptor heterodimeric or multimeric receptor complex comprising a soluble IL-10 receptor polypeptide (SEQ ID NO:36); and wherein the polypeptide elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.

[0423] Within another aspect the present specification describes an antibody produced by the method as disclosed above, which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex comprising a polypeptide as shown in SEQ ID NO:2 from amino acid 22 to 231 or 28 to 231. In one embodiment, the antibody disclosed above is a monoclonal antibody.

[0424] Within another aspect the present specification describes an antibody which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex as

[0425] Within another aspect the present invention provides an invitro method for inhibiting IL-TIF-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors, comprising culturing bone marrow or peripheral blood cells with an amount of the soluble cytokine receptor polypeptide as shown in SEQ ID NO:2 from amino acid 28 to 230 or 28 to 231, sufficient to reduce proliferation or differentiation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble cytokine receptor. In one embodiment, the method is as defined in the claims, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells. In another embodiment, the method is as defined in the claims wherein the lymphoid cells are macrophages or T cells.

[0426] Within another aspect the present invention provides for reducing IL-TIF-induced inflammation mammal with inflammation using an amount of the polypeptide as shown in SEQ ID NO:2 from amino acid 28 to 230 or 28 to 231 sufficient to reduce inflammation.

[0427] Within another aspect the present invention provides for use in heating inflammation in a mammal by suppressing an inflammatory response, as part of a method comprising: (1) determining a level of serum amyloid A protein; (2) the use of soluble zcytor16 cytokine receptor polypeptide as defined in the claims in an acceptable pharmaceutical vehicle determining a post administration level of serum amyloid A protein; (3) comparing the level of serum amyloid A protein in step (1) to the level of serum amyloid A protein in step (2), wherein a lack of increase or a decrease in serum amyloid A protein level is indicative of suppressing an inflammatory response.

[0428] Within another aspect the present specification describes method for detecting a genetic abnormality in a patient, comprising: obtaining a genetic sample from a patient; producing a first reaction product by incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1 or of SEQ ID NO:37 or the complement of SEQ ID NO:37, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence; visualizing the first reaction product; and comparing said first reaction product to a control reaction product from a wild type patient, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.

[0429] Within another aspect the present specification describes a method for detecting a cancer in a patient, comprising: obtaining a tissue or biological sample from a patient; incubating the tissue or biological sample with an antibody as disclosed above under conditions wherein the antibody binds to its complementary polypeptide in the tissue or biological sample; visualizing the antibody bound in the tissue or biological sample; and comparing levels of antibody bound in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the level of antibody bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.

[0430] Within another aspect the present specification describes a method for detecting a cancer in a patient, comprising: obtaining a tissue or biological sample from a patient; labeling a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1 or of SEQ ID NO:37 or the complement of SEQ ID NO:37; incubating the tissue or biological sample with under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence; visualizing the labeled polynucleotide in the tissue or biological sample; and comparing the level of labeled polynucleotide hybridization in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the labeled polynucleotide hybridization to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.

[0431] Within another aspect the present invention provides the use of an antagonist of IL-TIF for the manufacture of a medicament for an inflammatory disease in which IL-TIF or serum amyloid A plays a role, in a mammal, wherein the as defined in the claims. antagonist is a polypeptide as defined in the claims. In one embodiment, the disease is a chronic inflammatory disease. In another embodiment the disease is a chronic inflammatory disease selected from the group consisting of: inflammatory bowel disease; ulcerative colitis; Crohn's disease; arthritis; and psoriasis. In another embod-

iment, the disease is an acute inflammatory disease. In another embodiment, the disease is an acute inflammatory disease selected from the group consisting of: endotoxemia; septicemia; toxic shock syndrome; and infectious disease. In another embodiment, the antagonist soluble receptor comprising a polypeptide or cytokine binding domain fragment of zcytor11 (SEQ ID NO:34) further comprises a polypeptide or cytokine binding domain fragment of CRF2-4 (SEQ ID NO:35).

[0432] The invention is further illustrated by the following non-limiting examples.

EXAMPLES

Example 1

Cloning of zcytor16 and Construction of Mammalian Expression Vectors That Express zcytor16 Soluble Receptors: zcytor16CEE, zcytor16CFLG, zcytor16CHIS and zcytor16-Fc4

A. Cloning of Zcytor16 Extracellular domain

[0433] Scanning of a translated human genomic database resulted in identification of a class II cytokine receptor named zcytor16. The sequence for zcytor16 was subsequently identified a clone from an in-house derived shallow tonsil library. The insert in the tonsil library clone was sequenced, and shown to encode the zcytor16 extracellular domain. The polynucleotide sequence of the zcytor16 clone is shown in SEQ ID NO:1 and polypeptide sequence shown in SEQ ID NO:2.

B. Mammalian Expression Construction of Soluble zcytor16 receptor zcytor16-Fc4 Construction of mammalian expression vectors that express zcytor16 soluble receptor zcytor16sR/Fc4

[0434] An expression vector was prepared to express the soluble zcytor16 polypeptide (zcytor16sR, i.e., from residue 22 (Thr) to residue 231 (Pro) of SEQ ID NO:2; SEQ ID NO:13) fused to a C-terminal Fc4 tag (SEQ ID NO:5).

[0435] A PCR generated zcytor16 DNA fragment of about 630 bp was created using oligo ZC29,181 (SEQ ID NO:6) and oligo ZC29,182 (SEQ ID NO:7) as PCR primers to add BamHI and Bg12 restriction sites at 5' and 3' ends respectively, of the zcytor16 DNA encoding the soluble receptor. A plasmid containing the zcytor16 cDNA (SEQ ID NO:1) (Example 1A) was used as a template. PCR amplification of the zcytor16 fragment was performed as follows: One cycle at 94°C for 1 minute; 25 cycles at 94°C for 30 seconds, 68°C for 90 seconds, followed by an additional 68°C incubation for 4 minutes, and hold at 10°C. The reaction was purified by chloroform/phenol extraction and isopropanol precipitation, and digested with BamHI and Bg12 (Boehringer Mannheim, Indianapolis, IN). A band of approximately 630 bp, as visualized by 1% agarose gel electrophoresis, was excised and the DNA was purified using a QiaexII™ purification kit (Qiagen, Valencia, CA) according to the manufacturer's instruction.

[0436] The Fc4/pzmp20 plasmid is a mammalian expression vector containing an expression cassette having the CMV promoter, human tPA leader peptide, multiple restriction sites for insertion of coding sequences, a Fc4 tag, and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, an enhancer and an origin of replication, as well as a DHFR gene, and SV40 terminator. The zcytor 16sR/Fc4pzmp20 expression vector uses the human tPA leader peptide (SEQ ID NO:8 and SEQ ID NO:9) and attaches the Fc4 tag (SEQ ID NO:5) to the C-terminus of the extracellular portion of the zcytor16 polypeptide sequence. Fc4 is the Fc region derived from human IgG, which contains a mutation so that it no longer binds the Fc receptor

[0437] About 30 ng of the restriction digested zcytor16sR insert and about 10 ng of the digested vector (which had been cut with Bg12) were ligated at 11°C overnight. One microliter of ligation reaction was electroporated into DH10B competent cells (Gibco BRL, Rockville, MD) according to manufacturer's direction and plated onto LB plates containing 50 mg/ml ampicillin, and incubated overnight. Colonies were screened by restriction analysis of DNA, which was prepared from 2 ml liquid cultures of individual colonies. The insert sequence of positive clones was verified by sequence analysis. A large-scale plasmid preparation was done using a Qiagen® Mega prep kit (Qiagen) according to manufacturer's instruction.

[0438] Similar methods are used to prepare non-zcytor16 subunits of heterodimeric and multimeric receptors, such as CRF2-4 and IL-10R tagged with Fc4.

C. Construction of zcytor16 Mammalian Expression Vector containing zcytor16CEE, zcytor16CFLG and zcytor16CHIS

[0439] An expression vector is prepared for the expression of the soluble, extracellular domain of the zcytor16 polypeptide (e.g., amino acids 22-231 of SEQ NO:2; SEQ ID NO:13), pC4zcytor16CEE, wherein the construct is designed to express a zcytor16 polypeptide comprised of the predicted initiating methionine and truncated adjacent to the predicted

EP 1 373 508 B1

transmembrane domain, and with a C-terminal Glu-Glu tag (SEQ ID NO:10).

[0440] A zcytor16 DNA fragment comprising the zcytor16 extracellular cytokine binding domain (e.g., SEQ ID NO:13) is created using PCR, and purified. The excised DNA is subcloned into a plasmid expression vector that has a signal peptide, e.g., the native zcytor16 signal peptide, tPA leader, and attaches a Glu-Glu tag (SEQ ID NO:10) to the C-terminus of the zcytor16 polypeptide-encoding polynucleotide sequence. Such an expression vector mammalian expression vector contains an expression cassette having a mammalian promoter, multiple restriction sites for insertion of coding sequences, a stop codon and a mammalian terminator. The plasmid can also have an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the SV40 terminator.

[0441] Restriction digested zcytor16 insert and previously digested vector are ligated using standard molecular biological techniques, and electroporated into competent cells such as DH10B competent cells (GIBCO BRL, Gaithersburg, MD) according to manufacturer's direction and plated onto LB plates containing 50 mg/ml ampicillin, and incubated overnight. Colonies are screened by restriction analysis of DNA prepared from individual colonies. The insert sequence of positive clones is verified by sequence analysis. A large-scale plasmid preparation is done using a QIAGEN® Maxi prep kit (Qiagen) according to manufacturer's instructions.

[0442] The same process is used to prepare the zcytor16 soluble homodimeric, heterodimeric or multimeric receptors (including non-zcytor16 soluble receptor subunits, such as, soluble CRF2-4 or IL-10R) with a C-terminal HIS tag, composed of 6 His residues in a row (SEQ ID NO:12); and a C-terminal FLAG (SEQ ID NO:11) tag, zcytor16CFLAG. To construct these constructs, the aforementioned vector has either the HIS or the FLAG® tag in place of the glu-glu tag (SEQ ID NO:10).

Example 2

Transfection And Expression of Soluble Receptor Polypeptides

[0443] The day before the transfection, BHK 570 cells (ATCC No. CRL-10314; ATCC, Manassas, VA) were plated in a 10-cm plate with 50% confluence in normal BHK DMEM (Gibco/BRL High Glucose) media. The day of the transfection, the cells were washed once with Serum Free (SF) DMEM, followed by transfection with the zcytor16sR/Fc4/pzmp20 expression plasmids. Sixteen micrograms of zcytor16sR-Fc4 DNA construct (Example 1B) were diluted into a total final volume of 640 μ l SF DMEM. A diluted LipofectAMINE™ (Gibco BRL, Gaithersburg, MD) mixture (35 μ l LipofectAMINE™ in 605 μ l SF media) was added to the DNA mix, and incubated for 30 minutes at room temperature. Five milliliters of SF media was added to the DNA/LipofectAMINE™ mixture, which was then added to BHK cells. The cells were incubated at 37°C/5% CO₂ for 5 hours, after which 6.4ml of BHK media with 10% FBS was added. The cells were incubated overnight at 37°C/5% CO₂.

[0444] Approximately 24 hours post-transfection, the BHK cells were split into selection media with 1 μ M methotrexate (MTX). The cells were repeatedly split in this manner until stable zcytor16sR-Fc4/BHK cell lines were identified. To detect the expression level of the zcytor16 soluble receptor fusion proteins, the transfected BHK cells were washed with PBS and incubated in SF media for 72 hours. The SF condition media was collected and 20 μ l of the sample was run on 10% SDS-PAGE gel under reduced conditions. The protein bands were transferred to nitrocellulose filter by Western blot, and the fusion proteins were detected using goat-anti-human IgG/HRP conjugate (Jackson ImmunoResearch Laboratories, Inc, West Grove, PA). An expression vector containing a different soluble receptor fused to the Fc4 was used as a control. The expression level of the stable zcytor16sR-Fc4/BHK cells was approximately 2 mg/L.

[0445] For protein purification, the transfected BHK cells were transferred into T-162 flasks. Once the cells reached about 80% confluence, they were washed with PBS and incubated in 100ml SF media for 72 hours, and then the condition media was collected for protein purification (Example 11).

Example 3

Expression of zcytor16 Soluble Receptor in *E. coli*

A. Construction of expression vector pCZR225 that expresses huzcytor16/MBP-6H fusion polypeptide

[0446] An expression plasmid containing a polynucleotide encoding a zcytor16 soluble receptor fused C-terminally to maltose binding protein (MBP) is constructed via homologous recombination. The fusion polypeptide contains an N-terminal approximately 388 amino acid MBP portion fused to the zcytor16 soluble receptor (e.g., SEQ ID NO:13). A fragment of zcytor16 cDNA (SEQ ID NO:1) is isolated using PCR as described herein. Two primers are used in the production of the zcytor16 fragment in a standard PCR reaction: (1) one containing about 40 bp of the vector flanking sequence and about 25 bp corresponding to the amino terminus of the zcytor16, and (2) another containing about 40

bp of the 3' end corresponding to the flanking vector sequence and about 25 bp corresponding to the carboxyl terminus of the zcytor16. Two μl of the 100 μl PCR reaction is run on a 1.0% agarose gel with 1 x TBE buffer for analysis, and the expected approximately fragment is seen. The remaining PCR reaction is combined with the second PCR tube and precipitated with 400 μl of absolute ethanol. The precipitated DNA used for recombining into an appropriately restriction

5 digested recipient vector pTAP98 to produce the construct encoding the MBP-zcytor16 fusion, as described below.
[0447] Plasmid pTAP98 is derived from the plasmids pRS316 and pMAL-c2. The plasmid pRS316 is a *Saccharomyces cerevisiae* shuttle vector (Hieter P. and Sikorski, R., Genetics 122:19-27, 1989). pMAL-C2 (NEB) is an *E. coli* expression plasmid. It carries the tac promoter driving *MalE* (gene encoding MBP) followed by a His tag, a thrombin cleavage site, a cloning site, and the *rrnB* terminator. The vector pTAP98 is constructed using yeast homologous recombination. 100ng of EcoR1 cut pMAL-c2 is recombined with 1 μg PvuI cut pRS316, 1 μg linker, and 1 μg ScaI/EcoR1 cut pRS316 are combined in a PCR reaction. PCR products are concentrated via 100% ethanol precipitation.

10 **[0448]** Competent yeast cells (*S. cerevisiae*) are combined with about 10 μl of a mixture containing approximately 1 μg of the zcytor16 receptor PCR product above, and 100 ng of digested pTAP98 vector, and electroporated using standard methods and plated onto URA-D plates and incubated at 30°C.

15 **[0449]** After about 48 hours, the Ura+ yeast transformants from a single plate are picked, DNA isolated, and transformed into electrocompetent *E. coli* cells (e.g., MC1061, Casadaban et. al. J. Mol. Biol. 138, 179-207), and plated on MM/CA +AMP 100 mg/L plates (Pryor and Leitinger, Protein Expression and Purification 10:309-319, 1997).using standard procedures. Cells are grown in MM/CA with 100 $\mu\text{g}/\text{ml}$ Ampicillin for two hours, shaking, at 37°C. 1ml of the culture is induced with 1mM IPTG. 2-4 hours later the 250 μl of each culture is mixed with 250 μl acid washed glass beads and 20
 20 250 μl Thorner buffer with 5% βME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2mM EDTA, 5% SDS). Samples are vortexed for one minute and heated to 65°C for 10 minutes. 20 μl are loaded per lane on a 4%-12% PAGE gel (NOVEX). Gels are run in 1XMES buffer. The positive clones are designated pCZR225 and subjected to sequence analysis.

25 **[0450]** One microliter of sequencing DNA is used to transform strain BL21. The cells are electropulsed at 2.0 kV, 25 μF and 400 ohms. Following electroporation, 0.6 ml MM/CA with 100 mg/L Ampicillin. Cells are grown in MM/CA and induced with IPTG as described above. The positive clones are used to grow up for protein purification of the huzcytor16/MBP-6H fusion protein using standard techniques.

30 Example 4

Zcytor16 Soluble Receptor Polyclonal Antibodies

35 **[0451]** Polyclonal antibodies are prepared by immunizing female New Zealand white rabbits with the purified huzcytor16/MBP-6H polypeptide (Example 3), or the purified recombinant zcytor16CEE soluble receptor (Example 1; Example 11). The rabbits are each given an initial intraperitoneal (IP) injection of about 200 mg of purified protein in Complete Freund's Adjuvant (Pierce, Rockford, IL) followed by booster IP injections of 100 mg purified protein in Incomplete Freund's Adjuvant every three weeks. Seven to ten days after the administration of the third booster injection, the animals are bled and the serum is collected. The rabbits are then boosted and bled every three weeks.

40 **[0452]** The zcytor16-specific polyclonal antibodies are affinity purified from the rabbit serum using an CNBr-SEPHAROSE 4B protein column (Pharmacia LKB) that is prepared using about 10 mg of the appropriate purified zcytor16 polypeptide per gram CNBr-SEPHAROSE, followed by 20X dialysis in PBS overnight. Zcytor16-specific antibodies are characterized by an ELISA titer check using 1 mg/ml of the appropriate protein antigen as an antibody target. The lower limit of detection (LLD) of the rabbit anti-zcytor16 affinity purified antibodies is determined using standard methods.

45 Example 5

Zcytor16 Receptor Monoclonal Antibodies

50 **[0453]** Zcytor16 receptor Monoclonal antibodies are prepared by immunizing male BalbC mice (Harlan Sprague Dawley, Indianapolis, IN) with the purified recombinant zcytor16 proteins described herein. The mice are each given an initial intraperitoneal (IP) injection of 20 mg of purified protein in Complete Freund's Adjuvant (Pierce, Rockford, IL) followed by booster IP injections of 10 mg purified protein in Incomplete Freund's Adjuvant every two weeks. Seven to ten days after the administration of the third booster injection, the animals are bled and the serum is collected, and antibody titer assessed.

55 **[0454]** Splenocytes are harvested from high-titer mice and fused to murine SP2/0 myeloma cells using PEG 1500 (Boehringer Mannheim, UK) in two separate fusion procedures using a 4:1 fusion ratio of splenocytes to myeloma cells (Antibodies: A Laboratory Manual, E. Harlow and D. Lane, Cold Spring Harbor Press). Following 10 days growth post-fusion, specific antibody-producing hybridomas are identified by ELISA using purified recombinant zcytor16 soluble

receptor protein (Example 6C) as an antibody target and by FACS using Baf3 cells expressing the zcytor16 sequence (Example 8) as an antibody target. The resulting hybridomas positive by both methods are cloned three times by limiting dilution.

5 Example 6

Assessing Zcytor16 Receptor Heterodimerization Using ORIGEN Assay

10 **[0455]** Soluble zcytor16 receptor (Example 11), or gp130 (Hibi, M. et al., *Cell* 63:1149-1157, 1990) are biotinylated by reaction with a five-fold molar excess of sulfo-NHS-LC-Biotin (Pierce, Inc., Rockford, IL) according to the manufacturer's protocol. Soluble zcytor16 receptor and another soluble receptor subunit, for example, soluble IL-10R (sIL-10R) or CRF2-4 receptor (CRF2-4), soluble zcytor11 receptor (US Pat. No. 5,965,704) or soluble zcytor7 receptor (US patent No. 5,945,511) are labeled with a five fold molar excess of Ru-BPY-NHS (Igen, Inc., Gaithersburg, MD) according to manufacturer's protocol. The biotinylated and Ru-BPY-NHS-labeled forms of the soluble zcytor16 receptor can be re-
15 spectively designated Bio-zcytor16 receptor and Ru-zcytor16; the biotinylated and Ru-BPY-NHS-labeled forms of the other soluble receptor subunit can be similarly designated. Assays can be carried out using conditioned media from cells expressing a ligand, such as IL-TIF, that binds zcytor16 heterodimeric receptors, or using purified IL-TIF.

20 **[0456]** For initial receptor binding characterization a panel of cytokines or conditioned medium are tested to determine whether they can mediate homodimerization of zcytor16 receptor and if they can mediate the heterodimerization of zcytor16 receptor with the soluble receptor subunits described above. To do this, 50 μ l of conditioned media or TBS-B containing purified cytokine, is combined with 50 μ l of TBS-B (20 mM Tris, 150 mM NaCl, 1 mg/ml BSA, pH 7.2) containing e.g., 400 ng/ml of Ru-zcytor16 receptor and Bio-zcytor16, or 400 ng/ml of Ru-zcytor16 receptor and e.g., Bio-gp130, or 400 ng/ml of e.g., Ru-CRF2-4 and Bio-zcytor16. Following incubation for one hour at room temperature, 30 μ g of streptavidin coated, 2.8 mm magnetic beads (Dynal, Inc., Oslo, Norway) are added and the reaction incubated an
25 additional hour at room temperature. 200 μ l ORIGEN assay buffer (Igen, Inc., Gaithersburg, MD) is then added and the extent of receptor association measured using an M8 ORIGEN analyzer (Igen, Inc.).

Example 7

30 Construct for Generating a zcytor16 Receptor Heterodimer

[0457] A vector expressing a secreted human zcytor16 heterodimer is constructed. In this construct, the extracellular cytokine-binding domain of zcytor16 (e.g., SEQ ID NO:13) is fused to the heavy chain of IgG gamma 1 (IgG γ 1) while the extracellular portion of the heteromeric cytokine receptor subunit (e.g., an CRF2-4, IL-9, IL-10, zcytor7, zcytor11, IL-4
35 receptor component) is fused to a human kappa light chain (human κ light chain).

A. Construction of IgG gamma 1 and human κ light chain fusion vectors

40 **[0458]** The heavy chain of IgG γ 1 can be cloned into the Zem229R mammalian expression vector (ATCC deposit No. 69447) such that any desired cytokine receptor extracellular domain having a 5' EcoRI and 3' NheI site can be cloned in resulting in an N-terminal extracellular domain-C-terminal IgG γ 1 fusion. The IgG γ 1 fragment used in this construct is made by using PCR to isolate the IgG γ 1 sequence from a Clontech hFetal Liver cDNA library as a template. PCR products are purified using methods described herein and digested with MluI and EcoRI (Boehringer-Mannheim), ethanol precipitated and ligated with oligos which comprise an desired restriction site linker, into Zem229R previously digested with
45 and EcoRI using standard molecular biology techniques disclosed herein.

[0459] The human κ light chain can be cloned in the Zem228R mammalian expression vector (ATCC deposit No. 69446) such that any desired cytokine receptor extracellular domain having a 5' EcoRI site and a 3' KpnI site can be cloned in resulting in a N-terminal cytokine extracellular domain-C-terminal human κ light chain fusion. As a KpnI site is located within the human κ light chain sequence, a special primer is designed to clone the 3' end of the desired
50 extracellular domain of a cytokine receptor into this KpnI site: The primer is designed so that the resulting PCR product contains the desired cytokine receptor extracellular domain with a segment of the human κ light chain up to the KpnI site. This primer preferably comprises a portion of at least 10 nucleotides of the 3' end of the desired cytokine receptor extracellular domain fused in frame 5' to fragment cleaved at the KpnI site. The human κ light chain fragment used in this construct is made by using PCR to isolate the human κ light chain sequence from the same Clontech human Fetal
55 Liver cDNA library used above. PCR products are purified using methods described herein and digested with MluI and EcoRI (Boehringer-Mannheim), ethanol precipitated and ligated with the MluI/EcoRI linker described above, into Zem228R previously digested with and EcoRI using standard molecular biology techniques disclosed herein.

B. Insertion of zcytor16 receptor or heterodimeric subunit extracellular domains into fusion vector constructs

[0460] Using the construction vectors above, a construct having zcytor16 fused to IgG γ 1 is made. This construction is done by PCRing the extracellular cytokine-binding domain of zcytor16 receptor (SEQ ID NO:13) from a tonsil cDNA library (Clontech) or plasmid (Example 1A) using standard methods and oligos that provide EcoRI and NheI restriction sites. The resulting PCR product is digested with EcoRI and NheI, gel purified, as described herein, and ligated into a previously EcoRI and NheI digested and band-purified Zem229R/IgG γ 1 described above. The resulting vector is sequenced to confirm that the zcytor16/IgG gamma 1 fusion is correct.

[0461] A separate construct having a heterodimeric cytokine receptor subunit extracellular domain fused to κ light is also constructed as above. The CRF2-4/human κ light chain construction is performed as above by PCRing from, e.g., a lymphocyte cDNA library (Clontech) using standard methods, and oligos that provide EcoRI and KpnI restriction sites. The resulting PCR product is digested with EcoRI and KpnI and then ligating this product into a previously EcoRI and KpnI digested and band-purified Zem228R/human κ light chain vector described above. The resulting vector is sequenced to confirm that the cytokine receptor subunit/human κ light chain fusion is correct.

D. Co-expression of the zcytor16 and heterodimeric cytokine receptor subunit extracellular domain

[0462] Approximately 15 μ g of each of vectors above, are co-transfected into mammalian cells, e.g., BHK-570 cells (ATCC No. CRL-10314) using LipofectaminePlus™ reagent (Gibco/BRL), as per manufacturer's instructions. The transfected cells are selected for 10 days in DMEM + 5%FBS (Gibco/BRL) containing 1 μ M of methotrexate (MTX) (Sigma, St. Louis, MO) and 0.5 mg/ml G418 (Gibco/BRL) for 10 days. The resulting pool of transfectants is selected again in 10 μ M of MTX and 0.5 mg/ml G418 for about 10 days.

[0463] The resulting pool of doubly selected cells is used to generate protein. Three Factories (Nunc, Denmark) of this pool are used to generate 10 L of serum free conditioned medium. This conditioned media is passed over a 1 ml protein-A column and eluted in about 10, 750 microliter fractions. The fractions having the highest protein concentration are pooled and dialyzed (10 kD MW cutoff) against PBS. Finally the dialyzed material is submitted for amino acid analysis (AAA) using routine methods.

Example 8Determination of Receptor Subunits That Heterodimerize or Multimerize With zcytor16 Receptor Using a Proliferation Assay

[0464] Using standard methods described herein, cells expressing a BaF3/zcytor16-MPL chimera (wherein the extracellular domain of the zcytor16 (e.g., SEQ ID NO:13) is fused in frame to the intracellular signaling domain of the mpl receptor) are tested for proliferative response in the presence of IL-TIF. Such cells serve as a bioassay cell line to measure ligand binding of monomeric or homodimeric zcytor16 receptors. In addition, BaF3/zcytor16-MPL chimera cells transfected with an additional heterodimeric cytokine receptor subunit can be assessed for proliferative response in the presence of IL-TIF. In the presence of IL-TIF, if the BaF3/zcytor16-MPL cells signal, this would suggest that zcytor16 receptor can homodimerize to signal. Transfection of the BaF3/MPL-zcytor16 cell line with an additional MPL-class II cytokine receptor fusion that signals in the presence of the IL-TIF ligand, such as CRF2-4, determines which heterodimeric cytokine receptor subunits are required for zcytor16 receptor signaling. Use of MPL-receptor fusions for this purpose alleviates the requirement for the presence of an intracellular signaling domain for the zcytor16 receptor.

[0465] Each independent receptor complex cell line is then assayed in the presence of IL-TIF and proliferation measured using routine methods (e.g., Alamar Blue assay). The BaF3/MPL-zcytor16 bioassay cell line serves as a control for the monomeric or homodimeric receptor activity, and is thus used as a baseline to compare signaling by the various receptor complex combinations. The untransfected bioassay cell line serves as a control for the background activity, and is thus used as a baseline to compare signaling by the various receptor complex combinations. A BaF3/MPL-zcytor16 without ligand (IL-TIF) is also used as a control. The IL-TIF in the presence of the correct receptor complex, is expected to increase proliferation of the BaF3/zcytor16-MPL receptor cell line approximately 5 fold over background or greater in the presence of IL-TIF. Cells expressing the components of zcytor16 heterodimeric and multimeric receptors should proliferate in the presence of IL-TIF.

Example 9Reconstitution of zcytor16 Receptor *in vitro*

[0466] To identify components involved in the zcytor16-signaling complex, receptor reconstitution studies are per-

formed as follows. BHK 570 cells (ATCC No. CRL-10314) transfected, using standard methods described herein, with a luciferase reporter mammalian expression vector plasmid serve as a bioassay cell line to measure signal transduction response from a transfected zcytor16 receptor complex to the luciferase reporter in the presence of IL-TIF. BHK cells do not endogenously express the zcytor16 receptor. An exemplary luciferase reporter mammalian expression vector is the KZ134 plasmid which was constructed with complementary oligonucleotides that contain STAT transcription factor binding elements from 4 genes. A modified c-fos Sis inducible element (m67SIE, or hSIE) (Sadowski, H. et al., Science 261:1739-1744, 1993), the p21 SIE1 from the p21 WAF1 gene (Chin, Y. et al., Science 272:719-722, 1996), the mammary gland response element of the β -casein gene (Schmitt-Ney, M. et al., Mol. Cell. Biol. 11:3745-3755, 1991), and a STAT inducible element of the FcgRI gene, (Seidel, H. et al., Proc. Natl. Acad. Sci. 92:3041-3045, 1995). These oligonucleotides contain Asp718-XhoI compatible ends and were ligated, using standard methods, into a recipient firefly luciferase reporter vector with a c-fos promoter (Poulsen, L.K. et al., J. Biol. Chem. 273:6229-6232, 1998) digested with the same enzymes and containing a neomycin selectable marker. The KZ134 plasmid is used to stably transfect BHK, or BaF3 cells, using standard transfection and selection methods, to make a BHK/KZ134 or BaF3/KZ134 cell line respectively.

[0467] The bioassay cell line is transfected with zcytor16-*mpl* fusion receptor alone, or co-transfected along with one of a variety of other known receptor subunits. Receptor complexes include but are not limited to zcytor16-*mpl* receptor only, various combinations of zcytor16-*mpl* receptor with one or more of the CRF2-4, IL-9, IL-10, zcytor11, zcytor7 class II cytokine receptor subunits, or IL-4 receptor components, or the IL-2 receptor components (IL-2R α , IL-2R β , IL-2R γ); zcytor16-*mpl* receptor with one or more of the IL-4/IL-13 receptor family receptor components (IL-4R α , IL-13R α , IL-13R α'), as well as other Interleukin receptors (e.g., IL-15 R α , IL-7R α , IL-9R α , IL-21R (zalpha11; WIPO publication WO 00/17235; Parrish-Novak, J et al., Nature 408:57-63, 2000)). Each independent receptor complex cell line is then assayed in the presence of cytokine-conditioned media or purified cytokines and luciferase activity measured using routine methods. The untransfected bioassay cell line serves as a control for the background luciferase activity, and is thus used as a baseline to compare signaling by the various receptor complex combinations. The conditioned medium or cytokine that binds the zcytor16 receptor in the presence of the correct receptor complex, is expected to give a luciferase readout of approximately 5 fold over background or greater.

[0468] As an alternative, a similar assay can be performed wherein BaF3/zcytor16-*mpl* cell lines are co-transfected as described above and proliferation measured (Example 8).

Example 10

COS Cell Transfection and Secretion Trap

[0469] COS cell transfections were performed as follows: A mixture of 0.5 μ g DNA and 5 μ l lipofectamine (Gibco BRL) in 92ul serum free DMEM media (55 mg sodium pyruvate, 146 mg L-glutamine, 5 mg transferrin, 2.5mg insulin, 1 μ g selenium and 5 mg fetuin in 500ml DMEM) was incubated at room temperature for 30 minutes and then 400 μ l serum free DMEM media added. A 500 μ l mixture was added onto COS cells plated on 12-well tissue culture plate at 1.5×10^5 COS cells/well and previously incubated for 5 hours at 37°C. An additional 500 μ l 20% FBS DMEM media (100 ml FBS, 55 mg sodium pyruvate and 146 mg L-glutamine in 500 ml DMEM) was added and the plates were incubated overnight.

[0470] The secretion trap was performed as follows: Media was rinsed off cells with PBS and fixed for 15 minutes with 1.8% Formaldehyde in PBS. Cells were then washed with TNT (0.1M Tris-HCl, 0.15M NaCl, and 0.05% Tween-20 in H₂O). Cells were permeated with 0.1% Triton-X in PBS for 15 minutes and washed again with TNT. Cells were blocked for 1 hour with TNB (0.1M Tris-HCl, 0.15M NaCl and 0.5% Blocking Reagent (NEN Renaissance TSA-Direct Kit; NEN) in H₂O). Cells were again washed with TNT. Cells were then incubated for 1 hour with 1-3 μ g/ml zcytor16 soluble receptor Fc4 fusion protein (zcytor16sR-Fc4) (Example 11) in TNB. Cells were washed with TNT, and then incubated for another hour with 1:200 diluted goat-anti-human Ig-HRP (Fc specific; Jackson ImmunoResearch Laboratories, Inc.) in TNB. Cells were again washed with TNT. Antibodies positively binding to the zcytor16sR-Fc4 were detected with fluorescein tyramide reagent diluted 1:50 in dilution buffer (NEN kit) and incubated for 4-6 minutes. Cells were again washed with TNT. Cells were preserved with Vectashield Mounting Media (Vector Labs) diluted 1:5 in TNT. Cells were visualized using FITC filter on fluorescent microscope.

[0471] Since zcytor16 is a Class II cytokine receptor, the binding of zcytor16sR/Fc4 fusion protein with known or orphan Class II cytokines was tested. The pZP7 expression vectors containing cDNAs of cytokines (including human IL-TIF, interferon alpha, interferon beta, interferon gamma, IL-10, amongst others) were transfected into COS cells, and the binding of zcytor16sR/Fc4 to transfected COS cells were carried out using the secretion trap assay described above. Human IL-TIF showed positive binding. Based on these data, human IL-TIF and zcytor16 is a potential ligand-receptor pair.

Example 11Purification of zcytor16-Fc4 Polypeptide From Transfected BHK 570 Cells

5 [0472] Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying zcytor16 polypeptide containing C-terminal fusion to human Fc4 (zcytor16-Fc4; Example 1). About 16,500 ml of conditioned media from BHK 570 cells transfected with zcytor16-Fc4 (Example 2) was filtered through a 0.2 µm sterilizing filter and then supplemented with a solution of protease inhibitors, to final concentrations of, 0.001 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). A Poros protein A50 column (20 ml bed volume, Applied Biosystems) was packed and washed with 400 ml PBS (Gibco/BRL) The supplemented conditioned media was passed over the column with a flow rate of 15 ml/minute, followed by washing with 800 ml PBS (BRL/Gibco). Zcytor16-Fc4 was eluted from the column with 0.1 M Glycine pH 3.0 and 5 ml fractions were collected directly into 0.5 ml 2M Tris pH 7.8, to adjust the final pH to 7.4 in the fractions.

10 [0473] Column performance was characterized through western blotting of reducing SDS-PAGE gels of the starting media and column pass through. Western blotting used anti-human IgG HRP (Amersham) antibody, which showed an immunoreactive protein at 60,000 Da in the starting media, with nothing in the pass through, suggesting complete capture. The protein A50 eluted fractions were characterized by reducing SDS PAGE gel. This gel showed an intensely Coomassie stained band at 60,000 Da in fractions 3 to 11. Fractions 3 to 11 were pooled.

15 [0474] Protein A 50 elution pool was concentrated from 44 ml to 4 ml using a 30,000 Da Ultrafree Biomax centrifugal concentrator (15 ml volume, Millipore). A Sephacryl S-300 gel filtration column (175 ml bed volume; Pharmacia) was washed with 350 ml PBS (BRL/Gibco). The concentrated pool was injected over the column with a flow rate of 1.5 ml/min, followed by washing with 225 ml PBS (BRL/Gibco). Eluted peaks were collected into 2 ml fractions.

20 [0475] Eluted fractions were characterized by reducing and non-reducing silver stained (Geno Technology) SDS PAGE gels. Reducing silver stained SDS PAGE gels showed an intensely stained band at 60,000 Da in fractions 14 - 31, while non-reducing silver stained SDS PAGE gels showed an intensely stained band at 160,000 Da in fractions 14 - 31. Fractions 1 - 13 showed many bands of various sizes. Fractions 14 - 31 were pooled, concentrated to 22 ml using 30,000 Da Ultrafree Biomax centrifugal concentrator (15 ml volume, Millipore). This concentrate was filtered through a 0.2 µm Acrodisc sterilizing filter (Pall Corporation).

25 [0476] The protein concentration of the concentrated pooled fractions was performed by BCA analysis (Pierce, Rockford, IL) and the material was aliquoted, and stored at -80°C according to our standard procedures. The concentration of the pooled fractions was 1.50 mg/ml.

Example 12Human zcytor16 Tissue Distribution in Tissue Panels Using Northern Blot and PCRA. Human zcytor16 Tissue Distribution using Northern Blot and Dot Blot

35 [0477] Northern blot analysis was performed using Human Multiple Tissue Northern Blots I, II, III (Clontech) and an in house generated U-937 northern blot. U-937 is a human monoblastic promonocytic cell line. The cDNA probe was generated using oligos ZC25,963 (SEQ NO:16) and ZC28,354 (SEQ ID NO:17). The PCR conditions were as follows: 94° for 1 minute; 30 cycles of 94° , 15 seconds; 60° , 30 seconds; 72° , 30 seconds and a final extension for 5 minutes at 72°. The 364 bp product was gel purified by gel electrophoresis on a 1% TBE gel and the band was excised with a razor blade. The cDNA was extracted from the agarose using the QIAquick Gel Extraction Kit (Qiagen). 94 ng of this fragment was radioactively labeled with ³²P-dCTP using Rediprime II (Amersham), a random prime labeling system, according to the manufacturer's specifications. Unincorporated radioactivity was removed using a Nuc-Trap column (Stratagene) according to manufacturer's instructions. Blots were prehybridized at 65° for 3 hours in ExpressHyb (Clontech) solution. Blots were hybridized overnight at 65° in Expresshyb solution containing 1.0 x 10⁶ cpm/ml of labeled probe, 0.1 mg/ml of salmon sperm DNA and 0.5 µg/ml of human cot-1 DNA. Blots were washed in 2 x SSC, 0.1% SDS at room temperature with several solution changes then washed in 0.1 x SSC, 0.1% SDS at 55° for 30 minutes twice. Transcripts of approximately 1.6 kb and 3.0 kb size were detected in spleen and placenta, but not other tissues examined. The same sized transcripts plus an additional approximate 1.2 kb transcript was detected in U-937 cell line.

B. Tissue Distribution in tissue cDNA panels using PCR

55 [0478] A panel of cDNAs from human tissues was screened for zcytor16 expression using PCR. The panel was made in-house and contained 94 marathon cDNA and cDNA samples from various normal and cancerous human tissues and cell lines are shown in Table 5, below. The cDNAs came from in-house libraries or marathon cDNAs from in-house RNA

EP 1 373 508 B1

preps, Clontech RNA, or Invitrogen RNA. The marathon cDNAs were made using the marathon-Ready™ kit (Clontech, Palo Alto, CA) and QC tested with clathrin primers ZC21195 (SEQ ID NO:18) and ZC21196 (SEQ ID NO:19) and then diluted based on the intensity of the clathrin band. To assure quality of the panel samples, three tests for quality control (QC) were run: (1) To assess the RNA quality used for the libraries, the in-house cDNAs were tested for average insert size by PCR with vector oligos that were specific for the vector sequences for an individual cDNA library; (2) Standardization of the concentration of the cDNA in panel samples was achieved using standard PCR methods to amplify full length alpha tubulin or G3PDH cDNA using a 5' vector oligo ZC14,063 (SEQ ID NO:20) and 3' alpha tubulin specific oligo primer ZC17,574 (SEQ ID NO:21) or 3' G3PDH specific oligo primer ZC17,600 (SEQ ID NO:22); and (3) a sample was sent to sequencing to check for possible ribosomal or mitochondrial DNA contamination. The panel was set up in a 96-well format that included a human genomic DNA (Clontech, Palo Alto, CA) positive control sample. Each well contained approximately 0.2-100 pg/μl of cDNA. The PCR reactions were set up using oligos ZC25,963 (SEQ ID NO: 16) and ZC27,659 (SEQ ID NO:23), Advantage 2 DNA Polymerase Mix (Clontech) and Rediload dye (Research Genetics, Inc., Huntsville, AL). The amplification was carried out as follow: 1 cycle at 94°C for 2 minutes, 30 cycles of 94°C for 20 seconds, 58°C for 30 seconds and 72°C for 1 minute, followed by 1 cycle at 72°C for 5 minutes. About 10 μl of the PCR reaction product was subjected to standard Agarose gel electrophoresis using a 2% agarose gel. The correct predicted DNA fragment size was not observed in any tissue or cell line. Subsequent experiments showing expression of zcytor16 indicated that the negative results from this panel were likely due to the primers used.

Table 5

Tissue/Cell line	#samples	Tissue/Cell line	#samples
Adrenal gland	1	Bone marrow	3
Bladder	1	Fetal brain	3
Bone Marrow	1	Islet	2
Brain	1	Prostate	3
Cervix	1	RPMI #1788 (ATCC # CCL-156)	2
Colon	1	Testis	4
Fetal brain	1	Thyroid	2
Fetal heart	1	WI38 (ATCC # CCL-75	2
Fetal kidney	1	ARIP (ATCC # CRL-1674 - rat)	1
Fetal liver	1	HaCat - human keratinocytes	1
Fetal lung	1	HPV (ATCC # CRL-2221)	1
Fetal muscle	1	Adrenal gland	1
Fetal skin	1	Prostate SM	2
Heart	2	CD3+ selected PBMC's Ionomycin + PMA stimulated	1
K562 (ATCC # CCL-243)	1	HPVS (ATCC # CRL-2221) - selected	1
Kidney	1	Heart	1
Liver	1	Pituitary	1
Lung	1	Placenta	2
Lymph node	1	Salivary gland	1
Melanoma	1	HL60 (ATCC # CCL-240)	3
Pancreas	1	Platelet	1
Pituitary	1	HBL-100	1
Placenta	1	Renal mesangial	1
Prostate	1	T-cell	1
Rectum	1	Neutrophil	1

EP 1 373 508 B1

(continued)

	Tissue/Cell line	#samples		Tissue/Cell line	#samples
5	Salivary Gland	1		MPC	1
	Skeletal muscle	1		Hut-102 (ATCC # TIB-162)	1
	Small intestine	1		Endothelial	1
	Spinal cord	1		HepG2 (ATCC # HB-8065)	1
10	Spleen	1		Fibroblast	1
	Stomach	1		E. Histo	1
	Testis	2			
	Thymus	1			
15	Thyroid	1			
	Trachea	1			
	Uterus	1			
20	Esophagus tumor	1			
	Gastric tumor	1			
	Kidney tumor	1			
	Liver tumor	1			
25	Lung tumor	1			
	Ovarian tumor	1			
	Rectal tumor	1			
30	Uterus tumor	1			

[0479] An additional panel of cDNAs from human tissues was screened for zcytor16 expression using PCR. This panel was made in-house and contained 77 marathon cDNA and cDNA samples from various normal and cancerous human tissues and cell lines are shown in Table 6, below. Aside from the PCR reaction, the assay was carried out as per above. The PCR reactions were set up using oligos ZC25,963 (SEQ ID NO:30) and ZC25,964 (SEQ ID NO:31), Advantage 2 DNA Polymerase Mix (Clontech) and Rediload dye (Research Genetics, Inc., Huntsville, AL). The amplification was carried out as follow: 1 cycle at 94°C for 1 minute, 38 cycles of 94°C for 10 seconds, 60°C for 30 seconds and 72°C for 30 seconds, followed by 1 cycle at 72°C for 5 minutes. The correct predicted DNA fragment size was observed in bone marrow, fetal heart, fetal kidney, fetal muscle, fetal skin, heart, mammary gland, placenta, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, kidney, fetal brain, esophageal tumor, uterine tumor, stomach tumor, ovarian tumor, rectal tumor, lung tumor and RPMI-1788 (a B-lymphocyte cell line). Zcytor16 expression was not observed in the other tissues and cell lines tested in this panel. The expression pattern of zcytor16 shows expression in certain tissue-specific tumors especially, e.g., ovarian cancer, stomach cancer, uterine cancer, rectal cancer, lung cancer and esophageal cancer, where zcytor 16 is not expressed in normal tissue, but is expressed in the tumor tissue. One of skill in the art would recognize that the polynucleotides, polypeptides, antibodies, and binding partners of the present invention can be used as a diagnostic to detect cancer, or cancer tissue in a biopsy, tissue, or histologic sample, particularly e.g., ovarian cancer, stomach cancer, uterine cancer, rectal cancer, lung cancer and esophageal cancer tissue. Such diagnostic uses for the molecules of the present invention are known in the art and described herein.

[0480] In addition, because the expression pattern of zcytor16, one of IL-TIF's receptors, shows expression in certain specific tissues as well as tissue-specific tumors, binding partners including the natural ligand, IL-TIF, can also be used as a diagnostic to detect specific tissues (normal or abnormal), cancer, or cancer tissue in a biopsy, tissue, or histologic sample, where IL-TIF receptors are expressed, and particularly e.g., ovarian cancer, stomach cancer, uterine cancer, rectal cancer, lung cancer and esophageal cancer tissue. IL-TIF can also be used to target other tissues wherein its receptors, e.g., zcytor16 and zcytor11 are expressed. Moreover, such binding partners could be conjugated to chemotherapeutic agents, toxic moieties and the like to target therapy to the site of a tumor or diseased tissue. Such diagnostic and targeted therapy uses are known in the art and described herein.

[0481] A commercial 1st strand cDNA panel (Human Blood Fractions MTC Panel, Clontech, Palo Alto, CA) was also

EP 1 373 508 B1

assayed as above. The panel contained the following samples: mononuclear cells, activated mononuclear cells, resting CD4+ cells, activated CD4+ cells, resting CD8+ cells, activated CD8+ cells, resting CD14+ cells, resting CD19+ cells and activated CD19+ cells. Activated CD4+ cells and activated CD19+ cells showed zcytor16 expression, whereas the other cells tested, including resting CD4+ cells and resting CD19+ cells, did not.

5

Table 6

10

15

20

25

30

35

40

45

Tissue	#samples		Tissue	#samples
adrenal gland	1		bladder	1
bone marrow	3		brain	2
cervix	1		colon	1
fetal brain	3		fetal heart	2
fetal kidney	1		fetal liver	2
fetal lung	1		fetal skin	1
heart	2		fetal muscle	1
kidney	2		liver	1
lung	1		lymph node	1
mammary gland	1		melanoma	1
ovary	1		pancreas	1
pituitary	2		placenta	3
prostate	3		rectum	1
salivary gland	2		skeletal muscle	1
small intestine	1		spinal cord	2
spleen	1		uterus	1
stomach	1		adipocyte library	1
testis	5		islet	1
thymus	1		prostate SMC	1
thyroid	2		RPMI 1788	1
trachea	1		WI38	1
esophageal tumor	1		lung tumor	1
liver tumor	1		ovarian tumor	1
rectal tumor	1		stomach tumor	1
uterine tumor	2		CD3+ library	1
HaCAT library	1		HPV library	1
HPVS library	1		MG63 library	1
K562	1			

50

C. Tissue Distribution in Human Tissue and Cell Line RNA Panels Using RT-PCR

55

[0482] A panel of RNAs from human cell lines was screened for zcytor16 expression using RT-PCR. The panels were made in house and contained 84 RNAs from various normal and cancerous human tissues and cell lines as shown in Tables 7-10 below. The RNAs were made from in house or purchased tissues and cell lines using the RNAeasy Midi or Mini Kit (Qiagen, Valencia, CA). The panel was set up in a 96-well format with 100 ngs of RNA per sample. The RT-PCR reactions were set up using oligos ZC25,963 (SEQ ID NO:30) and ZC25,964 (SEQ ID NO:31), Rediload dye and SUPERSCRIPT One Step RT-PCR System (Life Technologies, Gaithersburg, MD). The amplification was carried out

EP 1 373 508 B1

as follows: one cycle at 55° for 30 minutes followed by 40 cycles of 94°, 15 seconds; 59°, 30 seconds; 72°, 30 seconds; then ended with a final extension at 72° for 5 minutes. 8 to 10 μl of the PCR reaction product was subjected to standard Agarose gel electrophoresis using a 4% agarose gel. The correct predicted cDNA fragment size of 184 bps was observed in cell lines U-937, HL-60, ARPE-19, HaCat#1, HaCat#2, HaCat#3, and HaCat#4; bladder, cancerous breast, normal breast adjacent to a cancer, bronchus, colon, ulcerative colitis colon, duodenum, endometrium, esophagus, gastro-esophageal, heart left ventricle, heart ventricle, ileum, kidney, lung, lymph node, lymphoma, mammary adenoma, mammary gland, cancerous ovary, pancreas, parotid and skin, spleen lymphoma and small bowel. Zcytor16 expression was not observed in the other tissues and cell lines tested in this panel.

[0483] Zcytor16 is detectably expressed by PCR in normal tissues: such as, the digestive system, e.g., esophagus, gastro-esophageal, pancreas, duodenum, ileum, colon, small bowel; the female reproductive system, e.g., mammary gland, endometrium, breast (adjacent to cancerous tissues); and others systems, e.g., lymph nodes, skin, parotid, bladder, bronchus, heart ventricles, and kidney. Moreover, Zcytor16 is detectably expressed by PCR in several human tumors: such as tumors associated with female reproductive tissues e.g., mammary adenoma, ovary cancer, uterine cancer, other breast cancers; and other tissues such as lymphoma, stomach tumor, and lung tumor. The expression of zcytor16 is found in normal tissues of female reproductive organs, and in some tumors associated with these organs. As such, zcytor16 can serve as a marker for these tumors wherein the zcytor16 may be over-expressed. Several cancers positive for zcytor16 are associated with ectodermal/epithelial origin (mammary adenoma, and other breast cancers). Hence, zcytor16 can serve as a marker for epithelial tissue, such as epithelial tissues in the digestive system and female reproductive organs (e.g., endometrial tissue, columnar epithelium), as well as cancers involving epithelial tissues. Moreover, in a preferred embodiment, zcytor16 can serve as a marker for certain tissue-specific tumors especially, e.g., ovarian cancer, stomach cancer, uterine cancer, rectal cancer, lung cancer and esophageal cancer, where zcytor 16 is not expressed in normal tissue, but is expressed in the tumor tissue. Use of polynucleotides, polypeptides, and antibodies of the present invention for diagnostic purposes are known in the art, and disclosed herein.

Table 7

Tissue	#samples		Tissue	#samples
adrenal gland	6		duodenum	1
bladder	3		endometrium	5
brain	2		cancerous endometrium	1
brain meningioma	1		gastric cancer	1
breast	1		esophagus	7
cancerous breast	4		gastro-esophageal	1
normal breast adjacent to cancer	5		heart aorta	1
bronchus	3		heart left ventricle	4
colon	15		heart right ventricle	2
cancerous colon	1		heart ventricle	1
normal colon adjacent to cancer	1		ileum	3
ulcerative colitis colon	1		kidney	15
			cancerous kidney	1

Table 8

Tissue/Cell Line	#samples		Tissue/Cell Line	#samples
293	1		HBL-100	1
C32	1		Hs-294T	1
HaCat#1	1		Molt4	1
HaCat#2	1		RPMI	1
HaCat#3	1		U-937	1

EP 1 373 508 B1

(continued)

5
10
15
20
25
30
35
40
45
50
55

Tissue/Cell Line	#samples		Tissue/Cell Line	#samples
HaCat#4	1		A-375	1
WI-38	1		HCT-15	1
WI-38 + 2 um ionomycin #1	1		HT-29	1
WI-38 + 2 um ionomycin #2	1		MRC-5	1
WI-38 + 5 um ionomycin #1	1		RPT-1	1
WI-38 + 5 um ionomycin #2	1		RPT-2	1
Caco-2,	1		WM-115	1
Caco-2,differentiated	1		A-431	1
DLD-1	1		WERI-Rb-1	1
HRE	1		HEL-92.1.7	1
HRCE	1		HuH-7	1
MCF7	1		MV-4-11	1
PC-3	1		U-138	1
TF-1	1		CCRF-CEM	1
5637	1		Y-79	1
143B	1		A-549	1
ME-180	1		EL-4	1
prostate epithelia	1		HeLa 229	1
U-2 OS	1		HUT 78	1,
T-47D	1		NCI-H69	1
Mg-63	1		SaOS2	1
Raji	1		USMC	1
U-373 MG	1		UASMC	2
A-172	1		AoSMC	1
CRL-1964	1		UtSMC	1
CKL-1964 + butyric acid	1		HepG2	1
HUVEC	1		HepG2- IL6	1
SK-Hep-1	1		NHEK#1	1
SK-Lu-1	1		NHEK#2	1
Sk-MEL-2	1		NHEK#3	1
K562	1		NHEK#4	1
BeWo	1		ARPE-19	1
FHS74.Int	1		G-361	1
HL-60	1		HISM	1
Malme 3M	1		3AsubE	1
FHC	1		INT407	1
HREC	1			

Table 9

Tissue	#samples		Tissue	#samples
liver	10		lung	13
lymph node	1		cancerous lung	2
lymphoma	4		normal lung adjacent to cancer	1
mammary adenoma	1		muscle	3
mammary gland	3		neuroblastoma	1
melinorioma	1		omentum	2
osteogenic sarcoma	2		ovary	6
pancreas	4		cancerous ovary	2
skin	5		parotid	7
sarcoma	2		salivary gland	4

Table 10

Tissue	#samples		Tissue	#samples
small bowel	10		uterus	11
spleen	3		uterine cancer	1
spleen lymphoma	1		thyroid	9
stomach	13			
stomach cancer	1			

Example 13Construction of Expression Vector Expressing Full-length zcytor11

[0484] The entire zcytor11 receptor (commonly owned US Patent No. 5,965,704) was isolated by digestion with EcoRI and XhoI from plasmid pZP7P, containing full-length zcytor11 receptor cDNA (SEQ ID NO:24) and a puromycin resistance gene. The digest was run on a 1% low melting point agarose (Boehringer Mannheim) gel and the approximately 1.5 kb zcytor11 cDNA was isolated using Qiaquick™ gel extraction kit (Qiagen) as per manufacturer's instructions. The purified zcytor11 DNA was inserted into an expression vector as described below.

[0485] Recipient expression vector pZP7Z was digested with EcoRI (BRL) and XhoI (Boehringer Mannheim) as per manufacturer's instructions, and gel purified as described above. This vector fragment was combined with the EcoRI and XhoI cleaved zcytor11 fragment isolated above in a ligation reaction. The ligation was run using T4 Ligase (BRL) at 12°C overnight. A sample of the ligation was electroporated in to DH10B electroMAX™ electrocompetent *E. coli* cells (25μF, 200Ω, 1.8V). Transformants were plated on LB+Ampicillin plates, and single colonies were picked into 2 ml LB+Ampicillin and grown overnight. Plasmid DNA was isolated using Wizard Minipreps (Promega), and each was digested with EcoRI and XhoI to confirm the presence of insert. The insert was approximately 1.5 kb, and was full-length. Digestion with SpeI and PstI was used to confirm the identity of the vector.

Example 14Construction of BaF3 Cells Expressing the CRF2-4 receptor (BaF3/CRF2-4 cells) and BaF3 Cells Expressing the CRF2-4 receptor with the zcytor11 receptor (BaF3/CRF2-4/zcytor11 cells)

[0486] BaF3 cells expressing the full-length CFR2-4 receptor were constructed, using 30μg of a CFR2-4 expression vector, described below. The BaF3 cells expressing the CFR2-4 receptor were designated as BaF3/CFR2-4. These cells were used as a control, and were further transfected with full-length zcytor11 receptor (US Patent No. 5,965,704)

and used to construct a screen for IL-TIF activity as described below.

A. Construction of BaF3 Cells Expressing the CRF2-4 receptor

5 **[0487]** The full-length cDNA sequence of CRF2-4 (Genbank Accession No. Z17227) was isolated from a Daudi cell line cDNA library, and then cloned into an expression vector pZP7P, as described in Example 6.

[0488] BaF3, an interleukin-3 (IL-3) dependent pre-lymphoid cell line derived from murine bone marrow (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986), was maintained in complete media (RPMI medium (JRH Bioscience Inc., Lenexa, KS) supplemented with 10% heat-inactivated fetal calf serum, 2 ng/ml murine IL-3 (mIL-3) (R & D, Minneapolis, MN), 2 mM L-glutaMax-1™ (Gibco BRL), 1 mM Sodium Pyruvate (Gibco BRL), and PSN antibiotics (GIBCO BRL)). Prior to electroporation, CRF2-4/pZP7P was prepared and purified using a Qiagen Maxi Prep kit (Qiagen) as per manufacturer's instructions. For electroporation, BaF3 cells were washed once in serum-free RPMI media and then resuspended in serum-free RPMI media at a cell density of 10⁷ cells/ml. One ml of resuspended BaF3 cells was mixed with 30 μg of the CRF2-4/pZP7P plasmid DNA and transferred to separate disposable electroporation chambers (GIBCO BRL). Following a 15-minute incubation at room temperature the cells were given two serial shocks (800 1Fad/300 V.; 1180 1Fad/300 V.) delivered by an electroporation apparatus (CELL-PORATOR™; GIBCO BRL). After a 5-minute recovery time, the electroporated cells were transferred to 50 ml of complete media and placed in an incubator for 15-24 hours (37°C, 5% CO₂). The cells were then spun down and resuspended in 50 ml of complete media containing 2 μg/ml puromycin in a T-162 flask to isolate the puromycin-resistant pool. Pools of the transfected BaF3 cells, hereinafter called BaF3/CRF2-4 cells, were assayed for signaling capability as described below. 20 Moreover these cells were further transfected with zcytor11 receptor as described below.

B. Construction of BaF3 Cells Expressing CRF2-4 and zcytor11 receptors

25 **[0489]** BaF3/CRF2-4 cells expressing the full-length zcytor11 receptor were constructed as per Example 5A above, using 30 μg of the zcytor11 expression vector, described in Example 6 above. Following recovery, transfectants were selected using 200 μg/ml zeocin and 2 μg/ml puromycin. The BaF3/CRF2-4 cells expressing the zcytor11 receptor were designated as BaF3/CRF2-4/zcytor11 cells. These cells were used to screen for IL-TIF activity as well as zcytor16 antagonist activity described IN Example 15

30

Example 15

Screening for IL-TIF antagonist activity using BaF3/CRF2-4/zcytor11 cells using an Alamar Blue Proliferation Assay

A. Screening for IL-TIF activity using BaF3/CRF2-4/zcytor11 cells using an Alamar Blue Proliferation Assay

35 **[0490]** Purified IL-TIF-CEE (Example 19) was used to test for the presence of proliferation activity as described below. Purified zcytor16-Fc4 (Example 11) was used to antagonize the proliferative response of the IL-TIF in this assay as described below.

40 **[0491]** BaF3/CRF2-4/zcytor11 cells were spun down and washed in the complete media, described in Example 7A above, but without mIL-3 (hereinafter referred to as "mIL-3 free media"). The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 μl per well using the mIL-3 free media.

[0492] Proliferation of the BaF3/CRF2-4/zcytor11 cells was assessed using IL-TIF-CEE protein diluted with mIL-3 free media to 50, 10, 2, 1, 0.5, 0.25, 0.13, 0.06 ng/ml concentrations. 100 μl of the diluted protein was added to the BaF3/CRF2-4/zcytor11 cells. The total assay volume is 200 μl. The assay plates were incubated at 37°C, 5% CO₂ for 3 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20 μl/well. Plates were again incubated at 37°C, 5% CO₂ for 24 hours. Alamar Blue gives a fluourometric readout based on number of live cells, and is thus a direct measurement of cell proliferation in comparison to a negative control. Plates were again incubated at 37°C, 5% CO₂ for 24 hours. Plates were read on the Fmax™ plate reader (Molecular Devices Sunnyvale, CA) using the SoftMax™ Pro program, at wavelengths 544 (Excitation) and 590 (Emmission). Results confirmed the dose-dependent proliferative response of the BaF3/CRF2-4/zcytor1 cells to IL-TIF-CEE. The response, as measured, was approximately 15-fold over background at the high end of 50ng/ml down to a 2-fold induction at the low end of 0.06ng/ml. The BaF3 wild type cells, and BaF3/CRF2-4 cells did not proliferate in response to IL-TIF-CEE, showing that IL-TIF is specific for the 50 CRF2-4/zcytor11 heterodimeric receptor.

[0493] In order to determine if zcytor16 is capable of antagonizing IL-TIF activity, the assay described above was repeated using purified soluble zcytor16/Fc4. When IL-TIF was combined with zcytor16 at 10 μg/ml, the response to IL-TIF at all concentrations was brought down to background. That the presence of soluble zcytor16 ablated the proliferative

EP 1 373 508 B1

effects of IL-TIF demonstrates that it is a potent antagonist of the IL-TIF ligand.

Example 16

5 IL-TIF activation of a reporter mini-gene in MES 13 cells and inhibition of activity by zcytor16-Fc4

[0494] MES 13 cells (ATCC No. CRL-1927) were plated at 10,000 cells/well in 96-well tissue culture clusters (Costar) in DMEM growth medium (Life Technologies) supplemented with pyruvate and 10% serum (HyClone). Next day, the medium was switched to serum free DMEM medium by substituting 0.1% BSA (Fraction V; Sigma) for serum. This medium also contained the adenoviral construct KZ136 (below) that encodes a luciferase reporter mini-gene driven by SRE and STAT elements, at a 1000:1 multiplicity of infection (m.o.i.), i.e. 1000 adenoviral particles per cell. After allowing 10 24h for the incorporation of the adenoviral construct in the cells, the media were changed and replaced with serum-free media. Human recombinant IL-TIF with or without a recombinant zcytor16-Fc4 fusion was added at the indicated final concentration in the well (as described in Table 11, below). Dilutions of both the IL-TIF and zcytor16-Fc4 were performed in serum-free medium. 0.1% BSA was added for a basal assay control. 4h later, cells were lysed and luciferase activity, denoting activation of the reporter gene, was determined in the lysate using an Luciferase Assay System assay kit (Promega) and a Labsystems Luminoskan luminometer (Labsystems, Helsinki, Finland). Activity was expressed as luciferase units (LU) in the lysate. Results are shown in Table 11, below.

20 Table 11

Level of IL-TIF (ng/ml)	LU w/o zcytoR16	LU w/ 10µg/ml zcytoR16
0 (basal BSA control)	103±2	104±2
0.03	105±3	104±4
0.3	108±4	99±6
3	134±8	98±15
30	188±16	110±3
300	258±21	112±30

[0495] These results demonstrate two things: First, that MES 13 cells respond to human recombinant IL-TIF and therefore possess endogenous functional receptors for the cytokine. Second, that the zcytoR16-Fc4 receptor fusion acts as an antagonist that effectively blocks the response to IL-TIF, even at the highest dose that this cytokine was used. Therefore, zcyto16 is an effective antagonist of IL-TIF on cells (MES 13) that are intrinsically capable of responding to IL-TIF, i.e. cells that do not require exogenous expression of additional receptor components to respond to the cytokine.

[0496] The construction of the adenoviral KZ136 vector was as follows. The original KZ136 vector is disclosed in Poulsen, LK et al. J. Biol. Chem. 273:6228-6232, 1998. The CMV promoter/enhancer and SV40 pA sequences were removed from pACCMV.pLpA (T.C. Becker et al., Meth. Immunology 43:161-189, 1994.) and replaced with a linker containing Asp718/KpnI and HindIII sites (oligos ZC13252 (SEQ ID NO:26) and ZC13453 (SEQ ID NO:27)). The STAT/SRE driven luciferase reporter cassette was excised from vector KZ136 (Poulsen, LK et al., supra.) as a Asp718/KpnI-HindIII fragment and inserted into the adapted pAC vector. Recombinant KZ136 Adenovirus was produced by transfection with JM17 Adenovirus into 293 cells as described in T.C. Becker et al. supra. Plaque purified virus was amplified and used to infect cultured cells at 5-50 pfu/cell 12-48 hours before assay. Luciferase reporter assays were performed as described in 96 well microplates as per Poulsen, LK et al., supra.

B. IL-TIF Reporter Gene Assay on HCT-15 and HT-29 Cell Lines

[0497] HCT-15 (human colon adenocarcinoma, ATCC #CCL-225) and HT-29 (human epithelial colorectal adenocarcinoma, ATCC #HTB-38) cells were plated at 3000 cells/100ul/well in RPMI (Life Technologies) supplemented with 10% fetal bovine serum, 1% Glutamax, and 1% Na pyruvate into 96 well opaque plates (Costar). These cells were incubated 24 hours in a 37°C, 5% CO2 incubator.

[0498] Cells were then infected with KZ136 adenovirus (STAT/SRE/Lucif) described above in 50 µl/well DMEM/F12 media (Life Technologies) supplemented with 1% ITS and 2% HEPES (Serum Free Media) using an M.O.I. of 5000. Cells were incubated for 24 hours.

[0499] After removal of the adenovirus, cell samples were diluted in serum free media with serial concentrations of IL-TIF in the presence or absence of Zcytor16-Fc4 fusion soluble receptor, and added to a 96-well plate in a volume of

EP 1 373 508 B1

100 μ l/well, and incubated for 4 hours. Serum-free medium alone was used as a background control. Cells were then lysed and exposed to luciferase substrate using reagents and protocols from Promega as per manufacturer's instructions. Plates were read on the Berthold MicroLumat Plus LB96V2R (Perkin-Elmer Life Sciences) using a 40 μ l injection and 5 second integration protocol.

5 **[0500]** HCT-15 cells showed a 2.5 fold induction over media alone to the IL-TIF at 10ng/ml and a 2.2 fold induction at 5 ng/ml. This IL-TIF response was blocked to background levels when Zcytor16-Fc4 fusion soluble receptor was added in at 1 μ g/ml.

10 **[0501]** HT-29 cells showed a nice dose response to IL-TIF starting with a 6.2 fold induction at 10 ng/ml titering down to a 2 fold induction at 0.08 ng/ml. This IL-TIF response was completely blocked down to background levels when 1 μ g/ml Zcytor16-Fc4 fusion soluble receptor was added in.

Example 17

Construct for Generating CEE-tagged IL-TIF

15 **[0502]** Oligonucleotides were designed to generate a PCR fragment containing the Kozak sequence and the coding region for IL-TIF, without its stop codon. These oligonucleotides were designed with a KpnI site at the 5' end and a BamHI site at the 3' end to facilitate cloning into pHZ200-CEE, our standard vector for mammalian expression of C-terminal Glu-Glu tagged (SEQ ID NO:10) proteins. The pHZ200 vector contains an MT-1 promoter.

20 **[0503]** PCR reactions were carried out using Turbo Pfu polymerase (Stratagene) to amplify a IL-TIF cDNA fragment. About 20 ng human IL-TIF polynucleotide template (SEQ ID NO:14), and oligonucleotides ZC28590 (SEQ ID NO:28) and ZC28580 (SEQ ID NO:29) were used in the PCR reaction. PCR reaction conditions were as follows: 95°C for 5 minutes,; 30 cycles of 95°C for 60 seconds, 55°C for 60 seconds, and 72°C for 60 seconds; and 72°C for 10 minutes; followed by a 4°C hold. PCR products were separated by agarose gel electrophoresis and purified using a QiaQuick™ (Qiagen) gel extraction kit. The isolated, approximately 600 bp, DNA fragment was digested with KpnI and BamHI (Boehringer-Mannheim), gel purified as above and ligated into pHZ200-CEE that was previously digested with KpnI and BamHI.

25 **[0504]** About one microliter of the ligation reaction was electroporated into DH10B ElectroMax™ competent cells (GIBCO BRL, Gaithersburg, MD) according to manufacturer's direction and plated onto LB plates containing 100 μ g/ml ampicillin, and incubated overnight. Colonies were picked and screened by PCR using oligonucleotides ZC28,590 (SEQ ID NO:28) and ZC28,580 (SEQ ID NO:29), with PCR conditions as described above. Clones containing inserts were then sequenced to confirm error-free IL-TIF inserts. Maxipreps of the correct pHZ200-IL-TIF-CEE construct, as verified by sequence analysis, were performed.

35 Example 18

Transfection And Expression Of IL-TIF Soluble Receptor Polypeptides

40 **[0505]** BHK 570 cells (ATCC No. CRL-10314), were plated at about 1.2×10^6 cells/well (6-well plate) in 800 μ l of serum free (SF) DMEM media (DMEM, Gibco/BRL High Glucose) (Gibco BRL, Gaithersburg, MD). The cells were transfected with an expression plasmid containing IL-TIF-CEE described above (Example 17), using Lipofectin™ (Gibco BRL), in serum free (SF) DMEM according to manufacturer's instructions.

45 **[0506]** The cells were incubated at 37°C for approximately five hours, then transferred to separate 150 mm MAXI plates in a final volume of 30 ml DMEM/5% fetal bovine serum (FBS) (Hyclone, Logan, UT). The plates were incubated at 37°C, 5% CO₂, overnight and the DNA: Lipofectin™ mixture was replaced with selection media (5% FBS/DMEM with 1 μ M methotrexate (MTX)) the next day.

50 **[0507]** Approximately 10-12 days post-transfection, colonies were mechanically picked to 12-well plates in one ml of 5%FCS/DMEM with 5 μ M MTX, then grown to confluence. Positive expressing clonal colonies Conditioned media samples were then tested for expression levels via SDS-PAGE and Western analysis. A high-expressing clone was picked and expanded for ample generation of conditioned media for purification of the IL-TIF-CEE expressed by the cells (Example 19).

Example 19

55 Purification of IL-TIF-CEE from BHK 570 cells

[0508] Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying IL-TIF polypeptide containing C-terminal GluGlu (EE) tags (SEQ ID NO:10). Conditioned media from BHK cells expressing

EP 1 373 508 B1

IL-TIF-CEE (Example 18) was concentrated with an Amicon S10Y3 spiral cartridge on a ProFlux A30. A Protease inhibitor solution was added to the concentrated conditioned media to final concentrations of 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co. St. Louis, MO), 0.003 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). Samples were removed for analysis and the bulk volume was frozen at -80°C until the purification was started. Total target protein concentrations of the concentrated conditioned media were determined via SDS-PAGE and Western blot analysis with the anti-EE HRP conjugated antibody.

[0509] About 100 ml column of anti-EE G-Sepharose (prepared as described below) was poured in a Waters AP-5, 5 cm x 10 cm glass column. The column was flow packed and equilibrated on a BioCad Sprint (PerSeptive BioSystems, Framingham, MA) with phosphate buffered saline (PBS) pH 7.4. The concentrated conditioned media was thawed, 0.2 micron sterile filtered, pH adjusted to 7.4, then loaded on the column overnight with about 1 ml/minute flow rate. The column was washed with 10 column volumes (CVs) of phosphate buffered saline (PBS, pH 7.4), then plug eluted with 200 ml of PBS (pH 6.0) containing 0.5 mg/ml EE peptide (Anaspec, San Jose, CA) at 5 ml/minute. The EE peptide used has the sequence EYMPME (SEQ ID NO:10). The column was washed for 10 CVs with PBS, then eluted with 5 CVs of 0.2M glycine, pH 3.0. The pH of the glycine-eluted column was adjusted to 7.0 with 2 CVs of 5X PBS, then equilibrated in PBS (pH 7.4). Five ml fractions were collected over the entire elution chromatography and absorbance at 280 and 215 nM were monitored; the pass through and wash pools were also saved and analyzed. The EE-polypeptide elution peak fractions were analyzed for the target protein via SDS-PAGE Silver staining and Western Blotting with the anti-EE HRP conjugated antibody. The polypeptide elution fractions of interest were pooled and concentrated from 60 ml to 5.0 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

[0510] To separate IL-TIF-CEE from other co-purifying proteins, the concentrated polypeptide elution pooled fractions were subjected to a POROS HQ-50 (strong anion exchange resin from PerSeptive BioSystems, Framingham, MA) at pH 8.0. A 1.0 x 6.0 cm column was poured and flow packed on a BioCad Sprint. The column was counter ion charged then equilibrated in 20mM TRIS pH 8.0 (Tris (Hydroxymethyl Aminomethane)). The sample was diluted 1:13 (to reduce the ionic strength of PBS) then loaded on the Poros HQ column at 5 ml/minute. The column was washed for 10 CVs with 20mM Tris pH 8.0 then eluted with a 40 CV gradient of 20 mM Tris/ 1 M sodium chloride (NaCl) at 10 ml/minute. 1.5 ml fractions were collected over the entire chromatography and absorbance at 280 and 215 nM were monitored. The elution peak fractions were analyzed via SDS-PAGE Silver staining. Fractions of interest were pooled and concentrated to 1.5-2 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

[0511] To separate IL-TIF-CEE polypeptide from free EE peptide and any contaminating co-purifying proteins, the pooled concentrated fractions were subjected to size exclusion chromatography on a 1.5 x 90 cm Sephadex S200 (Pharmacia, Piscataway, NJ) column equilibrated and loaded in PBS at a flow rate of 1.0 ml/min using a BioCad Sprint. 1.5 ml fractions were collected across the entire chromatography and the absorbance at 280 and 215 nM were monitored. The peak fractions were characterized via SDS-PAGE Silver staining, and only the most pure fractions were pooled. This material represented purified IL-TIF-CEE polypeptide.

[0512] This purified material was finally subjected to a 4 ml ActiClean Etox (Sterogene) column to remove any remaining endotoxins. The sample was passed over the PBS equilibrated gravity column four times then the column was washed with a single 3 ml volume of PBS, which was pooled with the "cleaned" sample. The material was then 0.2 micron sterile filtered and stored at -80°C until it was aliquoted.

[0513] On Western blotted, Coomassie Blue and Silver stained SDS-PAGE gels, the IL-TIF-CEE polypeptide was one major band. The protein concentration of the purified material was performed by BCA analysis (Pierce, Rockford, IL) and the protein was aliquoted, and stored at -80°C according to standard procedures.

[0514] To prepare anti-EE Sepharose, a 100 ml bed volume of protein G-Sepharose (Pharmacia, Piscataway, NJ) was washed 3 times with 100 ml of PBS containing 0.02% sodium azide using a 500 ml Nalgene 0.45 micron filter unit. The gel was washed with 6.0 volumes of 200 mM triethanolamine, pH 8.2 (TEA, Sigma, St. Louis, MO), and an equal volume of EE antibody solution containing 900 mg of antibody was added. After an overnight incubation at 4°C, unbound antibody was removed by washing the resin with 5 volumes of 200 mM TEA as described above. The resin was resuspended in 2 volumes of TEA, transferred to a suitable container, and dimethylpimilimidate-2HCl (Pierce, Rockford, IL) dissolved in TEA, was added to a final concentration of 36 mg/ml of protein G-Sepharose gel. The gel was rocked at room temperature for 45 min and the liquid was removed using the filter unit as described above. Nonspecific sites on the gel were then blocked by incubating for 10 min. at room temperature with 5 volumes of 20 mM ethanolamine in 200 mM TEA. The gel was then washed with 5 volumes of PBS containing 0.02% sodium azide and stored in this solution at 4°C.

Example 20Human zcytor11 Tissue Distribution in Tissue Panels Using Northern Blot and PCR5 A. Human zcytor11 Tissue Distribution in tissue panels using PCR

[0515] A panel of cDNAs from human tissues was screened for zcytor11 expression using PCR. The panel was made in-house and contained 94 marathon cDNA and cDNA samples from various normal and cancerous human tissues and cell lines are shown in Table 6 above. Aside from the PCR reaction, the method used was as shown in Example 12. The PCR reactions were set up using oligos ZC14,666 (SEQ ID NO: 32) and ZC14,742 (SEQ ID NO:33), Advantage 2 cDNA polymerase mix (Clontech, Palo Alto, CA), and Rediload dye (Research Genetics, Inc., Huntsville, AL). The amplification was carried out as follows: 1 cycle at 94°C for 2 minutes, 40 cycles of 94°C for 15 seconds, 51°C for 30 seconds and 72°C for 30 seconds, followed by 1 cycle at 72°C for 7 minutes. The correct predicted DNA fragment size was observed in bladder, brain, cervix, colon, fetal brain, fetal heart, fetal kidney, fetal liver, fetal lung, fetal skin, heart, kidney, liver, lung, melanoma, ovary, pancreas, placenta, prostate, rectum, salivary gland, small intestine, testis, thymus, trachea, spinal cord, thyroid, lung tumor, ovarian tumor, rectal tumor, and stomach tumor. Zcytor11 expression was not observed in the other tissues and cell lines tested in this panel.

[0516] A commercial 1st strand cDNA panel (Human Blood Fractions MTC Panel, Clontech, Palo Alto, CA) was also assayed as above. The panel contained the following samples: mononuclear cells, activated mononuclear cells, resting CD4+ cells, activated CD4+ cells, resting CD8+ cells, activated CD8+ cells, resting CD14+ cells, resting CD19+ cells and activated CD19+ cells. The following samples showed positive expression of zcytor11: mononuclear cells, resting CD8+ and resting CD19+ cells.

25 B. Tissue Distribution of Zcytor11 in Human Cell Line and Tissue Panels Using RT-PCR

[0517] A panel of RNAs from human cell lines was screened for zcytor11 expression using RT-PCR. The panels were made in house and contained 84 RNAs from various normal and cancerous human tissues and cell lines as shown in Tables 7-10 above. The RNAs were made from in house or purchased tissues and cell lines using the RNAeasy Midi or Mini Kit (Qiagen, Valencia, CA). The panel was set up in a 96-well format with 100 ngs of RNA per sample. The RT-PCR reactions were set up using oligos ZC14,666 (SEQ ID NO:32) and ZC14,742 (SEQ ID NO:33), Rediload dye and SUPERSRIPT One Step RT-PCR System (Life Technologies, Gaithersburg, MD). The amplification was carried out as follows: one cycle at 50° for 30 minutes followed by 45 cycles of 94°, 15 seconds; 52°, 30 seconds; 72°, 30 seconds; then ended with a final extension at 72° for 7 minutes. 8 to 10 uls of the PCR reaction product was subjected to standard Agarose gel electrophoresis using a 4% agarose gel. The correct predicted cDNA fragment size was observed in adrenal gland, bladder, breast, bronchus, normal colon, colon cancer, duodenum, endometrium, esophagus, gastric cancer, gastro-esophageal cancer, heart ventricle, ileum, normal kidney, kidney cancer, liver, lung, lymph node, pancreas, parotid, skin, small bowel, stomach, thyroid, and uterus. Cell lines showing expression of zcytor11 were A-431, differentiated CaCO2, DLD-1, HBL-100, HCT-15, HepG2, HepG2+IL6, HuH7, and NHEK #1-4. Zcytor11 expression was not observed in the other tissues and cell lines tested in this panel.

[0518] In addition, because the expression pattern of zcytor11, one of IL-TIF's receptors, shows expression in certain specific tissues, binding partners including the natural ligand, IL-TIF, can also be used as a diagnostic to detect specific tissues (normal or abnormal), cancer, or cancer tissue in a biopsy, tissue, or histologic sample, particularly in tissues where IL-TIF receptors are expressed. IL-TIF can also be used to target other tissues wherein its receptors, e.g., zcytor16 and zcytor11 are expressed. Moreover, such binding partners could be conjugated to chemotherapeutic agents, toxic moieties and the like to target therapy to the site of a tumor or diseased tissue. Such diagnostic and targeted therapy uses are known in the art and described herein.

[0519] The expression patterns of zcytor11 (above) and zcytor16 (Example 12, and Example 21) indicated target tissues and cell types for the action of IL-TIF, and hence IL-TIF antagonists, such as zcytor16. The zcytor11 expression generally overlapped with zcytor16 expression in three physiologic systems: digestive system, female reproductive system, and immune system. Moreover, the expression pattern of the receptor (zcytor11) indicated that an IL-TIF antagonist such as zcytor16 would have therapeutic application for human disease in two areas: inflammation (e.g., IBD, Chron's disease, pancreatitis) and cancer (e.g., ovary, colon). That is, the polynucleotides, polypeptides and antibodies of the present invention can be used to antagonize the inflammatory, and other cytokine-induced effects of IL-TIF interaction with the cells expressing the zcytor11 receptor.

[0520] Moreover, the expression of zcytor11 appeared to be downregulated or absent in an ulcerative colitis tissue, HepG2 liver cell line induced by IL-6, activated CD8+ T-cells and CD19+ B-cells. However, zcytor16 appeared to be upregulated in activated CD19+ B-cells (Example 12), while zcytor11 is downregulated in activated CD19+ cells, as compared to the resting CD19+ cells (above). The expression of zcytor11 and zcytor16 has a reciprocal correlation in

this case. These RT-PCR experiments demonstrate that CD19+ peripheral blood cells, B lymphocytes, express receptors for IL-TIF, namely zcytoR11 and zcytoR16. Furthermore B cells display regulated expression of zcytoR11 and zcytoR16. B-lymphocytes activated with mitogens decrease expression of zcytoR11 and increase expression of zcytoR16. This represents a classical feedback inhibition that would serve to dampen the activity of IL-TIF on B cells and other cells as well. Soluble zcytoR16 would act as an antagonist to neutralize the effects of IL-TIF on B cells. This would be beneficial in diseases where B cells are the key players: Autoimmune diseases including systemic lupus erythmatosus (SLE), myasthenia gravis, immune complex disease, and B-cell cancers that are exacerbated by IL-TIF. Also autoimmune diseases where B cells contribute to the disease pathology would be targets for zcytoR16 therapy: Multiple sclerosis, inflammatory bowel disease (IBD) and rheumatoid arthritis are examples. ZcytoR16 therapy would be beneficial to dampen or inhibit B cells producing IgE in atopic diseases including asthma, allergy and atopic dermatitis where the production of IgE contributes to the pathogenesis of disease.

[0521] B cell malignancies may exhibit a loss of the "feedback inhibition" described above. Administration of zcytoR16 would restore control of IL-TIF signaling and inhibit B cell tumor growth. The administration of zcytoR16 following surgical resection or chemotherapy may be useful to treat minimal residual disease in patients with B cell malignancies. The loss of regulation may lead to sustain or increased expression of zcytoR11. Thus creating a target for therapeutic monoclonal antibodies targeting zcytoR11.

Example 21

Identification of cells expressing zcytor16 using *in situ* hybridization

[0522] Specific human tissues were isolated and screened for zcytor16 expression by *in situ* hybridization. Various human tissues prepared, sectioned and subjected to *in situ* hybridization included cartilage, colon, appendix, intestine, fetal liver, lung, lymph node, lymphoma, ovary, pancreas, placenta, prostate, skin, spleen, and thymus. The tissues were fixed in 10% buffered formalin and blocked in paraffin using standard techniques. Tissues were sectioned at 4 to 8 microns. Tissues were prepared using a standard protocol ("Development of non-isotopic *in situ* hybridization" at The Laboratory of Experimental Pathology (LEP), NIEHS, Research Triangle Park, NC; web address <http://dir.niehs.nih.gov/dirlep/ish.html>). Briefly, tissue sections were deparaffinized with HistoClear (National Diagnostics, Atlanta, GA) and then dehydrated with ethanol. Next they were digested with Proteinase K (50 μ g/ml) (Boehringer Diagnostics, Indianapolis, IN) at 37°C for 2 to 7 minutes. This step was followed by acetylation and re-hydration of the tissues.

[0523] One *in situ* probe was designed against the human zcytor16 sequence (nucleotide 1-693 of SEQ ID NO:1), and isolated from a plasmid containing SEQ ID NO:1 using standard methods. T3 RNA polymerase was used to generate an antisense probe. The probe was labeled with digoxigenin (Boehringer) using an *In Vitro* transcription System (Promega, Madison, WI) as per manufacturer's instruction.

[0524] *In situ* hybridization was performed with a digoxigenin-labeled zcytor16 probe (above). The probe was added to the slides at a concentration of 1 to 5 pmol/ml for 12 to 16 hours at 62.5°C. Slides were subsequently washed in 2XSSC and 0.1XSSC at 55°C. The signals were amplified using tyramide signal amplification (TSA) (TSA, *in situ* indirect kit; NEN) and visualized with Vector Red substrate kit (Vector Lab) as per manufacturer's instructions. The slides were then counter-stained with hematoxylin (Vector Laboratories, Burlingame, CA).

[0525] Signals were observed in several tissues tested: The lymph node, plasma cells and other mononuclear cells in peripheral tissues were strongly positive. Most cells in the lymphatic nodule were negative. In lymphoma samples, positive signals were seen in the mitotic and multinuclear cells. In spleen, positive signals were seen in scattered mononuclear cells at the periphery of follicles were positive. In thymus, positive signals were seen in scattered mononuclear cells in both cortex and medulla were positive. In fetal liver, a strong signal was observed in a mixed population of mononuclear cells in sinusoid spaces. A subset of hepatocytes might also have been positive. In the inflamed appendix, mononuclear cells in peyer's patch and infiltration sites were positive. In intestine, some plasma cells and ganglia nerve cells were positive. In normal lung, zcytor16 was expressed in alveolar epithelium and mononuclear cells in interstitial tissue and circulation. In the lung carcinoma tissue, a strong signal was observed in mostly plasma cells and some other mononuclear cells in peripheral of lymphatic aggregates. In ovary carcinoma, epithelium cells were strongly positive. Some interstitial cells, most likely the mononuclear cells, were also positive. There was no signal observed in the normal ovary. In both normal and pancreatitis pancreas samples, acinar cells and some mononuclear cells in the mesentery were positive. In the early term (8 weeks) placenta, signal was observed in trophoblasts. In skin, some mononuclear cells in the inflamed infiltrates in the superficial dermis were positive. Keratinocytes were also weakly positive. In prostate carcinoma, scatted mononuclear cells in interstitial tissues were positive. In articular cartilage, chondrocytes were positive. Other tissues tested including normal ovary and a colon adenocarcinoma were negative.

[0526] In summary, the *in situ* data was consistent with expression data described above for the zcytor16. Zcytor16 expression was observed predominately in mononuclear cells, and a subset of epithelium was also positive. These results confirmed the presence of zcytor16 expression in immune cells and point toward a role in inflammation, autoim-

immune disease, or other immune function, for example, in binding pro-inflammatory cytokines, including but not limited to IL-TIF. Moreover, detection of zcytor16 expression can be used for example as an marker for mononuclear cells in histologic samples.

[0527] Zcytor16 is expressed in mononuclear cells, including normal tissues (lymph nodes, spleen, thymus, pancreas and fetal liver, lung), and abnormal tissues (inflamed appendix, lung carcinoma, ovary carcinoma, pancreatitis, inflamed skin, and prostate carcinoma). It is notable that plasma cells in the lymph node, intestine, and lung carcinoma are positive for zcytor16. Plasma cells are immunologically activated lymphocytes responsible for antibody synthesis. In addition, IL-TIF, is expressed in activated T cells. In addition, the expression of zcytor16 is detected only in activated (but not in resting) CD4+ and CD19+ cells (Example 12). Thus, zcytor16 can be used as a marker for or as a target in isolating certain lymphocytes, such as mononuclear leucocytes and limited type of activated leucocytes, such as activated CD4+ and CD 19+.

[0528] Furthermore, the presence of zcytor16 expression in activated immune cells such as activated CD4+ and CD19+ cells showed that zcytor16 may be involved in the body's immune defensive reactions against foreign invaders: such as microorganisms and cell debris, and could play a role in immune responses during inflammation and cancer formation.

[0529] Moreover, as discussed herein, epithelium from several tissues was positive for zcytor16 expression, such as hepatocytes (endoderm-derived epithelia), lung alveolar epithelium (endoderm-derived epithelia), and ovary carcinoma epithelium (mesoderm-derived epithelium). The epithelium expression of zcytor16 could be altered in inflammatory responses and/or cancerous states in liver and lung. Thus, Zcyto16 could be used as marker to monitor changes in these tissues as a result of inflammation or cancer. Moreover, analysis of zcytor16 *in situ* expression showed that normal ovary epithelium is negative for zcytor16 expression, while it is strongly positive in ovary carcinoma epithelium providing further evidence that zcytor16 polynucleotides, polypeptides and antibodies can be used as a diagnostic marker and/or therapeutic target for the diagnosis and treatment of ovarian cancers, and ovary carcinoma, as described herein.

[0530] Zcytor16 was also detected in other tissues, such as acinar cells in pancreas (normal and pancreatitis tissues), trophoblasts in placenta (ectoderm-derived), chondrocytes in cartilage (mesoderm-derived), and ganglia cells in intestine (ectoderm-derived). As such, zcytor16 may be involved in differentiation and/or normal functions of corresponding cells in these organs. As such, potential utilities of zcytor16 include maintenance of normal metabolism and pregnancy, bone formation/homeostasis, and physiological function of intestine, and the like.

Example 22

In vivo affects of IL-TIF polypeptide

[0531] Mice (female, C57B1, 8 weeks old; Charles River Labs, Kingston, NY) were divided into three groups. An adenovirus expressing an IL-TIF polypeptide (SEQ ID NO:15) was previously made using standard methods. On day 0, parental or IL-TIF adenovirus was administered to the first (n=8) and second (n=8) groups, respectively, via the tail vein, with each mouse receiving a dose of -1×10^{11} particles in ~ 0.1 ml volume. The third group (n=8) received no treatment. On days 12, mice were weighed and blood was drawn from the mice. Samples were analyzed for complete blood count (CBC) and serum chemistry. Statistically significant elevations in neutrophil and platelet counts were detected in the blood samples from the IL-TIF adenovirus administered group relative to the parental adenovirus treated group. Also, lymphocyte and red blood cell counts were significantly reduced from the IL-TIF adenovirus administered group relative to the parental adenovirus treated group. In addition, the IL-TIF adenovirus treated mice decreased in body weight, while parental adenovirus treated mice gained weight. Also the serum zcyto18 level was increased and the glucose level decreased at day 3. In summary, zcyto18 adeno-mice displayed acute phase response that can also be initiated by other pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and gp130 cytokines. The acute phase response is the set of immediate inflammatory responses initiated by pattern recognition molecules. The acute phase proteins provide enhanced protection against microorganisms and modify inflammatory responses by effects on cell trafficking and mediator release. For example, SAA has potent leukocyte activating function including induction of chemotaxis, enhancement of leukocyte adhesion to endothelial cells, and increased phagocytosis. Understanding the factors that initiate and alter the magnitude and duration of the acute phase response represents an important step in the development of new therapies for infectious and inflammatory diseases.

[0532] The results suggested that IL-TIF affects hematopoiesis, i.e., blood cell formation *in vivo*. As such, IL-TIF could have biological activities effecting different blood stem cells, thus resulting increase or decrease of certain differentiated blood cells in a specific lineage. For instance, IL-TIF appears to reduce lymphocytes, which is likely due to inhibition of the committed progenitor cells that give rise to lymphoid cells. IL-TIF also decreases red blood cells, supporting the notion that IL-TIF could play a role in anemia, infection, inflammation, and/or immune diseases by influencing blood cells involved in these process. Antagnists against IL-TIF, such as antibodies or its soluble receptor zcytor16, could be used as therapeutic reagents in these diseases.

[0533] Moreover, these experiments using IL-TIF adenovirus in mice suggest that IL-TIF over-expression increases the level of neutrophils and platelets *in vivo*. It is conceivable that there are other factors (such as cytokines and modifier genes) involved in the responses to IL-TIF in the whole animal system. Nevertheless, these data strongly support the involvement of IL-TIF in hematopoiesis. Thus, IL-TIF and its receptors are suitable reagents/targets for the diagnosis and treatment in variety of disorders, such as inflammation, immune disorders, infection, anemia, hematopoietic and other cancers, and the like.

Example 24

Chromosomal Assignment and Placement of Zcytor16

[0534] Zcytor16 was mapped to chromosome 6 by polymerase chain reaction (PCR) using the commercially available version of the Stanford G3 Human/Hamster Radiation Hybrid (RH) Mapping Panel (Research Genetics, Inc., Huntsville, AL) in conjunction with publicly available WWW servers (e.g, Stanford Human Genome Center, Stanford University, CA server, <http://shgc-www.stanford.edu/>; and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, <http://www.ncbi.nlm.nih.gov/genemap99/>).

[0535] The PCR reactions were carried out using Zcytor16 specific sense and antisense primers ZC27,713 (SEQ ID NO:40), and ZC27,714 (SEQ ID NO:41). These yield a 226-bp amplicon in the 3' UTR. For the PCR reactions, HotStarTaq DNA polymerase and buffer (Qiagen Inc., Valencia, CA) were used. The PCR cyclers conditions were as follows: an initial 1 cycle 15 min denaturation at 95°C, followed by 35 cycles of a 1 min denaturation at 95°C, 1 min annealing at 56°C and 1 min and 15 s extension at 72°C, and a final 1 cycle extension of 7 min at 72°C. The reactions were separated by electrophoresis on a 2% agarose gel (EM Science, Gibbstown, NJ) and visualized with ethidium bromide staining. The data vector obtained for the Stanford G3 RH mapping panel was: 01000 00000 10000 00000 00000 00010 00000 00000 00000 00000 10000 00010 00010 10000 00010 10000 000.

[0536] The radiation hybrid (RH) mapping linked Zcytor16 to chromosome 6 on the Stanford G3 RH mapping panel. The RH results placed Zcytor16 0 cR₁₀₀₀₀ from the Stanford G3 framework marker SHGC-9657 (LOD = 12.38, 1 cR₁₀₀₀₀ = -29kb). SHGC-9657 (D6S1835) is a STS genomic, sequence tagged site for the human interferon-gamma receptor (IFN γ R1). IFN γ R1 has been mapped to 6q24.1-q24.2 by *in situ* hybridization (Papanicolaou et al., Cytogenet. Cell Genet. 76: 181-182, 1997) and is in the D6S442 (158.5 cM) - D6S1581 (165.0 cM) interval on the NCBI GeneMap '99. Due to the close proximity of Zcytor16 to IFN γ R1, it can be assumed that Zcytor16 is also located in the 6q23-q24 chromosomal region.

Example 25

IL-TIF-Expressing Transgenic Mice

A. Generation of transgenic mice expressing mouse IL-TIF

[0537] DNA fragments from a transgenic vector containing 5' and 3' flanking sequences of the lymphoid specific E μ LCK promoter, mouse IL-TIF (SEQ ID NO:42; polypeptide shown in SEQ ID NO:43), the rat insulin II intron, IL-TIF cDNA and the human growth hormone poly A sequence were prepared using standard methods, and used for microinjection into fertilized B6C3f1 (Taconic, Germantown, NY) murine oocytes, using a standard microinjection protocol. See, Hogan, B. et al., *Manipulating the Mouse Embryo. A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1994.

[0538] Twenty-five mice transgenic for mouse IL-TIF with the lymphoid-specific E μ LCK promoter were identified among 154 pups. Eleven of the transgenic pups died within hours of birth, 9 transgenic pups with a shiny appearance were necropsied the day of birth, and 2 grew to adulthood. Expression levels were low in one adult animal. Tissues from the necropsied pups were prepared and histologically examined as described below.

[0539] The shiny appearance of the neonate pups appeared to be associated with a stiffening of the skin, as if they were drying out, resulting in a reduction of proper nursing. Their movements became stiffened in general.

B. Genotypic and Expression analysis from transgenic mice

[0540] From the mouse IL-TIF transgenic line driven by the E μ Lck promoter, described above, newborn pups were observed for abnormalities on day one (day of birth) and sacrificed for tissue collection. All pups were given a unique ear tag number, and those designated as having a shiny skin phenotype at the time of sacrifice were noted. Of the twelve pups, six were observed to have the shiny skin phenotype, with two designated as "severe" phenotypes. Severe phenotypes were defined as small pups with little mobility whose skin was especially shiny and very dry. Skin was collected from the left lateral side of each pup, and frozen in Tissue-Tek embedding medium.

[0541] Genotyping confirmed that shiny skin was a good indicator of transgenic status, although no expression data was collected. Frozen skin blocks were sectioned to 7 microns on a cryostat and stained to look for the presence of CD3, CD4, CD8, mouse macrophages, B-cells, CD80, and MHC class II. The staining protocol involved binding of commercially available antibodies to the tissue, detection with a peroxidase labeled secondary antibody, and DAB chromogen reaction to visualize staining.

[0542] Transgenic animals were found to be higher in MHC class II and CD80, which stain for antigen-presenting cells and dendritic cells respectively. The macrophage marker also detected more cells in the severe and non-severe transgenics than in the wild type animals, although the distribution of these cells was very localized in the high dermis. Animals classified as severe phenotypes had the most robust staining with all three of these markers, showing a dramatic increase in cell intensity and number when compared to the wild type. This variability may be due to a difference in expression level of IL-TIF in these transgenic founder pups. The MHC class II positive cells were located in the lower dermis arranged in loose open clusters, while the CD80 positive cells were predominantly below the dermis either in or just above the muscle/fat layer. These two cell populations do not appear to overlap. All other markers were of equivalent staining in all animals. Toluidine blue staining for mast cells revealed slight to no difference between wild type and transgenic animals.

C. Microscopic evaluation of tissues from transgenic mice: IL-TIF TG with EuLck promoter has a neonatal lethal-histology

[0543] On the day of birth, pups from litters containing IL-TIF transgenics were humanely euthanized and the whole body immersion fixed in 10% buffered formalin. Six transgenic and two non-transgenic pups were submitted for further workup. Four of the six transgenics were noted to have shiny skin at the time of euthanasia. The fixed tissues were trimmed into 5 sections (longitudinal section of the head and cross sections of the upper and lower thorax and upper and lower abdomen). The tissues were embedded in paraffin, routinely processed, sectioned at 5 μ m (Jung 2065 Supercut microtome, Leica Microsystems, Wetzlar, Germany) and stained with H&E. The stained tissues were evaluated under a light microscope (Nikon Eclipse E600, Nikon Inc., Melville, NY) by a board (ACVP) certified veterinary pathologist.

[0544] On microscopic examination, the epidermis of two of the transgenic pups was observed to be thicker than the epidermis of the other six mice including the controls. No other abnormalities were noted in the skin and other tissues of any of the mice. Representative areas of skin from corresponding regions of the thorax and abdomen were imaged with the 40X objective lens and with a CoolSnap digital camera (Roper Scientific, Inc., San Diego, CA) that was attached to the microscope. The thickness of the epidermis was then determined using histomorphometry software (Scion Image for Windows (NIH Image), Scion Corp., Frederick, MD, v. B4.0.2). The results were as follows:

Genotype/phenotype	Average thoracic skin thickness (μ m)	Average abdominal skin thickness (μ m)
Non-transgenic/normal	5.2	5.4
Transgenic/non-shiny	5.0	6.7
Transgenic/shiny	8.2	7.4
Transgenic/all	7.1	7.1

[0545] There were insufficient numbers of mice to determine statistical significance; however, the transgenics, especially those with shiny skin, tended to have a thicker epidermis than the non-shiny transgenics and non-transgenic controls. The shiny transgenics may have a higher expression level of IL-TIF than the non-shiny transgenics.; however, expression levels were not determined for these mice.

Example 26

In vivo affects of IL-TIF polypeptide

A. Mice infected with IL-TIF Adenovirus show induction of SAA

[0546] Mice (female, C57B1, 8 weeks old; Charles River Labs, Kingston, NY) were divided into three groups. An adenovirus expressing an IL-TIF polypeptide (SEQ ID NO:15) was previously made using standard methods. On day 0, parental or IL-TIF adenovirus was administered to the first (n=8) and second (n=8) groups, respectively, via the tail vein, with each mouse receiving a dose of $\sim 1 \times 10^{11}$ particles in ~ 0.1 ml volume. The third group (n=8) received no treatment. On day 12, mice were weighed and blood was drawn from the mice. On day 20 of the study, mice were sacrificed, body weight was recorded, and blood and tissues were collected for analysis.

[0547] All blood samples were analyzed for complete blood count (CBC) and serum chemistry. At both day 12 and

20, statistically significant elevations in neutrophil and platelet counts were detected in the blood samples from the IL-TIF adenovirus administered group relative to the parental adenovirus treated group. Also, lymphocyte counts were significantly reduced from the IL-TIF adenovirus administered group relative to the parental adenovirus treated group at day 12, but at day 20 the opposite effect was observed. In addition, the IL-TIF adenovirus treated mice decreased in body weight, while parental adenovirus treated mice gained weight. Glucose was significantly reduced at both time points in the serum samples from the IL-TIF adenovirus administered group relative to the parental adenovirus treated group. Serum albumin was also significantly reduced at both time points. Blood urea nitrogen levels were significantly reduced at day 20. Serum globulin levels were significantly increased the IL-TIF adenovirus administered group relative to the parental adenovirus treated group at both time points. Microscopically, one observed histomorphological change attributed to IL-TIF was tubular regeneration in the kidney. While not uncommon in mice, there was an increased incidence and severity in this group of animals. Nephropathy is characterized as multifocal areas of basophilia of cortical tubular epithelial cells.

[0548] An additional experiment, identical in design to the one described above, was carried out in order to verify results and collect additional samples. In this study, body weight was recorded every three days, blood was collected from the mice 3 days following adenovirus injection, and mice were sacrificed for blood and tissue collection on day 10 (n=4 per group) and day 20 (n=4 per group). Elevated neutrophil and platelet counts were again detected in blood samples from the IL-TIF adenovirus administered group relative to the parental adenovirus treated group. This effect was evident for neutrophils by day 3, but platelet count was not significantly different until day 10. Also, lymphocyte counts were significantly reduced from the IL-TIF adenovirus administered group relative to the parental adenovirus treated group at 3 and 10, but they were not elevated on day 20 as in the previous study. Again, mice given IL-TIF adenovirus lost weight over the course of the study, while control virus treated and untreated mice gained weight. Serum chemistry parameters were consistent with the previous study. Histological findings of tubular regeneration in the kidney associated with IL-TIF adenovirus treatment were also confirmed in this study. This was consistent with the additional finding of moderate proteinuria in mice given IL-TIF adenovirus (day 20).

[0549] The results suggested that IL-TIF affects hematopoiesis, i.e., blood cell formation *in vivo*. As such, IL-TIF could have biological activities effecting different blood stem cells, thus resulting in an increase or decrease of certain differentiated blood cells in a specific lineage. For instance, IL-TIF appears to reduce lymphocytes, which is likely due to inhibition of the committed progenitor cells that give rise to lymphoid cells, supporting the notion that IL-TIF could play a role in anemia, infection, inflammation, and/or immune diseases by influencing blood cells involved in these processes. Antagonists against IL-TIF, such as antibodies or its soluble receptor zcytor16, could be used as therapeutic reagents in these diseases.

[0550] Moreover, these experiments using IL-TIF adenovirus in mice suggest that IL-TIF over-expression increases the level of neutrophils and platelets *in vivo*. It is conceivable that there are other factors (such as cytokines and modifier genes) involved in the responses to IL-TIF in the whole animal system. Nevertheless, these data strongly support the involvement of IL-TIF in hematopoiesis. Thus, IL-TIF, anti-IL-TIF antibodies, and its receptors, such as zcytor16 and soluble zcytor11/CRF2-4, are suitable reagents/targets for the diagnosis and treatment in variety of disorders, such as inflammation, immune disorders, infection, anemia, hematopoietic and other cancers, and the like.

[0551] Association of IL-TIF expression with weight loss, appearance of acute phase protein SAA, and metabolic perturbations evidenced by decreased serum glucose, albumin and urea nitrogen suggest that IL-TIF is a cytokine which acts early in certain inflammatory responses. Mice given IL-TIF adenovirus may represent a state of chronic inflammation, such as that observed in IBD, ulcerative colitis, arthritis, psoriasis, asthma, and the like. Certain detrimental inflammatory processes might be inhibited by use of an antagonist to IL-TIF, such as anti-IL-TIF antibodies, and its receptors, such as zcytor16 and soluble zcytor11/CRF2-4, and the like.

B. IL-TIF is a pro-inflammatory cytokine: Serum Level of SAA in Adeno-IL-TIF mice:

[0552] An ELISA was performed to determine the level of SAA in IL-TIF-Adeno mice, using a Mouse SAA Immunoassay Kit and protocol (Biosource International, California, USA). Diluted standards and unknowns were plated along with HRP-anti-mouse SAA into assay plates pre-coated with anti-mouse SAA antibody. Plates were incubated for one hour at 37 degrees C and then washed according to kit instructions. Plates were developed for 15 minutes at room temperature using TMB and stopped with 2M H₂SO₄. The absorbance at 450 nm was read using a Spectromax 190 (Molecular Devices, California, USA). The resulting data was analyzed using Softmax Pro (Molecular Devices, California, USA) and Excel (Microsoft Corp., Washington, USA).

[0553] Mice infected with IL-TIF-Adenovirus had highly elevated levels of mSAA, over 10-fold, relative to the Parental-Adenovirus control.

C. Flow cytometry analysis of IL-TIF-adenovirus infected mice

[0554] To analyze the effects of IL-TIF expression *in vivo* by adenovirus, we isolated peripheral blood, spleen, and bone marrow from IL-TIF-adenovirus infected C57BL/6 mice, at day 10 and day 20 after infection. Approximately 100 μ l of blood was collected in heparinized tubes, then depleted of red blood cells by hypotonic lysis (cells were lysed in 4.5 ml dH₂O for -5 seconds before adding 1.5 ml 3.6% NaCl). Spleens were crushed between two frosted glass slides, and the cells released were passed over a Nytex membrane (cell strainer) and pelleted. Bone marrow was obtained by crushing one femur in a mortar and pestle and passing the cells over a cell strainer (Falcon). Cells were resuspended in FACS wash buffer (WB = HBSS/1%BSA/10 mM hepes), counted in trypan blue, and 1×10^6 viable cells of each type were aliquoted into 5 ml polystyrene tubes. Cells were washed and pelleted, then incubated for 20 min on ice with cocktails of fluorescently-labeled (FITC, PE, and CyChrome) monoclonal antibodies (PharMingen, San Diego, CA) recognizing various cell surface markers used to identify particular immune cell subsets. These markers include the following (listed in the groups of 3 we tested). For blood staining: CD3, Gr1, and B220; for spleen staining: CD62L, CD44, and CD3; CD21, CD23, and B220; IgD, IgM, and B220; CD11b, Gr1, and CD8; for bone marrow staining: CD11b, Gr1, CD3; IgD, IgM, and B220. Cells were washed with 1.5 ml WB and pelleted, then resuspended in 0.4 ml of WB and analyzed on a FACScan using CellQuest software (Becton Dickinson, Mountain View, CA).

[0555] We found that the fraction of neutrophils in the blood of IL-TIF-Adeno-treated mice was elevated 4-13 fold at Day 10 and 2-3-fold at Day 20. At Day 10, this difference resulted in a concomitant decrease in the fraction of lymphocytes and monocytes in the blood. In the bone marrow, we found that the total number of B cells decreased ~1.5-fold while the percentage of mature recirculating B cells increased and the total number of immature B cells dropped slightly at Day 10. At Day 20, many of these differences were not apparent, though we did find a slight increase in the fraction of mature recirculating B cells. In the spleen, the total number of B cells decreased slightly (1.5-2-fold) on both days tested, while on Day 20, the fraction of marginal zone B cells (CD21+CD23-B220+) increased by 2-fold and the number of follicular B cells (CD21+CD23+B220+) dropped 2-fold. Marginal zone B cells are considered to be the first line of defense against pathogens, as they are more sensitive to B cell mitogens (e.g. LPS) than the more common follicular B cells, and when they encounter their cognate antigen they differentiate very quickly into antibody-secreting cells. It is possible that IL-TIF either enhances the conversion of follicular to marginal zone B cells, or that it selectively depletes the less mature follicular cells. The changes in B cell numbers found in the bone marrow may reflect an enhanced differentiation of pre/pro and/or immature B cells, or an increased influx of recirculating B cells from the blood/spleen, and perhaps a coincident increase in export of immature B cells to the periphery. The actual number of mature BM B cells does not increase, so IL-TIF may not enhance their proliferation. Alternatively, IL-TIF may block differentiation of immature B cells and thereby increase the relative representation of mature B cells.

D. Zcytor16/Fc4 neutralizes IL-TIF activity in vivo: SAA ELISA showing SAA Expression induced by IL-TIF is inhibited by zcytor16-Fc4 injection:

[0556] To assess whether zcytor16 could inhibit the SAA induction by IL-TIF mice (female, C3H/HEJ, 8 weeks old; Jackson Labs, Bar Harbor, ME) were divided into five groups of three animals each and treated by IP injection of proteins as shown in Table 12 below:

Table 12

Group #	IL-TIF	Zcytor16
Group 1:	-	-
Group 2:	-	100 μ g
Group 3:	3 μ g	-
Group 4:	3 μ g	20 μ g
Group 5:	3 μ g	100 μ g

[0557] The zcytor16 injections preceded the IL-TIF injection by 15 minutes. Both protein injections were given by the intraperitoneal route. A blood sample was taken from each mouse prior to treatment, then at 2 and 6 hours after treatment. Serum was prepared from each of the samples for measurement of SAA and IL-TIF.

[0558] An ELISA was performed as described previously to determine the level of SAA in mice treated with IL-TIF and a soluble receptor for IL-TIF, zcytor16-Fc4 described herein. Mice treated with 3 μ g IL-TIF in conjunction with zcytor16-Fc4 at concentrations between 20-100ug showed a reduction in the level of SAA induced by IL-TIF alone to background

levels, demonstrating that zcytor16 inhibited the SAA induction activity of IL-TIF in vivo.

Example 27

5 Expression of IL-TIF in Inflammatory Bowel Disease mouse model

[0559] Inflammatory Bowel disease (IBD) is a multifactorial disease, divided into two types, ulcerative colitis (UC) and Crohn's Disease (CD). The etiology of these diseases is currently not known and clinical manifestations differ. UC is restricted to the colon, and symptoms include bloody diarrhea, weight loss and abdominal pain. Macroscopic features of UC include punctuated ulcers and a shortened colon. In contrast, Crohn's Disease can also affect other parts of the bowel. Symptoms include diarrhea (which is less often bloody than seen in UC), a low-grade fever and pain. Macroscopic features include fibrotic and stenotic bowel with strictures, deep ulcers, fissures and fistulas.

[0560] Several animal models are available that mimic these human diseases. Three commonly used models of colitis for new drug screening are the 2,4,6-trinitrobenzene sulphonic acid (TNBS) induced rat model, the mouse T-cell transfer model, and the dextran sodium sulfate, or DSS-induced mouse model. The DSS model was derived from a model by Dr. S. Murthy, using a disease activity index scoring system (S.N.S. Murthy, Treatment of Dextran Sulfate Sodium-Induced Murine Colitis by Intracolonic Cyclosporin, Digestive Diseases and Sciences, Vol. 38, No. 9 (September 1993), pp.1722-1734).

[0561] In the present study, an acute colitis resulted when mice were fed DSS in their drinking water for 6 days. The animals exhibited weight loss and bloody diarrhea, mimicking the condition of UC patients. The mechanism of the DSS injury is not well characterized, but it is thought that it induces a nonspecific inflammatory immune response and mimics environmental effects on the bowel. It is possible that H₂S is produced, which could be toxic to cells. In addition, changes in luminal bacterial flora occur. Activated monocytes, macrophages and mast cells have been demonstrated in the colon. Mediators for all three animal models include inflammatory prostaglandins, leukotriene metabolites and cytokines.

25 A. Method

[0562] Colitis was induced by DSS ingestion in Swiss Webster female mice from Charles River Laboratories. The mice were 10 and 11 weeks old at the start of the study. Mice were given 4% DSS in the drinking water for a period of 6 days (treated mice), or were given only normal drinking water (control mice). A Disease Activity Index clinical score (DAI) was used, which comprises a combination of measurements including stool quality, occult blood and weight loss. DAI was obtained daily for each mouse beginning one day after DSS treatment. After 6 days, DSS was removed from the drinking water of the treated mice. All mice were monitored by DAI clinical score until sacrifice at either 2, 7 or 10 days from the start of the study. On each of days 2 and 7, four DSS-treated mice and one control mouse were sacrificed. On day 10, four DSS-treated mice and two control mice were sacrificed. For all animals after sacrifice, the colon length was measured. Colon sections were fixed in 10% neutral buffered formalin for histologic analysis or frozen for mRNA extraction.

40 B. Histologic scoring and Disease Activity Index (DAI) scoring

[0563] Histologic index scores were obtained following the method in reference 1. Generally, the colon sections were scored blinded by a pathologist for crypt scores, hyperplastic epithelium, crypt distortion and inflammation.

[0564] Daily, each mouse was graded as to a clinical score based on weight loss, stool consistence and intestinal bleeding. Higher scores were assigned for increasing amounts of weight loss, diarrhea and bleeding. The daily score for each mouse was the mean grade obtained from the three results/observations.

C. Results

[0565] The colon lengths for DSS-treated mice were somewhat shorter on days 7 and 10 than non-treated controls, but the results may not have been significant (not checked by a statistical application). The clinical DAI scores reflected a rise in disease symptoms in the DSS-treated mice similar to that seen in past studies using this model. Occult blood was greatest on approximately days 4 and 5, while loose stools were more prevalent on days 6 and 7. Histopathology results show that disease scores were different from the controls on all sacrifice days, especially days 7 (peak) and 10. The histopathology screening scores were: controls=0.5, day 2 DSS-treated mice=8.8, day 7 DSS-treated mice=21, day 10 DSS-treated mice=18. Clinical and histopathology scores show that the DSS-treated mice had significant colon disease relative to the non-treated controls. The frozen tissue samples were used later for mRNA determinations as described below.

EP 1 373 508 B1

D. Tissue Expression of IL-TIF RNA in Murine IBD Colon Samples using RT-PCR:

[0566] To determine the relative expression of mouse IL-TIF RNA (SEQ ID NO:42) in an inflammatory bowel disease model, the distal colons of DSS-treated mice were collected and snap frozen in liquid nitrogen. In this experiment mice were treated with DSS and samples were taken on days 2, 7 and 10 post-treatment. Samples from normal untreated mice were collected as well. RNA was then isolated from the samples using the standard RNeasy Midiprep™ Kit (Qiagen, Valencia, CA) as per manufacturer's instructions.

[0567] The RT-PCR reactions used the 'Superscript One-Step RT-PCR System with Platinum Taq.' (Life Technologies, Gaithersburg, MD) Each 25 µl reaction consisted of the following: 12.5 µl of 2X Reaction Buffer, 0.5ul (20pmol/µl) ZC39,289 (SEQ ID NO:44), 0.5 µl (20pmol/ul) ZC39,290 (SEQ ID NO:45), 0.4 µl RT/Taq polymerase mix, 10ul RNase-free water, 1.0 µl total RNA (100ng/µl). The amplification was carried out as follows: one cycle at 50° for 30 minutes followed by 35 cycles of 94°, 30 seconds; 58°, 30 seconds; 72°, 60 seconds; then ended with a final extension at 72° for 7 minutes. 8 to 10 µl of the PCR reaction product was subjected to standard agarose gel electrophoresis using a 2% agarose gel. The correct predicted cDNA fragment size was observed as follows: There was a faint band in both day 2 samples. Two of three day 7 samples generated a strong band while the third day 7 sample generated a very strong band. The three day 10 samples generated a strong band. Finally, the two 'normal' control samples didn't generate any band. These results suggest that there may be an upregulation of IL-TIF in certain types of inflammatory responses in the colon, including those associated with IBD, UC, and CD. The data is summarized in Table 13 below where Relative Expression was scored as follows: 0 = No band, 1 = faint band, 2 = strong band, 3 = very strong band.

Table 13

<u>Tissue</u>	<u>Relative Expression (0-3)</u>
Normal Colon	0
Normal Colon	0
Day 2 Post Treatment	1
Day 2 Post Treatment	1
Day 7 Post Treatment	3
Day 7 Post Treatment	2
Day 7 Post Treatment	2
Day 10 Post Treatment	2
Day 10 Post Treatment	2
Day 10 Post Treatment	2

Example 28

Construct for generating hzcytor11/hCRF2-4 heterodimer

[0568] A cell line expressing a secreted hzcytor11/hCRF2-4 heterodimer was constructed. In this construct, the extracellular domain of hzcytor11 (SEQ ID NO:46) was fused to the heavy chain of IgG gamma4 (Fc4) (SEQ ID NO:5) with a Glu-Glu tag (SEQ ID NO:59) at the C-terminus, while the extracellular domain of CRF2-4 (SEQ ID NO:47) was fused to Fc4 with a His tag (SEQ ID NO:60) at the C-terminus. For both of the hzcytor11 and hCRF2-4 arms of the heterodimer, a Gly-Ser spacer of 8 amino acids (SEQ ID NO:48) was engineered between the extracellular portion of the receptor and the n-terminus of Fc4. In addition, a thrombin cleavage site was engineered between the Fc4 domain and the c-terminal tag to enable possible proteolytic removal of the tag.

[0569] For construction of the hzcytor11/Fc4-CEE portion of the heterodimer, the extracellular portion of hzcyto11 was PCR'd from a vector containing human zcytor11 fused to Fc4 (hzcytor11/IgG) with oligos ZC39335 (SEQ ID NO:49) and ZC39434 (SEQ ID NO:50) with EcoRI and BamHI restriction sites engineered at the 5' and 3' ends, respectively, under conditions as follows: 25 cycles of 94°C for 60 sec., 57 °C for 60 sec., and 72 °C for 120 sec.; and 72°C for 7 min. PCR products were purified using QIAquick PCR Purification Kit (Qiagen), digested with EcoRI and BamHI (Boehringer-Mannheim), separated by gel electrophoresis and purified using a QIAquick gel extraction kit (Qiagen). The hzcytor11 EcoRI/BamHI fragment was ligated into pZP-9 hzcytor7/Fc4-TCS-CEE that had been digested with EcoRI and BamHI. This vector has the extracellular portion of hzcytor7 (US Patent No. 5,945,511) fused to Fc4 (SEQ ID NO:5) with a CEE

EP 1 373 508 B1

tag (SEQ ID NO:10), and digesting with EcoRI and BamHI removes the extracellular portion of hzcytor7 and allows substitution of hzcytor11. Minipreps of the resulting ligation were screened for an EcoRI/BamHI insert of the correct size and positive minipreps were sequenced to confirm accuracy of the PCR reaction. The polypeptide sequence of the hzcytor11/Fc4-CEE fusion polypeptide is shown in SEQ ID NO:61.

[0570] For construction of the hCRF2-4/Fc4-cHIS portion of the heterodimer, the extracellular portion of hCRF2-4 was PCR'd from pZP-9 CRF with oligos ZC39,319 (SEQ ID NO:51) and ZC39,325 (SEQ ID NO:52) under conditions as follows: 30 cycles of 94°C for 60 sec., 57 °C for 60 sec., and 72 °C for 120 sec; and 72°C for 7 min. PCR product were purified as described above and then digested with EcoRI and BamHI. Because the PCR product had an internal EcoRI site two bands were obtained upon digestion; a 0.101kB EcoRI/EcoRI fragment and a 0.574 kB EcoRI/BamHI fragment. The 0.574 EcoRI/BamHI fragment was ligated into vector pHZ-1 DR1/Fc4-TCS-cHIS that had been digested with EcoRI and BamHI. This vector has the extracellular portion of hDR-1 fused to Fc4 with a C-HIS tag (SEQ ID NO:12), and digesting with EcoRI and BamHI removes the extracellular portion of hDR-1 and allows substitution of hCRF2-4. Minipreps of the resulting ligation were screened for an EcoRI/BamHI insert of the correct size, and positive minipreps, were EcoRI digested and band purified for further construction. The 0.101kB EcoRI/EcoRI fragment was ligated into the EcoRI digested minipreps and clones were screened for proper orientation of insertion by KpnI/NdeI restriction digestion. Clones with the correct size insertion were submitted for DNA sequencing to confirm the accuracy of the PCR reaction. The polypeptide sequence of the hzcytor11/Fc4-CEE fusion polypeptide is shown in SEQ ID NO:62.

[0571] About 16 µg each of the hzcytor11/Fc4-cEE and hCRF2-4/Fc4-cHIS were co-transfected into BHK-570 (ATCC No. CRL-10314) cells using Lipofectamine (Gibco/BRL), as per manufacturer's instructions. The transfected cells were selected for 10 days in DMEM + 5%FBS (Gibco/BRL) containing 1 µM methotrexate (MTX) (Sigma, St. Louis, MO) and 0.5 mg/ml G418 (Gibco/BRL) for 10 days. The resulting pool of transfectants was selected again in 10 µM MTX and 0.5mg./ml G418 for 10 days.

Example 29

Purification of zcytor11/CRF2-4 heterodimer receptor

[0572] Conditioned culture media zcytor11/CRF2-4 heterodimer was filtered through 0.2 µm filter and 0.02% (w/v) Sodium Azide was added. The conditioned media was directly loaded a Poros Protein A 50 Column at 10 - 20 ml/min. Following load the column was washed with PBS and the bound protein eluted with 0.1M Glycine pH 3.0. The eluted fractions containing protein were adjusted to pH 7.2 and Concentrated to <80ml using YM30 Stirred Cell Membrane (Millipore).

[0573] The 80 ml eluate from the Protein A column was loaded onto a 318ml Superdex 200 HiLoad 26/60 Column (Pharmacia). The column was eluted with PBS pH 7.2 at 3 ml/ min.. Protein containing fractions were pooled to eliminate aggregates. The Superdex 200 pool was adjusted to 0.5M NaCl, 10mM Imidazole using solid NaCl and Imidazole and the pH was adjusted to 7.5 with NaOH. The adjusted protein solution was loaded onto a 200 ml NiNTA column (Qiagen) at 2 CV/hr. The bound protein was eluted, following PBS wash of the column, with five concentration steps of Imidazole : 40mM, 100mM, 150mM, 250mM, 500mM. The fractions eluted at each step of imidazole were pooled and analyzed by N-terminal sequencing. Pools containing heterodimer, determined by sequencing were pooled and concentrated to 50 ml using a YM30 Stirred Cell Membrane (Millipore). The 50 ml eluate from the NiNTA column was loaded onto a 318 ml Superdex 200 HiLoad 26/60 Column (Pharmacia). The column was eluted with PBS pH 7.2 at 3 ml/ min.. Protein containing fractions were pooled to eliminate aggregates, as determined by SEC MALS analysis.

[0574] Purified proteins were analyzed by N-terminal sequencing, amino acid analysis, and SEC-MALS. Binding affinities and biological activities were determined.

Example 30

Comparison of Zcytor16-Fc4 activity with CRF2-4/Zcytor11-Fc4 activity using BaF3/CRF2-4/zcytor11 cells in an Alamar Blue Proliferation Assay

[0575] BaF3/CRF2-4/zcytor11 cells described herein were spun down and washed in PBS 2 times to ensure the removal of the mIL-3, and then spun a third time and re-suspended in the complete media (RPMI 1640, 10%FBS, 1% GlutaMAX, 1% Sodium Pyruvate), but without mIL-3 (hereinafter referred to as "mIL-3 free media"). Cells were then counted in a hemocytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mIL-3 free media.

[0576] IL-TIF protein (SEQ ID NO:15) was diluted to 200 µg/ml in mIL-3 free media. Zcytor16-Fc4 fusion protein (described herein) was diluted to 1 µg/ml in the mIL-3 free/IL-TIF media on the top row of the plate, and then diluted serially 1:2 down the remaining 7 rows on the 96-well plate, leaving a volume of 100 µl in each well. This was then added

EP 1 373 508 B1

to the 100 μ l of cells, for a final IL-TIF concentration of 100 pg/ml in all wells, and final Zcytor16-Fc4 concentrations of approximately 1, 0.5, 0.25, 0.125, 0.063, 0.31, 0.016, and 0.008 μ g/ml in a total assay volume of 200 μ l. CRF2-4/zcytor11-Fc4 was diluted to 8 μ g/ml in the mL-3 free/IL-TIF media on the top row of the plate, and then diluted serially 1:2 down the remaining 7 rows on the 96-well plate, leaving a volume of 100 μ l in each well. This was then added to the 100 μ l of cells, for a final IL-TIF concentration of 100 pg/ml in all wells, and final CRF2-4/zcytor11-Fc4 concentrations of approximately 8, 4, 2, 1, .05, 0.25, 0.125 and 0.063 μ g/ml, in a total assay volume of 200 μ l. The assay plates were incubated at 37°C, 5% CO₂ for 4 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20 μ l/well. Plates were again incubated at 37°C, 5% CO₂ for 16 hours. Alamar Blue gives a fluourometric readout based on number of live cells, and is thus a direct measurement of cell proliferation in comparison to a negative control. Plates were read on the Wallac Victor 2 1420 Multilabel Counter (Wallac, Turku, Finland) at wavelengths 530 (Excitation) and 590 (Emmssion). Results showed a strong dose-dependant inhibition of the proliferative effect of IL-TIF on BaF3/CRF2-4/zcytor11 cells by Zcytor16-Fc4. CRF2-4/zcytor11-Fc4 showed a much weaker inhibition of IL-TIF. IL-TIF alone stimulated the cells 13-fold over background. Zcytor16 completely inhibited that proliferation at concentrations from 0.025-1 μ g/ml, and partially inhibited proliferation at all the remaining concentrations down to 8 ng/ml. CRF2-4/zcytor11-Fc4 was only able to completely inhibit proliferation at the highest concentration of 8 μ g/ml, it partially inhibited proliferation at 0.125-4 μ g/ml, and inhibition was barely detectable at the lowest concentration of 63 ng/ml.

Example 31

Zcytor16 Decreases IL-6 and SAA Levels in Mouse Collagen Induced Arthritics (CIA) Model

A. Mouse Collagen Induced Arthritis (CIA) Model

[0577] Ten week old male DBA/1J mice (Jackson Labs) were divided into 3 groups of 13 mice/group. On day-21, animals were given a subcutaneous injection of 50-100 μ l of 1mg/ml chick Type II collagen formulated in Complete Freund's Adjuvant (prepared by Chondrex, Redmond, WA), and three weeks later on Day 0 they were given a 100 μ l (25 μ g) injection of LPS from E. coli 0111:B4, prepared as 250 μ g/ml from a lyophilized aliquot (Sigma, St. Louis, MO). Zcytor16 was administered as an intraperitoneal injection 3 times a week for 4 weeks, from Day 0 to Day 25. The first two groups received either 100 or 10 μ g of zcytor16 per animal per dose, and the third group received the vehicle control, PBS (Life Technologies, Rockville, MD). Animals began to show symptoms of arthritis following the LPS injection, with most animals developing inflammation within 2-3 weeks. The extent of disease was evaluated in each paw by using a caliper to measure paw thickness, and by assigning a clinical score (0-3) to each paw: 0=Normal, 0.5=Toe(s) inflamed, 1=Mild paw inflammation, 2=Moderate paw inflammation, and 3=Severe paw inflammation as detailed below.

Monitoring Disease:

[0578] Animals can begin to show signs of paw inflammation soon after the second collagen injection, and some animals may even begin to have signs of toe inflammation prior to the second collagen injection. Most animals develop arthritis within 2-3 weeks of the boost injection, but some may require a longer period of time. Incidence of disease in this model is typically 95-100%, and 0-2 non-responders (determined after 6 weeks of observation) are typically seen in a study using 40 animals. Note that as inflammation begins, a common transient occurrence of variable low-grade paw or toe inflammation can occur. For this reason, an animal is not considered to have established disease until marked, persistent paw swelling has developed.

[0579] All animals were observed daily to assess the status of the disease in their paws, which was done by assigning a qualitative clinical score to each of the paws. Every day, each animal has its 4 paws scored according to its state of clinical disease. To determine the clinical score, the paw can be thought of as having 3 zones, the toes, the paw itself (manus or pes), and the wrist or ankle joint. The extent and severity of the inflammation relative to these zones was noted including observation all the toes for any joint swelling, torn nails, or redness, notation of any evidence of edema or redness in any of the paws, and notation any loss of fine anatomic demarcation of tendons or bones, and evaluation the wrist or ankle for any edema or redness, and notation if the inflammation extends proximally up the leg. A paw a score of 1, 2, or 3 was based first on the overall impression of severity, and second on how many zones were involved. The scale used for clinical scoring is shown below.

Clinical Score:

[0580]

0 = Normal

EP 1 373 508 B1

0.5 = One or more toes involved, but only the toes are inflamed

1 = mild inflammation involving the paw (1 zone), and may include a toe or toes

2 = moderate inflammation in the paw & may include some of the toes and/or the wrist/ankle (2 zones)

3 = severe inflammation in the paw, wrist/ankle, and some or all of the toes (3 zones)

5

[0581] Established disease is defined as a qualitative score of paw inflammation ranking 2 or more, that persists overnight (two days in a row). Once established disease is present, the date is recorded and designated as that animal's first day with "established disease".

10

[0582] Blood was collected throughout the experiment to monitor serum levels of anti-collagen antibodies. Animals were euthanized on Day 21, and blood was collected for serum and for CBC's. From each animal, one affected paw was collected in 10%NBF for histology and one was frozen in liquid nitrogen and stored at -80°C for mRNA analysis. Also, 1/2 spleen, 1/2 thymus, 1/2 mesenteric lymph node, one liver lobe and the left kidney were collected in RNAlater for RNA analysis, and .1/2 spleen, 1/2 thymus, 1/2 mesenteric lymph node, the remaining liver, and the right kidney were collected in 10% NBF for histology. Serum was collected and frozen at -80°C for immunoglobulin and cytokine assays.

15

20

[0583] No statistically significant differences were found between the groups when the paw scores and measurements data were analyzed, although there was a suggestion that one treatment group receiving zcytor16 may have had a delay in the onset and progression of paw inflammation. There were no significant differences between the groups for changes in body weight, CBC parameters, or anti-collagen antibody levels. These early results indicate that zcytor16 does not adversely effect body weight, red or white blood cells, or antibody production, but may be able to reduce inflammation. Further investigations into dosing, mechanism of action, and efficacy are under way.

B. Anti-collagen ELISA data in mouse CIA model

25

[0584] Serum samples were collected on days 0, 7, 14, 21 and 28 relative to date of LPS challenge (day 0) from the murine model of collagen induced arthritis (Example 31A above). The serum samples were screened by ELISA for anti-collagen antibody titers. There were no statistically significant effects of zcytor16 treatment in 100 µg or 10 µg treatment groups on levels of anti-collagen antibodies compared with PBS controls. Below is a description of anti-collagen ELISA methods and materials.

30

35

[0585] Reagents used for anti-collagen ELISAs were Maxisorp 96-well microtiter plates (NUNC, Rochester, NY), chick type-II collagen (Chondrex, Redmond, WA), Super Block (Pierce, Rockford, IL.), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG+A+M (H+L) (Zymed, South San Francisco, CA) and o-phenylenediamine dihydrochloride substrate (Pierce, Rockford, IL). Buffers used in all assays were ELISA B diluent buffer (PBS + 0.1% BSA + 0.05% Tween (Sigma, St. Louis, MO)), ELISA C wash buffer (PBS + 0.05% Tween) and NovoD developing buffer (0.063M sodium citrate, 0.037M citric acid), H₂O₂ (Sigma) and 1N H₂SO₄ (VWR, Tukwilla, WA).

40

45

[0586] Approximately 100 µL of peripheral blood was collected by retro-orbital bleed into serum separator tubes (Becton Dickinson). Serum was collected by centrifugation (2-3 min, 16,000 x g, 4-6°C) and stored at -20°C until analyzed. To determine anti-collagen Ig antibody levels, NUNC plates were coated with 10 µg/mL chick type-II collagen (Chondrex, Redmond WA) and incubated overnight at 4°C. Plates were washed with ELISA C, blocked (5 minutes, room temperature) with Super Block (Pierce, Rockford, IL), and washed with ELISA C. Diluted serum samples (diluted in ELISA B 5-fold from 1:5000 to 1:625,000) were added to ELISA plates in triplicate and the plates were incubated overnight at 4°C. After incubation, the plates were washed with ELISA C, and peroxidase-labeled goat anti-mouse Ig Fc (Zymed, 1:2000 in ELISA B) was added. The plates were incubated (room temperature, 90 minutes), rinsed again using ELISA C, and HRP activity was developed using o-phenylenediamine dihydrochloride substrate (10 mL NovoD + 1 tablet OPD + 10 µL H₂O₂, Pierce). The reaction was stopped with 1N H₂SO₄. Relative optical density measurements of serum samples at 1:25,000 dilution were taken at 490 nm using a Spectra MAX 190, and data were analyzed using SoftMax Pro software (Molecular Devices Corporation, Palo Alto, CA).

C. IL-6 and SAA analysis in mouse CIA model

50

[0587] Day 0 serum samples were harvested from CIA mice (Example 31A above) 4 hr post administration of 25 µg LPS intraperitoneally. Samples were screened for IL-6 and serum amyloid A (SAA) concentrations by commercial ELISA kits purchased for Biosource International (Camarillo, CA) as per manufacturer's instructions.

55

[0588] The IL-6 levels were 9651 +/- 1563 pg/ml, 10,865 +/- 1478 pg/ml and 15,006 +/- 2,099 pg/ml in the mice groups subjected to 100 µg zcytor16, 10 µg zcytor16 and PBS control, respectively. The IL-6 concentration in the group of CIA mice exposed to the 100 µg dose of zcytor16 was significantly lower compared to PBS control mice with p = 0351. Statistical significance was calculated using Fisher's PLSD with a significance level of 5% (ABACUS Concepts, INC, Berkeley, CA).

[0589] In addition, SAA concentrations were 381 +/-40 µg/ml, 348 +/- 37 µg/ml and 490 +/- 50 µg/ml in the mice groups subjected to 100 µg zcytor16, 10 µg zcytor16 and PBS control groups, respectively. The SAA concentration in the group of CIA mice exposed to the 10 µg dose of zcytor16 was significantly lower compared with PBS control mice with $p = .0257$. Statistical significance was calculated using Fisher's PLSD with a significance level of 5% (ABACUS Concepts, INC, Berkeley, CA).

Example 32

Expression of IL-TIF receptor, Zcytor11, in the DSS mouse model

[0590] Quantitative RT-PCR was performed to measure expression levels of mouse zcytor11 in the colons of mice with DSS-induced IBD (Example 27). RNA was isolated from normal mouse colon and from the distal colons of DSS-treated mice from treatment days 2, 7 and 10. RT-PCR was performed using Applied Biosystems 7700 TaqMan instrument and protocols. Briefly, "Primer Express" software was used to designed primers against the mouse zcytor11 sequence (ZC39776 (SEQ ID NO:53) and ZC39777 (SEQ ID NO:54)) and a FAM/TAMRA labeled TaqMan probe (ZC38752 (SEQ ID NO:55)) according to Applied Biosystems guidelines. 25ng of RNA was added to each reaction, along with PE/Applied Biosystems TaqMan EZ RT-PCR Core Reagents and the above mentioned primers and probe. RT-PCR reactions were run in duplicate under the following conditions: 50°C for 2 minutes, 60°C for 30 minutes, 95°C for 5 minutes, 40 cycles of 94°C for 20 seconds and 60°C for 1 minute. Expression values were compared to a standard curve of known numbers of molecules of a synthetic mouse zcytor11 RNA transcript, and expression is reported as absolute number of molecules of mouse zcytor11 per reaction. Preliminary data suggests that mouse zcytor11 expression may be slightly down-regulated in the distal colons of day 7 and day 10 mice with DSS-induced IBD when compared to expression levels in normal mouse colon.

Example 33

IL-TIF and Proinflammatory Indicators in mild endotoxemia model: LPS-induced endotoxemia mouse model

A. LPS-induced endotoxemia mouse model: Assessment proinflammatory cytokines and body temperature in the LPS-induced endotoxemia mouse model

[0591] An *in vivo* experiment was designed to examine the effect of zcytor16 in a mouse LPS model of mild endotoxemia. To initially assess the model, we measured proinflammatory cytokines and body temperature to collect reference data for the model.

[0592] Briefly, six month Balb/c (CRL) female mice were injected with 25 µg LPS (Sigma) in sterile PBS intraperitoneally (IP). Serum samples were collected at 0, 1, 4, 8, 16, 24, 48 and 72 hr from groups of 8 mice for each time point. Serum samples were assayed for inflammatory cytokine levels. IL-1b, IL-6, TNFa, IL-10 and serum amyloid A protein (SAA) levels were measured using commercial ELISA kits purchased from Biosource International (Camarillo, CA).

[0593] TNFa levels peaked to 4000pg/ml and IL-10 levels were 341 pg/ml at 1 hr post LPS injection. At 4 hr post LPS injection, IL-6, IL-1b and IL-10 were 6,100 pg/ml, 299 pg/ml and 229 pg/ml, respectively. The SAA levels in serum were 0.405 mg/ml by 4 hr post LPS injection. SAA concentrations in serum continued to increase to 3.9 mg/ml by 24 hr post LPS, however SAA levels greater than 1 to 2 mg/ml in serum are difficult to measure accurately or reproducibly with the existing ELISA kit due to interactions between SAA and other serum components. These results indicated that proinflammatory cytokines, in addition to IL-TIF (Example 33B), were indeed produced in this model. Thus the following criteria were established as biological markers for the LPS model of mild endotoxemia: TNFa serum levels 1 hr post LPS, IL-6 serum levels 4 hr post LPS and SAA serum levels 4 and 8 hr post LPS.

[0594] Body temperatures in a separate group of animals were monitored by surgically implanted telemetry devices over the course of the 72 hr experiment. Body temperatures in mice dropped maximally by 2°C from 37.07 °C to 34.98 °C 30 minutes after LPS injection.

[0595] Injection of 100 ug zcytor16-Fc fusion protein 30 minutes prior to the LPS injection significantly reduced about 50% of the SAA induction at 4hr and 8hr time point, while 10 ug zcytor16-Fc did not have significant effect. There is no significant change to the TNF-alpha and IL-6 level. Zcytor16-Fc injection reduced neutrophil count in circulation at 1hr time point. It showed the administration of zcytor16-Fc can neutralize zcyto18 activity in terms of SAA induction.

B. Detection of IL-TIF Activity in Mouse Serum from LPS-induced endotoxemia mouse model using BaF3/CRF2-4/zcytor11 cells in an Alamar Blue Proliferation Assay

[0596] BaF3/CRF2-4/zcytor11 cells, described herein, were spun down and washed in PBS 2 times to ensure the

EP 1 373 508 B1

removal of the mL-3, and then spun a third time and re-suspended in the complete media (RPMI 1640, 10%FBS, 1% GlutaMAX, 1% Sodium Pyruvate), but without mL-3 (hereinafter referred to as "mL-3 free media"). Cells were then counted in a hemocytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 μ l per well using the mL-3 free media.

5 **[0597]** Serum from the LPS-induced endotoxemia mice from the experiment described in Example 33A above, was diluted to 2% in mL-3 free media on the top row of the plate and then diluted serially 1:2 down the remaining 7 rows on the 96-well plate, leaving a volume of 100 μ l in each well. This was then added to the 100 μ l of cells, for final serum concentrations of 1%, 0.5%, 0.25%, 0.125%, 0.063%, 0.031%, 0.016%, and 0.018% in a total assay volume of 200 μ l. The assay plates were incubated at 37°C, 5% CO₂ for 4 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20 μ l/well. Plates were again incubated at 37°C, 5% CO₂ for 16 hours. Alamar Blue gives a fluourometric readout based on number of live cells, and is thus a direct measurement of cell proliferation in comparison to a negative control. Plates were read on the Wallac Victor 2 1420 Multilabel Counter (Wallac, Turku, Finland) at wavelengths 530 (Excitation) and 590 (Emmssion).

10 **[0598]** Results showed no significant proliferation above background levels in the 0 hour, 1 hour, 8 hour, and 16 hour time points. Serum samples from the 4 hour time point showed 4-fold to greater than 10-fold increases in proliferation above background, indicating the presence of IL-TIF in those samples.

C. LPS-induced endotoxemia mouse model: Experiment to assess effects of zcytor16

20 **[0599]** The ability of zcytor16 treatment to effect proinflammatory indicators induced with a single 25 μ g LPS dose IP in mice was tested. All samples were analyzed for SAA, IL-TIF and circulating neutrophil counts. Subsets from each group were analyzed for particular cytokine levels (1 hour samples were screened for TNF alpha, 4 hour samples were analyzed for IL-6). Animals were sacrificed at indicated time points in Table 14 below and whole blood and serum were collected and aliquoted for analysis.

25 **[0600]** 72 B1/6 female mice (CRL) were given a single IP dose of zcytor16 as described in Table 14, below. Control mice were C57B1/6 (CRL).

30 **[0601]** 30 minutes later, they received another IP injection of 25 μ g LPS (Sigma) in 100 μ l, to initiate an endotoxemia cascade. Mice in each group were sacrificed at corresponding time points as indicated in Table 14, 50 μ l whole blood were collected to measure total numbers of circulating neutrophils and the rest were spun for serum and aliquoted for various assays described herein.

Table 14

Group	No	Treatment	LPS	Sacrifice	Samples
A	8	100 μ g zcytor16 IP	25 μ g IP 30min post tx	1 hour	Serum aliquots Blood for CBC
B	8	10 μ g zcytor16 IP	25 μ g IP 30min post tx	1 hour	Serum aliquots Blood for CBC
C	8	200 μ l PBS IP	25 μ g IP 30min post tx	1 hour	Serum aliquots Blood for CBC
D	8	100 μ g zcytor16 IP	25ug IP 30min post tx	4 hours	Serum aliquots Blood for CBC
E	8	10 μ g zcytor 16 IP	25 μ g IP 30min post tx	4 hours	Serum aliquots Blood for CBC
F	8	200 μ l PBS IP	25 μ g IP 30min post tx	4 hours	Serum aliquots Blood for CBC
G	8	100 μ g zcytor16 IP	25 μ g IP 30min post tx	8 hours	Serum aliquots Blood for CBC
H	8	10 μ g zcytor16 IP	25 μ g IP 30min post tx	8 hours	Serum aliquots Blood for CBC
J	8	200 μ l PBS IP	25 μ g IP 30min post tx	8 hours	Serum aliquots Blood for CBC
K	5	controls	none	Pre LPS	Serum aliquots Blood for CBC

D. Zcytor16/Fc4 neutralizes SAA induction *in vivo*: SAA ELISA showing SAA Expression induced by LPS in LPS-induced endotoxemia mouse model is inhibited by zcytor16-Fc4 injection:

50 **[0602]** To assess whether zcytor16 could inhibit the SAA induction in the LPS-induced endotoxemia mouse model, mice were injected with Zcytor16, 30 minutes prior to LPS injection, as shown in Table 14 in Example 33C above.

55 **[0603]** An ELISA to determine SAA levels in the 4 hour and 8 hour samples was performer using the Mouse SAA Immunoassay Kit (BioSource International, California) following the manufacturer's directions. At the 4 hour time point, mice treated with 100 μ g or 10 μ g of Zcytor16 showed a dose-dependant, statistically significant reduction in SAA levels

EP 1 373 508 B1

relative to the PBS injected mice. At the 8 hour time point, mice treated with 100 μ g, continued to show a statistically significant reduction in SAA levels relative to the PBS injected mice. This indicates that the presence of Zcytor16 is able to inhibit the induction of SAA by *LPS in vivo*.

5 Example 34

Baculovirus Expression of FlagTBXzCyt16

10 **[0604]** An expression vector, pzBV37L:egtNF(tbx)sCyt16, was designed and prepared to express FlagTBXzCyt16 polypeptides in insect cells.

Expression of FlagTBXzCyt16

15 **[0605]** An expression vector, pzBV37L:egtNF(tbx)sCyt16 was designed to express zCyt16 polypeptide with an upstream 6 amino acid thrombin cleavage site and an n-terminal Flag epitope tag upstream of the enzyme cleavage site. This construct can be used to express a flag tagged zCyt16 with an enzyme processing site directly upstream of the soluble receptor sequence, after the signal peptide has been cleaved off.

A. Construction of pzBV37LegtNF(tbx)sCyt16

20 **[0606]** A 698 bp, FlagTBXzCyt16 sequence fragment containing Bspe1 and Xba1 restriction sites on the 5' and 3' ends, respectively, was generated by two rounds of PCR amplification from a zCyt16 cDNA containing template. Primers ZC40,940 (SEQ ID NO:56) and ZC40,943 (SEQ ID NO:57) were used in the first round and primers ZC40942 (SEQ ID NO:58) and ZC40,943 (SEQ ID NO:57) in the second round. For the first round of PCR, reaction conditions were as follows: utilized the Expand High Fidelity PCR System (Boehringer Mannheim) for a 100ul vol. reaction. 1 cycle at 94°C for 2 minutes; 35 cycles of 94°C for 15 seconds, 50°C for 30 seconds, and 72°C for 60 seconds; 1 cycle at 72°C for 5 min; followed by 4°C soak. 5ul of the first round reaction mix was visualized by gel electrophoresis (1% NuSieve agarose). Once the presence of a correct size PCR product was confirmed, the second round of PCR was set up using 1ul of the first round reaction as template. Conditions of the second reaction were the same as the first. 5ul of the second round PCR was visualized by gel electrophoresis (1% NuSieve agarose). The remainder of the reaction mix was purified via Qiagen PCR purification kit as per manufacturers instructions and eluted in 30ul water. The cDNA was digested in a 35 ul vol. using Bspe1 and Xba1 (New England Biolabs, Beverly, MA) in appropriate buffer conditions at 37 degrees C. The digested PCR product band was run through a 1% agarose TAE gel, excised and extracted using a QIAquick™ Gel Extraction Kit (Qiagen, Cat. No. 28704) and eluted in 30ul of water. The digested FlagTBXzCyt16 PCR was ligated into the MCS of vector pZBV37L at the Bspe1 and Xba1 sites. The pZBV37L vector is a modification of the pFastBac1™ (Life Technologies) expression vector, where the polyhedron promoter has been removed and replaced with the late activating Basic Protein Promoter and the EGT leader signal sequence upstream of the MCS.. 5ul of the restriction enzyme digested FlagTBXzCyt16 PCR fragment and apx. 50 ng of the corresponding pZBV37L vector were ligated overnight at 16°C in a 20 ul vol. in appropriate buffer conditions. 5 ul of the ligation mix was transformed into 50 ul of ElectoMAX™ DH12s™ cells (Life Technologies, Cat. No. 18312-017) by electroporation at 400 Ohms, 2V and 25 μ F in a 2mm gap electroporation cuvette (BTX, Model No. 620). The transformed cells were diluted in 350 μ l of SOC media (2% Bacto Tryptone, 0.5% Bacto Yeast Extract, 10 ml 1M NaCl, 1.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄ and 20 mM glucose) outgrown for 1hr at 37 degrees C and 50 μ l of the dilution were plated onto LB plates containing 100 μ g/ml ampicillin. Clones were analyzed by PCR and positive clones were selected, plated and submitted for sequencing. Once proper sequence was confirmed, 25 ngs of positive clone DNA was transformed into 100 μ l DH10Bac™ Max Efficiency® competent cells (GIBCO-BRL Cat. No. 10361-012) by heat shock for 45 seconds in a 42°C heat block. The transformed DH10Bac™ cells were diluted in 900 μ l SOC media (2% Bacto Tryptone, 0.5% Bacto Yeast Extract, 10 ml 1M NaCl, 1.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄ and 20 mM glucose) outgrown for 1hr at 37 degrees C and 100 μ l were plated onto Luria Agar plates containing 50 μ g/ml kanamycin, 7 μ g/ml gentamicin, 10 μ g/ml tetracycline, 40 μ g/mL IPTG and 200 μ g/mL Bluo Gal. The plates were incubated for 48 hours at 37°C. A color selection was used to identify those cells having transposed viral DNA (referred to as a "bacmid"). Those colonies, which were white in color, were picked for analysis. Colonies were analyzed by PCR and positive colonies (containing desired bacmid) were selected for outgrow. Clones were screened for the correct M.W. insert by amplifying DNA using primers to the transposable element in the bacmid via PCR using primers ZC447 (SEQ ID NO:34) and ZC976 (SEQ ID NO:7). The PCR reaction conditions were as follows: 1 cycle at 94°C for 2 minutes; 25 cycles of 94°C for 10 seconds, 50°C for 30 seconds, and 72°C for 120 seconds; 1 cycle at 72°C for 5 min; followed by 4°C soak. The PCR product was run on a 1% agarose gel to check the insert size. Those having the correct size insert were outgrown and the bacmid DNA isolated and purified. This bacmid DNA was used to transfect Spodoptera Frugiperda (Sf9) cells.

EP 1 373 508 B1

B. Transfection

5 **[0607]** Sf9 cells were seeded at 1×10^6 cells per well in a 6-well plate and allowed to attach for 1 hour at 27°C. Approximately five μg . of bacmid DNA were diluted with 100 μl Sf-900 II SFM (Life Technologies). Twenty μl of Lipo-
fectamine™ Reagent (Life Technologies, Cat. No. 18324-012) were diluted with 100 μl Sf-900 II SFM. The bacmid DNA
and lipid solutions were gently mixed and incubated 45 minutes at room temperature. Eight hundred microliters of Sf-
900 II SFM was added to the lipid-DNA mixture. The media was aspirated from the well and the 1 ml of DNA-lipid mix
10 added to the cells. The cells were incubated at 27°C overnight. The DNA-lipid mix was aspirated and 2 ml of Sf-900 II
media was added to each plate. The plates were incubated at 27°C, 90% humidity, for approximately 7 days after which
the virus was harvested.

C. Amplification

15 **[0608]** Sf9 cells were seeded at 1×10^6 cells per well in a 6-well plate in 2mls SF-900II. 500 μl of virus from the
transfection plate were placed in the well and the plate was incubated at 27°C, 90% humidity, for 96 hours after which
the virus was harvested (primary amplification).

[0609] A second round of amplification proceeded as follows: Sf9 cells were seeded at 1×10^6 cells per well in a 6-well
plate in 2mls SF-900II. 100 μl of virus from the primary amplification plate were placed in the well and the plate was
incubated at 27°C, 90% humidity, for 144 hours after which the virus was harvested (Secondary amplification).

20 **[0610]** An additional round of amplification was performed (3rd round amp.) Sf9 cells were grown in 50 ml Sf-900 II
SFM in a 250 ml shake flask to an approximate density of 1×10^6 cells/ml. They were then infected with 1ml of the viral
stock from the above plate and incubated at 27°C for 4 days after which time the virus was harvested.

[0611] This viral stock was titered by a growth inhibition curve and the titer culture that indicated a MOI of 1 was allowed
to proceed for a total of 48hrs. The supernatant was analyzed via Western blot using a primary monoclonal antibody
25 specific for the n-terminal Flag epitope and a HRP conjugated Gt anti Mu secondary antibody. Results indicated a band
of apx. 30 kDa. Supernatant was also provided for activity analysis.

[0612] A large viral stock was then generated by the following method: Sf9 cells were grown in 1L Sf-900 II SFM in a
2800 ml shake flask to an approximate density of 1×10^6 cells/ml. They were then infected with 5 mls of the viral stock
from the 3rd round amp. and incubated at 27°C for 96hrs after which time the virus was harvested.

30 **[0613]** Larger scale infections were completed to provide material for downstream purification.

SEQUENCE LISTING

[0614]

35 <110> ZymoGenetics, Inc.
<120> Human Cytokine Receptor
40 <130> 01-12
<150> US 60/279,222
<151> 2001-03-27
45 <160> 62
<170> FastSEQ for Windows Version 3.0
<210> 1
50 <211> 2149
<212> DNA
<213> Homo sapiens
<220>
55 <221> CDS
<222> (1)...(693)
<400> 1

EP 1 373 508 B1

ggaaattcta aagctccctg agaacaggat gactcgtggt tgaaggatct tattttaaatt 783
 tgtttttgta ttttcttaaa gcaatattca ctgttacacc ttggggactt ctttgtttat 843
 5 ccattctttt atcctttata tttcatttta aactatattt gaacgacatt cccccgaaa 903
 aattgaaatg taaagatgag gcagagaata aagtgttcta tgaattcag aactttattt 963
 ctgaatgtaa catccctaata aacaacctt attcttctaa tacagcaaaa taaaaattta 1023
 acaaccaagg aatagatattt aagaaaatgt tgaataaatt tttttaaatt agcattacag 1083
 10 actgaggcgg tcctgaagca atggtttttc actctcttat tgagccaatt aaattgacat 1143
 tgctttgaca attttaaact tctataaagg tgaatatttt tcatacattt ctattttata 1203
 tgaatatact ttttatatat ttattattat taaatatttc tacttaatga atcaaaattt 1263
 tgttttaaag tctactttat gtaaataaga acaggttttg gggaaaaaaa tcttatgatt 1323
 15 tctggattga tatctgaatt aaaactatca acaacaagga agtctactct gtacaattgt 1383
 ccctcattta aaagatatat taagcttttc ttttctggtt gtttttggtt tgtttagttt 1443
 ttaatcctgt cttagaagaa cttatcttta ttctcaaat taaatgtaat ttttttagtg 1503
 acaaagaaga aaggaaacct cactactcaa tccttctggc caagagtgtc ttgcttggtg 1563
 20 cgccttctc atctctatat aggaggatcc catgaatgat ggtttattgg gaactgctgg 1623
 ggtcgacccc atacagagaa ctcagcttga agctggaagc acacagtggg tagcaggaga 1683
 aggaccggtg ttggtaggtg cctacagaga ctatagagct agacaaagcc ctccaaactg 1743
 gccctcctg ctactgcct ctctgagta gaaatctggt gacctaaagg tcagtgcggt 1803
 25 caacagaaag ctgccttctt cacttgaggc taagtcttca tatatgttta aggttgctt 1863
 tctagtgagg agatacatat cagagaacat ttgtacaatt ccccatgaaa attgctccaa 1923
 agttgataac aatatagtcg gtgcttctag ttatatgcaa gtactcagtg ataaatggat 1983
 taaaaaataat tcagaaatgt attggggggg ggaggagaat aagaggcaga gcaagagcta 2043
 30 gagaattggt ttcttgctt ccctgtatgc tcagaaaaca ttgatttgag catagacgca 2103
 gagactgaaa aaaaaaaaaat gctcgagcgg ccgcatatc cttggt 2149

35 <210> 2
 <211> 231
 <212> PRT
 <213> Homo sapiens

40 <400> 2

Met Met Pro Lys His Cys Phe Leu Gly Phe Leu Ile Ser Phe Phe Leu
 1 5 10 15
 45 Thr Gly Val Ala Gly Thr Gln Ser Thr His Glu Ser Leu Lys Pro Gln
 20 25 30
 Arg Val Gln Phe Gln Ser Arg Asn Phe His Asn Ile Leu Gln Trp Gln
 35 40 45
 50 Pro Gly Arg Ala Leu Thr Gly Asn Ser Ser Val Tyr Phe Val Gln Tyr
 50 55 60
 55 Lys Ile Tyr Gly Gln Arg Gln Trp Lys Asn Lys Glu Asp Cys Trp Gly
 65 70 75 80

EP 1 373 508 B1

Thr Gln Glu Leu Ser Cys Asp Leu Thr Ser Glu Thr Ser Asp Ile Gln
 85 90 95
 5 Glu Pro Tyr Tyr Gly Arg Val Arg Ala Ala Ser Ala Gly Ser Tyr Ser
 100 105 110
 Glu Trp Ser Met Thr Pro Arg Phe Thr Pro Trp Trp Glu Thr Lys Ile
 115 120 125
 10 Asp Pro Pro Val Met Asn Ile Thr Gln Val Asn Gly Ser Leu Leu Val
 130 135 140
 Ile Leu His Ala Pro Asn Leu Pro Tyr Arg Tyr Gln Lys Glu Lys Asn
 145 150 155 160
 15 Val Ser Ile Glu Asp Tyr Tyr Glu Leu Leu Tyr Arg Val Phe Ile Ile
 165 170 175
 Asn Asn Ser Leu Glu Lys Glu Gln Lys Val Tyr Glu Gly Ala His Arg
 180 185 190
 20 Ala Val Glu Ile Glu Ala Leu Thr Pro His Ser Ser Tyr Cys Val Val
 195 200 205
 Ala Glu Ile Tyr Gln Pro Met Leu Asp Arg Arg Ser Gln Arg Ser Glu
 210 215 220
 25 Glu Arg Cys Val Glu Ile Pro
 225 230

<210> 3
 <211> 693
 30 <212> DNA
 <213> Artificial Sequence

<220>
 <223> This degenerate nucleotide sequence encodes the amino acid sequence of SEQ ID NO:2.

<221> misc_feature
 <222> (1)...(693)
 <223> n = A,T,C or G

<400> 3

atgatgccna arcaytgytt ytnngntty ytnathwsnt tyttyytnac ngngntngcn 60
 ggnacncarw snacncayga rwsnytnaar ccncarmng tncarttyca rwsnmgnaay 120
 45 ttycayaaya thytncartg gcarccnggn mgngcnytna cnggnaayws nwsngtntay 180
 ttygtncart ayaarathta yggncarmgn cartggaara ayaargarga ytgytgggg 240
 acncargary tnwsntgyga yytnacnwsn garacnwsng ayathcarga rccntaytay 300
 ggnmgngtnm gngcngcnws ngcnggnwsn taywsngart ggwsnatgac nccnmgntty 360
 50 acncntggt ggaracnaa rathgayccn ccngtnatga ayathacnca rgtnaaygg 420
 wsnytnytng tnathytnca ygcncnaay ytnccntaym gntaycaraa rgaraaraay 480

55

EP 1 373 508 B1

5 gtnwsnathg argaytayta ygarytynytn taymgngtnt tyathathaa yaaywsnytn 540
 garaargarc araargnta ygargngcn caymgngcng tngarathga rgcnynnacn 600
 ccncaywsnw sntaytgygt ngtngcngar athtaycarc cnatgytnga ymgnmgwnsn 660
 carmgwnsng argarmgtg ygtngarath ccn 693

10 <210> 4
 <211> 16.
 <212> PRT
 <213> Artificial Sequence

15 <220>
 <223> Peptide linker.

<400> 4

20 Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

25 <210> 5
 <211> 699
 <212> DNA
 <213> Homo sapiens

<400> 5

30 gagcccagat cttcagacaa aactcacaca tgcccaccgt gccagcacc tgaagccgag 60
 ggggcaccgt cagtcttctt cttccccca aaaccaagg acaccctcat gatctcccgg 120
 acccctgagg tcacatgctt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 180
 aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag 240
 35 tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 300
 ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc catcctccat cgagaaaacc 360
 atctccaaag ccaagggca gccccgagaa cccacaggtgt acaccctgcc cccatcccgg 420
 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc 480
 40 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 540
 cccgtgctgg actccgacgg ctcttcttct ctctacagca agctcaccgt qqacaagagc 600
 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 660
 tacacgcaga agagcctctc cctgtctccg ggtaaataa 699

45 <210> 6
 <211> 32
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Oligonucleotide primer ZC29181

55 <400> 6
 gcggatccac tcagtcaacg catgagtctc tg 32

<210> 7
 <211> 33

EP 1 373 508 B1

<212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC29182

<400> 7
 gcagatcttg gaattccac acatctctct tca 33

<210> 8
 <211> 108
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(108)

<400> 8

atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg tgt ggc 48
 Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15

gcc gtc ttc gtt tcg ctc agc cag gaa atc cat gcc gag ttg aga cgc 96
 Ala Val Phe Val Ser Leu Ser Gln Glu Ile His Ala Glu Leu Arg Arg
 20 25 30

ttc cgt aga tcc 108
 Phe Arg Arg Ser
 35

<210> 9
 <211> 36
 <212> PRT
 <213> Homo sapiens

<400> 9

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15
 Ala Val Phe Val Ser Leu Ser Gln Glu Ile His Ala Glu Leu Arg Arg
 20 25 30
 Phe Arg Arg Ser
 35

<210> 10
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>

EP 1 373 508 B1

<223> Glu-Glu (CEE) Tag amino acid sequence

<400> 10

5

Glu Tyr Met Pro Met Glu
1 5

<210> 11

10

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

15

<223> FLAG Tag amino acid sequence

<400> 11

20

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

<210> 12

25

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

30

<223> His Tag amino acid sequence

<400> 12

35

His His His His His His
1 5

<210> 13

40

<211> 210

<212> PRT

<213> Homo sapiens

<400> 13

45

50

55

EP 1 373 508 B1

Thr Gln Ser Thr His Glu Ser Leu Lys Pro Gln Arg Val Gln Phe Gln
 1 5 10 15
 Ser Arg Asn Phe His Asn Ile Leu Gln Trp Gln Pro Gly Arg Ala Leu
 5 20 25 30
 Thr Gly Asn Ser Ser Val Tyr Phe Val Gln Tyr Lys Ile Tyr Gly Gln
 35 40 45
 Arg Gln Trp Lys Asn Lys Glu Asp Cys Trp Gly Thr Gln Glu Leu Ser
 10 50 55 60
 Cys Asp Leu Thr Ser Glu Thr Ser Asp Ile Gln Glu Pro Tyr Tyr Gly
 65 70 75 80
 Arg Val Arg Ala Ala Ser Ala Gly Ser Tyr Ser Glu Trp Ser Met Thr
 15 85 90 95
 Pro Arg Phe Thr Pro Trp Trp Glu Thr Lys Ile Asp Pro Pro Val Met
 100 105 110
 20
 Asn Ile Thr Gln Val Asn Gly Ser Leu Leu Val Ile Leu His Ala Pro
 115 120 125
 Asn Leu Pro Tyr Arg Tyr Gln Lys Glu Lys Asn Val Ser Ile Glu Asp
 25 130 135 140
 Tyr Tyr Glu Leu Leu Tyr Arg Val Phe Ile Ile Asn Asn Ser Leu Glu
 145 150 155 160
 Lys Glu Gln Lys Val Tyr Glu Gly Ala His Arg Ala Val Glu Ile Glu
 30 165 170 175
 Ala Leu Thr Pro His Ser Ser Tyr Cys Val Val Ala Glu Ile Tyr Gln
 180 185 190
 Pro Met Leu Asp Arg Arg Ser Gln Arg Ser Glu Glu Arg Cys Val Glu
 35 195 200 205
 Ile Pro
 210

40 <210> 14
 <211> 1116
 <212> DNA
 <213> Homo sapiens

45 <220>
 <221> CDS
 <222> (21)...(557)

50 <400> 14

55

EP 1 373 508 B1

	tcgagttaga attgtctgca atg gcc gcc ctg cag aaa tct gtg agc tct ttc	53
	Met Ala Ala Leu Gln Lys Ser Val Ser Ser Phe	
5	1 5 10	
	ctt atg ggg acc ctg gcc acc agc tgc ctc ctt ctc ttg gcc ctc ttg	101
	Leu Met Gly Thr Leu Ala Thr Ser Cys Leu Leu Leu Leu Ala Leu Leu	
10	15 20 25	
	gta cag gga gga gca gct gcg ccc atc agc tcc cac tgc agg ctt gac	149
	Val Gln Gly Gly Ala Ala Ala Pro Ile Ser Ser His Cys Arg Leu Asp	
15	30 35 40	
	aag tcc aac ttc cag cag ccc tat atc acc aac cgc acc ttc atg ctg	197
	Lys Ser Asn Phe Gln Gln Pro Tyr Ile Thr Asn Arg Thr Phe Met Leu	
20	45 50 55	
	gct aag gag gct agc ttg gct gat aac aac aca gac gtt cgt ctc att	245
	Ala Lys Glu Ala Ser Leu Ala Asp Asn Asn Thr Asp Val Arg Leu Ile	
25	60 65 70 75	
	ggg gag aaa ctg ttc cac gga gtc agt atg agt gag cgc tgc tat ctg	293
	Gly Glu Lys Leu Phe His Gly Val Ser Met Ser Glu Arg Cys Tyr Leu	
30	80 85 90	
	atg aag cag gtg ctg aac ttc acc ctt gaa gaa gtg ctg ttc cct caa	341
	Met Lys Gln Val Leu Asn Phe Thr Leu Glu Glu Val Leu Phe Pro Gln	
35	95 100 105	
	tct gat agg ttc cag cct tat atg cag gag gtg gtg ccc ttc ctg qcc	389
	Ser Asp Arg Phe Gln Pro Tyr Met Gln Glu Val Val Pro Phe Leu Ala	
40	110 115 120	
	agg ctc agc aac agg cta agc aca tgt cat att gaa ggt gat gac ctg	437
	Arg Leu Ser Asn Arg Leu Ser Thr Cys His Ile Glu Gly Asp Asp Leu	
45	125 130 135	
	cat atc cag agg aat gtg caa aag ctg aag gac aca gtg aaa aag ctt	485
	His Ile Gln Arg Asn Val Gln Lys Leu Lys Asp Thr Val Lys Lys Leu	
50	140 145 150 155	

55

EP 1 373 508 B1

gga gag agt gga gag atc aaa gca att gga gaa ctg gat ttg ctg ttt 533
 Gly Glu Ser Gly Glu Ile Lys Ala Ile Gly Glu Leu Asp Leu Leu Phe
 5 160 165 170

atg tct ctg aga aat gcc tgc att tgaccagagc aaagctgaaa aatgaataac 587
 Met Ser Leu Arg Asn Ala Cys Ile
 10 175

taaccccctt tcctgctag aaataacaat tagatgcccc aaagcgattt tttttaacca 647
 aaaggaagat gggaagccaa actccatcat gatgggtgga ttccaaatga acccctgcgt 707
 15 tagttacaaa ggaaaccaat gccacttttg tttataagac cagaaggtag actttctaag 767
 catagatatt tattgataac atttcattgt aactgggtgt ctatacacag aaaacaattt 827
 attttttaa taattgtcct tttccataaa aaagattact ttccattcct ttaggggaaa 887
 aaaccctaa atagcttcat gtttccataa tcagtacttt atatttataa atgtatttat 947
 20 tattattata agactgcatt ttatttataat cattttatta atatggattt atttatagaa 1007
 acatcattcg atattgctac ttgagtgtaa ggctaataat gatatttatg acaataatta 1067
 tagagctata acatgtttat ttgacctcaa taaacacttg gatataccta 1116

25 <210> 15
 <211> 179
 <212> PRT
 <213> Homo sapiens

30 <400> 15

Met Ala Ala Leu Gln Lys Ser Val Ser Ser Phe Leu Met Gly Thr Leu
 1 5 10 15
 35 Ala Thr Ser Cys Leu Leu Leu Leu Ala Leu Leu Val Gln Gly Gly Ala
 20 25 30
 Ala Ala Pro Ile Ser Ser His Cys Arg Leu Asp Lys Ser Asn Phe Gln
 35 40 45
 40 Gln Pro Tyr Ile Thr Asn Arg Thr Phe Met Leu Ala Lys Glu Ala Ser
 50 55 60
 Leu Ala Asp Asn Asn Thr Asp Val Arg Leu Ile Gly Glu Lys Leu Phe
 65 70 75 80
 45 His Gly Val Ser Met Ser Glu Arg Cys Tyr Leu Met Lys Gln Val Leu
 85 90 95
 Asn Phe Thr Leu Glu Glu Val Leu Phe Pro Gln Ser Asp Arg Phe Gln
 100 105 110
 50 Pro Tyr Met Gln Glu Val Val Pro Phe Leu Ala Arg Leu Ser Asn Arg
 115 120 125
 Leu Ser Thr Cys His Ile Glu Gly Asp Asp Leu His Ile Gln Arg Asn
 55 130 135 140

EP 1 373 508 B1

<223> Oligonucleotide primer ZC14063

<400> 20
caccagacat aatagctgac agact 25

5

<210> 21
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Oligonucleotide primer ZC17574

<400> 21
ggtrttgctc agcatgcaca c 21

15

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

20

<220>
<223> Oligonucleotide primer ZC17600

25

<400> 22
catgtaggcc atgaggcca ccac 24

30

<210> 23
<211> 22
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Oligonucleotide primer ZC27659

<400> 23
tcaagctgag ttctctgat gg 22

40

<210> 24
<211> 2831
<212> DNA
<213> Homo sapiens

45

<220>
<221> CDS
<222> (34)...(1755)

<400> 24

50

55

EP 1 373 508 B1

	tagaggccaa gggagggctc tgtgccagcc ccg atg agg acg ctg ctg acc atc	54
	Met Arg Thr Leu Leu Thr Ile	
	1 5	
5		
	ttg act gtg gga tcc ctg gct gct cac gcc cct gag gac ccc tcg gat	102
	Leu Thr Val Gly Ser Leu Ala Ala His Ala Pro Glu Asp Pro Ser Asp	
	10 10 15 20	
10		
	ctg ctc cag cac gtg aaa ttc cag tcc agc aac ttt gaa aac atc ctg	150
	Leu Leu Gln His Val Lys Phe Gln Ser Ser Asn Phe Glu Asn Ile Leu	
	15 25 30 35	
15		
	acg tgg gac agc ggg cca gag ggc acc cca gac acg gtc tac agc atc	198
	Thr Trp Asp Ser Gly Pro Glu Gly Thr Pro Asp Thr Val Tyr Ser Ile	
	20 40 45 50 55	
20		
	gag tat aag acg tac gga gag agg gac tgg gtg gca aag aag ggc tgt	246
	Glu Tyr Lys Thr Tyr Gly Glu Arg Asp Trp Val Ala Lys Lys Gly Cys	
	25 60 65 70	
25		
	cag cgg atc acc cgg aag tcc tgc aac ctg acg gtg gag acg ggc aac	294
	Gln Arg Ile Thr Arg Lys Ser Cys Asn Leu Thr Val Glu Thr Gly Asn	
	30 75 80 85	
30		
35		
40		
45		
50		
55		

EP 1 373 508 B1

5 ctc acg gag ctc tac tat gcc agg gtc acc gct gtc agt gcg gga ggc 342
 Leu Thr Glu Leu Tyr Tyr Ala Arg Val Thr Ala Val Ser Ala Gly Gly
 90 95 100

10 cgg tca gcc acc aag atg act gac agg ttc agc tct ctg cag cac act 390
 Arg Ser Ala Thr Lys Met Thr Asp Arg Phe Ser Ser Leu Gln His Thr
 105 110 115

15 acc ctc aag cca cct gat gtg acc tgt atc tcc aaa gtg aga tcg att 438
 Thr Leu Lys Pro Pro Asp Val Thr Cys Ile Ser Lys Val Arg Ser Ile
 120 125 130 135

20 cag atg att gtt cat cct acc ccc acg cca atc cgt gca ggc gat ggc 486
 Gln Met Ile Val His Pro Thr Pro Thr Pro Ile Arg Ala Gly Asp Gly
 140 145 150

25 cac cgg cta acc ctg gaa gac atc ttc cat gac ctg ttc tac cac tta 534
 His Arg Leu Thr Leu Glu Asp Ile Phe His Asp Leu Phe Tyr His Leu
 155 160 165

30 gag ctc cag gtc aac cgc acc tac caa atg cac ctt gga ggg aag cag 582
 Glu Leu Gln Val Asn Arg Thr Tyr Gln Met His Leu Gly Gly Lys Gln
 170 175 180

35 aga gaa tat gag ttc ttc ggc ctg acc cct gac aca gag ttc ctt ggc 630
 Arg Glu Tyr Glu Phe Phe Gly Leu Thr Pro Asp Thr Glu Phe Leu Gly
 185 190 195

40 acc atc atg att tgc gtt ccc acc tgg gcc aag gag agt gcc ccc tac 678
 Thr Ile Met Ile Cys Val Pro Thr Trp Ala Lys Glu Ser Ala Pro Tyr
 200 205 210 215

45 atg tgc cga gtg aag aca ctg cca gac cag aca tgg acc tac tcc ttc 726
 Met Cys Arg Val Lys Thr Leu Pro Asp Arg Thr Trp Thr Tyr Ser Phe
 220 225 230

50 tcc gga gcc ttc ctg ttc tcc atg ggc ttc ctc gtc gca gta ctc tgc 774
 Ser Gly Ala Phe Leu Phe Ser Met Gly Phe Leu Val Ala Val Leu Cys
 235 240 245

55 tac ctg agc tac aga tat gtc acc aag ccg cct gca cct ccc aac tcc 822
 Tyr Leu Ser Tyr Arg Tyr Val Thr Lys Pro Pro Ala Pro Pro Asn Ser
 250 255 260

EP 1 373 508 B1

5	ctg aac gtc cag cga gtc ctg act ttc cag ccg ctg cgc ttc atc cag Leu Asn Val Gln Arg Val Leu Thr Phe Gln Pro Leu Arg Phe Ile Gln 265 . 270 275	870
10	gag cac gtc ctg atc cct gtc ttt gac ctc agc ggc ccc agc agt ctg Glu His Val Leu Ile Pro Val Phe Asp Leu Ser Gly Pro Ser Ser Leu 280 285 290 295	918
15	gcc cag cct gtc cag tac tcc cag atc agg gtg tct gga ccc agg gag Ala Gln Pro Val Gln Tyr Ser Gln Ile Arg Val Ser Gly Pro Arg Glu 300 305 310	966
20	ccc gca gga gct cca cag cgg cat agc ctg tcc gag atc acc tac tta Pro Ala Gly Ala Pro Gln Arg His Ser Leu Ser Glu Ile Thr Tyr Leu 315 320 325	1014
25	ggg cag cca gac atc tcc atc ctc cag ccc tcc aac gtg cca cct ccc Gly Gln Pro Asp Ile Ser Ile Leu Gln Pro Ser Asn Val Pro Pro Pro 330 335 . 340	1062
30	cag atc ctc tcc cca ctg tcc tat gcc cca aac gct gcc cct gag gtc Gln Ile Leu Ser Pro Leu Ser Tyr Ala Pro Asn Ala Ala Pro Glu Val 345 350 355	1110
35	ggg ccc cca tcc tat gca cct cag gtg acc ccc gaa gct caa ttc cca Gly Pro Pro Ser Tyr Ala Pro Gln Val Thr Pro Glu Ala Gln Phe Pro 360 365 370 375	1158
40	ttc tac gcc cca cag gcc atc tct aag gtc cag cct tcc tcc tat gcc Phe Tyr Ala Pro Gln Ala Ile Ser Lys Val Gln Pro Ser Ser Tyr Ala 380 385 390	1206
45	cct caa gcc act ccg gac agc tgg cct ccc tcc tat ggg gta tgc atg Pro Gln Ala Thr Pro Asp Ser Trp Pro Pro Ser Tyr Gly Val Cys Met 395 400 405	1254
50	gaa ggt tct ggc aaa gac tcc ccc act ggg aca ctt tct agt cct aaa Glu Gly Ser Gly Lys Asp Ser Pro Thr Gly Thr Leu Ser Ser Pro Lys 410 415 420	1302
55	cac ctt agg cct aaa ggt cag ctt cag aaa gag cca cca gct gga agc	1350

EP 1 373 508 B1

	His	Leu	Arg	Pro	Lys	Gly	Gln	Leu	Gln	Lys	Glu	Pro	Pro	Ala	Gly	Ser	
		425					430					435					
5	tgc	atg	tta	ggt	ggc	ctt	tct	ctg	cag	gag	gtg	acc	tcc	ttg	gct	atg	1398
	Cys	Met	Leu	Gly	Gly	Leu	Ser	Leu	Gln	Glu	Val	Thr	Ser	Leu	Ala	Met	
	440				445					450					455		
10	gag	gaa	tcc	caa	gaa	gca	aaa	tca	ttg	cac	cag	ccc	ctg	ggg	att	tgc	1446
	Glu	Glu	Ser	Gln	Glu	Ala	Lys	Ser	Leu	His	Gln	Pro	Leu	Gly	Ile	Cys	
				460					465					470			
15	aca	gac	aga	aca	tct	gac	cca	aat	gtg	cta	cac	agt	ggg	gag	gaa	ggg	1494
	Thr	Asp	Arg	Thr	Ser	Asp	Pro	Asn	Val	Leu	His	Ser	Gly	Glu	Glu	Gly	
				475					480					485			
20	aca	cca	cag	tac	cta	aag	ggc	cag	ctc	ccc	ctc	ctc	tcc	tca	gtc	cag	1542
	Thr	Pro	Gln	Tyr	Leu	Lys	Gly	Gln	Leu	Pro	Leu	Leu	Ser	Ser	Val	Gln	
			490				495						500				
25	atc	gag	ggc	cac	ccc	atg	tcc	ctc	cct	ttg	caa	cct	cct	tcc	ggt	cca	1590
	Ile	Glu	Gly	His	Pro	Met	Ser	Leu	Pro	Leu	Gln	Pro	Pro	Ser	Gly	Pro	
		505					510					515					
30	tgt	tcc	ccc	tcg	gac	caa	ggt	cca	agt	ccc	tgg	ggc	ctg	ctg	gag	tcc	1638
	Cys	Ser	Pro	Ser	Asp	Gln	Gly	Pro	Ser	Pro	Trp	Gly	Leu	Leu	Glu	Ser	
	520					525					530				535		
35	ctt	gtg	tgt	ccc	aag	gat	gaa	gcc	aag	agc	cca	gcc	cct	gag	acc	tca	1686
	Leu	Val	Cys	Pro	Lys	Asp	Glu	Ala	Lys	Ser	Pro	Ala	Pro	Glu	Thr	Ser	
				540						545					550		
40	gac	ctg	gag	cag	ccc	aca	gaa	ctg	gat	tct	ctt	ttc	aga	ggc	ctg	gcc	1734
	Asp	Leu	Glu	Gln	Pro	Thr	Glu	Leu	Asp	Ser	Leu	Phe	Arg	Gly	Leu	Ala	
				555					560					565			
45	ctg	act	gtg	cag	tgg	gag	tcc	tgaggggaat	gggaaaggct	tggtgcttcc							1785
	Leu	Thr	Val	Gln	Trp	Glu	Ser										
			570														
50	tcctgtccc	taccagtg	caatccttg	gctgtcaatc	ccatgcctgc	ccatgccaca											1845
	cactctgca	tctggcctca	gacgggtgcc	cttgagagaa	gcagaggag	tgcatgcag											1905
	ggcccctgcc	atgggtgcgc	tcctaccgg	aacaaagcag	catgataagg	actgcagcgg											1965
55	gggagctctg	gggagcagct	tgtgtagaca	agcgcgtgct	cgctgagccc	tgcaaggcag											2025

EP 1 373 508 B1

5 aaatgacagt gcaaggagga aatgcaggga aactcccagag gtccagagcc ccacctccta 2085
 acaccatgga ttcaaagtgc tcaggaatt tgcctctcct tgccccattc ctggccagtt 2145
 tcacaatcta gctcgacaga gcatgaggcc cctgcctctt ctgtcattgt tcaaaggtgg 2205
 gaagagagcc tggaaaagaa ccaggcctgg aaaagaacca gaaggaggct gggcagaacc 2265
 agaacaacct gcacttctgc caaggccagg gccagcagga cggcaggact ctagggaggg 2325
 gtgtggcctg cagctcattc ccagccaggg caactgcctg acgttgcacg atttcagctt 2385
 10 cattcctctg atagaacaaa gcgaaatgca ggtccaccag ggagggagac acacaagcct 2445
 tttctgcagg caggagtttc agaccctatc ctgagaatgg ggtttgaaag gaaggtgagg 2505
 gctgtggccc ctggacgggt acaataacac actgtactga tgtcacaact ttgcaagctc 2565
 tgccttgggt tcagcccatac tgggctcaaa ttccagcctc accactcaca agctgtgtga 2625
 15 cttcaaacia atgaaatcag tgcccagaac ctcggtttcc tcatctgtaa tgtggggatc 2685
 ataacaccta cctcatggag ttgtggtgaa gatgaaatga agtcatgtct ttaaagtgct 2745
 taatagtgcc tggtagatgg gcagtgccca ataaacggta gctatttaaa aaaaaaaaaa 2805
 aaaaaaaaaa atagcggccg cctcga 2831

20
 <210> 25
 <211> 574
 <212> PRT
 <213> Homo sapiens
 25
 <400> 25

30 Met Arg Thr Leu Leu Thr Ile Leu Thr Val Gly Ser Leu Ala Ala His
 1 5 10 15
 Ala Pro Glu Asp Pro Ser Asp Leu Leu Gln His Val Lys Phe Gln Ser
 20 25 30
 35 Ser Asn Phe Glu Asn Ile Leu Thr Trp Asp Ser Gly Pro Glu Gly Thr
 35 40 45
 Pro Asp Thr Val Tyr Ser Ile Glu Tyr Lys Thr Tyr Gly Glu Arg Asp
 50 55 60
 40 Trp Val Ala Lys Lys Gly Cys Gln Arg Ile Thr Arg Lys Ser Cys Asn
 65 70 75 80
 Leu Thr Val Glu Thr Gly Asn Leu Thr Glu Leu Tyr Tyr Ala Arg Val
 85 90 95
 45 Thr Ala Val Ser Ala Gly Gly Arg Ser Ala Thr Lys Met Thr Asp Arg
 100 105 110
 Phe Ser Ser Leu Gln His Thr Thr Leu Lys Pro Pro Asp Val Thr Cys
 115 120 125
 50 Ile Ser Lys Val Arg Ser Ile Gln Met Ile Val His Pro Thr Pro Thr
 130 135 140
 Pro Ile Arg Ala Gly Asp Gly His Arg Leu Thr Leu Glu Asp Ile Phe
 145 150 155 160
 55 His Asp Leu Phe Tyr His Leu Glu Leu Gln Val Asn Arg Thr Tyr Gln
 165 170 175

EP 1 373 508 B1

Met His Leu Gly Gly Lys Gln Arg Glu Tyr Glu Phe Phe Gly Leu Thr
 180 185 190
 5 Pro Asp Thr Glu Phe Leu Gly Thr Ile Met Ile Cys Val Pro Thr Trp
 195 200 205
 Ala Lys Glu Ser Ala Pro Tyr Met Cys Arg Val Lys Thr Leu Pro Asp
 210 215 220
 10 Arg Thr Trp Thr Tyr Ser Phe Ser Gly Ala Phe Leu Phe Ser Met Gly
 225 230 235 240
 Phe Leu Val Ala Val Leu Cys Tyr Leu Ser Tyr Arg Tyr Val Thr Lys
 245 250 255
 15 Pro Pro Ala Pro Pro Asn Ser Leu Asn Val Gln Arg Val Leu Thr Phe
 260 265 270
 Gln Pro Leu Arg Phe Ile Gln Glu His Val Leu Ile Pro Val Phe Asp
 275 280 285
 20 Leu Ser Gly Pro Ser Ser Leu Ala Gln Pro Val Gln Tyr Ser Gln Ile
 290 295 300
 Arg Val Ser Gly Pro Arg Glu Pro Ala Gly Ala Pro Gln Arg His Ser
 305 310 315 320
 25 Leu Ser Glu Ile Thr Tyr Leu Gly Gln Pro Asp Ile Ser Ile Leu Gln
 325 330 335
 Pro Ser Asn Val Pro Pro Pro Gln Ile Leu Ser Pro Leu Ser Tyr Ala
 340 345 350
 30 Pro Asn Ala Ala Pro Glu Val Gly Pro Pro Ser Tyr Ala Pro Gln Val
 355 360 365
 Thr Pro Glu Ala Gln Phe Pro Phe Tyr Ala Pro Gln Ala Ile Ser Lys
 370 375 380
 35 Val Gln Pro Ser Ser Tyr Ala Pro Gln Ala Thr Pro Asp Ser Trp Pro
 385 390 395 400
 Pro Ser Tyr Gly Val Cys Met Glu Gly Ser Gly Lys Asp Ser Pro Thr
 405 410 415
 40 Gly Thr Leu Ser Ser Pro Lys His Leu Arg Pro Lys Gly Gln Leu Gln
 420 425 430
 Lys Glu Pro Pro Ala Gly Ser Cys Met Leu Gly Gly Leu Ser Leu Gln
 435 440 445
 45 Glu Val Thr Ser Leu Ala Met Glu Glu Ser Gln Glu Ala Lys Ser Leu
 450 455 460
 His Gln Pro Leu Gly Ile Cys Thr Asp Arg Thr Ser Asp Pro Asn Val
 465 470 475 480
 50 Leu His Ser Gly Glu Glu Gly Thr Pro Gln Tyr Leu Lys Gly Gln Leu
 485 490 495
 Pro Leu Leu Ser Ser Val Gln Ile Glu Gly His Pro Met Ser Leu Pro
 500 505 510
 55

EP 1 373 508 B1

5 Leu Gln Pro Pro Ser Gly Pro Cys Ser Pro Ser Asp Gln Gly Pro Ser
 515 520 525
 Pro Trp Gly Leu Leu Glu Ser Leu Val Cys Pro Lys Asp Glu Ala Lys
 530 535 540
 Ser Pro Ala Pro Glu Thr Ser Asp Leu Glu Gln Pro Thr Glu Leu Asp
 545 550 555 560
 10 Ser Leu Phe Arg Gly Leu Ala Leu Thr Val Gln Trp Glu Ser
 565 570

15 <210> 26
 <211> 39
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Oligonucleotide linker ZC13252

<400> 26
 ggctgaaag ctcggataa tgaaggacc tgtagaaa 39

25 <210> 27
 <211> 27
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Oligonucleotide linker ZC13453

<400> 27
 ttaggatccg gccctcccc agatact 27

35 <210> 28
 <211> 36
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Oligonucleotide primer ZC28590

<400> 28
 ttgggtacct ctgcaatggc cgccctgcag aaatct 36

45 <210> 29
 <211> 33
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Oligonucleotide primer ZC28580

55 <400> 29
 ttgggatcca atgcaggcat ttctcagaga cat 33

<210> 30
 <211> 23

<212> DNA
 <213> Artificial Sequence

 <220>
 5 <223> Oligonucleotide primer ZC25963

 <400> 30
 agtcaacgca tgagtctctg aag 23

 10 <210> 31
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 15 <220>
 <223> Oligonucleotide primer ZC25964

 <400> 31
 20 gttcttgagt accccaacag tct 23

 <210> 32
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 25
 <220>
 <223> Oligonucleotide primer ZC14666

 <400> 32
 30 agccaccaag atgactga 18

 <210> 33
 <211> 22
 <212> DNA
 35 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide primer ZC14742

 40 <400> 33
 tgcatttggt aggtgcggtt ga 22

 <210> 34
 <211> 211
 45 <212> PRT
 <213> Homo sapiens

 <400> 34

 50

 55

EP 1 373 508 B1

Met Val Pro Pro Pro Glu Asn Val Arg Met Asn Ser Val Asn Phe Lys
 1 5 10 15
 5 Asn Ile Leu Gln Trp Glu Ser Pro Ala Phe Ala Lys Gly Asn Leu Thr
 20 25 30
 Phe Thr Ala Gln Tyr Leu Ser Tyr Arg Ile Phe Gln Asp Lys Cys Met
 35 40 45
 10 Asn Thr Thr Leu Thr Glu Cys Asp Phe Ser Ser Leu Ser Lys Tyr Gly
 50 55 60
 Asp His Thr Leu Arg Val Arg Ala Glu Phe Ala Asp Glu His Ser Asp
 65 70 75 80
 15 Trp Val Asn Ile Thr Phe Cys Pro Val Asp Asp Thr Ile Ile Gly Pro
 85 90 95
 Pro Gly Met Gln Val Glu Val Leu Ala Asp Ser Leu His Met Arg Phe
 100 105 110
 20 Leu Ala Pro Lys Ile Glu Asn Glu Tyr Glu Thr Trp Thr Met Lys Asn
 115 120 125
 Val Tyr Asn Ser Trp Thr Tyr Asn Val Gln Tyr Trp Lys Asn Gly Thr
 130 135 140
 25 Asp Glu Lys Phe Gln Ile Thr Pro Gln Tyr Asp Phe Glu Val Leu Arg
 145 150 155 160
 Asn Leu Glu Pro Trp Thr Thr Tyr Cys Val Gln Val Arg Gly Phe Leu
 165 170 175
 30 Pro Asp Arg Asn Lys Ala Gly Glu Trp Ser Glu Pro Val Cys Glu Gln
 180 185 190
 Thr Thr His Asp Glu Thr Val
 195

35 <210> 36
 <211> 211
 <212> PRT
 <213> Homo sapiens

40 <400> 36

Ser Asp Ala His Gly Thr Glu Leu Pro Ser Pro Pro Ser Val Trp Phe
 45 1 5 10 15

50

55

EP 1 373 508 B1

atg cct aaa cat tgc ttt cta ggc ttc ctc atc agt ttc ttc ctt act 287
 Met Pro Lys His Cys Phe Leu Gly Phe Leu Ile Ser Phe Phe Leu Thr
 5 5 10 15

ggt gta gca gga act cag tca acg cat gag tct ctg aag cct cag agg 335
 Gly Val Ala Gly Thr Gln Ser Thr His Glu Ser Leu Lys Pro Gln Arg
 10 20 25 30

gta caa ttt cag tcc cga aat ttt cac aac att ttg caa tgg cag cct 383
 Val Gln Phe Gln Ser Arg Asn Phe His Asn Ile Leu Gln Trp Gln Pro
 15 35 40 45

ggg agg gca ctt act ggc aac agc agt gtc tat ttt gtg cag tac aaa 431
 Gly Arg Ala Leu Thr Gly Asn Ser Ser Val Tyr Phe Val Gln Tyr Lys
 20 50 55 60 65

ata tat gga cag aga caa tgg aaa aat aaa gaa gac tgt tgg ggt act 479
 Ile Tyr Gly Gln Arg Gln Trp Lys Asn Lys Glu Asp Cys Trp Gly Thr
 25 70 75 80

caa gaa ctc tct tgt gac ctt acc agt gaa acc tca gac ata cag gaa 527
 Gln Glu Leu Ser Cys Asp Leu Thr Ser Glu Thr Ser Asp Ile Gln Glu
 30 85 90 95

cct tat tac ggg agg gtg agg gcg gcc tcg gct ggg agc tac tca gaa 575
 Pro Tyr Tyr Gly Arg Val Arg Ala Ala Ser Ala Gly Ser Tyr Ser Glu
 35 100 105 110

tgg agc atg acg ccg cgg ttc act ccc tgg tgg gaa aca aaa ata gat 623
 Trp Ser Met Thr Pro Arg Phe Thr Pro Trp Trp Glu Thr Lys Ile Asp
 40 115 120 125

cct cca gtc atg aat ata acc caa gtc aat ggc tct ttg ttg gta att 671
 Pro Pro Val Met Asn Ile Thr Gln Val Asn Gly Ser Leu Leu Val Ile
 45 130 135 140 145

ctc cat gct cca aat ttà cca tat aga tac caa aag gaa aaa aat gta 719
 Leu His Ala Pro Asn Leu Pro Tyr Arg Tyr Gln Lys Glu Lys Asn Val
 50 150 155 160

tct ata gaa gat tac tat gaa cta cta tac cga gtt ttt ata att aac 767
 55

EP 1 373 508 B1

Ser Ile Glu Asp Tyr Tyr Glu Leu Leu Tyr Arg Val Phe Ile Ile Asn
165 170 175

5 aat tca cta gaa aag gag caa aag gtt tat gaa ggg gct cac aga gcg 815
Asn Ser Leu Glu Lys Glu Gln Lys Val Tyr Glu Gly Ala His Arg Ala
180 185 190

10 gtt gaa att gaa gct cta aca cca cac tcc agc tac tgt gta gtg gct 863
Val Glu Ile Glu Ala Leu Thr Pro His Ser Ser Tyr Cys Val Val Ala
195 200 205

15 gaa ata tat cag ccc atg tta gac aga aga agt cag aga agt gaa gag 911
Glu Ile Tyr Gln Pro Met Leu Asp Arg Arg Ser Gln Arg Ser Glu Glu
210 215 220 225

20 aga tgt gtg gaa att cca tga cttgtggaat ttggcattca gcaatgtgga 962
Arg Cys Val Glu Ile Pro *
230

25 aattctaaag ctccctgaga acaggatgac tcgtgtttga aggatcttat ttaaaattgt 1022
ttttgtatth tcttaaagca atattcactg ttacacctg gggacttctt tgtttatcca 1082
ttcttttatc ctttatatth catttgtaaa ctatattga acgacattcc .ccccgaaaaa 1142

30 ttgaaatgta aagatgaggc agagaataaa gtgttctatg aaattcagaa ctttatttct 1202
gaatgtaaca tccctaataa caaccttcat tcttctaata cagcaaaata aaaatttaac 1262
aaccaaggaa tagtatttaa gaaaatggtg aaataattht tttaaaatag cattacagac 1322
tgaggcggtc ctgaagcaat ggtttttcac tctcttattg agccaattaa attgacattg 1382

35 ctttgacaat ttaaaacttc tataaagggtg aatatttttc atacatttct attttatatg 1442
aatatactth ttatatatth attattatta aatatttcta cttaatgaat caaaattttg 1502
ttttaaagtc tactttatgt aaataagaac aggttttggg gaaaaaaatc ttatgatttc 1562
tggattgata tctgaattaa aactatcaac aacaaggaaa aaaaaaaaaa aaaaaa 1618

40 <210> 38
<211> 231
<212> PRT
<213> Homo sapiens

45 <400> 38

50 Met Met Pro Lys His Cys Phe Leu Gly Phe Leu Ile Ser Phe Phe Leu
1 5 10 15
Thr Gly Val Ala Gly Thr Gln Ser Thr His Glu Ser Leu Lys Pro Gln
20 25 30
55 Arg Val Gln Phe Gln Ser Arg Asn Phe His Asn Ile Leu Gln Trp Gln
35 40 45

EP 1 373 508 B1

Pro Gly Arg Ala Leu Thr Gly Asn Ser Ser Val Tyr Phe Val Gln Tyr
 50 55 60
 Lys Ile Tyr Gly Gln Arg Gln Trp Lys Asn Lys Glu Asp Cys Trp Gly
 5 65 70 75 80
 Thr Gln Glu Leu Ser Cys Asp Leu Thr Ser Glu Thr Ser Asp Ile Gln
 85 90 95
 Glu Pro Tyr Tyr Gly Arg Val Arg Ala Ala Ser Ala Gly Ser Tyr Ser
 10 100 105 110
 Glu Trp Ser Met Thr Pro Arg Phe Thr Pro Trp Trp Glu Thr Lys Ile
 115 120 125
 Asp Pro Pro Val Met Asn Ile Thr Gln Val Asn Gly Ser Leu Leu Val
 15 130 135 140
 Ile Leu His Ala Pro Asn Leu Pro Tyr Arg Tyr Gln Lys Glu Lys Asn
 145 150 155 160
 Val Ser Ile Glu Asp Tyr Tyr Glu Leu Leu Tyr Arg Val Phe Ile Ile
 20 165 170 175
 Asn Asn Ser Leu Glu Lys Glu Gln Lys Val Tyr Glu Gly Ala His Arg
 180 185 190
 Ala Val Glu Ile Glu Ala Leu Thr Pro His Ser Ser Tyr Cys Val Val
 25 195 200 205
 Ala Glu Ile Tyr Gln Pro Met Leu Asp Arg Arg Ser Gln Arg Ser Glu
 210 215 220
 Glu Arg Cys Val Glu Ile Pro
 30 225 230

<210> 39
 <211> 4
 35 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SXWS polypeptide motif

<221> VARIANT
 <222> (1)...(4)
 45 <223> Xaa = Any Amino Acid

<400> 39

Ser Xaa Trp Ser
 1

<210> 40
 <211> 18
 55 <212> DNA
 <213> Artificial Sequence

<220>

EP 1 373 508 B1

<223> Oligonucleotide primer ZC27713

<400> 40
agctgccttc ttcacttg 18

5

<210> 41
<211> 18
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Oligonucleotide primer ZC27714

<400> 41
ttgctctgcc tcttattc 18

15

<210> 42
<211> 1050
<212> DNA
<213> Mus musculus

20

<220>
<221> CDS
<222> (5)...(589)

25

<400> 42

aaca ggc tct cct ctc act tat caa ctt ttg aca ctt gtg cga tcg gtg 49
Gly Ser Pro Leu Thr Tyr Gln Leu Leu Thr Leu Val Arg Ser Val
1 5 10 15

30

atg gct gtc ctg cag aaa tct atg agt ttt tcc ctt atg ggg act ttg 97
Met Ala Val Leu Gln Lys Ser Met Ser Phe Ser Leu Met Gly Thr Leu
20 25 30

35

gcc gcc agc tgc ctg ctt ctc att gcc ctg tgg gcc cag gag gca aat 145
Ala Ala Ser Cys Leu Leu Leu Ile Ala Leu Trp Ala Gln Glu Ala Asn
35 40 45

40

gcg ctg ccc atc aac acc cgg tgc aag ctt gag gtg tcc aac ttc cag 193

45

50

55

EP 1 373 508 B1

Ala Leu Pro Ile Asn Thr Arg Cys Lys Leu Glu Val Ser Asn Phe Gln
50 55 60

5 cag ccg tac atc gtc aac cgc acc ttt atg ctg gcc aag gag gcc agc 241
Gln Pro Tyr Ile Val Asn Arg Thr Phe Met Leu Ala Lys Glu Ala Ser
65 70 75 .

10 ctt gca gat aac aac aca gac gtc cgg ctc atc ggg gag aaa ctg ttc 289
Leu Ala Asp Asn Asn Thr Asp Val Arg Leu Ile Gly Glu Lys Leu Phe
80 85 90 95

15 cga gga gtc agt gct aag gat cag tgc tac ctg atg aag cag gtg ctc 337
Arg Gly Val Ser Ala Lys Asp Gln Cys Tyr Leu Met Lys Gln Val Leu
100 105 110

20 aac ttc acc ctg gaa gac att ctg ctc ccc cag tca gac agg ttc cgg 385
Asn Phe Thr Leu Glu Asp Ile Leu Leu Pro Gln Ser Asp Arg Phe Arg
115 120 125

25 ccc tac atg cag gag gtg gtg cct ttc ctg acc aaa ctc agc aat cag 433
Pro Tyr Met Gln Glu Val Val Pro Phe Leu Thr Lys Leu Ser Asn Gln
130 135 140

30 ctc agc tcc tgt cac atc agt ggt gac gac cag aac atc cag aag aat 481
Leu Ser Ser Cys His Ile Ser Gly Asp Asp Gln Asn Ile Gln Lys Asn
145 150 155

35 gtc aga agg ctg aag gag aca gtg aaa aag ctt gga gag agc gga gag 529
Val Arg Arg Leu Lys Glu Thr Val Lys Lys Leu Gly Glu Ser Gly Glu
160 165 170 175

40 atc aaa gcg atc ggg gaa ctg gac ctg ctg ttt atg tct ctg aga aat 577
Ile Lys Ala Ile Gly Glu Leu Asp Leu Leu Phe Met Ser Leu Arg Asn
180 185 190

45 gct tgc gtc tga gcgagaagaa gctagaaaac gaagaactgc tccttctgac 629
Ala Cys Val *

50

cttctaataaa gaacaataag atccctgaat ggactttttt actaaaggaa agtgagaagc 689
taacgtccac catcattaga agatttcaca tgaacactgg ctgagttgaa agagaaaata 749
gtgtcaagtt gtccatgaga ccagaggtag acttgataac cacaaagatt cattgacaat 809
55 attttattgt cattgataat gcaacagaaa aagtatgtac tttaaaaaat tgtttgaaag 869

EP 1 373 508 B1

gaggttacct ctcattcctc tagaagaaaa gcctatgtaa cttcatttcc ataaccaata 929
 ctttatatat gtaagtttat ttattataag tatacathtt atttatgtca gtttattaat 989
 5 atggatttat ttatagaaaa attatctgat gttgatattt gagtataaag caaataatat 1049
 t 1050

<210> 43
 <211> 194
 10 <212> PRT
 <213> Mus musculus

<400> 43
 15 Gly Ser Pro Leu Thr Tyr Gln Leu Leu Thr Leu Val Arg Ser Val Met
 1 5 10 15
 Ala Val Leu Gln Lys Ser Met Ser Phe Ser Leu Met Gly Thr Leu Ala
 20 20 25 30
 Ala Ser Cys Leu Leu Leu Ile Ala Leu Trp Ala Gln Glu Ala Asn Ala
 35 40 45
 Leu Pro Ile Asn Thr Arg Cys Lys Leu Glu Val Ser Asn Phe Gln Gln
 25 50 55 60
 Pro Tyr Ile Val Asn Arg Thr Phe Met Leu Ala Lys Glu Ala Ser Leu
 65 70 75 80
 Ala Asp Asn Asn Thr Asp Val Arg Leu Ile Gly Glu Lys Leu Phe Arg
 30 85 90 95
 Gly Val Ser Ala Lys Asp Gln Cys Tyr Leu Met Lys Gln Val Leu Asn
 100 105 110
 Phe Thr Leu Glu Asp Ile Leu Leu Pro Gln Ser Asp Arg Phe Arg Pro
 35 115 120 125
 Tyr Met Gln Glu Val Val Pro Phe Leu Thr Lys Leu Ser Asn Gln Leu
 130 135 140
 Ser Ser Cys His Ile Ser Gly Asp Asp Gln Asn Ile Gln Lys Asn Val
 40 145 150 155 160
 Arg Arg Leu Lys Glu Thr Val Lys Lys Leu Gly Glu Ser Gly Glu Ile
 165 170 175
 Lys Ala Ile Gly Glu Leu Asp Leu Leu Phe Met Ser Leu Arg Asn Ala
 45 180 185 190
 Cys Val

<210> 44
 50 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 55 <223> Oligonucleotide primer ZC39289

<400> 44
 tccgaggagt caatgctaag 20

EP 1 373 508 B1

<210> 45
 <211> 20
 <212> DNA
 <213> Artificial Sequence

5

<220>
 <223> Oligonucleotide primer ZC39280

<400> 45
 tccaagcttt ttcaactgtct 20

10

<210> 46
 <211> 684
 <212> DNA
 <213> Homo Sapiens

15

<400> 46

20	atgaggacgc tgctgacat cttgactgtg ggatccctgg ctgctcacgc ccctgaggac	60
	ccctcggatc tgctccagca cgtgaaattc cagtccagca actttgaaaa catcctgacg	120
	tgggacagcg ggccagaggg caccccagac acgggtctaca gcatcgagta taagacgtac	180
	ggagagaggg actgggtggc aaagaagggc tgtcagcggg tcacccggaa gtcctgcaac	240
25	ctgacggtgg agacgggcaa cctcacggag ctctactatg ccagggtcac cgctgtcagt	300
	gcgggaggcc ggtcagccac caagatgact gacaggttca gctctctgca gcacactacc	360
	ctcaagccac ctgatgtgac ctgtatctcc aaagtgagat cgattcagat gattgttcat	420
	cctaccccca cgccaatccg tgcagggcag ggccaccggc taaccctgga agacatcttc	480
30	catgacctgt tctaccactt agagctccag gtcaaccgca cctaccaa at gcaccttggg	540
	gggaagcaga gagaatatga gttcttcggc ctgacccttg acacagagtt ccttqqcacc	600
	atcatgattt gcgttccac ctgggccaag gagagtgcc cctacatgtg ccgagtgaag	660
	acactgccag accggacatg gacc	684

35

<210> 47
 <211> 660
 <212> DNA
 <213> Homo Sapiens

40

<400> 47

45	atggcgtgga gtcttgggag ctggctgggt ggctgcctgc tgggtgcagc attgggaatg	60
----	-------------------------------------------------------------------	----

45

50

55

EP 1 373 508 B1

5
 10
 15
 20
 25

gtaccacctc	ccgaaaatgt	cagaatgaat	tctgttaatt	tcaagaacat	tctacagtgg	120
gagtcacctg	cttttgccaa	agggaacctg	actttcacag	ctcagtacct	aagttatagg	180
atattccaag	ataaatgcat	gaatactacc	ttgacggaat	gtgatttctc	aagtccttcc	240
aagtatggtg	accacacctt	gagagtcagg	gctgaatttg	cagatgagca	ttcagactgg	300
gtaaacaatca	ccttctgtcc	tgtggatgac	accattattg	gacccccctgg	aatgcaagta	360
gaagtacttg	atgattcttt	acatatgcgt	ttcttagccc	ctaaaattga	gaatgaatac	420
gaaacttgga	ctatgaagaa	tgtgtataac	tcatggactt	ataatgtgca	atactggaaa	480
aacggtactg	atgaaaagtt	tcaaattact	ccccagtatg	actttgaggt	cctcagaaac	540
ctggagccat	ggacaactta	ttgtgttcaa	gttcgagggg	ttcttcctga	tcggaacaaa	600
gctgggggaat	ggagtgagcc	tgtctgtgag	caaacaaccc	atgacgaaac	ggtccccctcc	660

<210> 48

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Gly-Ser spacer peptide

<400> 48

Gly Ser Gly Ser Gly Ser Gly Ser

1

5

30 <210> 49

<211> 70

<212> DNA

<213> Artificial Sequence

35 <220>

<223> Oligonucleotide Primer ZC39335

<400> 49

40 atcggaaattc gcagaagcca tgaggacgct gctgaccatc ttgactgtgg ggtcccctggc 60
 tgctcacgcc 70

45 <210> 50

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

50 <223> Oligonucleotide Primer ZC39434

<400> 50

cagtgatcc tggcagtgct ttactcggc a 31

55 <210> 51

<211> 37

<212> DNA

<213> Artificial Sequence

EP 1 373 508 B1

<220>
<223> Oligonucleotide Primer ZC39319

5 <400> 51
atcggaa⁵tc gcagaagcca tggcgtggag ccttggg 37

<210> 52
<211> 28
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Oligonucleotide Primer ZC39325

15 <400> 52
cagtggatcc ggaggggacc gtttcg¹⁵tc 28

<210> 53
<211> 16
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide Primer ZC39776

25 <400> 53
gggccc²⁵gcta gcacct 16

<210> 54
<211> 16
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide Primer ZC39777

35 <400> 54
gggtgatccg ctggca 16

40 <210> 55
<211> 36
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Oligonucleotide Primer ZC38752

50 <400> 55
ccagccactt tctctctccg tatttctat attcca 36

<210> 56
<211> 39
<212> DNA
55 <213> Artificial Sequence

<220>
<223> Oligonucleotide Primer ZC40940

EP 1 373 508 B1

<400> 56
 ttggtccctc gtggaagcac tcagtcaacg catgagtct 39

5 <210> 57
 <211> 39
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Oligonucleotide Primer ZC40943

<400> 57
 atgcattcta gatcatggaa ttccacaca tctctctc 39

15 <210> 58
 <211> 57
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Oligonucleotide Primer ZC40942

<400> 58
 atgcattccg gagattataa ggatgatgat gataagttgg tccctcgtgg aagcact 57

25 <210> 59
 <211> 10
 <212> PRT
 <213> Artificial Sequence

30 <220>
 <223> Glu-Glu (CEE) Tag amino acid sequence with spacer

35 <400> 59

Gly	Ser	Gly	Gly	Glu	Tyr	Met	Pro	Met	Glu
1				5					10

40 <210> 60
 <211> 10
 <212> PRT
 <213> Artificial Sequence

45 <220>
 <223> C-terminal HIS tag, with spacer

<400> 60

50 <400> 60

Gly	Ser	Gly	Gly	His	His	His	His	His	His
1				5					10

55 <210> 61
 <211> 484
 <212> PRT
 <213> Artificial Sequence

EP 1 373 508 B1

<220>

<223> human zcytor11/Fc4-CEE fusion polypeptide

<400> 61

5

Met Arg Thr Leu Leu Thr Ile Leu Thr Val Gly Ser Leu Ala Ala His
1 5 10 15

10

Ala Pro Glu Asp Pro Ser Asp Leu Leu Gln His Val Lys Phe Gln Ser
20 25 30

15

20

25

30

35

40

45

50

55

EP 1 373 508 B1

Ser Asn Phe Glu Asn Ile Leu Thr Trp Asp Ser Gly Pro Glu Gly Thr
 35 40 45
 5 Pro Asp Thr Val Tyr Ser Ile Glu Tyr Lys Thr Tyr Gly Glu Arg Asp
 50 55 60
 Trp Val Ala Lys Lys Gly Cys Gln Arg Ile Thr Arg Lys Ser Cys Asn
 65 70 75 80
 10 Leu Thr Val Glu Thr Gly Asn Leu Thr Glu Leu Tyr Tyr Ala Arg Val
 85 90 95
 Thr Ala Val Ser Ala Gly Gly Arg Ser Ala Thr Lys Met Thr Asp Arg
 100 105 110
 15 Phe Ser Ser Leu Gln His Thr Thr Leu Lys Pro Pro Asp Val Thr Cys
 115 120 125
 Ile Ser Lys Val Arg Ser Ile Gln Met Ile Val His Pro Thr Pro Thr
 130 135 140
 20 Pro Ile Arg Ala Gly Asp Gly His Arg Leu Thr Leu Glu Asp Ile Phe
 145 150 155 160
 His Asp Leu Phe Tyr His Leu Glu Leu Gln Val Asn Arg Thr Tyr Gln
 165 170 175
 25 Met His Leu Gly Gly Lys Gln Arg Glu Tyr Glu Phe Phe Gly Leu Thr
 180 185 190
 Pro Asp Thr Glu Phe Leu Gly Thr Ile Met Ile Cys Val Pro Thr Trp
 195 200 205
 30 Ala Lys Glu Ser Ala Pro Tyr Met Cys Arg Val Lys Thr Leu Pro Asp
 210 215 220
 Arg Thr Trp Thr Gly Ser Gly Ser Gly Ser Gly Ser Glu Pro Arg Ser
 225 230 235 240
 35 Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu
 245 250 255
 Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 260 265 270
 40 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 275 280 285
 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 290 295 300
 45 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 305 310 315 320
 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 325 330 335
 50 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser Ser
 340 345 350
 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 355 360 365
 55

EP 1 373 508 B1

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 370 375 380
 5 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 385 390 395 400
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Tyr Lys Thr Thr Pro
 405 410 415
 10 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 420 425 430
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 435 440 445
 15 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 450 455 460
 Ser Pro Gly Lys Leu Val Pro Arg Gly Ser Gly Ser Gly Gly Glu Tyr
 465 470 475 480
 20 Met Pro Met Glu

<210> 62

<211> 476

<212> PRT

25 <213> Artificial Sequence

<220>

<223> human CRF2-4/Fc4-CHIS fusion polypeptide

30 <400> 62

Met Ala Trp Ser Leu Gly Ser Trp Leu Gly Gly Cys Leu Leu Val Ser
 1 5 10 15
 35 Ala Leu Gly Met Val Pro Pro Pro Glu Asn Val Arg Met Asn Ser Val
 20 25 30
 Asn Phe Lys Asn Ile Leu Gln Trp Glu Ser Pro Ala Phe Ala Lys Gly
 35 40 45
 40 Asn Leu Thr Phe Thr Ala Gln Tyr Leu Ser Tyr Arg Ile Phe Gln Asp
 50 55 60
 Lys Cys Met Asn Thr Thr Leu Thr Glu Cys Asp Phe Ser Ser Leu Ser
 65 70 75 80
 45 Lys Tyr Gly Asp His Thr Leu Arg Val Arg Ala Glu Phe Ala Asp Glu
 85 90 95
 50 His Ser Asp Trp Val Asn Ile Thr Phe Cys Pro Val Asp Asp Thr Ile
 100 105 110
 Ile Gly Pro Pro Gly Met Gln Val Glu Val Leu Asp Asp Ser Leu His
 115 120 125

55

EP 1 373 508 B1

Met Arg Phe Leu Ala Pro Lys Ile Glu Asn Glu Tyr Glu Thr Trp Thr
 130 135 140
 5 Met Lys Asn Val Tyr Asn Ser Trp Thr Tyr Asn Val Gln Tyr Trp Lys
 145 150 155 160
 Asn Gly Thr Asp Glu Lys Phe Gln Ile Thr Pro Gln Tyr Asp Phe Glu
 165 170 175
 10 Val Leu Arg Asn Leu Glu Pro Trp Thr Thr Tyr Cys Val Gln Val Arg
 180 185 190
 Gly Phe Leu Pro Asp Arg Asn Lys Ala Gly Glu Trp Ser Glu Pro Val
 195 200 205
 15 Cys Glu Gln Thr Thr His Asp Glu Thr Val Pro Ser Gly Ser Gly Ser
 210 215 220
 Gly Ser Gly Ser Glu Pro Arg Ser Ser Asp Lys Thr His Thr Cys Pro
 225 230 235 240
 20 Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe
 245 250 255
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 260 265 270
 25 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 275 280 285
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 290 295 300
 30 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 305 310 315 320
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 325 330 335
 35 Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
 340 345 350
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 355 360 365
 40 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 370 375 380
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 385 390 395 400
 45 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 405 410 415
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 420 425 430
 50 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 435 440 445
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Leu Val Pro Arg
 450 455 460
 55

Gly Ser Gly Ser Gly Gly His His His His His His
 465 470 475

5

Claims

1. An isolated polypeptide consisting of an amino acid sequence from the group of:
- 10 (a) amino acid residues 28 to 127 of SEQ ID NO:2;
 (b) amino acid residues 132 to 231 of SEQ ID NO:2;
 (c) amino acid residues 28 to 231 of SEQ ID NO:2;
 (d) amino acid residues 23 to 230 of SEQ ID NO:2;
 (e) amino acid residues 23 to 231 of SEQ ID NO:2;
 15 (f) amino acid residues 22 to 230 of SEQ ID NO:2;
 (g) amino acid residues 32-123 of SEQ ID NO:2;
 (h) amino acid residues 132-230 of SEQ ID NO:2;
 (i) amino acid residues 32-230 of SEQ ID NO:2; and
 (j) amino acid residues 28-230 of SEQ ID NO:2.
- 20 2. An isolated polypeptide according to Claim 1, wherein said polypeptide consists of amino acid residues 28 to 231 of SEQ ID NO: 2 or amino acid residues 28 to 230 of SEQ ID NO: 2.
3. A fusion protein consisting of a first polypeptide and a second polypeptide, wherein said first polypeptide consists of the polypeptide of Claim 1 or 2, and wherein said second polypeptide is selected from the group consisting of:
- 25 (i) a secretory signal sequence from another secreted protein;
 (ii) an immunoglobulin heavy chain constant region;
 (iii) a dimerizing protein;
 30 (iv) a peptide tag;
 (v) a glutathione S-transferase polypeptide;
 (vi) a maltose-binding protein polypeptide; and
 (vii) the C-terminal domain of a truncated Protein A.
- 35 4. The fusion protein of Claim 3, wherein the second polypeptide is an Fc fragment.
5. An isolated soluble cytokine receptor polypeptide consisting of a soluble cytokine receptor subunit and an affinity tag, chemical moiety, toxin, or label;
 wherein the soluble cytokine receptor subunit consists of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 231, or a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid
 40 28 to 230;
 wherein said soluble cytokine receptor polypeptide forms a homodimeric, heterodimeric or multimeric receptor complex;
 and wherein said soluble cytokine receptor polypeptide binds IL-TIF or antagonizes IL-TIF activity.
- 45 6. An isolated heterodimeric or multimeric soluble receptor complex consisting of soluble receptor subunits, wherein at least one of the soluble receptor subunits consists of amino acid residues 28-231 of SEQ ID NO:2 or amino acid residues 28-230 of SEQ ID NO:2.
- 50 7. An isolated heterodimeric or multimeric soluble receptor complex according to Claim 6, wherein one of said soluble receptor subunits is a soluble Class I or Class II cytokine receptor polypeptide.
8. An isolated heterodimeric or multimeric soluble receptor complex according to Claim 7, wherein said soluble Class I Or Class II cytokine receptor polypeptide consists of the soluble CRF2-4 receptor polypeptide of SEQ ID NO:35, the soluble IL-10 receptor polypeptide of SEQ ID NO:36, or the soluble zcytor11 receptor polypeptide of SEQ ID
 55 NO:34.
9. A method of producing an antibody to a soluble cytokine receptor polypeptide, wherein the inoculated polypeptide

consists of a soluble cytokine receptor polypeptide selected from the group of:

- (a) a polypeptide consisting of amino acids 28 to 231 of SEQ ID NO:2 or amino acids 28 to 230 of SEQ ID NO:2;
- (b) a polypeptide consisting of amino acids 28 to 231 of SEQ ID NO:2 or amino acids 28 to 230 of SEQ ID NO:2 complexed with a soluble Class I or Class II cytokine receptor polypeptide;
- (c) a polypeptide complex of (b) wherein the soluble Class I or Class II cytokine receptor polypeptide consists of the soluble CRF2-4 receptor polypeptide of SEQ ID NO:35; and
- (d) a polypeptide complex of (b) wherein the soluble Class I or Class II cytokine receptor polypeptide consists of the soluble IL-10 receptor polypeptide of SEQ ID NO:36;

wherein an antibody is produced against the inoculated polypeptide; and isolating the antibody from a non-human animal.

10. A soluble cytokine receptor polypeptide for use in a method of producing an antibody in a non-human animal; wherein the soluble cytokine receptor polypeptide is selected from the group consisting of:

- (a) a polypeptide consisting of amino acids 28 to 231 of SEQ ID NO: 2 or amino acids 28 to 230 of SEQ ID NO: 2;
- (b) a polypeptide consisting of amino acids 28 to 231 of SEQ ID NO: 2 or amino acids 28 to 230 of SEQ ID NO: 2 complexed with a soluble Class I or Class II cytokine receptor polypeptide;
- (c) a polypeptide complex of (b) wherein the soluble Class I or Class II cytokine receptor polypeptide consists of the soluble CRF2-4 receptor polypeptide of SEQ ID NO: 35; and
- (d) a polypeptide complex of (b) wherein the soluble Class I or Class II cytokine receptor polypeptide consists of the soluble IL-10 receptor polypeptide of SEQ ID NO: 36.

11. An isolated nucleic acid molecule, selected from:

- (a) a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:37, or the complement thereof;
- (b) a nucleic acid molecule consisting of:

- (i) nucleotides 64-693 of SEQ ID NO: 1;
- (ii) nucleotides 67-693 of SEQ ID NO: 1;
- (iii) nucleotides 82-693 of SEQ ID NO: 1; or
- (iv) nucleotides 94-693 of SEQ ID NO:1;

or the complement thereof; or

- (c) a nucleic acid molecule consisting of:

- (v) nucleotides 94-369 of SEQ ID NO: 1;
- (vi) nucleotides 394-690 of SEQ ID NO: 1;
- (vii) nucleotides 94-690 of SEQ ID NO: 1; or
- (viii) nucleotides 82-690 of SEQ ID NO: 1.

12. The isolated nucleic acid molecule of Claim 11, consisting of:

- (i) nucleotides 64 to 693 of SEQ ID NO:1,
- (ii) nucleotides 82 to 693 of SEQ ID NO:1, or
- (iii) nucleotides 82-690 of SEQ ID NO: 1.

13. An isolated polynucleotide that encodes a soluble cytokine receptor subunit consisting of the sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 231 or the sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 230.

14. An isolated polynucleotide that encodes a soluble cytokine receptor polypeptide, wherein said soluble cytokine receptor polypeptide consists of:

- (i) soluble receptor subunit consisting of the sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 231 or the sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 230; and

(ii) a soluble Class I or Class II cytokine receptor, an intracellular domain, and/ or an affinity tag;

wherein said soluble cytokine receptor polypeptide forms a homodimeric, heterodimeric or multimeric receptor complex;

and wherein said soluble cytokine receptor polypeptide binds IL-TIF or antagonizes IL-TIF activity.

15. An isolated polynucleotide according to Claim 14, wherein said soluble Class I or Class II cytokine receptor consists of the soluble CRF2-4 receptor polypeptide of SEQ ID NO:35, the soluble IL-10 receptor polypeptide of SEQ ID NO:36, or the soluble zcytor11 receptor polypeptide of SEQ ID NO:34.

16. An expression vector consisting of a transcription promoter, a DNA segment consisting of the nucleic acid molecule of Claim 12, and a transcription terminator; wherein the promoter is operably linked with the isolated nucleic acid molecule of Claim 12, and wherein the DNA segment is operably linked with the transcription terminator.

17. An expression vector consisting of:

(i) a first transcription promoter, a first DNA segment consisting of the nucleic acid molecule of Claim 12, and a first transcription terminator; and

(ii) a second transcription promoter; a second DNA segment encoding a soluble Class I or Class II cytokine receptor polypeptide; and a second transcription terminator.

18. A pair of independent expression vectors, consisting of

(i) a first expression vector according to Claim 16; and

(ii) a second expression vector consisting of the following operably linked elements: a second transcription promoter; a second DNA segment encoding a soluble Class I or Class II cytokine receptor polypeptide; and a transcription terminator.

19. An expression vector consisting of:

(i) a first transcription promoter, a first DNA segment consisting of the nucleic acid molecule of Claim 12 operably linked to a secretory signal sequence, and a first transcription terminator; and

(ii) a second transcription promoter; a second DNA segment encoding a soluble Class I or Class II cytokine receptor polypeptide operably linked to a secretory signal sequence; and a second transcription terminator.

20. A pair of independent expression vectors, consisting of

(i) a first expression vector consisting of the following operably linked elements: a transcription promoter, a DNA segment consisting of the nucleic acid molecule of Claim 12 operably linked to a secretory signal sequence, and a transcription terminator; and

(ii) a second expression vector consisting of the following operably linked elements: a second transcription promoter; a second DNA segment encoding a soluble Class I or Class II cytokine receptor polypeptide operably linked to a secretory signal sequence; and a transcription terminator.

21. An expression vector according to Claim 17, or a pair of expression vectors according to Claim 18, wherein the second DNA segment encodes a polypeptide consisting of the soluble CRF2-4 receptor polypeptide of SEQ ID NO:35, the soluble IL-10 receptor polypeptide of SEQ ID NO:36, or the soluble zcytor11 receptor polypeptide of SEQ ID NO:34.

22. A DNA construct encoding a fusion protein consisting of:

a first DNA segment encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 231 or a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 28 to 230; and

at least one other DNA segment encoding a soluble Class I or Class II cytokine receptor polypeptide, wherein the first and other DNA segments are connected in-frame; and wherein the first and other DNA segments encode the fusion protein.

23. A DNA construct according to Claim 22, wherein said at least one other DNA segment encodes a polypeptide consisting of the soluble CRF2-4 receptor polypeptide of SEQ ID NO:35, the soluble IL-10 receptor polypeptide of SEQ ID NO:36, or the soluble zcytor11 receptor polypeptide of SEQ ID NO:34.
- 5 24. An expression vector consisting of the following operably linked elements:
- a transcription promoter;
 - a DNA construct according to Claim 22; and
 - 10 a transcription terminator,
- wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.
- 15 25. A cultured cell comprising an expression vector according to Claim 24, wherein the cell expresses a polypeptide encoded by the DNA construct.
- 20 26. A recombinant host cell comprising the expression vector of Claim 16, wherein the host cell is from the group of bacterium, yeast cell, fungal cell, insect cell, mammalian cell, and plant cell.
27. A cultured cell comprising an expression vector according to Claim 17, or a pair of expression vectors according to Claim 18, wherein the cell expresses the polypeptides encoded by the DNA segments.
28. A cultured cell according to Claim 27, comprising a pair of expression vectors according to Claim 18, wherein the independent expression vectors are co-transfected into the cell, and cell expresses the polypeptides encoded by the DNA segments.
- 25 29. A cultured cell according to Claim 27, wherein the cell expresses a heterodimeric or multimeric soluble receptor polypeptide encoded by the DNA segments.
- 30 30. A cell according to Claim 27, wherein the cell secretes a soluble cytokine receptor polypeptide heterodimer or multimeric complex.
31. A cell according to Claim 30, wherein said soluble cytokine receptor polypeptide heterodimeric or multimeric complex binds IL-TIF or antagonizes IL-TIF activity.
- 35 32. A method of producing a protein, the method comprising culturing recombinant host cells that comprise the expression vector of Claim 16, and that produce the protein.
33. The method of Claim 32, further comprising the step of isolating the protein from the cultured recombinant host cells.
- 40 34. A method of producing a fusion protein comprising: culturing a cell according to Claim 25; and isolating the polypeptide produced by the cell.
35. A method of producing a soluble cytokine receptor polypeptide that forms a heterodimeric or multimeric complex, the method comprising: culturing a cell according to Claim 27; and isolating the soluble receptor polypeptides produced by the cell.
- 45 36. An *in vitro* method for inhibiting IL-TIF-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors, comprising culturing bone marrow or peripheral blood cells with an amount of a soluble cytokine receptor polypeptide consisting of amino acids 28 to 231 of SEQ ID NO:2 or amino acids 28 to 230 of SEQ ID NO:2 sufficient to reduce proliferation or differentiation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble cytokine receptor.
- 50 37. The method of Claim 36, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.
- 55 38. The method of Claim 37, wherein the lymphoid cells are macrophages or T cells.
39. Use of a polypeptide consisting of amino acids 28-231 of SEQ ID NO:2 or amino acids 28-230 of SEQ ID NO:2, for

the manufacture of a medicament for reducing IL-TIF-induced inflammation.

- 5 40. Use of the isolated polypeptide of Claim 2 in an acceptable pharmaceutical vehicle for the manufacture of a medicament for treating inflammation in a mammal by suppressing an inflammatory response; wherein said medicament is for administration as part of a method comprising:

10 (1) determining a pre-administration level of serum amyloid A protein;
(2) determining a post administration level of serum amyloid A protein; and
(3) comparing the level of serum amyloid A protein in step (1) to the level of serum amyloid A protein in step (2), wherein a lack of increase or a decrease in serum amyloid A protein level is indicative of suppressing an inflammatory response.

- 15 41. Use of an antagonist of IL-TIF for the manufacture of a medicament for treating an inflammatory disease in which IL-TIF or serum amyloid A plays a role in a mammal, wherein the antagonist is a polypeptide according to Claim 1.

42. Use according to Claim 41, wherein the disease is a chronic inflammatory disease.

43. Use according to Claim 42, wherein the chronic inflammatory disease is selected from the group of:

20 (a) inflammatory bowel disease;
(b) ulcerative colitis;
(c) Crohn's disease;
(d) arthritis; and
(e) psoriasis.

- 25 44. Use according to Claim 41, wherein the disease is an acute inflammatory disease.

45. Use according to Claim 44, wherein the acute inflammatory disease is selected from the group of:

30 (a) endotoxemia;
(b) septicemia;
(c) toxic shock syndrome; and
(d) infectious disease.

35 **Patentansprüche**

1. Isoliertes Polypeptid, das aus einer Aminosäuresequenz aus der folgenden Gruppe besteht:

40 (a) Aminosäurereste 28 bis 127 von SEQ ID Nr.: 2;
(b) Aminosäurereste 132 bis 231 von SEQ ID Nr.: 2;
(c) Aminosäurereste 28 bis 231 von SEQ ID Nr.: 2;
(d) Aminosäurereste 23 bis 230 von SEQ ID Nr.: 2;
(e) Aminosäurereste 23 bis 231 von SEQ ID Nr.: 2;
45 (f) Aminosäurereste 22 bis 230 von SEQ ID Nr.: 2;
(g) Aminosäurereste 32 bis 123 von SEQ ID Nr.: 2;
(h) Aminosäurereste 132 bis 230 von SEQ ID Nr.: 2;
(i) Aminosäurereste 32 bis 230 von SEQ ID Nr.: 2; und
(j) Aminosäurereste 28 bis 230 von SEQ ID Nr.: 2.

- 50 2. Isoliertes Polypeptid nach Anspruch 1, wobei das Polypeptid aus Aminosäureresten 28 bis 231 von SEQ ID Nr.: 2 oder Aminosäureresten 28 bis 230 von SEQ ID Nr.: 2 besteht.

- 55 3. Fusionsprotein, das aus einem ersten Polypeptid und einem zweiten Polypeptid besteht, wobei das erste Polypeptid aus dem Polypeptid nach Anspruch 1 oder 2 besteht, und wobei das zweite Polypeptid aus der Gruppe ausgewählt ist, die aus den folgenden Komponenten besteht:

(i) einer sekretorischen Signalsequenz von einem anderen sezernierten Protein;

- (ii) einer konstanten Region einer schweren Immunglobulinkette;
- (iii) einem dimerisierenden Protein;
- (iv) einem Peptidanhang;
- (v) einem Glutathion-S-Transferase-Polypeptid;
- (vi) einem maltosebindenden Proteinpolypeptid; und
- (vii) der C-terminalen Domäne eines trunkierten (verkürzten) Proteins A.

4. Fusionsprotein nach Anspruch 3, wobei das zweite Polypeptid ein Fc-Fragment ist.

5. Isoliertes lösliches Cytokinrezeptor-Polypeptid, das aus einer löslichen Cytokinrezeptor-Untereinheit und einem Affinitätsanhang, einer chemischen Komponente, einem Toxin oder Marker besteht; wobei die lösliche Cytokinrezeptor-Untereinheit aus einer Sequenz von Aminosäureresten besteht, wie in SEQ ID Nr.: 2 von Aminosäure 28 bis 231 dargestellt, oder aus einer Sequenz von Aminosäureresten, wie in SEQ ID Nr.: 2 von Aminosäure 28 bis 230 dargestellt; wobei das lösliche Cytokinrezeptor-Polypeptid einen homodimeren, heterodimeren oder multimeren Rezeptorkomplex bildet; und wobei das lösliche Cytokinrezeptor-Polypeptid IL-TIF bindet oder der IL-TIF-Aktivität entgegenwirkt.

6. Isolierter heterodimerer oder multimerer löslicher Rezeptorkomplex, der aus löslichen Rezeptor-Untereinheiten besteht, wobei mindestens eine der löslichen Rezeptor-Untereinheiten aus Aminosäureresten 28-231 von SEQ ID Nr.: 2 oder Aminosäureresten 28-230 von SEQ ID Nr.: 2 besteht.

7. Isolierter heterodimerer oder multimerer löslicher Rezeptorkomplex nach Anspruch 6, wobei eine der löslichen Rezeptor-Untereinheiten ein lösliches Cytokinrezeptor-Polypeptid der Klasse I oder Klasse II ist.

8. Isolierter heterodimerer oder multimerer löslicher Rezeptorkomplex nach Anspruch 7, wobei das lösliche Cytokinrezeptor-Polypeptid der Klasse I oder Klasse II aus dem löslichen Rezeptorpolypeptid CRF2-4 gemäß SEQ ID Nr.: 35, dem löslichen Rezeptorpolypeptid IL-10 gemäß SEQ ID Nr.: 36 oder dem löslichen Rezeptorpolypeptid zcytor11 gemäß SEQ ID Nr.: 34 besteht.

9. Verfahren zur Herstellung eines Antikörpers zu einem löslichen Cytokinrezeptor-Polypeptid, wobei das überimpfte Polypeptid aus einem löslichen Cytokinrezeptor-Polypeptid besteht, das aus der folgenden Gruppe ausgewählt ist:

- (a) einem Polypeptid, das aus den Aminosäuren 28 bis 231 von SEQ ID Nr.: 2 oder den Aminosäuren 28 bis 230 von SEQ ID Nr.: 2 besteht;
- (b) einem Polypeptid, das aus den Aminosäuren 28 bis 231 von SEQ ID Nr.: 2 oder den Aminosäuren 28 bis 230 von SEQ ID Nr.: 2 besteht, die mit einem löslichen Cytokinrezeptor-Polypeptid der Klasse I oder Klasse II komplexiert sind;
- (c) einem Polypeptid-Komplex gemäß (b), wobei das lösliche Cytokinrezeptor-Polypeptid der Klasse I oder Klasse II aus dem löslichen Rezeptorpolypeptid CRF2-4 gemäß SEQ ID Nr.: 35 besteht; und
- (d) einem Polypeptid-Komplex gemäß (b), wobei das lösliche Cytokinrezeptor-Polypeptid der Klasse I oder Klasse II aus dem löslichen Rezeptorpolypeptid IL-10 gemäß SEQ ID Nr.: 36 besteht;

wobei ein Antikörper gegen das überimpfte Polypeptid gebildet wird; und Isolieren des Antikörpers aus einem nichthumanen Tier.

10. Lösliches Cytokinrezeptor-Polypeptid zur Verwendung in einem Verfahren zur Erzeugung eines Antikörpers in einem nichthumanen Tier; wobei das lösliche Cytokinrezeptor-Polypeptid aus der Gruppe ausgewählt ist, die aus den folgenden besteht:

- (a) einem Polypeptid, das aus den Aminosäuren 28 bis 231 von SEQ ID Nr.: 2 oder den Aminosäuren 28 bis 230 von SEQ ID Nr.: 2 besteht;
- (b) einem Polypeptid, das aus den Aminosäuren 28 bis 231 von SEQ ID Nr.: 2 oder den Aminosäuren 28 bis 230 von SEQ ID Nr.: 2 besteht, die mit einem löslichen Cytokinrezeptor-Polypeptid der Klasse I oder Klasse II komplexiert sind;
- (c) einem Polypeptid-Komplex gemäß (b), wobei das lösliche Cytokinrezeptor-Polypeptid der Klasse I oder Klasse II aus dem löslichen Rezeptorpolypeptid CRF2-4 gemäß SEQ ID Nr.: 35 besteht; und
- (d) einem Polypeptid-Komplex gemäß (b), wobei das lösliche Cytokinrezeptor-Polypeptid der Klasse I oder

EP 1 373 508 B1

Klasse II aus dem löslichen Rezeptorpolypeptid IL-10 gemäß SEQ ID Nr.: 36 besteht.

11. Isoliertes Nucleinsäuremolekül, das unter den folgenden ausgewählt ist:

- 5 (a) einem Nucleinsäuremolekül, das aus der Nucleotidsequenz gemäß SEQ ID Nr.: 37 oder deren Komplement besteht;

(b) einem Nucleinsäuremolekül, bestehend aus:

- 10 (i) den Nucleotiden 64-693 von SEQ ID Nr.: 1;
(ii) den Nucleotiden 67-693 von SEQ ID Nr.: 1;
(iii) den Nucleotiden 82-693 von SEQ ID Nr.: 1; oder
(iv) den Nucleotiden 94-693 von SEQ ID Nr.: 1;

oder dem Komplement davon; oder

15 (c) einem Nucleinsäuremolekül, bestehend aus:

- (v) den Nucleotiden 94-369 von SEQ ID Nr.: 1;
(vi) den Nucleotiden 394-690 von SEQ ID Nr.: 1;
(vii) den Nucleotiden 94-690 von SEQ ID Nr.: 1; oder
20 (viii) den Nucleotiden 82-690 von SEQ ID Nr.: 1.

12. Isoliertes Nucleinsäuremolekül nach Anspruch 11, bestehend aus:

- 25 (i) den Nucleotiden 64-693 von SEQ ID Nr.: 1;
(ii) den Nucleotiden 82-693 von SEQ ID Nr.: 1; oder
(iii) den Nucleotiden 82-690 von SEQ ID Nr.: 1.

13. Isoliertes Polynucleotid, das für eine lösliche Cytokinrezeptor-Untereinheit codiert, die aus der in SEQ ID Nr.: 2 von Aminosäure 28 bis 231 dargestellten Sequenz von Aminosäureresten oder der in SEQ ID Nr.: 2 von Aminosäure 28 bis 230 dargestellten Sequenz von Aminosäureresten besteht.

14. Isoliertes Polynucleotid, das für ein lösliches Cytokinrezeptor-Polypeptid codiert, wobei das lösliche Cytokinrezeptor-Polypeptid aus den folgenden Komponenten besteht:

- 35 (i) einer löslichen Rezeptor-Untereinheit, die aus der in SEQ ID Nr.: 2 von Aminosäure 28 bis 231 dargestellten Sequenz von Aminosäureresten oder der in SEQ ID Nr.: 2 von Aminosäure 28 bis 230 dargestellten Sequenz von Aminosäureresten besteht; und
(ii) einem löslichen Cytokinrezeptor der Klasse I oder Klasse II, einer intrazellulären Domäne und/oder einem Affinitätsanhang;

40 wobei das lösliche Cytokinrezeptor-Polypeptid einen homodimeren, heterodimeren oder multimeren Rezeptorkomplex bildet;
und wobei das lösliche Cytokinrezeptor-Polypeptid IL-TIF bindet oder der IL-TIF-Aktivität entgegenwirkt.

45 15. Isoliertes Polynucleotid nach Anspruch 14, wobei der lösliche Cytokinrezeptor der Klasse I oder Klasse II aus dem löslichen Rezeptor-Polypeptid CRF2-4 gemäß SEQ ID Nr.: 35, dem löslichen Rezeptor-Polypeptid IL-10 gemäß SEQ ID Nr.: 36 oder dem löslichen Rezeptor-Polypeptid zcytor11 gemäß SEQ ID Nr.: 34 besteht.

50 16. Expressionsvektor, der aus einem Transkriptionspromotor, einem aus dem Nucleinsäuremolekül nach Anspruch 12 bestehenden DNA-Segment und einem Transkriptionsterminator besteht; wobei der Promotor funktionsfähig mit dem isolierten Nucleinsäuremolekül nach Anspruch 12 gekoppelt ist, und wobei das DNA-Segment funktionsfähig mit dem Transkriptionsterminator gekoppelt ist.

17. Expressionsvektor, bestehend aus:

- 55 (i) einem ersten Transkriptionspromotor, einem aus dem Nucleinsäuremolekül nach Anspruch 12 bestehenden ersten DNA-Segment und einem ersten Transkriptionsterminator; und
(ii) einem zweiten Transkriptionspromotor; einem zweiten DNA-Segment, das für ein lösliches Cytokinrezeptor-

Polypeptid der Klasse I oder Klasse II codiert; und einem zweiten Transkriptionsterminator.

18. Paar von unabhängigen Expressionsvektoren, bestehend aus:

- 5 (i) einem ersten Expressionsvektor nach Anspruch 16; und
(ii) einem zweiten Expressionsvektor, der aus den folgenden funktionsfähig gekoppelten Elementen besteht:
einem zweiten Transkriptionspromotor, einem zweiten DNA-Segment, das für ein lösliches Cytokinrezeptor-
Polypeptid der Klasse I oder Klasse II codiert; und einem Transkriptionsterminator.

10 19. Expressionsvektor, bestehend aus:

- (i) einem ersten Transkriptionspromotor, einem aus dem Nucleinsäuremolekül nach Anspruch 12 bestehenden
ersten DNA-Segment, das funktionsfähig an eine sekretorische Signalsequenz gekoppelt ist, und einem ersten
Transkriptionsterminator; und
15 (ii) einem zweiten Transkriptionspromotor; einem zweiten DNA-Segment, das für ein lösliches Cytokinrezeptor-
Polypeptid der Klasse I oder Klasse II codiert, das funktionsfähig an eine sekretorische Signalsequenz gekoppelt
ist; und einem zweiten Transkriptionsterminator.

20 20. Paar von unabhängigen Expressionsvektoren, bestehend aus:

- (i) einem ersten Expressionsvektor, der aus den folgenden funktionsfähig gekoppelten Elementen besteht:
einem Transkriptionspromotor, einem aus dem Nucleinsäuremolekül nach Anspruch 12 bestehenden, funkti-
onsfähig an eine sekretorische Signalsequenz gekoppelten DNA-Segment und einem Transkriptionsterminator;
und
25 (ii) einem zweiten Expressionsvektor, der aus den folgenden funktionsfähig gekoppelten Elementen besteht:
einem zweiten Transkriptionspromotor, einem zweiten DNA-Segment, das für ein lösliches Cytokinrezeptor-
Polypeptid der Klasse I oder Klasse II codiert, das funktionsfähig an eine sekretorische Signalsequenz gekoppelt
ist; und einem Transkriptionsterminator.

30 21. Expressionsvektor nach Anspruch 17 oder Paar von Expressionsvektoren nach Anspruch 18, wobei das zweite
DNA-Segment für ein Polypeptid codiert, das aus dem löslichen Rezeptor-Polypeptid CRF2-4 gemäß SEQ ID Nr.:
35, dem löslichen Rezeptor-Polypeptid IL-10 gemäß SEQ ID Nr.: 36 oder dem löslichen Rezeptor-Polypeptid zcytor11
gemäß SEQ ID Nr.: 34 besteht.

35 22. DNA-Konstrukt, das für ein Fusionsprotein codiert, das aus den folgenden Komponenten besteht:

- einem ersten DNA-Segment, das für ein Polypeptid codiert, das aus einer in SEQ ID Nr.: 2 von Aminosäure 28
bis 231 dargestellten Sequenz von Aminosäureresten oder aus einer in SEQ ID Nr.: 2 von Aminosäure 28 bis
230 dargestellten Sequenz von Aminosäureresten besteht; und
40 mindestens einem weiteren DNA-Segment, das für ein lösliches Cytokinrezeptor-Polypeptid der Klasse I oder
Klasse II codiert,
wobei das erste und die weiteren DNA-Segmente in-frame (im Leserahmen) verbunden sind; und
wobei das erste und die weiteren DNA-Segmente für das Fusionsprotein codieren.

45 23. DNA-Konstrukt nach Anspruch 22, wobei das mindestens eine weitere DNA-Segment für ein Polypeptid codiert,
das aus dem löslichen Rezeptor-Polypeptid CRF2-4 gemäß SEQ ID Nr.: 35, dem löslichen Rezeptor-Polypeptid IL-
10 gemäß SEQ ID Nr.: 36 oder dem löslichen Rezeptor-Polypeptid zcytor11 gemäß SEQ ID Nr.: 34 besteht.

50 24. Expressionsvektor, bestehend aus: den folgenden funktionsfähig gekoppelten Elementen:

- einem Transkriptionspromotor;
einem DNA-Konstrukt nach Anspruch 22; und
einem Transkriptionsterminator,
wobei der Promotor funktionsfähig an das DNA-Konstrukt gekoppelt ist und das DNA-Konstrukt funktionsfähig
55 an den Transkriptionsterminator gekoppelt ist.

25. Kultivierte Zelle, die einen Expressionsvektor nach Anspruch 24 aufweist, wobei die Zelle ein Polypeptid exprimiert,
das durch das DNA-Konstrukt codiert wird.

EP 1 373 508 B1

26. Rekombinante Wirtszelle, die den Expressionsvektor nach Anspruch 16 aufweist, wobei die Wirtszelle aus der Gruppe ausgewählt ist, die aus einem Bakterium, einer Hefezelle, Pilzzelle, Insektenzelle, Säugetierzelle und Pflanzenzelle besteht.
- 5 27. Kultivierte Zelle, die einen Expressionsvektor nach Anspruch 17 oder ein Paar von Expressionsvektoren nach Anspruch 18 aufweist, wobei die Zelle die durch die DNA-Segmente codierten Polypeptide exprimiert.
28. Kultivierte Zelle nach Anspruch 27, die ein Paar von Expressionsvektoren nach Anspruch 18 aufweist, wobei die voneinander unabhängigen Expressionsvektoren in die Zelle kotransfiziert werden und die Zelle die durch die DNA-Segmente codierten Polypeptide exprimiert.
- 10 29. Kultivierte Zelle nach Anspruch 27, wobei die Zelle ein durch die DNA-Segmente codiertes heterodimeres oder multimeres lösliches Rezeptor-Polypeptid exprimiert.
- 15 30. Zelle nach Anspruch 27, wobei die Zelle einen heterodimeren oder multimeren Komplex eines löslichen Cytokinrezeptor-Polypeptids sezerniert.
31. Zelle nach Anspruch 30, wobei der heterodimere oder multimeren Komplex des löslichen Cytokinrezeptor-Polypeptids IL-TIF bindet oder der IL-TIF-Aktivität entgegenwirkt.
- 20 32. Verfahren zu Herstellung eines Proteins, wobei das Verfahren die Kultivierung von rekombinanten Wirtszellen beinhaltet, die den Expressionsvektor nach Anspruch 16 aufweisen und die das Protein erzeugen.
33. Verfahren nach Anspruch 32, das ferner den Schritt zum Isolieren des Proteins aus den kultivierten rekombinanten Wirtszellen beinhaltet.
- 25 34. Verfahren zur Herstellung eines Fusionsproteins, das aufweist: Kultivieren einer Zelle nach Anspruch 25 und Isolieren des durch die Zelle produzierten Polypeptids.
- 30 35. Verfahren zur Herstellung eines löslichen Cytokinrezeptor-Polypeptids, das einen heterodimeren oder multimeren Komplex bildet, wobei das Verfahren aufweist:
- Kultivieren einer Zelle nach Anspruch 27 und Isolieren der durch die Zelle produzierten löslichen Rezeptor-Polypeptide.
- 35 36. In-vitro-Verfahren zur Inhibition von IL-TIF-induzierter Proliferation oder Differenzierung von hämatopoetischen Zellen und hämatopoetischen Zellvorläufern, wobei das Verfahren aufweist: Kultivieren von Knochenmark- oder peripheren Blutzellen mit einer Menge eines löslichen Cytokinrezeptor-Polypeptids, das aus den Aminosäuren 28 bis 231 von SEQ ID Nr.: 2 oder den Aminosäuren 28 bis 230 von SEQ ID Nr.: 2 besteht, wobei die Menge ausreicht, um die Proliferation oder Differenzierung der hämatopoetischen Knochenmarkzellen oder peripheren Blutzellen im Vergleich zu in Abwesenheit des löslichen Cytokinrezeptors kultivierten Knochenmarkzellen oder peripheren Blutzellen zu reduzieren.
- 40 37. Verfahren nach Anspruch 36, wobei die hämatopoetischen Zellen und hämatopoetischen Vorläuferzellen Lymphoidzellen sind.
- 45 38. Verfahren nach Anspruch 37, wobei die Lymphoidzellen Makrophagen oder T-Zellen sind.
39. Verwendung eines Polypeptids, das aus den Aminosäuren 28-231 von SEQ ID Nr.: 2 oder den Aminosäuren 28-230 von SEQ ID Nr.: 2 besteht, für die Herstellung eines Medikaments zur Verminderung einer IL-TIF-induzierten Entzündung.
- 50 40. Verwendung des isolierten Polypeptids nach Anspruch 2 in einer pharmazeutisch akzeptierbaren Trägersubstanz für die Herstellung eines Medikaments zur Behandlung von Entzündung bei einem Säugetier durch Suppression einer Entzündungsreaktion; wobei das Medikament zur Verabreichung als Teil einer Methode vorgesehen ist, die aufweist:
- 55

(1) Bestimmen eines Serumspiegels von Amyloid A-Protein vor der Verabreichung;

EP 1 373 508 B1

(2) Bestimmen eines Serumspegels von Amyloid A-Protein nach der Verabreichung; und
(3) Vergleich des Serumspegels von Amyloid A-Protein im Schritt (1) mit dem Serumspegel von Amyloid A-Protein im Schritt (2), wobei ein fehlender Anstieg oder ein Abfall des Serumspegels von Amyloid A-Protein auf Suppression einer Entzündungsreaktion schließen lässt.

5

41. Verwendung eines Antagonisten von IL-TIF für die Herstellung eines Medikaments zur Behandlung einer entzündlichen Erkrankung bei einem Säugetier, wobei IL-TIF oder Serum-Amyloid A eine Rolle spielt, wobei der Antagonist ein Polypeptid nach Anspruch 1 ist.

10

42. Verwendung nach Anspruch 41, wobei die Erkrankung eine chronische entzündliche Erkrankung ist.

43. Verwendung nach Anspruch 42, wobei die chronische entzündliche Erkrankung aus der folgenden Gruppe ausgewählt ist:

15

- (a) entzündliche Darmerkrankung;
- (b) Colitis ulcerosa;
- (c) Morbus Crohn;
- (d) Arthritis; und
- (e) Psoriasis.

20

44. Verwendung nach Anspruch 41, wobei die Erkrankung eine akute entzündliche Erkrankung ist.

45. Verwendung nach Anspruch 44, wobei die akute entzündliche Erkrankung aus der folgenden Gruppe ausgewählt ist:

25

- (a) Endotoxämie;
- (b) Septikämie;
- (c) toxisches Schocksyndrom; und
- (d) Infektionskrankheit.

30

Revendications

1. Polypeptide isolé constitué d'une séquence d'acides aminés du groupe:

35

- (a) des résidus d'acide aminé 28 à 127 de la SEQ ID NO:2;
- (b) des résidus d'acide aminé 132 à 231 de la SEQ ID NO:2;
- (c) des résidus d'acide aminé 28 à 231 de la SEQ ID NO:2;
- (d) des résidus d'acide aminé 23 à 230 de la SEQ ID NO:2;
- (e) des résidus d'acide aminé 23 à 231 de la SEQ ID NO:2;
- (f) des résidus d'acide aminé 22 à 230 de la SEQ ID NO:2;
- (g) des résidus d'acide aminé 32 à 123 de la SEQ ID NO:2;
- (h) des résidus d'acide aminé 132 à 230 de la SEQ ID NO:2;
- (i) des résidus d'acide aminé 32 à 230 de la SEQ ID NO:2; et
- (j) des résidus d'acide aminé 28 à 230 de la SEQ ID NO:2.

45

2. Polypeptide isolé selon la revendication 1, où ledit polypeptide est constitué des résidus d'acide aminé 28 à 231 de la SEQ ID NO:2 ou des résidus d'acide aminé 28 à 230 de la SEQ ID NO:2.

50

3. Protéine de fusion constituée d'un premier polypeptide et d'un deuxième polypeptide, dans laquelle ledit premier polypeptide est constitué du polypeptide selon la revendication 1 ou 2 et dans laquelle ledit deuxième polypeptide est choisi dans le groupe constitué:

55

- (i) d'une séquence signal de sécrétion provenant d'une autre protéine sécrétée;
- (ii) d'une région constante de chaîne lourde d'immunoglobuline;
- (iii) d'une protéine de dimérisation;
- (iv) d'une étiquette peptidique;
- (v) d'un polypeptide de glutathione S-transférase;
- (vi) d'un polypeptide de protéine de liaison de maltose; et

EP 1 373 508 B1

(vii) du domaine C-terminal d'une protéine A tronquée.

4. Protéine de fusion selon la revendication 3, dans laquelle le deuxième polypeptide est un fragment Fc.

5 5. Polypeptide de récepteur de cytokine soluble isolé constitué d'une sous-unité de récepteur de cytokine soluble et d'une étiquette d'affinité, d'une fraction chimique, d'une toxine ou d'un marqueur;
où la sous-unité de récepteur de cytokine soluble est constituée d'une séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 231 ou d'une séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 230;
10 où ledit polypeptide de récepteur de cytokine soluble forme un complexe de récepteur homodimère, hétérodimère ou multimère;
et où ledit polypeptide de récepteur de cytokine soluble se lie à IL-TIF ou antagonise l'activité de IL-TIF.

15 6. Complexe de récepteur soluble hétérodimère ou multimère isolé constitué de sous-unités de récepteurs solubles, dans lequel au moins une des sous-unités de récepteurs solubles est constituée de résidus d'acide aminé 28-231 de la SEQ ID NO:2 ou de résidus d'acide aminé 28-230 de la SEQ ID NO:2.

20 7. Complexe de récepteur soluble hétérodimère ou multimère isolé selon la revendication 6, dans lequel une desdites sous-unités de récepteurs solubles est un polypeptide de récepteur de cytokine de classe I ou de classe II soluble.

25 8. Complexe de récepteur soluble hétérodimère ou multimère isolé selon la revendication 7, dans lequel ledit polypeptide de récepteur de cytokine de classe I ou de classe II soluble est constitué du polypeptide de récepteur de CRF2-4 soluble de la SEQ ID NO:35, du polypeptide de récepteur de IL-10 soluble de la SEQ ID NO:36 ou du polypeptide de récepteur de zcytor11 soluble de la SEQ ID NO:34.

30 9. Procédé pour la production d'un anticorps vis-à-vis d'un polypeptide de récepteur de cytokine soluble, dans lequel le polypeptide inoculé est constitué d'un polypeptide de récepteur de cytokine soluble choisi dans le groupe:

30 (a) d'un polypeptide constitué des acides aminés 28 à 231 de la SEQ ID NO:2 ou des acides aminés 28 à 230 de la SEQ ID NO:2;

(b) d'un polypeptide constitué des acides aminés 28 à 231 de la SEQ ID NO:2 ou des acides aminés 28 à 230 de la SEQ ID NO:2 complexé avec un polypeptide de récepteur de cytokine de classe I ou de classe II soluble;

35 (c) d'un complexe de polypeptides de (b) dans lequel le polypeptide de récepteur de cytokine de classe I ou de classe II soluble est constitué du polypeptide de récepteur de CRF2-4 soluble de la SEQ ID NO:35; et

(d) d'un complexe de polypeptides de (b) dans lequel le polypeptide de récepteur de cytokine de classe I ou de classe II soluble est constitué du polypeptide de récepteur de IL-10 soluble de la SEQ ID NO:36,

40 dans lequel un anticorps est produit contre le polypeptide inoculé; et l'anticorps est isolé à partir d'un animal non humain.

45 10. Polypeptide de récepteur de cytokine soluble pour une utilisation dans un procédé pour la production d'un anticorps dans un animal non humain; où le polypeptide de récepteur de cytokine soluble est choisi dans le groupe constitué:

45 (a) d'un polypeptide constitué des acides aminés 28 à 231 de la SEQ ID NO:2 ou des acides aminés 28 à 230 de la SEQ ID NO:2;

(b) d'un polypeptide constitué des acides aminés 28 à 231 de la SEQ ID NO:2 ou des acides aminés 28 à 230 de la SEQ ID NO:2 complexé avec un polypeptide de récepteur de cytokine de classe I ou de classe II soluble;

50 (c) d'un complexe de polypeptides de (b) dans lequel le polypeptide de récepteur de cytokine de classe I ou de classe II soluble est constitué du polypeptide de récepteur de CRF2-4 soluble de la SEQ ID NO:35; et

(d) d'un complexe de polypeptides de (b) dans lequel le polypeptide de récepteur de cytokine de classe I ou de classe II soluble est constitué du polypeptide de récepteur de IL-10 soluble de la SEQ ID NO:36.

55 11. Molécule d'acide nucléique isolée, choisie parmi:

(a) une molécule d'acide nucléique constituée de la séquence de nucléotides de la SEQ ID NO:37 ou du complément de celle-ci;

(b) une molécule d'acide nucléique constituée:

- (i) des nucléotides 64-693 de la SEQ ID NO:1,
- (ii) des nucléotides 67-693 de la SEQ ID NO:1;
- (iii) des nucléotides 82-693 de la SEQ ID NO:1, ou
- (iv) des nucléotides 94-693 de la SEQ ID NO:1;

5

ou du complément de celle-ci; ou
(c) une molécule d'acide nucléique constituée:

- (v) des nucléotides 94-369 de la SEQ ID NO:1;
- (vi) des nucléotides 394-690 de la SEQ ID NO:1;
- (vii) des nucléotides 94-690 de la SEQ ID NO:1; ou
- (viii) des nucléotides 82-690 de la SEQ ID NO:1.

10

12. Molécule d'acide nucléique isolée selon la revendication 11, constituée:

15

- (i) des nucléotides 64 à 693 de la SEQ ID NO:1;
- (ii) des nucléotides 82 à 693 de la SEQ ID NO:1, ou
- (iii) des nucléotides 82-690 de la SEQ ID NO:1.

20

13. Polynucléotide isolé qui code pour une sous-unité de récepteur de cytokine soluble constituée de la séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 231 ou de la séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 230.

25

14. Polynucléotide isolé qui code pour un polypeptide de récepteur de cytokine soluble, dans lequel ledit polypeptide de récepteur de cytokine soluble est constitué:

- (i) d'une sous-unité de récepteur soluble constituée de la séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 231 ou de la séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 230; et
- (ii) d'un récepteur de cytokine de classe I ou de classe II soluble, d'un domaine intracellulaire et/ou d'une étiquette d'affinité;

30

dans lequel ledit polypeptide de récepteur de cytokine soluble forme un complexe de récepteur homodimère, hétérodimère ou multimère;

35

et dans lequel ledit polypeptide de récepteur de cytokine soluble se lie à IL-TIF ou antagonise l'activité de IL-TIF.

15. Polynucléotide isolé selon la revendication 14, dans lequel ledit récepteur de cytokine de classe I ou de classe II soluble est constitué du polypeptide de récepteur de CRF2-4 soluble de la SEQ ID NO:35, du polypeptide de récepteur de IL-10 soluble de la SEQ ID NO:36 ou du polypeptide de récepteur de zcytor11 soluble de la SEQ ID NO:34.

40

16. Vecteur d'expression constitué d'un promoteur de transcription, d'un segment d'ADN constitué de la molécule d'acide nucléique selon la revendication 12 et d'un terminateur de transcription; dans lequel le promoteur est lié de manière fonctionnelle avec la molécule d'acide nucléique isolée selon la revendication 12 et dans lequel le segment d'ADN est lié de manière fonctionnelle avec le terminateur de transcription.

45

17. Vecteur d'expression constitué:

- (i) d'un premier promoteur de transcription, d'un premier segment d'ADN constitué de la molécule d'acide nucléique selon la revendication 12 et d'un premier terminateur de transcription; et
- (ii) d'un deuxième promoteur de transcription, d'un deuxième segment d'ADN codant pour un polypeptide de récepteur de cytokine de classe I ou de classe II soluble et d'un deuxième terminateur de transcription.

50

18. Paire de vecteurs d'expression indépendants, constituée:

55

- (i) d'un premier vecteur d'expression selon la revendication 16; et
- (ii) d'un deuxième vecteur d'expression constitué des éléments liés de manière fonctionnelle suivants: un deuxième promoteur de transcription; un deuxième segment d'ADN codant pour un polypeptide de récepteur de

cytokine de classe I ou de classe II soluble; et un terminateur de transcription.

19. Vecteur d'expression constitué:

- 5 (i) d'un premier promoteur de transcription, d'un premier segment d'ADN constitué de la molécule d'acide nucléique selon la revendication 12 liée de manière fonctionnelle à une séquence signal de sécrétion et d'un premier terminateur de transcription; et
10 (ii) d'un deuxième promoteur de transcription, d'un deuxième segment d'ADN codant pour un polypeptide de récepteur de cytokine de classe I ou de classe II soluble lié de manière fonctionnelle à une séquence signal de sécrétion et d'un deuxième terminateur de transcription.

20. Paire de vecteurs d'expression indépendants, constituée:

- 15 (i) d'un premier vecteur d'expression constitué des éléments liés de manière fonctionnelle suivants: un promoteur de transcription; un segment d'ADN constitué de la molécule d'acide nucléique selon la revendication 12 liée de manière fonctionnelle à une séquence signal de sécrétion; et un terminateur de transcription; et
20 (ii) d'un deuxième vecteur d'expression constitué des éléments liés de manière fonctionnelle suivants: un deuxième promoteur de transcription; un deuxième segment d'ADN codant pour un polypeptide de récepteur de cytokine de classe I ou de classe II soluble lié de manière fonctionnelle à une séquence signal de sécrétion; et un terminateur de transcription.

21. Vecteur d'expression selon la revendication 17, ou une paire de vecteurs d'expression selon la revendication 18, dans lequel le deuxième segment d'ADN code pour un polypeptide constitué du polypeptide de récepteur de CRF2-4 soluble de la SEQ ID NO:35, du polypeptide de récepteur de IL-10 soluble de la SEQ ID NO:36 ou du polypeptide de récepteur de zcytor11 soluble de la SEQ ID NO:34.

22. Construction d'ADN codant pour une protéine de fusion constituée:

- 30 d'un premier segment d'ADN codant pour un polypeptide constitué d'une séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 231 ou d'une séquence de résidus d'acide aminé telle que montrée dans la SEQ ID NO:2 des acides aminés 28 à 230; et
35 d'au moins un autre segment d'ADN codant pour un polypeptide de récepteur de cytokine de classe I ou de classe II soluble,
dans laquelle le premier et les autres segments d'ADN sont reliés en cadre; et
dans laquelle le premier et les autres segments d'ADN codent pour la protéine de fusion.

23. Construction d'ADN selon la revendication 22, dans laquelle ledit au moins un autre segment d'ADN code pour un polypeptide constitué du polypeptide de récepteur de CRF-2-4 soluble de la SEQ ID NO:35, du polypeptide de récepteur de IL-10 soluble de la SEQ ID NO:36 ou du polypeptide de récepteur de zcytor11 soluble de la SEQ ID NO:34.

24. Vecteur d'expression constitué des éléments liés de manière fonctionnelle suivants:

- 45 un promoteur de transcription;
une construction d'ADN selon la revendication 22; et
un terminateur de transcription,
dans lequel le promoteur est lié de manière fonctionnelle à la construction d'ADN et la construction d'ADN est liée de manière fonctionnelle au terminateur de transcription.

25. Cellule cultivée comprenant un vecteur d'expression selon la revendication 24, où la cellule exprime un polypeptide codé par la construction d'ADN.

26. Cellule hôte recombinante comprenant le vecteur d'expression selon la revendication 16, où la cellule hôte est issue du groupe de bactérie, de cellule de levure, de cellule fongique, de cellule d'insecte, de cellule mammifère et de cellule de plante.

27. Cellule cultivée comprenant un vecteur d'expression selon la revendication 17 ou une paire de vecteurs d'expression selon la revendication 18, où la cellule exprime les polypeptides codés par les segments d'ADN.

EP 1 373 508 B1

28. Cellule cultivée selon la revendication 27, comprenant une paire de vecteurs d'expression selon la revendication 18, dans laquelle les vecteurs d'expression indépendants sont co-transfectés dans la cellule et la cellule exprime les polypeptides codés par les segments d'ADN.
- 5 29. Cellule cultivée selon la revendication 27, où la cellule exprime un polypeptide de récepteur soluble hétérodimère ou multimère codé par les segments d'ADN.
30. Cellule selon la revendication 27, où la cellule sécrète un complexe hétérodimère ou multimère de polypeptide de récepteur de cytokine soluble.
- 10 31. Cellule selon la revendication 30, dans laquelle ledit complexe hétérodimère ou multimère de polypeptide de récepteur de cytokine soluble se lie à IL-TIF ou antagonise l'activité de IL-TIF.
- 15 32. Procédé pour la production d'une protéine, le procédé comprenant la culture de cellules hôtes recombinantes qui comprennent le vecteur d'expression selon la revendication 16 et qui produisent la protéine.
33. Procédé selon la revendication 32, comprenant en outre l'étape d'isolement de la protéine à partir des cellules hôtes recombinantes cultivées.
- 20 34. Procédé pour la production d'une protéine de fusion comprenant: la culture d'une cellule selon la revendication 25; et l'isolement du polypeptide produit par la cellule.
- 25 35. Procédé pour la production d'un polypeptide de récepteur de cytokine soluble qui forme un complexe hétérodimère ou multimère, le procédé comprenant: la culture d'une cellule selon la revendication 27; et l'isolement des polypeptides de récepteurs solubles produits par la cellule.
- 30 36. Procédé in vitro pour l'inhibition d'une prolifération ou d'une différenciation induite par IL-TIF de cellules hématopoïétiques et de progéniteurs de cellules hématopoïétiques, comprenant la culture de cellules de moelle osseuse ou de sang périphérique avec une quantité d'un polypeptide de récepteur de cytokine soluble constitué des acides aminés 28 à 231 de la SEQ ID NO:2 ou des acides aminés 28 à 230 de la SEQ ID NO:2 suffisante pour réduire la prolifération ou la différenciation des cellules hématopoïétiques dans les cellules de moelle osseuse ou de sang périphérique par comparaison avec des cellules de moelle osseuse ou de sang périphérique cultivées en l'absence de récepteur de cytokine soluble.
- 35 37. Procédé selon la revendication 36, dans lequel les cellules hématopoïétiques et les cellules progénitrices hématopoïétiques sont des cellules lymphoïdes.
38. Procédé selon la revendication 37, dans lequel les cellules lymphoïdes sont des macrophages ou des cellules T.
- 40 39. Utilisation d'un polypeptide constitué des acides aminés 28-231 de la SEQ ID NO:2 ou des acides aminés 28-230 de la SEQ ID NO:2 pour la fabrication d'un médicament pour la réduction d'une inflammation induite par IL-TIF.
- 45 40. Utilisation du polypeptide isolé selon la revendication 2 dans un véhicule pharmaceutique acceptable pour la fabrication d'un médicament pour le traitement d'une inflammation chez un mammifère par la suppression d'une réponse inflammatoire;
dans laquelle ledit médicament est pour une administration en tant que partie d'un procédé comprenant:
- 50 (1) la détermination d'un niveau de pré-administration de protéine A amyloïde de sérum;
(2) la détermination d'un niveau de post-administration de protéine A amyloïde de sérum; et
(3) la comparaison du niveau de protéine A amyloïde de sérum dans l'étape (1) avec le niveau de protéine A amyloïde de sérum dans l'étape (2), dans laquelle une absence d'augmentation ou une diminution dans le niveau de protéine A amyloïde de sérum est indicatrice d'une suppression d'une réponse inflammatoire.
- 55 41. Utilisation d'un antagoniste de IL-TIF pour la fabrication d'un médicament pour le traitement d'une maladie inflammatoire dans laquelle IL-TIF ou la protéine A amyloïde de sérum joue un rôle chez un mammifère, dans laquelle l'antagoniste est un polypeptide selon la revendication 1.
42. Utilisation selon la revendication 41, dans laquelle la maladie est une maladie inflammatoire chronique.

EP 1 373 508 B1

43. Utilisation selon la revendication 42, dans laquelle la maladie inflammatoire chronique est choisie dans le groupe:

- (a) d'une maladie intestinale inflammatoire;
- (b) d'une colite ulcéreuse;
- (c) d'une maladie de Crohn;
- (d) d'une arthrite; et
- (e) d'un psoriasis.

5

44. Utilisation selon la revendication 41, dans laquelle la maladie est une maladie inflammatoire aiguë.

10

45. Utilisation selon la revendication 44, dans laquelle la maladie inflammatoire aiguë est choisie dans le groupe:

- (a) d'une endotoxémie;
- (b) d'une septicémie;
- (c) d'un syndrome de choc toxique; et
- (d) d'une maladie infectieuse.

15

20

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5965704 A [0052] [0174] [0290] [0293] [0455] [0484] [0486]
- US 5641670 A [0103]
- US 5223409 A, Ladner [0135] [0239] [0281] [0387]
- WO 9206204 A, Huse [0135]
- WO 9720078 A [0136]
- US 5300435 A [0159]
- US 4599311 A, Kawasaki [0161]
- US 4931373 A, Kawasaki [0161]
- US 4870008 A, Brake [0161]
- US 5037743 A, Welch [0161] [0184]
- US 4845075 A, Murray [0161]
- US 4615974 A, Kingsman [0161]
- US 4977092 A, Bitter [0161]
- US 4990446 A [0161]
- US 5063154 A [0161]
- US 5139936 A [0161]
- US 4661454 A [0161]
- US 4882279 A, Cregg [0162]
- US 4935349 A, McKnight [0162]
- US 5162228 A, Sumino [0162]
- US 4486533 A, Lambowitz [0162]
- US 5716808 A, Raymond [0163]
- US 5736383 A, Raymond [0163]
- WO 9717450 A [0163]
- WO 9717451 A [0163]
- WO 9802536 A [0163]
- WO 9802565 A [0163]
- US 5945511 A [0174] [0293] [0455] [0569]
- WO 9521930 A [0177]
- US 5783384 A, Verdine [0182]
- US 5143830 A, Holland [0184]
- US 5641655 A [0185]
- US 6018026 A, Sledziewski, AZ [0187]
- US 5750375 A [0187]
- US 5155027 A [0188]
- US 5567584 A [0188]
- US 5723125 A, Chang [0192]
- EP 742830 A, LaRochelle [0193]
- WO 9521258 A [0193]
- US 5252714 A, Harris [0204]
- EP 0154316 A [0206]
- US 5382657 A, Karasiewicz [0206] [0214]
- US 5738846 A, Greenwald [0214]
- WO 9111465 A, Goldenberg [0230]
- US 4331647 A, Goldenberg [0235]
- US 4946778 A, Ladner [0238] [0239] [0281] [0387]
- US 5403484 A, Ladner [0239] [0281] [0387]
- US 5571698 A, Ladner [0239] [0281] [0387]
- US 5693762 A, Queen [0241]
- US 5208146 A, Irie [0242]
- US 5686272 A, Marshall [0256]
- US 1997 A [0256]
- WO 0024758 A [0290]
- JP 4244018 A [0329]
- US 4603044 A, Geho [0330]
- US 4769331 A [0340]
- US 4859587 A [0340]
- US 5288641 A [0340]
- US 5328688 A [0340]
- US 5399346 A, Anderson [0340]
- US 5496698 A, Draper and Macejak [0348]
- US 5525468 A, McSwiggen [0348]
- US 5631359 A, Chowrira and McSwiggen [0348]
- US 5225337 A, Robertson and Goldberg [0348]
- US 5168053 A, Altman [0349]
- WO 9618733 A, Pace [0349]
- WO 9621731 A, George [0349]
- WO 9733991 A, Werner [0349]
- US 9825228 B [0374]
- WO 9824893 A [0383]
- WO 0017235 A [0467]
- US 60279222 B [0614]

Non-patent literature cited in the description

- **ARAI et al.** *Annu. Rev. Biochem.*, 1990, vol. 59, 783 [0002]
- **MOSMANN.** *Curr. Opin. Immunol.*, 1991, vol. 3, 311 [0002]
- **PAUL ; SEDER.** *Cell*, 1994, vol. 76, 241 [0002]
- **YAO et al.** *J. Immunol.*, 1995, vol. 155, 5483 [0002]
- **FOSSIEZ et al.** *J. Exp. Med.*, 1996, vol. 183, 2593 [0002]
- **MCGEHEE et al.** *Mol. Endocrinol.*, 1993, vol. 7, 551 [0036]
- **TREISMAN.** *Seminars in Cancer Biol.*, 1990, vol. 1, 47 [0036]
- **O'REILLY et al.** *J. Biol. Chem.*, 1992, vol. 267, 19938 [0036]
- **YE et al.** *J. Biol. Chem.*, 1994, vol. 269, 25728 [0036]
- **LOEKEN.** *Gene Expr.*, 1993, vol. 3, 253 [0036]

- Molecular Biology of the Gene. The Benjamin/Cummings Publishing Company, Inc, 1987 [0036]
- **LEMAIGRE ; ROUSSEAU.** *Biochem. J.*, 1994, vol. 303, 1 [0036]
- **NILSSON et al.** *EMBO J.*, 1985, vol. 4, 1075 [0067]
- **NILSSON et al.** *Methods Enzymol.*, 1991, vol. 198, 3 [0067]
- **SMITH ; JOHNSON.** *Gene*, 1988, vol. 67, 31 [0067]
- **GRUSSENMEYER et al.** *Proc. Nat'l Acad. Sci. USA*, 1985, vol. 82, 7952 [0067]
- **HOPP et al.** *Biotechnology*, 1988, vol. 6, 1204 [0067]
- **FORD et al.** *Protein Expression and Purification*, 1991, vol. 2, 95 [0067]
- **PERUSKI ; PERUSKI.** The Internet and the New Biology: Tools for Genetic and Molecular Research. ASM Press, Inc, 1997 [0079]
- Information Superhighway and Computer Databases of Nucleic Acids and Proteins. Methods in Gene Biotechnology. CRC Press, Inc, 1997, 123-151 [0079]
- Guide to Human Genome Computing. Academic Press, Inc, 1998 [0079]
- Short Protocols in Molecular Biology. John Wiley & Sons, 1995, 4-14-6 [0087]
- **WU et al.** Methods in Gene Biotechnology. CRC Press, Inc, 1997, 33-41 [0087]
- **CHIRGWIN et al.** *Biochemistry*, 1979, vol. 18, 52 [0088]
- **AVIV ; LEDER.** *Proc. Nat'l Acad. Sci. USA*, 1972, vol. 69, 1408 [0089]
- Constructing and Screening cDNA Libraries in λ gt10 and λ gt11. **HUYNH et al.** DNA Cloning: A Practical Approach. IRL Press, 1985, vol. I, 49 [0091]
- Use of the Polymerase Chain Reaction to Screen Phage Libraries. **YU et al.** Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications. Humana Press, Inc, 1993, vol. 15, 211-215 [0098]
- Use of Degenerate Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members. **PRESTON.** Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications. Humana Press, Inc, 1993, vol. 15, 317-337 [0098]
- Screening λ expression libraries with antibody and protein probes. **MARGOLIS et al.** DNA Cloning 2: Expression Systems. Oxford University Press, 1995, 1-14 [0099]
- **ADANG et al.** *Plant Molec. Biol.*, 1993, vol. 21, 1131 [0100]
- **BAMBOT et al.** *PCR Methods and Applications*, 1993, vol. 2, 266 [0100]
- Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes. **DILLON et al.** Methods in Molecular Biology, Vol 15; PCR Protocols; Current Methods and Applications. Humana Press, Inc, 1993, vol. 15, 263-268 [0100]
- **HLOWACHUK et al.** *PCR Methods Appl.*, 1995, vol. 4, 299 [0100]
- **GLICK ; PASTERNAK.** Molecular Biotechnology, Principles and Applications of Recombinant DNA. ASM Press, 1994 [0101]
- **ITAKURA et al.** *Annu. Rev. Biochem.*, 1984, vol. 53, 323 [0101]
- **CLIMIE et al.** *Proc. Nat'l Acad. Sci. USA*, 1990, vol. 87, 633 [0101]
- **GRANTHAM et al.** *Nucl. Acids Res.*, 1980, vol. 8, 1893 [0108]
- **HAAS.** *Curr. Biol.*, 1996, vol. 6, 315 [0108]
- **WAIN-HOBSON et al.** *Gene*, 1981, vol. 13, 355 [0108]
- **GROSJEAN ; FIERS.** *Gene*, 1982, vol. 18, 199 [0108]
- **HOLM.** *Nucl. Acids Res.*, 1986, vol. 14, 3075 [0108]
- **IKEMURA.** *J. Mol. Biol.*, 1982, vol. 158, 573 [0108]
- **SHARP ; MATASSI.** *Curr. Opin. Genet. Dev.*, 1994, vol. 4, 851 [0108]
- **KANE.** *Curr. Opin. Biotechnol.*, 1995, vol. 6, 494 [0108]
- **MAKRIDES.** *Microbiol. Rev.*, 1996, vol. 60, 512 [0108]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, 1989 [0115]
- Current Protocols in Molecular Biology. John Wiley and Sons, Inc, 1987 [0115]
- Guide to Molecular Cloning Techniques. Academic Press, Inc, 1987 [0115]
- **WETMUR.** *Crit. Rev. Biochem. Mol. Biol.*, 1990, vol. 26, 227 [0115]
- **ALTSCHUL et al.** *Bull. Math. Bio.*, 1986, vol. 48, 603 [0124]
- **HENIKOFF ; HENIKOFF.** *Proc. Nat'l Acad. Sci. USA*, 1992, vol. 89, 10915 [0124]
- **PEARSON ; LIPMAN.** *Proc. Nat'l Acad. Sci. USA*, 1988, vol. 85, 2444 [0125]
- **PEARSON.** *Meth. Enzymol.*, 1990, vol. 183, 63 [0125]
- **NEEDLEMAN ; WUNSCH.** *J. Mol. Biol.*, 1970, vol. 48, 444 [0125]
- **SELLERS.** *SIAM J. Appl. Math.*, 1974, vol. 26, 787 [0125]
- **HENIKOFF ; HENIKOFF.** *Proc. Nat'l Acad. Sci. USA*, 1992, vol. 89, 10915 [0127]
- Directed Mutagenesis: A Practical Approach. IRL Press, 1991 [0129]
- **ROBERTSON et al.** *J. Am. Chem. Soc.*, 1991, vol. 113, 2722 [0130]
- **ELLMAN et al.** *Methods Enzymol.*, 1991, vol. 202, 301 [0130]
- **CHUNG et al.** *Science*, 1993, vol. 259, 806 [0130]
- **CHUNG et al.** *Proc. Nat'l Acad. Sci. USA*, 1993, vol. 90, 10145 [0130]
- **TURCATTI et al.** *J. Biol. Chem.*, 1996, vol. 271, 19991 [0131]
- **KOIDE et al.** *Biochem.*, vol. 33, 7470 [0131]
- **WYNN ; RICHARDS.** *Protein Sci.*, 1993, vol. 2, 395 [0131]

- **CUNNINGHAM ; WELLS.** *Science*, 1989, vol. 244, 1081 [0133]
- **BASS et al.** *Proc. Nat'l Acad. Sci. USA*, 1991, vol. 88, 4498 [0133]
- Site-Directed Mutagenesis and Protein Engineering. **COOMBS ; COREY.** *Proteins: Analysis and Design.* Academic Press, Inc, 1998, 259-311 [0133]
- **HILTON et al.** *J. Biol. Chem.*, 1996, vol. 271, 4699 [0133]
- **DE VOS et al.** *Science*, 1992, vol. 255, 306 [0134] [0203]
- **SMITH et al.** *J. Mol. Biol.*, 1992, vol. 224, 899 [0134] [0203]
- **WLODAVER et al.** *FEBS Lett.*, 1992, vol. 309, 59 [0134] [0203]
- **REIDHAAR-OLSON ; SAUER.** *Science*, 1988, vol. 241, 53 [0135]
- **BOWIE ; SAUER.** *Proc. Nat'l Acad. Sci. USA*, 1989, vol. 86, 2152 [0135]
- **LOWMAN et al.** *Biochem.*, 1991, vol. 30, 10832 [0135]
- **DERBYSHIRE et al.** *Gene*, 1986, vol. 46, 145 [0135]
- **NER et al.** *DNA*, 1988, vol. 7, 127 [0135]
- **STEMMER.** *Nature*, 1994, vol. 370, 389 [0136]
- **STEMMER.** *Proc. Nat'l Acad. Sci. USA*, 1994, vol. 91, 10747 [0136]
- **HORISBERGER ; DI MARCO.** *Pharmac. Ther.*, 1995, vol. 66, 507 [0139]
- **TREUTER et al.** *Molec. Gen. Genet.*, 1993, vol. 240, 113 [0139]
- Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon. **CONTENT et al.** *Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems.* 1987, 65-72 [0139]
- The EGF Receptor. **HERSCHMAN et al.** *Control of Animal Cell Proliferation.* Academic Press, 1985, vol. 1, 169-199 [0139]
- **COUMAILLEAU et al.** *J. Biol. Chem.*, 1995, vol. 270, 29270 [0139]
- **FUKUNAGA et al.** *J. Biol. Chem.*, 1995, vol. 270, 25291 [0139]
- **YAMAGUCHI et al.** *Biochem. Pharmacol.*, 1995, vol. 50, 1295 [0139]
- **MEISEL et al.** *Plant Molec. Biol.*, 1996, vol. 30, 1 [0139]
- **GEYSEN et al.** *Proc. Nat'l Acad. Sci. USA*, 1983, vol. 81, 3998 [0142] [0377]
- **SUTCLIFFE et al.** *Science*, 1983, vol. 219, 660 [0143] [0378]
- **LANE ; STEPHEN.** *Curr. Opin. Immunol.*, 1993, vol. 5, 268 [0144] [0379]
- **CORTESE et al.** *Curr. Opin. Biotechnol.*, 1996, vol. 7, 616 [0144] [0379]
- Epitope Mapping. **MOLE.** *Methods in Molecular Biology.* The Humana Press; Inc, 1992, vol. 10, 105-116 [0144]
- Production and Characterization of Synthetic Peptide-Derived Antibodies. **PRICE.** *Monoclonal Antibodies: Production, Engineering, and Clinical Application.* Cambridge University Press, 1995, 60-84 [0144] [0379]
- *Current Protocols in Immunology.* John Wiley & Sons, 1997, 9.3.1-9.3.59.4.1-9.4.11 [0144]
- **CHASIN et al.** *Som. Cell. Molec. Genet.*, 1986, vol. 12, 555 [0148]
- **HAMER et al.** *J. Molec. Appl. Genet.*, 1982, vol. 1, 273 [0150]
- **MCKNIGHT.** *Cell*, 1982, vol. 31, 355 [0150]
- **BENOIST et al.** *Nature*, 1981, vol. 290, 304 [0150]
- **GORMAN et al.** *Proc. Nat'l Acad. Sci. USA*, 1982, vol. 79, 6777 [0150]
- **FOECKING et al.** *Gene*, 1980, vol. 45, 101 [0150]
- Expression of Engineered Proteins in Mammalian Cell Culture. **ETCHEVERRY et al.** *Protein Engineering: Principles and Practice.* John Wiley & Sons, Inc, 1996, 163-181 [0150]
- **ZHOU et al.** *Mol. Cell. Biol.*, 1990, vol. 10, 4529 [0151]
- **KAUFMAN et al.** *Nucl. Acids Res.*, 1991, vol. 19, 4485 [0151]
- *Gene Transfer and Expression Protocols.* Humana Press, 1991 [0153]
- **BECKER et al.** *Meth. Cell Biol.*, 1994, vol. 43, 161 [0155] [0341]
- **DOUGLAS ; CURIEL.** *Science & Medicine*, 1997, vol. 4, 44 [0155] [0341]
- **GARNIER et al.** *Cytotechnol.*, 1994, vol. 15, 145 [0156]
- **LUCKOW et al.** *J. Virol.*, 1993, vol. 67, 4566 [0157]
- **HILL-PERKINS ; POSSEE.** *J. Gen. Virol.*, 1990, vol. 71, 971 [0157] [0158]
- **BONNING et al.** *J. Gen. Virol.*, 1994, vol. 75, 1551 [0157] [0158]
- **CHAZENBALK ; RAPOPORT.** *J. Biol. Chem.*, 1995, vol. 270, 1543 [0157] [0158]
- **GRUSSENMEYER et al.** *Proc. Nat'l Acad. Sci.*, 1985, vol. 82, 7952 [0157]
- Manipulation of Baculovirus Vectors. **BAILEY et al.** *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols.* The Humana Press, Inc, 1991, vol. 7, 147-168 [0160]
- The baculovirus expression system. **PATEL et al.** *DNA Cloning 2: Expression Systems.* Oxford University Press, 1995, 205-244 [0160]
- **AUSUBEL.** *Baculovirus Expression Protocols.* The Humana Press, Inc, 1995, 16-3716-57 [0160]
- Insect Cell Expression Technology. **LUCKNOW et al.** *Protein Engineering: Principles and Practice.* John Wiley & Sons, Inc, 1996, 183-218 [0160]
- **GLEESON et al.** *J. Gen. Microbiol.*, 1986, vol. 132, 3459 [0162]
- **RAYMOND et al.** *Yeast*, 1998, vol. 14, 11-23 [0163]
- **HORSCH et al.** *Science*, 1985, vol. 227, 1229 [0164]
- **KLEIN et al.** *Biotechnology*, 1992, vol. 10, 268 [0164]

- Procedures for Introducing Foreign DNA into Plants. **MIKI et al.** *Methods in Plant Molecular Biology and Biotechnology*. CRC Press, 1993, 67-88 [0164]
- **GLICK**. *J. Ind. Microbiol.*, 1987, vol. 1, 277 [0165]
- **WATSON et al.** *Molecular Biology of the Gene*. Benjamin Cummins, 1987 [0165]
- *Molecular Biology Labfax*. Academic Press, 1991 [0166]
- *Bacillus Cloning Methods*. **HARDY**. *DNA Cloning: A Practical Approach*. IRL Press, 1985 [0166]
- Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies. **WILLIAMS et al.** *DNA Cloning 2: Expression Systems*. Oxford University Press, 1995, 15 [0168] [0229]
- Genetic Manipulation and Expression of Antibodies. **WARD et al.** *Monoclonal Antibodies: Principles and Applications*. Wiley-Liss, Inc, 1995, 137 [0168] [0240]
- Expression of Proteins in Bacteria. **GEORGIU et al.** *Protein Engineering: Principles and Practice*. John Wiley & Sons, Inc, 1996, 101 [0168]
- Expression of Engineered Proteins in Mammalian Cell Culture. **ETCHEVERRY et al.** *Protein Engineering: Principles and Practice*. Wiley-Liss, Inc, 1996, 163 [0170]
- Purification of over-produced proteins from *E. coli* cells. **GRISSHAMMER et al.** *DNA Cloning 2: Expression Systems*. Oxford University Press, 1995, 59-92 [0170]
- *Baculovirus Expression Protocols*. The Humana Press, Inc, 1995 [0170]
- **MERRIFIELD**. *J. Am. Chem. Soc.*, 1963, vol. 85, 2149 [0171]
- **STEWART et al.** *Solid Phase Peptide Synthesis*. Pierce Chemical Co, 1984 [0171]
- **BAYER ; RAPP**. *Chem. Pept. Prot.*, 1986, vol. 3, 3 [0171]
- **ATHERTON et al.** *Solid Phase Peptide Synthesis: A Practical Approach*. IRL Press, 1989 [0171]
- *Solid-Phase Peptide Synthesis*. **FIELDS ; COLOWICK**. *Methods in Enzymology*. Academic Press, 1997, vol. 289 [0171]
- **LLOYD-WILLIAMS et al.** *Chemical Approaches to the Synthesis of Peptides and Proteins*. CRC Press, Inc, 1997 [0171]
- **DAWSON et al.** *Science*, 1994, vol. 266, 776 [0171]
- **HACKENG et al.** *Proc. Nat'l Acad. Sci. USA*, 1997, vol. 94, 7845 [0171]
- **DAWSON**. *Methods Enzymol.*, 1997, vol. 287, 34 [0171]
- **MUIR et al.** *Proc. Nat'l Acad. Sci. USA*, 1998, vol. 95, 6705 [0171]
- **SEVERINOV ; MUIR**. *J. Biol. Chem.*, 1998, vol. 273, 16205 [0171]
- **PALACIOS ; STEINMETZ**. *Cell*, 1985, vol. 41, 727-734 [0174] [0488]
- **MOSMAN**. *J. Immunol. Meth.*, 1983, vol. 65, 55-63 [0176]
- **SHAW et al.** *Cell*, 1989, vol. 56, 563-572 [0176]
- **DEWET et al.** *Mol. Cell. Biol.*, 1987, vol. 7, 725 [0176]
- **BAUMGARTNER et al.** *J. Biol. Chem.*, 1994, vol. 269, 29094-29101 [0176]
- **SCHENBORN ; GOIFFIN**. *Promega_Notes*, 1993, vol. 41, 11 [0176]
- **DUMONTIER et al.** *J. Immunol.*, 2000, vol. 164, 1814-1819 [0178] [0290]
- **DUMOUTIER, L. et al.** *Proc. Nat'l. Acad. Sci.*, 2000, vol. 97, 10144-10149 [0178] [0290] [0292] [0294]
- **XIE MH et al.** *J. Biol. Chem.*, 2000, vol. 275, 31335-31339 [0178]
- **KOTENKO SV et al.** *JBC* [0178]
- **SOUYRI et al.** *Cell*, 1990, vol. 63, 1137-1147 [0179]
- **MONFARDINI et al.** *Proc. Assoc. Am. Physicians*, 1996, vol. 108, 420 [0181]
- **JORON et al.** *Ann. N Y Acad. Sci.*, 1992, vol. 672, 216 [0181]
- **FRIBOULET et al.** *Appl. Biochem. Biotechnol.*, 1994, vol. 47, 229 [0181]
- **AVALLE et al.** *Ann. N Y Acad. Sci.*, 1998, vol. 864, 118 [0181]
- **KAY et al.** *Phage Display of Peptides and Proteins*. Academic Press, 1996 [0182]
- Expression of Cloned Genes in Yeast. **ROMANOS et al.** *DNA Cloning 2: A Practical Approach*. Oxford University Press, 1995, 123-167 [0185]
- **HOPP et al.** *Biotechnology*. Eastman Kodak Co, 1988, vol. 6, 1204-1210 [0186]
- **TUAN et al.** *Connective Tissue Research*, 1996, vol. 34, 1-9 [0188]
- Expression of Foreign Proteins in *E. coli* Using Plasmid Vectors and Purification of Specific Polyclonal Antibodies. **WILLIAMS et al.** *DNA Cloning 2: A Practical Approach*. Oxford University Press, 1995, 15-58 [0189]
- **LUO et al.** *Arch. Biochem. Biophys.*, 1996, vol. 329, 215 [0190]
- **MORGANTI et al.** *Biotechnol. Appl. Biochem.*, 1996, vol. 23, 67 [0190]
- **ZHENG et al.** *Gene*, 1997, vol. 186, 55 [0190]
- **TUAN et al.** *Connective Tissue Research*, 1996, vol. 34, 1 [0196]
- *Immobilized Affinity Ligand Techniques*. Academic Press, 1992, 195-202 [0198]
- **MCCONNELL et al.** *Science*, 1992, vol. 257, 1906 [0199]
- **PITCHFORD et al.** *Meth. Enzymol.*, 1997, vol. 228, 84 [0199]
- **ARIMILLI et al.** *J. Immunol. Meth.*, 1998, vol. 212, 49 [0199]
- **VAN LIEFDE et al.** *Eur. J. Pharmacol.*, 1998, vol. 346, 87 [0199]
- **KARLSSON**. *Immunol. Methods*, 1991, vol. 145, 229 [0201]

- **CUNNINGHAM ; WELLS.** *J. Mol. Biol.*, 1993, vol. 234, 554 [0201]
- **DELGADO et al.** *Critical Reviews in Therapeutic Drug Carrier Systems*, 1992, vol. 9, 249 [0206]
- **DUNCAN ; SPREAFICO.** *Clin. Pharmacokinet.*, 1994, vol. 27, 290 [0206]
- **FRANCIS et al.** *Int J Hematol*, 1998, vol. 68, 1 [0206]
- **NIEFORTH et al.** *Clin. Pharmacol. Ther.*, 1996, vol. 59, 636 [0214]
- **MONKARSH et al.** *Anal. Biochem.*, 1997, vol. 247, 434 [0214]
- Affinity Chromatography: Principles & Methods. Pharmacia LKB Biotechnology, 1988 [0218]
- **DOONAN.** Protein Purification Protocols. The Humana Press, 1996 [0218]
- **SULKOWSKI.** *Trends in Biochem.*, 1985, vol. 3, 1 [0220]
- Meth. Enzymol. 1990, vol. 182, 529 [0220]
- **SCATCHARD.** *Ann. NY Acad. Sci.*, 1949, vol. 51, 660 [0223]
- **JAMESON ; WOLF.** *CABIOS*, 1988, vol. 4, 181 [0225]
- **HOPP et al.** *Proc. Nat'l Acad. Sci. USA*, 1981, vol. 78, 3824 [0226]
- **EMINI et al.** *J. Virology*, 1985, vol. 55, 836 [0226]
- **KARPLUS ; SCHULTZ.** *Naturwissenschaften*, 1985, vol. 72, 212 [0226]
- Prediction of Protein Structural Classes from Amino Acid Composition. **CHOU-FASMAN, CHOU.** Prediction of Protein Structure and the Principles of Protein Conformation. Plenum Press, 1990, 549-586 [0226]
- **GARNIER et al.** *J. Mol. Biol.*, 1978, vol. 120, 97 [0226]
- Production of Polyclonal Antisera. **GREEN et al.** Immunochemical Protocols. Humana Press, 1992, 1-5 [0229]
- **LOSMAN et al.** *Int. J. Cancer*, 1990, vol. 46, 310 [0230]
- **KOHLER et al.** *Nature*, 1975, vol. 256, 495 [0231]
- Current Protocols in Immunology. John Wiley & Sons, 1991, vol. 1, 2.5.1-2.6.7 [0231]
- Production of monoclonal antibodies against proteins expressed in *E. coli*. **PICKSLEY et al.** DNA Cloning 2: Expression Systems. Oxford University Press, 1995, 93 [0231]
- **GREEN et al.** *Nature Genet.*, 1994, vol. 7, 13 [0233]
- **LONBERG et al.** *Nature*, 1994, vol. 368, 856 [0233]
- **TAYLOR et al.** *Int. Immun.*, 1994, vol. 6, 579 [0233]
- Purification of Immunoglobulin G (IgG). **BAINES et al.** Methods in Molecular Biology. The Humana Press, Inc, 1992, vol. 10, 79-104 [0234]
- **NISONOFF et al.** *Arch Biochem. Biophys.*, 1960, vol. 89, 230 [0235]
- **PORTER.** *Biochem. J.*, 1959, vol. 73, 119 [0235]
- **EDELMAN et al.** Methods in Enzymology. Academic Press, 1967, vol. 1, 422 [0235]
- **INBAR et al.** *Proc. Nat'l Acad. Sci. USA*, 1972, vol. 69, 2659 [0237]
- **SANDHU.** *Crit. Rev. Biotech.*, 1992, vol. 12, 437 [0237] [0241]
- **WHITLOW et al.** *Methods: A Companion to Methods in Enzymology*, 1991, vol. 2, 97 [0238]
- **BIRD et al.** *Science*, 1988, vol. 242, 423 [0238]
- **PACK et al.** *Bio/Technology*, 1993, vol. 11, 1271 [0238]
- **KAY.** Phage Display of Peptides and Proteins. Academic Press, Inc, 1996 [0239]
- **LARRICK et al.** *Methods: A Companion to Methods in Enzymology*, 1991, vol. 2, 106 [0240]
- Genetic Manipulation of Monoclonal Antibodies. **COURTENAY-LUCK et al.** Monoclonal Antibodies: Production, Engineering and Clinical Application. Cambridge University Press, 1995, 166 [0240]
- **ORLANDI et al.** *Proc. Nat'l Acad. Sci. USA*, 1989, vol. 86, 3833 [0241]
- **JONES et al.** *Nature*, 1986, vol. 321, 522 [0241]
- **CARTER et al.** *Proc. Nat'l Acad. Sci. USA*, 1992, vol. 89, 4285 [0241]
- **SINGER et al.** *J. Immun.*, 1993, vol. 150, 2844 [0241]
- Antibody Engineering Protocols. Humana Press, Inc, 1995 [0241]
- Engineering Therapeutic Antibodies. **KELLEY et al.** Protein Engineering: Principles and Practice. John Wiley & Sons, Inc, 1996, 399-434 [0241]
- Production of Polyclonal Antisera. **GREEN et al.** Methods In Molecular Biology: Immunochemical Protocols. Humana Press, 1992, 1-12 [0242]
- **ALBERT, B. et al.** Molecular Biology of the Cell. Garland Publishing, 1994 [0246]
- Analysis of Gene Expression at the RNA Level. Methods in Gene Biotechnology. CRC Press, Inc, 1997, 225-239 [0249]
- Protocols for Nucleic Acid Analysis by Nonradioactive Probes. Humana Press, Inc, 1993 [0249]
- **TAVITIAN et al.** *Nature Medicine*, 1998, vol. 4, 467 [0250]
- Protocols in Human Molecular Genetics. Humana Press, Inc, 1991 [0251] [0257] [0262] [0263]
- PCR Protocols: Current . Methods and Applications. Humana Press, Inc, 1993 [0251]
- Molecular Diagnosis of Cancer. Humana Press, Inc, 1996 [0251] [0262]
- Tumor Marker Protocols. Humana Press, Inc, 1998 [0251] [0262]
- Clinical Applications of PCR. Humana Press, Inc, 1998 [0251] [0262]
- PCR in Bioanalysis. Humana Press, Inc, 1998 [0251] [0262]
- Rapid Isolation of Specific cDNAs or Genes by PCR. Methods in Gene Biotechnology. CRC Press, Inc, 1997, 15-28 [0253]
- **BEGGS et al.** *J. Clin. Microbiol.*, 1996, vol. 34, 2985 [0256]
- **BEKKAOUI et al.** *Biotechniques*, 1996, vol. 20, 240 [0256]

- **DYER et al.** *J. Virol. Methods*, 1996, vol. 60, 161 [0256]
- **EHRICHT et al.** *Eur. J. Biochem.*, 1997, vol. 243, 358 [0256]
- **CHADWICK et al.** *J. Virol. Methods*, 1998, vol. 70, 59 [0256]
- In Situ Hybridization Protocols. Humana Press, Inc, 1994 [0257]
- Analysis of Cellular DNA or Abundance of mRNA by Radioactive In Situ Hybridization. Methods in Gene Biotechnology. CRC Press, Inc, 1997, 259-278 [0257]
- Localization of DNA or Abundance of mRNA by Fluorescence In Situ Hybridization. Methods in Gene Biotechnology. CRC Press, Inc, 1997, 279-289 [0257]
- **COLEMAN ; TSONGALIS.** Molecular Diagnostics. Humana Press, Inc, 1996 [0257]
- **ELLES.** Molecular Diagnosis of Genetic Diseases. Humana Press, Inc, 1996 [0257]
- **AMSELEM, S et al.** *New Eng. J. Med.*, 1989, vol. 321, 989-995 [0258]
- **NOGUCHI, M et al.** *Cell*, 1993, vol. 73, 147-157 [0258] [0259]
- **IHARA, K et al.** *Proc. Nat. Acad. Sci.*, 1999, vol. 96, 3132-3136 [0258] [0259]
- **DE JONG, R et al.** *Science*, 1998, vol. 280, 1435-1438 [0258] [0259]
- **AMSELEM, S et al.** *New Eng. J. Med.*, 1989, vol. 321, 989-995 [0259]
- PCR Protocols: Current Methods and Applications. Humana Press, Inc, 1993 [0262]
- **MARIAN.** *Chest*, 1995, vol. 108, 255 [0263]
- **COLEMAN ; TSONGALIS.** Molecular Diagnostics. Human Press, Inc, 1996 [0263]
- Molecular Diagnosis of Genetic Diseases. Humana Press, Inc, 1996 [0263]
- Laboratory Protocols for Mutation Detection. Oxford University Press, 1996 [0263]
- Genome Analysis, Vol. 2: Detecting Genes. Cold Spring Harbor Laboratory Press, 1998, vol. 2 [0263]
- Current Protocols in Human Genetics. John Wiley & Sons, 1998 [0263]
- Molecular Diagnostic Testing. **RICHARDS ; WARD.** Principles of Molecular Medicine. Humana Press, Inc, 1998, 83-88 [0263]
- **STOPPA-LYONNET et al.** *Blood*, 1998, vol. 91, 3920 [0264]
- Current Protocols in Human Genetics. John Wiley & Sons, 1998, 9.11.1-9.11.18 [0264]
- Cell Marking Techniques and Their Application. **PONDER.** Mammalian Development: A Practical Approach. IRL Press, 1987, 115-38 [0269]
- Methods In Molecular Biology, Vol. 10: Immunochemical Protocols. The Humana Press, Inc, 1992, vol. 10 [0269]
- **KENNEDY et al.** *Clin. Chim. Acta*, 1976, vol. 70, 1 [0277]
- **SCHURS et al.** *Clin. Chim. Acta*, 1977, vol. 81, 1 [0277]
- **SHIH et al.** *Int'l J. Cancer*, 1990, vol. 46, 1101 [0277]
- **STEIN et al.** *Cancer Res.*, 1990, vol. 50, 1330 [0277]
- Avidin-Biotin Technology. Methods In Enzymology. Academic Press, 1990, vol. 184 [0278]
- Immunochemical Applications of Avidin-Biotin Technology. **BAYER et al.** Methods In Molecular Biology. The Humana Press, Inc, 1992, vol. 10, 149-162 [0278]
- Monoclonal Antibodies in Diagnostic Immunoassays. **COOK ; SELF.** Monoclonal Antibodies: Production, Engineering, and Clinical Application. Cambridge University Press, 1995, 180-208 [0279]
- The Role of Monoclonal Antibodies in the Advancement of Immunoassay Technology. **PERRY.** Monoclonal Antibodies: Principles and Applications. Wiley-Liss, Inc, 1995, 107-120 [0279]
- **DIAMANDIS.** Immunoassay. Academic Press, Inc, 1996 [0279]
- **HORNICK et al.** *Blood*, 1997, vol. 89, 4437-47 [0287] [0392]
- **SPENCER, SD et al.** *J. Exp. Med.*, 1998, vol. 187, 571-578 [0290]
- **GIBBS, VC ; PENNICA.** *Gene*, 1997, vol. 186, 97-101 [0290]
- **XIE, MH et al.** *J. Biol. Chem.*, 2000, vol. 275, 31335-31339 [0290]
- **KOTENKO, SV et al.** *J. Biol. Chem* [0290]
- **LIU Y et al.** *J Immunol.*, 1994, vol. 152, 1821-1829 [0290]
- **UHLAR, CM ; WHITEHEAD, AS.** *Eur. J. Biochem.*, 1999, vol. 265, 501-523 [0292]
- **BAUMANN H. ; GAULDIE, J.** *Immunology Today*, 1994, vol. 15, 74-80 [0292]
- **HUGHES C et al.** *J. Immunol*, 1994, vol. 153, 3319-3325 [0295]
- **HOLLIGER P ; HOOGENBOOM, H.** *Nature Biotech.*, 1998, vol. 16, 1015-1016 [0295]
- **SMITH JA et al.** *J. Immunol.*, 1998, vol. 160, 4841-4849 [0295]
- **TUTT, AL et al.** *J Immunol*, 1998, vol. 161, 3175-3185 [0295]
- **COSMAN, D.** *Cytokine*, 1993, vol. 5, 95-106 [0297]
- **FERNANDEZ-BOTRAN, R.** *Exp. Opin. Invest. Drugs*, 2000, vol. 9, 497-513 [0297]
- **HIROTA H. et al.** *Proc. Nat'l. Acad. Sci.*, 1995, vol. 92, 4862-4866 [0298]
- The Cytokine Handbook. 208-209 [0298]
- **GABAY.** *Expert. Opin. Biol. Ther.*, 2002, vol. 2 (2), 135-149 [0301]
- **WOOLEY.** *Curr. Opin. Rheum.*, 1999, vol. 3, 407-20 [0302]
- **WILLIAMS et al.** *Immunol.*, 1992, vol. 89, 9784-788 [0302]
- **MYERS et al.** *Life Sci.*, 1997, vol. 61, 1861-78 [0302]
- **WANG et al.** *Immunol.*, 1995, vol. 92, 8955-959 [0302]

- **GLAUSNER et al.** *Lancet*, 1991, vol. 338, 732 [0305]
- **DUMITRU et al.** *Cell*, 2000, vol. 103, 1071-1083 [0305]
- **BEUTLER et al.** *Science*, 1985, vol. 229, 869 [0306]
- **NEURATH et al.** *Intern. Rev. Immunol.*, 2000, vol. 19, 51-62 [0311]
- **BLUMBERG H et al.** *Cell*, 2001, vol. 104, 9-19 [0316]
- Oral Delivery of Microencapsulated Proteins. **DIBASE ; MORREL.** Protein Delivery: Physical Systems. Plenum Press, 1997, 255-288 [0322]
- **HINCHCLIFFE ; ILLUM.** *Adv. Drug Deliv. Rev.*, 1999, vol. 35, 199 [0322]
- **PETTIT ; GOMBOTZ.** *TIBTECH*, 1998, vol. 16, 343 [0322]
- **PATTON et al.** *Adv. Drug Deliv. Rev.*, 1999, vol. 35, 235 [0322]
- **MITRAGOTRI et al.** *Science*, 1995, vol. 269, 850 [0322]
- **POTTS et al.** *Pharm. Biotechnol.*, 1997, vol. 10, 213 [0322]
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1995 [0323] [0335]
- **BREMER et al.** *Pharm. Biotechnol.*, 1997, vol. 10, 239 [0325]
- Implants in Drug Delivery. **RANADE.** Drug Delivery Systems. CRC Press, 1995, 95-123 [0325]
- Protein Delivery with Infusion Pumps. **BREMER et al.** Protein Delivery: Physical Systems. Plenum Press, 1997, 239-254 [0325]
- Delivery of Proteins from a Controlled Release Injectable Implant. **YEWEY et al.** Protein Delivery: Physical Systems, Sanders and Hendren. Plenum Press, 1997, 93-117 [0325]
- **BAKKER-WOUDENBERG et al.** *Eur. J. Clin. Microbiol. Infect. Dis.*, 1993, vol. 12 (1), 61 [0326]
- **KIM.** *Drugs*, 1993, vol. 46, 618 [0326]
- Site-Specific Drug Delivery Using Liposomes as Carriers. **RANADE.** Drug Delivery Systems. CRC Press, 1995, 3-24 [0326]
- **MACHY et al.** Liposomes In Cell Biology And Pharmacology. John Libbey, 1987 [0326]
- **OSTRO et al.** *American J. Hosp. Pharm.*, 1989, vol. 46, 1576 [0326]
- **SCHERPHOF et al.** *Ann. N.Y. Acad. Sci.*, 1985, vol. 446, 368 [0327]
- **CLAASSEN et al.** *Biochim. Biophys. Acta*, 1984, vol. 802, 428 [0328]
- **ALLEN et al.** *Biochim. Biophys. Acta*, 1991, vol. 1068, 133 [0328]
- **ALLEN et al.** *Biochim. Biophys. Acta*, 1993, vol. 1150, 9 [0328] [0332]
- **KATO et al.** *Biol. Pharm. Bull.*, 1993, vol. 16, 960 [0329]
- **SHIMIZU et al.** *Biol. Pharm. Bull.*, 1997, vol. 20, 881 [0329]
- **KATO ; SUGIYAMA.** *Crit. Rev. Ther. Drug Carrier Syst.*, 1997, vol. 14, 287 [0330]
- **MURAHASHI et al.** *Biol. Pharm. Bull.*, 1997, vol. 20, 259 [0330]
- **WU et al.** *Hepatology*, 1998, vol. 27, 772 [0330]
- **KAMPS et al.** *Proc. Nat'l Acad. Sci. USA*, 1997, vol. 94, 11681 [0330]
- **HARASYM et al.** *Adv. Drug Deliv. Rev.*, 1998, vol. 32, 99 [0331]
- **ANDERSON et al.** *Infect. Immun.*, 1981, vol. 31, 1099 [0332]
- **ANDERSON et al.** *Cancer Res.*, 1990, vol. 50, 1853 [0332]
- **COHEN et al.** *Biochim. Biophys. Acta*, 1991, vol. 1063, 95 [0332]
- Preparation and Use of Liposomes in Immunological Studies. **ALVING et al.** Liposome Technology. 1993, vol. III, 317 [0332]
- **WASSEF et al.** *Meth. Enzymol.*, 1987, vol. 149, 124 [0332]
- **GOMBOTZ ; PETTIT.** *Bioconjugate Chem.*, 1995, vol. 6, 332 [0333]
- Role of Polymers in Drug Delivery. **RANADE.** Drug Delivery Systems. CRC Press, 1995, 51-93 [0333]
- Degradable Controlled Release Systems Useful for Protein Delivery. **ROSKOS ; MASKIEWICZ.** Protein Delivery: Physical Systems. Plenum Press, 1997, 45-92 [0333]
- **BARTUS et al.** *Science*, 1998, vol. 281, 1161 [0333]
- **PUTNEY ; BURKE.** *Nature Biotechnology*, 1998, vol. 16, 153 [0333]
- **PUTNEY.** *Curr. Opin. Chem. Biol.*, 1998, vol. 2, 548 [0333]
- **GRAF et al.** *Pharm. Biotechnol.*, 1997, vol. 10, 167 [0333]
- **ANSEL ; POPOVICH.** Pharmaceutical Dosage Forms and Drug Delivery Systems. Lea & Febiger, 1990 [0335]
- **RANADE ; HOLLINGER.** Drug Delivery Systems. CRC Press, 1996 [0335]
- **MULLIGAN.** *Science*, 1993, vol. 260, 926 [0338]
- **ROSENBERG et al.** *Science*, 1988, vol. 242, 1575 [0338]
- **LASALLE et al.** *Science*, 1993, vol. 259, 988 [0338]
- **WOLFF et al.** *Science*, 1990, vol. 247, 1465 [0338]
- **BREAKFIELD ; DELUCA.** *The New Biologist*, 1991, vol. 3, 203 [0338]
- **KASS-EISLER et al.** *Proc. Nat'l Acad. Sci. USA*, 1993, vol. 90, 11498 [0340]
- **KOLLS et al.** *Proc. Nat'l Acad. Sci. USA*, 1994, vol. 91, 215 [0340]
- **LI et al.** *Hum. Gene Ther.*, 1993, vol. 4, 403 [0340]
- **VINCENT et al.** *Nat. Genet.*, 1993, vol. 5, 130 [0340]
- **ZABNER et al.** *Cell*, 1993, vol. 75, 207 [0340]
- **FLOTTE et al.** *Proc. Nat'l Acad. Sci. USA*, 1993, vol. 90, 10613 [0340]
- **HERTZ ; HUANG.** *J. Vir.*, 1992, vol. 66, 857 [0340]
- **RAJU ; HUANG.** *J. Vir.*, 1991, vol. 65, 2501 [0340]
- **XIONG et al.** *Science*, 1989, vol. 243, 1188 [0340]

- **KOERING et al.** *Hum. Gene Therap.*, 1994, vol. 5, 457 [0340]
- **OZAKI et al.** *Biochem. Biophys. Res. Comm.*, 1993, vol. 193, 653 [0340]
- **PANICALI ; PAOLETTI.** *Proc. Nat'l Acad. Sci. USA*, 1982, vol. 79, 4927 [0340]
- **FISHER-HOCH et al.** *Proc. Nat'l Acad. Sci. USA*, 1989, vol. 86, 317 [0340]
- **FLEXNER et al.** *Ann. N.Y. Acad. Sci.*, 1989, vol. 569, 86 [0340]
- **BABA et al.** *J. Neurosurg*, 1993, vol. 79, 729 [0340]
- **RAM et al.** *Cancer Res.*, 1993, vol. 53, 83 [0340]
- **TAKAMIYA et al.** *J. Neurosci. Res*, 1992, vol. 33, 493 [0340]
- **VILE ; HART.** *Cancer Res.*, 1993, vol. 53, 962 [0340]
- **VILE ; HART.** *Cancer Res.*, 1993, vol. 53, 3860 [0340]
- **LUSKY et al.** *J. Virol.*, 1998, vol. 72, 2022 [0343]
- **RAPER et al.** *Human Gene Therapy*, 1998, vol. 9, 671 [0343]
- **AMALFITANO et al.** *J. Virol.*, 1998, vol. 72, 926 [0343]
- **YEH ; PERRICAUDET.** *FASEB J.*, 1997, vol. 11, 615 [0343]
- **BRANDT et al.** *J. Gen. Virol.*, 1991, vol. 72, 2043 [0344]
- **HEROLD et al.** *J. Gen. Virol.*, 1994, vol. 75, 1211 [0344]
- **VISALLI ; BRANDT.** *Virology*, 1991, vol. 185, 419 [0344]
- **GRAU et al.** *Invest. Ophthalmol. Vis. Sci.*, 1989, vol. 30, 2474 [0344]
- **BRANDT et al.** *J. Virol. Meth.*, 1992, vol. 36, 209 [0344]
- HSV Virus Protocols. Humana Press, 1997 [0344]
- **FELGNER et al.** *Proc. Nat'l Acad. Sci. USA*, 1987, vol. 84, 7413 [0345]
- **MACKEY et al.** *Proc. Nat'l Acad. Sci. USA*, 1988, vol. 85, 8027 [0345]
- **AIHARA ; MIYAZAKI.** *Nature Biotechnology*, 1998, vol. 16, 867 [0346]
- **YUAN et al.** *Science*, 1994, vol. 263, 1269 [0349]
- **HORTON et al.** *Proc. Nat'l Acad. Sci. USA*, 1999, vol. 96, 1553 [0350]
- Remington's Pharmaceutical Sciences. Mack Publishing Co, 1995 [0351]
- Gilman's the Pharmacological Basis of Therapeutics. MacMillan Publishing Co, 1985 [0351]
- Expression and Knockout of Interferons in Transgenic Mice. **JACOB.** Overexpression and Knockout of Cytokines in Transgenic Mice. Academic Press, Ltd, 1994, 111-124 [0354] [0367]
- Strategies in Transgenic Animal Science. ASM Press, 1995 [0354]
- Recombinant Protein Expression in Transgenic Mice. **ABBUD ; NILSON.** Gene Expression Systems: Using Nature for the Art of Expression. Academic Press, Inc, 1999, 367-397 [0354]
- **MENINO ; O'CLARAY.** *Biol. Reprod.*, 1986, vol. 77, 159 [0356]
- **DIENHART ; DOWNS.** *Zygote*, 1996, vol. 4, 129 [0356]
- Gene Underexpression in Cultured Cells and Animals by Antisense DNA and RNA Strategies. **WU et al.** Methods in Gene Biotechnology. CRC Press, 1997, 205-224 [0366]
- New Strategies for Gene Knockout. **WU et al.** Methods in Gene Biotechnology. CRC Press, 1997, 339-365 [0367]
- **KALLEN et al.** *J. Biol. Chem.*, 1999, vol. 274, 11859-11867 [0376]
- Epitope Mapping. **MOLE.** Methods in Molecular Biology. The Humana Press, Inc, 1992, vol. 10, 105-116 [0379]
- Current Protocols in Immunology. John Wiley & Sons, 1997, 9.3.1-9.3.59.4.1-9.4.11 [0379]
- Current Protocols in Immunology. National Institutes of Health, John Wiley and Sons, Inc, 1995 [0381] [0385]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, 1989 [0381]
- Monoclonal Hybridoma Antibodies: Techniques and Applications. CRC Press, Inc, 1982 [0381]
- **SCATCHARD, G.** *Ann. NY Acad. Sci.*, 1949, vol. 51, 660-672 [0384]
- Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1988 [0385] [0386]
- Fundamental Immunology. Raven Press, 1993 [0385]
- **GETZOFF et al.** *Adv. in Immunol.*, 1988, vol. 43, 1-98 [0385]
- Monoclonal Antibodies: Principles and Practice. Academic Press Ltd, 1996 [0385]
- **BENJAMIN et al.** *Ann. Rev. Immunol.*, 1984, vol. 2, 67-101 [0385]
- **HIETER P. ; SIKORSKI, R.** *Genetics*, 1989, vol. 122, 19-27 [0447]
- **CASADABAN.** *J. Mol. Biol.*, vol. 138, 179-207 [0449]
- **PRYOR ; LEITING.** *Protein Expression and Purification*, 1997, vol. 10, 309-319 [0449]
- **E. HARLOW ; D. LANE.** Antibodies: A Laboratory Manual. Cold Spring Harbor Press [0454]
- **SADOWSKI, H. et al.** *Science*, 1993, vol. 261, 1739-1744 [0466]
- **CHIN, Y. et al.** *Science*, 1996, vol. 272, 719-722 [0466]
- **SCHMITT-NEY, M. et al.** *Mol. Cell. Biol.*, 1991, vol. 11, 3745-3755 [0466]
- **SEIDEL, H. et al.** *Proc. Natl. Acad. Sci.*, 1995, vol. 92, 3041-3045 [0466]
- **POULSEN, L.K. et al.** *J. Biol. Chem.*, 1998, vol. 273, 6229-6232 [0466]
- **PARRISH-NOVAK, J et al.** *Nature*, 2000, vol. 408, 57-63 [0467]
- **MATHEY-PREVOT et al.** *Mol. Cell. Biol.*, 1986, vol. 6, 4133-4135 [0488]

EP 1 373 508 B1

- **POULSEN, LK et al.** *J. Biol. Chem.*, 1998, vol. 273, 6228-6232 [0496]
- **T.C. BECKER et al.** *Meth. Immunology*, 1994, vol. 43, 161-189 [0496]
- **PAPANICOLAOU et al.** *Cytogenet. Cell Genet.*, 1997, vol. 76, 181-182 [0536]
- **HOGAN, B. et al.** *Manipulating the Mouse Embryo. A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1994 [0537]
- **S.N.S. MURTHY.** Treatment of Dextran Sulfate Sodium-Induced Murine Colitis by Intracolonic Cyclosporin. *Digestive Diseases and Sciences*, September 1993, vol. 38 (9), 1722-1734 [0560]

专利名称(译)	人细胞因子受体		
公开(公告)号	EP1373508B1	公开(公告)日	2013-04-24
申请号	EP2002721533	申请日	2002-03-22
[标]申请(专利权)人(译)	津莫吉尼蒂克斯公司		
申请(专利权)人(译)	ZymoGenetics公司, INC.		
当前申请(专利权)人(译)	ZymoGenetics公司, INC.		
[标]发明人	PRESNELL SCOTT R XU WENFENG KINDSVOGEL WAYNE CHEN ZHI HUGHES STEVEN D		
发明人	PRESNELL, SCOTT, R. XU, WENFENG KINDSVOGEL, WAYNE CHEN, ZHI HUGHES, STEVEN, D.		
IPC分类号	C12N9/12 G01N33/53 A61K38/00 A61K39/395 A61P1/04 A61P17/06 A61P19/02 A61P29/00 A61P31/04 A61P39/02 C07K14/715 C07K16/28 C07K19/00 C12N1/15 C12N1/19 C12N1/21 C12N5/10 C12N15/09 C12N15/12 C12P21/02 G01N33/574		
CPC分类号	A61K38/00 A61P1/04 A61P17/06 A61P19/02 A61P29/00 A61P31/00 A61P31/04 A61P35/00 C07K14/715		
优先权	60/279222 2001-03-27 US		
其他公开文献	EP1373508A2 EP1373508A4		
外部链接	Espacenet		

摘要(译)	atg atg cct aaa cat tgc ttt cta ggc ttc ctc atc agt ttc ttc ctt	48
细胞因子及其受体已被证明在基础研究和治疗方面都是有用的。本发明提供了一种新的人细胞因子受体，命名为“Zcytor16”。	Met Met Pro Lys His Cys Phe Leu Gly Phe Leu Ile Ser Phe Phe Leu	
	1 5 10 15	
	act ggt gta gca gga act cag tca acg cat gag tct ctg aag cct cag	96
	Thr Gly Val Ala Gly Thr Gln Ser Thr His Glu Ser Leu Lys Pro Gln	
	20 25 30	
	agg gta caa ttt cag tcc cga aat ttt cac aac att ttg caa tgg cag	144
	Arg Val Gln Phe Gln Ser Arg Asn Phe His Asn Ile Leu Gln Trp Gln	
	35 40 45	
	cct ggg agg gca ctt act ggc aac agc agt gtc tat ttt gtg cag tac	192
	Pro Gly Arg Ala Leu Thr Gly Asn Ser Ser Val Tyr Phe Val Gln Tyr	
	50 55 60	